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Abstract 
Pharmacy, particularly in the community setting, has been subject to significant 
changes over the last three decades. Running concurrently to these changes has been 
the development of the field of pharmacogenetics, or ‘personalised medicine’, which 
is likely to have significant impacts on hospital and community pharmacy practice.    
Despite this, little sociological research has been undertaken to map the 
contemporary pharmacy landscape into which pharmacogenetics may be integrated 
and the effects that pharmacogenetics may have on pharmacy.    
 
Through 38 semi-structured interviews with diverse practitioners, this thesis 
addresses these gaps in the academic literature by positing a novel sociological 
model through which contemporary pharmacy practice may be analysed and 
examining the potential impacts of pharmacogenetics on it.  
 
It is argued that a dual approach to the management of medicines intersects both 
community and hospital pharmacy. Within this dual medicines management model, 
codified, organisational interests in medicines management are practised alongside 
a more negotiated approach which is enacted through what has been called here the 
‘pharmacy gaze’. The pharmacy gaze characterises the ways in which medicines and 
the patient bodies to which they are administered are co-constructed by pharmacists 
through discourses of risk and toxicity.  
 
Pharmacogenetics, it is argued, represents a way in which the pharmacy gaze, and 
patient bodies within it, may be increasingly molecularised and risk and toxicity 
increasingly managed at the genetic level within pharmacy practice. Within this, a 
number of ‘pharmacogenetic futures’ involving pharmacy testing, patient 
counselling and practitioner education are presented although these are argued to 
be highly speculative and to present a number of macro- and micro-level challenges 
for policy makers and pharmacists. The thesis concludes by making a number of 
recommendations as to how some of these challenges may be addressed.  
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Chapter One: Introduction 
1.1 Introduction 
This thesis explores the potential impacts of pharmacogenetics, or ‘personalised’ or 
‘stratified’ medicine on pharmacy practice in England. The pharmacy profession 
plays a key role in the healthcare system but has received relatively little attention 
within the social sciences. In recent years, pharmacy, particularly in the community 
setting has experienced significant changes with respect to the support and 
management of prescribed medicines and its increased clinical role with a move 
toward independent and supplementary prescribing by pharmacists themselves 
(Department of Health, 2005a; 2006).  
 
Running concurrently to these changes in pharmacy has been the 
development of pharmacogenetics (hereafter PGx), which has been identified as one 
of the most clinically and commercially useful applications of the data and 
technologies arising from the Human Genome Project (hereafter HGP). PGx is 
concerned with genetically-determined drug response variability and is premised on 
the notion of providing the ‘right drug to the right patient at the right dose’ in order 
to minimise the risk of adverse drug reactions (hereafter ADRs) and maximise 
therapeutic benefits (Piquette-Miller and Grant, 2007: 311). In doing so, it is argued 
that PGx has the potential to reduce the time and financial burden of ADRs and 
improve patients’ experiences of their medications. This paradigm of practice has, 
then, been identified by the UK government as an important feature of future 
healthcare delivery in the National Health Service (hereafter NHS) (Department of 
Health, 2003a). 
 
At present, PGx has made limited impact outside of secondary care where it 
is most commonly mobilised in medical specialisms with particularly severe and 
frequent ADRs, namely Oncology. Despite this, putative links between primary care 
drugs and genetically-determined drug reactions have been identified (Grice et al., 
2006) and the Department of Health’s (2003a) White Paper Our Inheritance, Our 
Future highlights the primary care drug Warfarin as an ‘early candidate’ for tailored 
dosage through PGx (also see Wadelius and Pirmohamed, 2006).  
13 
 
 
The uptake of PGx technology is likely to create greater demands on 
pharmacists and reorganise their everyday work around a more genetic approach to 
medicines and the patient body. However, commentary on the process and effects in 
integrating PGx into pharmacy is relatively limited. Work which does exist in this 
area is (generally) highly speculative, not based on empirical research and not 
analysed from a sociological perspective. As such Ryan et al. (2004: 51) suggest that 
since ‘pharmacy is likely to be at the forefront of the ‘new’ genetics...it would be 
beneficial to develop an understanding of how we [pharmacy] construct the new 
genetics and how they in turn construct us’. The paucity of work in this area of 
pharmacy and the new genetics reflects a wider neglect of the sector of pharmacy in 
the social sciences, despite pharmacists’, and the medications which they dispense, 
centrality to the UK healthcare system. This thesis goes some way to addressing this 
paucity of social science research in this area by examining the integration of PGx 
into community and hospital pharmacy and the ramifications it may have on 
everyday practice.  
 
This introductory chapter contextualises the subsequent work within this 
thesis by giving an overview of the sociological relevance of pharmacy and PGx. 
Following this, it outlines details of the specific research questions which underpin 
the fieldwork and analysis which have been undertaken and provides a structural 
breakdown of each chapter.   
1.2 Why Pharmacy? 
When compared with other healthcare practices, pharmacy is relatively under-
explored in the social sciences even though pharmacists play a key role in healthcare 
and are central to patients’ experiences of illness. 
 
In 2008, at the time of the most recent pharmacy workforce census, there 
were 48,749 registered pharmacists in the UK (Seston and Hassell, 2009). Over 90% 
of these were concentrated in community (71%) and hospital (21.4%) practice 
settings and it is the integration of PGx in both of these settings which this thesis is 
concerned with. This is not, of course, to say that pharmacy practice in primary care 
14 
 
(where 7.2% of registered pharmacists practice), academia (where 2.8% of registered 
pharmacists work) and industry (where 4.1% of registered pharmacists are based) is 
not sociologically interesting but community and hospital settings are the most 
relevant here
1
.    
 
This diversity of sectors in which registered pharmacists practise attests to 
the heterogeneity of pharmacy as a profession, which also typifies practice within 
these sectors. As such, there is a significant difference between the modes of 
employment and organisation of everyday work for community pharmacists 
employed in large multiples or supermarkets and owner-occupier community 
pharmacists. In the hospital setting such diversity is also evident with practices 
across specialist areas varying in terms of the nature of medications, types of patients 
and involvement with clinical trials. It is, in part, this diversity which makes 
pharmacy sociologically interesting.  
This thesis is concerned with the implementation of PGx into community and 
hospital pharmacy. It will be shown that there are significant differences between 
community and hospital practices and, as such, these two domains are treated as two 
divergent practice structures. Hence, although British community and hospital 
pharmacists share a common undergraduate education programme, the everyday 
work of community and hospital pharmacists in the UK is highly divergent. Bhakta 
(2010) specifically highlights working patterns, patients and medicines as three key 
areas where community and hospital pharmacy practice diverge. As such, whilst 
community pharmacists tend to work in relative isolation (Cooper et al., 2009) and 
focus on chronic conditions and medications, those practising in hospital settings 
work in a more inter-disciplinary environment which is typified by acutely ill 
patients and their more complex medication regimes. Moreover, the technologies 
which are central to the everyday work of pharmacists are also different in 
community and hospital settings. Given this, the processes and discourses around 
PGx in these two settings are highly divergent and can only be understood through 
the prism of these differences.  
                                                 
1
 The total percentage of active pharmacists is greater than 100% as pharmacists may have positions 
in two different sectors or two different jobs in one sector. 
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Despite these differences, however, the thesis argues that medications, risk 
and toxicity, the patient body, medicines management and the ‘pharmacy gaze’ (a 
novel concept developed in Chapter Six) are objects and discourses which are central 
to both community and hospital pharmacy. As such, the analytical framework of the 
thesis does not treat community and hospital pharmacy as two discrete landscapes 
but instead assesses the particularities of each through these shared discourses. In 
doing so, the thesis avoids a simplistic binaried division between practice in 
community and hospital settings and, instead, highlights the similarities between 
different pharmacy practices whist avoiding a homogenisation of the entirety of the 
pharmacy sector.  
 
The modern structures of both community and hospital pharmacy can be 
traced to the late twentieth century when the Department of Health began to 
reorganise the structure of practice in these settings. In the community setting, 
uncertainty about the future of community pharmacy was born out of the ubiquity of 
pre-packaged medicines largely displacing the manufacturing and compounding role 
of pharmacists (Harding and Taylor, 1997). Given this, concerns were voiced that 
community pharmacists were ‘over trained for what they do and underutilised in 
what they know’ (Eaton and Webb, 1979: 73). These concerns were addressed 
through the UK National Pharmacy Association’s 1982 Ask Your Pharmacist 
campaign. This initiative encouraged the public to utilise their local pharmacy and 
was followed in the 1990s by the implementation of the ‘extended role’. This 
extended role was grounded in what has become widely known in pharmacy practice 
research as the Nuffield Report (1986) and later expounded in other policy 
publications (Department of Health and Royal Pharmaceutical Society of Great 
Britain, 1992; Royal Pharmaceutical Society of Great Britain, 1995). The 
implementation of the suggestions from these reports culminated with the 
community pharmacy contract being expanded to include increased clinical work 
through prescribed medicines management; chronic illness management; common 
ailments management and the promotion of healthy lifestyles (Harding and Taylor, 
1997). This extended role, and the initiatives which existed around it, reconfigured 
community pharmacists as healthcare practitioners and relocated them outside of the 
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dispensary, thus discursively positioning them as a ‘first port of call’ for patients 
(Anderson, 2001: 23).  
 
In the hospital setting, significant structural changes began to be 
implemented during the 1970s. Prior to this, during the period in between the 
establishment of the NHS in 1948 and the publication of the Noel Hall Report in 
1970, hospital pharmacy was organised at the local level of the individual hospital. 
As such, there was a relative lack of standardisation in the profession and concerns 
around poor job prospects and low pay overshadowed attempts, such as agreeing 
national pay scales, to standardise and expand the sector (Anderson, 2001). In 
response to these concerns about hospital pharmacy, the Department of Health’s 
Noel Hall Report (Hall, 1970) recommended that hospital pharmacy should be 
organised at the regional level under the management of an Area Pharmaceutical 
Officer with every 4,000-6,000 hospital beds being served by around eight 
pharmacists. Additionally, it was suggested that new salary structures for principle 
pharmacists, staff pharmacists and pharmacy technicians and on-going training 
reviews would make hospital pharmacy a more appealing career for young people 
(Levitt, 1976; Stone and Curtis, 2002). By the end of the 1970s, most hospital 
pharmacists were routinely practising ward pharmacy (i.e. dispensing medications 
and offering medications counselling on wards rather than in the dispensary), which 
later became established as clinical pharmacy and during the following decades the 
profession became increasingly characterised by clinical specialisation in fields such 
as Oncology or paediatrics (Anderson, 2001).   
 
The role of pharmacists in both sectors has been further expanded since the 
turn of the twenty first century with the implementation of supplementary 
prescribing. In 2000, the Department of Health set out a number of principles in its 
NHS Plan in which pharmacist (and nurse) prescribing was identified as leading to 
improvements in patient care and safety, increased patient choice and access, more 
effective use of healthcare professionals’ time and more flexible working structures 
throughout the NHS (Department of Health, 2000). Following this, in 2006 
pharmacists were permitted to train as independent prescribers which gave them the 
ability to prescribe any medicine from within the British National Formulary 
independently of other healthcare professionals (Department of Health, 2006).  
17 
 
 
In 2008, the Department of Health published a seminal White Paper on the 
future of pharmacy services in the NHS. Within it, community pharmacists were 
discursively configured as central practitioners in medications safety and efficacy 
given their expertise in medicines and their associated ‘stuff’ (see Barber, 2005). 
Moreover, their proposed increased involvement in health promotion work such as 
smoking cessation support, Chlamydia screening and teenage pregnancy initiatives 
positioned community pharmacists as public health practitioners and redefined the 
community pharmacy space as an accessible ‘community-based healthy living 
centre’ (Department of Heath, 2008: 118) rather than retail spaces in which 
pharmacists only engage with dispensing work.  
 
More recently, in 2011 a new community pharmacy contract was 
implemented with community pharmacy’s Advanced Services being extended to 
include a new medicines service (NMS). This NMS involves community 
pharmacists counselling patients who have been prescribed a new medication for a 
long-term condition and has been proposed as a way in which community 
pharmacists can contribute to improved patient adherence and help patients to have a 
better experience of their medication regimes. In this way, community pharmacists’ 
role as advisors, rather than dispensers, is reinforced and supported by health policy.  
 
This is further reinforced by two recent reports around shared-decision 
making in which pharmacists, in both community and hospital settings, are 
positioned as central practitioners in medicines decisions making. In the first report, 
a subgroup of the Royal College of Physicians (2011) argue that collaboration 
between pharmacists, nurses, prescribers and other healthcare professionals is 
essential in order to provide the most effective medicines decisions based on diverse 
and complementary expertise. In the second, Cribb et al. (2011) on behalf of the 
Royal Pharmaceutical Society, argue for the need for collaboration between 
healthcare professionals (including pharmacists) and patients in decision-making in 
order to reach the most effective medications regime for individual patients. In both 
of these reports limited inter-professional communication is identified as a barrier to 
such collaborative practice and shared decision-making. Nonetheless, the positioning 
of pharmacists as the pharmacology experts in both hospital and community settings 
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attests to the centrality of pharmacists in the healthcare system and patients’ 
experiences of it.  
 
Pharmacy is, then, highly policy relevant and, moreover, sociologically 
interesting from a number of perspectives especially in regard to its changing profile 
as a profession. Despite this, there has been comparatively little work in this area by 
social scientists. Research which has been undertaken has variously focused on 
patient-pharmacist communication (Nguyen, 2006; Pilnick, 1998; Pilnick, 2003) 
inter-professional communication (Cooper et al., 2009; Hughes and McCann, 2003); 
professional identity and status (Birenbaum, 1982; Denzin and Mettlin, 1968; 
Edmunds and Calnan, 2001); boundary encroachment (Eaton and Webb, 1979; 
Messler, 1991) and new technologies (Barrett et al., 2011; Petrakaki et al., 2012). 
Within this work we see a focus on the status of pharmacy, particularly in the 
community setting, as a ‘profession’ as opposed to an ‘occupation’. Sociological 
analyses of professional autonomy and the ‘role strain’ (Harding and Taylor, 1997) 
generated by community pharmacists’ dual role as retailers and healthcare 
practitioners are especially prominent. As an example, the location of community 
pharmacy work within retail settings is understood by Harding and Taylor (2000) 
and Bush et al. (2009) in line with Ritzer’s (2000) McDonaldization framework as a 
corporatisation of pharmacy leading to a decline in pharmacists’ autonomy and a 
universality of ‘McPharmacists’. Moreover, Petrakaki et al.’s (2012) study of 
electronic prescribing systems (EPS) in community pharmacy and Barrett et al.’s 
(2011) study of dispensing robots in hospital pharmacy address the ways in which 
the implementation of innovations in pharmacy affect this autonomy and 
professional status. As an example, Petrakaki et al. (2012) argue that EPS acts to 
both de- and re-professionalise community pharmacy through automation 
simultaneously rendering practice more visible and so open to governmental control, 
yet providing increased opportunities for engagement in clinical work.   
 
Social science work in the area of pharmacy practice has tended to focus 
disproportionally on community pharmacy and tends to neglect practice within 
hospital settings. In doing so, these sociological analyses have tended to treat 
community and hospital pharmacy as two discrete professional worlds with the 
former (owing to its, arguably, dubious ‘professional’ status) being represented as 
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being of more sociological interest. Given this, very little work has been done to map 
the entirety of the contemporary pharmacy landscape.  
 
As an attempt to remedy this, this thesis presents a sociological overview of 
both community and hospital pharmacy practices through an analysis of the 
discourses and practices which intersect both of these settings. As such, although the 
differences between the everyday work of practitioners in these sectors are drawn 
out, the community and hospital are not treated as discrete professional worlds. In 
this way, the thesis offers something of a novel contribution to the sociological study 
of pharmacy practice. Moreover, in centralising hospital as well as community 
pharmacy, the thesis helps to address the paucity of social science research in the 
area of hospital pharmacy practice.   
1.3 Why Pharmacogenetics? 
Running concurrently to the recent changes in community and hospital pharmacy has 
been the development of the scientific field of PGx, or ‘personalised’ or ‘stratified’ 
medicine. This approach to drug development and clinical practice is concerned with 
genetically-determined drug response variability and is premised on the notion of 
providing the ‘right drug to the right patient at the right dose’ in order to minimise 
the risk of adverse drug reactions (hereafter ADRs) and maximise the therapeutic 
benefits (Piquette-Miller and Grant, 2007: 311). In the 1990s, PGx was regarded as 
one of the key applications of the genomics data and sequencing technologies 
emerging from the HGP and was central to global population stratification projects 
such as the SNP (pronounced ‘snip’) consortium and the International HapMap 
project (see Hedgecoe, 2004). More recently, the UK Technology Strategy Board 
announced stratified medicine as a key five year priority area and, in 2011, launched 
the Stratified Medicine Innovation Platform with the objective to invest £200 million 
in stratified medicine projects by 2016. 
 
PGx is posited as a way in which drug development processes and 
prescribing practices could be reorganised around a more stratified approach. In this 
way, it is argued that the traditional blockbuster drug production model and the trial-
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and-error approach to prescribing may be displaced by a more targeted model 
(Pirmohamed and Lewis, 2004). 
 
In terms of drug development, implementing PGx into clinical trials is 
understood as a way in which potential drug candidates could be targeted to genomic 
sub-populations who are most likely to respond well to therapies rather than the 
population as a whole where the chances for rejection by the UK National Institute 
for Clinical Excellence (NICE) or the US Food and Drug Administration (FDA) are 
increased due to ADRs. This stratification of clinical trial participants by likely drug 
response means that genomic sub-populations with a predisposition to good or poor 
reactions can be identified. By doing so, trials can exclude those with a propensity 
for ADRs, which would improve trial bias, improve the safety profile of the drug 
and, potentially, ‘rescue’ drugs which have been abandoned at the later stages of a 
clinical trial due to safety concerns (Martin et al., 2006; Shah, 2006; Webster et al., 
2004) 
 
This stratified approach to drug development is imagined to reduce the cost 
of research and development (hereafter R&D) and the time spent conducting clinical 
trials. As an example, writing some years ago Tollman et al. (2001) argued that the 
cost of drug development could be reduced by $140 million and one year could be 
taken off clinical trial time. This, he argued, is because the binary scenario which 
traditionally typifies the later stages of clinical trials (i.e. drugs are either show to be 
effective, pushed through clinical trials and marketed or shown to be minimally 
effective and abandoned as unmarketable) is displaced by a more flexible model 
where effectiveness and ineffectiveness can co-exist through stratified populations. 
In this way, ineffectiveness does not necessitate abandoning a drug but rather 
marketing it to a restricted sub-population. More recently, Amir-Aslani and 
Mangematin (2010) draw on trials of the Diabetes drug Sitagliptin, in which 
biomarkers for response variation were identified and employed early on, to argue 
that stratification in clinical trials could reduce the time taken to phase III trials from 
3.5 to 2.1 years.    
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The most commonly cited use of PGx in clinical practice is pre-prescription 
testing. The following vignette by Pfost et al. (2000: 334) demonstrates this use of 
PGx well; 
“In your doctor’s office, sometime in the future, you spit a sample 
of mouthwash into a vial. The following day, the doctor advises 
you not to take the drug that he had considered prescribing to treat 
your condition, because a genetic test for certain single nucleotide 
polymorphisms (SNPs) predicts that you could suffer a severe 
adverse reaction to it. By contrast, the same test indicates that you 
are expected to show an excellent response to a different 
medication with little chance of side effects, and you are given the 
appropriate prescription. This is the promise of pharmacogenetics 
– the optimization of drug therapy” 
  Martin et al. (2006) also identify this use of pre-prescription testing as a 
means to identify patients at risk of ADRs and those with an increased likelihood to 
respond well to medications. Through this use of PGx testing, it is argued that 
medications can be better targeted with the effect of minimising the risk of ADRs 
and maximising the therapeutic benefits of medications. This not only has the 
potential to improve patients’ experiences of their medication but is also widely 
argued to be a way of reducing the financial burden of ADRs (Department of Health, 
2003) which are estimated to cost the NHS around £2 billion annually (Compass, 
2008) and be responsible for 6.5% of all UK hospital admissions (Pirmohamed et al., 
2004). 
 
Pre-prescription testing, then, is argued to potentially offer a cost-effective 
way to identify the likelihood, and reduce the occurrence, of ADRs and non-
responsiveness in patients. Arguably the most common use of PGx pre-prescription 
testing is for the breast cancer therapy Herceptin where testing tumours’ protein 
expression identifies the 25-35% of patients whose tumours over-express the human 
epidermal growth factor receptor 2 (HER2) and will benefit from this medication. 
Given the ubiquitous use of HER2 testing in breast Oncology, Hedgecoe (2004: 99) 
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has described Herceptin as ‘the first example of a pharmacogenetic drug in regular 
clinical use’.  
 
Debates have appeared elsewhere about the cost-effectiveness of pre-
prescription testing for numerous medications across a diversity of disease areas (see 
Chalkidou and Rawlins, 2011; Veenstra et al., 2000). Central to these debates is the 
cost of providing testing compared with the cost of adopting a ‘trial and error’ model 
or testing efficacy through monitoring. With the decreasing cost and increasing 
speed of genotyping technologies, the parameters of these economic analyses are, 
however, subject to change. In a recent paper, Bowler et al. (2011) detail a dynamic 
chemistry approach to SNP testing where, they argue, identification of allelic 
variation could be undertaken at a significant time and cost advantage due to the 
circumvention of the need for complex assays and optimisation work. Hence, the 
potential for pre-prescription PGx testing to be undertaken for a relatively low cost 
within primary care clinical encounters is beginning to emerge as a realistic 
proposition.  
 
PGx, then, is a highly significant area of biomedicine and, as such, has been 
subject to examination by social scientists. Much of these analyses sit within a wider 
examination of the social impacts of genetics where sociologists have explored the 
implications of genetic testing for family (Lehtinen and Kääriäinen, 2005), doctor-
patient relationships (Cox and McKellin, 1999) and society as a whole (Tutton, 
2009). With respect to PGx specifically, Hedgecoe (2004) presents a comprehensive 
overview of the social and political implications of, and challenges posed by, PGx in 
drug discovery and clinical practice. Writing later, he also examined the differential 
degrees of uptake of PGx across medications and disease areas (Hedgecoe, 2008a). 
Within this, he argues that the limited integration in some medical specialisms 
should not be considered as ‘resistance’ but should, instead, be examined more 
sociologically. He posits, then, a framework of ‘clinical usefulness’ where he argues 
that PGx technologies are defined as useful or otherwise based on a number of social 
elements of practice such as clinician’s knowledge; differing interests between 
clinicians and researchers; clinical contexts; economics; and clinical cultures.  
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The uptake and integration of PGx has also been dealt with by other social 
scientists (see Hopkins et al., 2006; Martin et al., 2006; Webster et al., 2004). As an 
example, as part of a Wellcome Trust grant, Webster et al. (2004) identified five 
‘innovation options’ for the implementation of PGx into routine drug development 
and clinical practice. These were (i) using PGx to discover better drugs; (ii) using 
PGx to improve the safety of new drugs in development; (iii) using PGx to improve 
the efficacy of new drugs in development; (iv) using PGx to improve the safety of 
licensed drugs; and (v) using PGx to improve the efficacy of licensed drugs. In a 
later publication and following a number of other sociological projects on PGx, 
Martin et al. (2006) also identified disease stratification as a sixth potential area in 
which PGx may be useful. In addition to providing a sociological framework within 
which to understand PGx, these publications also demonstrate the centrality of 
sociological perspectives to the scientific work being undertaken in this area. 
Moreover, writing some years ago Allen Roses (2000: 857) of GlaxoSmithKline 
highlighted the ‘ongoing ethical debate concerning potential genetic applications and 
the impact on individuals and families’ as being central to PGx. More recently, 
Ozdemir (2011: 12) notes that ‘it is not just scientific and technical factors that are 
important to the uptake of innovative technologies’. Instead, he notes that the social 
implications of PGx are as central to the integrative landscape as the technology 
itself. PGx, then, is a highly relevant area for Sociology. 
 
 1.4 Why PGx in Pharmacy? 
Given the objective of PGx to better target medicines to improve safety and efficacy, 
the ‘promises’ (Hedgecoe and Martin, 2003) of PGx are well aligned with the 
discourses of medicines management which are central to pharmacy practice. Hence, 
both the paradigm of PGx and the practices (community and hospital) of pharmacy 
are underpinned by the same principles of safety, efficacy and personalisation. Given 
this, it has been argued elsewhere that PGx represents the ‘next challenge’ for 
pharmacy practice (Clemerson et al., 2006) and that pharmacists will be at ‘the 
forefront’ of PGx delivery (Ryan et al., 2004: 51) and will have an ‘essential role’ to 
play in future genetically-informed prescribing practices (Akhtar, 2002). The 
integration of PGx into pharmacy settings is likely to reorganise the everyday work 
of pharmacists around more genetically-defined patient bodies and medications. 
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Within this, the discourses and practices of risk which are central to medicines 
management are likely to take on a more molecular approach as the body becomes 
increasingly defined in such terms.  
 
Despite this, and the sociological importance of pharmacy, limited work has 
been done looking at the particularities of integrating PGx into pharmacy practice. 
What work has been done in this area is highly speculative, based on limited 
empirical evidence and has tended to come from disciplines outside of the social 
sciences. Given the constantly decreasing cost of genotyping and the shifts in 
practice which PGx will potentially entail, the present project is timely and relevant 
both sociologically and in terms of pharmacy and health policy.    
1.5 Thesis Overview 
Given this lack of empirical sociological work in the area of PGx and pharmacy, this 
thesis ascertains the perspectives of a variety of practitioners to understand the 
potential impacts of PGx on pharmacy in England. As such, it asks the following key 
research question; 
 
 What is the potential impact of pharmacogenetics on the everyday work of 
pharmacists practising in community and hospital settings?    
In addressing this question, three key sub-questions are asked and addressed in the 
empirical chapters; 
 
 How might the contemporary pharmacy practice landscape be sociologically 
characterised? (Chapter Six) 
 
 How are new technologies integrated into pharmacy in community and 
hospital settings and what effects do they have? (Chapter Seven) 
 
 What are the specificities of integrating PGx technologies into community 
and hospital pharmacy? (Chapter Eight) 
25 
 
The thesis starts with a literature review which expands the ideas and approaches 
highlighted above in asking Why Pharmacy? This chapter (Chapter Two) provides a 
narrative of the historical development of pharmacy and the sociological debates that 
this history has generated. In doing this, this literature review chapter traces a shift in 
sociological approaches to pharmacy from a relatively simplistic ‘Freidsonian’ trait 
approach to a more dynamic one based around the cultural role of pharmacists.  
 
Following on from this, Chapter Three expounds the ideas above in asking Why 
Pharmacogenetics? In doing so, this chapter describes the technical elements of PGx 
(i.e. why drug response variations occur), examines its historical development and 
outlines the sociological work which has been carried out in this area to date. In 
doing so, this chapter draws together scientific and social scientific literature to 
provide an overview of the contemporary PGx landscape.  
 
  Chapter Four presents an overview of the analytical frameworks which are 
used throughout the thesis to make sense of the empirical data. Within this, two 
broad frameworks are discussed as central to the later empirical chapters; Foucault’s 
(1994) ‘clinical gaze’ as a way of conceptualising professional approaches to the 
body and May and Finch’s (2009) normalisation process theory (herein NPT) as a 
tool for understanding the micro-level interactional work undertaken to integrate new 
innovations into routine practice.   
 
Chapter Five gives details of the methods used to gather the data. This 
chapter outlines the different practitioner groups which were interviewed, why these 
groups were targeted for inclusion and the particular challenges generated by 
conducting qualitative work with these practitioner groups. This chapter also details, 
and reflects on, the NHS ethics and governance process which was required for the 
interviews with NHS personnel.  
 
The remainder of the thesis comprises three analytical chapters, each dealing 
with one of the sub-questions highlighted above. Chapter Six, then, provides a 
sociological overview of the contemporary landscape of pharmacy in England. It 
draws on Serra’s (2010) notion of a ‘medical technocracy’ and Rabeharisoa and 
Bourret’s (Bourret, 2005; Rabeharisoa and Bourret, 2009) notion of a ‘bioclinical 
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collective’ to sociologically characterise the nature of practice and inter-professional 
relationships in the community and hospital setting. This chapter also offers a model 
of medicines management which is argued to be characterised by a dual approach to 
risk and toxicity. Within this, organisational interests in managing medicines are 
contrasted with medicines management practises which occur in everyday pharmacy 
work. Here, the novel concept of the ‘pharmacy gaze’ is developed to characterise 
the specific approach pharmacy takes to the patient body as a potential site of 
pharmacological risk.  
 
Chapter Seven uses these frameworks to offer an analysis of technology in 
pharmacy. This chapter deals with a variety of new technologies in pharmacy (for 
example, monoclonal antibody drug technologies; robots and electronic prescribing 
systems) and examines the ways in which these new technologies have the capacity 
to reorganise everyday work and professional boundaries in pharmacy settings. This 
chapter, then, demonstrates the ways in which May and Finch’s (2009) NPT and the 
dual medicines management model outlined in Chapter Six can be used to analyse 
the integration (or lack of integration) of new technological paradigms. This chapter 
concludes with a figure examining the themes which are important to analysing the 
integration of technology into pharmacy: the sector into which it is integrated; 
formalised, bureaucratisesd medicines management policies; and everyday working 
practices. This figure is re-visited in Chapter Nine where PGx technologies are 
positioned within this analytical table.  
  
These frameworks of analysis provided in Chapters Six and Seven are then 
employed in Chapter Eight where the particularities of integrating PGx into different 
pharmacy settings are examined. Here, community and hospital pharmacy are treated 
as two distinct landscapes given the different ways in which PGx is likely to be 
integrated and the divergent effects that this might have on practice in these two 
settings. In the hospital setting, the specialist area of Oncology is highlighted as a 
case study to demonstrate the ways in which PGx may become ‘normalised’ across 
disease areas. In the community setting, it is demonstrated that PGx has made 
limited impact due to the comparatively low severity of ADRs in this setting. Given 
this, and the lack of standardisation in community practice (as opposed to hospital 
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practice) a number of ‘macro’ and ‘micro’ challenges of integrating PGx into 
primary care are identified.  
 
In Chapter Nine, the analytical themes running through the thesis (the 
medical technocracy and bioclinical collective; the dual medicines management 
process; and the pharmacy gaze) are drawn together in a discussion of the 
implications of the thesis for pharmacists working in different sectors. In bringing 
the thesis together, the figure developed at the end of Chapter Seven is revisited in 
light of Chapter Eight’s analysis of PGx in pharmacy. As such, the particular issues 
in the integration of PGx into pharmacy are related to the themes (sector of practice; 
formalised medicines management policies and everyday practice) which intersect 
the integration of other technological forms. The thesis concludes by outlining its 
key implications for future research in the area of PGx and pharmacy and offering a 
number of recommendations for integrating PGx into pharmacy.  
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Chapter Two: Pharmacy: A Sociological Approach 
2.1 Introduction 
Chapter One noted that although pharmacy practice potentially offers a rich arena for 
sociological analysis, comparatively little work has been carried out in this area. The 
following chapter presents a review of the sociological literature as context for the 
subsequent conceptual and empirical analysis. The literature presented here has been 
identified through two methods. Firstly, ISI Web of Knowledge was used to identify 
sources where ‘pharmacy’, ‘pharmacy practice’ or ‘sociology of pharmacy’ were 
keywords or contained within the title of the work. These sources specifically 
discussing UK pharmacy practice (or those from other contexts, which were deemed 
highly relevant) were retained and those which dealt with the pharmacy practice 
landscape in other countries were discarded. These sources were then sorted by date 
in order to capture the most recent sociological writings in the area of pharmacy 
practice. Sources dating from before 2000 were only retained if they were deemed to 
be salient to the analysis being undertaken here.  
 
The second method used to identify literature was a ‘snowballing technique’ 
(Garrard, 2007). This technique involves using a publication’s reference lists as a 
resource for identifying other relevant sources, even where the publication used was 
not. Although academic and medical protocols often express a preference for the first 
method of literature identification described here, Greenhalgh and Peacock (2005) 
found that the latter snowballing method is often more efficient at identifying useful 
and highly relevant references. 
 
Based on these most relevant sources, this chapter is structured around a 
historical narrative of British pharmacy practice. Within this, sociological analyses 
are woven into understandings of the various periods of, and changes to, pharmacy 
practice. The chapter begins with the professional association of pharmacists with 
grocers through the guild system in the twelfth and thirteenth centuries and follows 
the development of pharmacy through to the contemporary era of ‘medicines 
optimisation’. Throughout this chapter there is a substantial focus on the professional 
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identity and status of pharmacy as this focus characterises much of the sociological 
literature in this area.  
 
2.2 Pharmacy’s History 
Prior to the seventeenth century, the ancient principles of Avicenna and 
Galen dominated the Western approach to medicine and medication
2
. From the 
European renaissance period onwards, knowledge and technological advances, such 
as Vesalius’ contribution to the understanding of anatomy in the early sixteenth 
century and the development of the microscope, meant that older medical models, 
largely based on humourism, lost their influence. Accompanying this was the formal 
organisation of medicine along the lines of specialist areas of expertise where 
boundaries of knowledge, and subsequently practice, were drawn (Freidson, 1970). 
The case of apothecaries and pharmacists is a good example of this.    
 
2.2.1 Apothecaries, Pharmacists and General Practitioners: Drawing Expert 
Boundaries 
The expertise and practice of apothecaries were originally associated with grocers 
through the guild system that emerged in the twelfth and thirteenth centuries as their 
everyday work was not understood to be wholly different (see Matthews, 1962: 29-
40 for an overview).  
 
As renaissance thinking saw the human body as increasingly complex, the 
specialisation of apothecaries was formally acknowledged in 1617 by the separation 
of apothecaries from the grocers’ guild by James I (Porter, 1999). The apothecaries’ 
charter stipulated that a seven year apprenticeship followed by an examination was 
necessary for apothecaries to keep a shop or make or sell any medicines within seven 
miles of London. Concurrently, by royal decree, only physicians were permitted to 
provide medical advice (Eaton and Webb, 1979). This formalised separation of the 
work of apothecaries from grocers, and physicians from other medical practitioners 
provided physicians with something of a monopoly over advice-giving and drew 
fairly rigid boundaries around their expertise and practice.  
                                                 
2
 So great was their influence on pre-enlightenment medicine that they are featured on the coat of 
arms of the Royal Pharmaceutical Society of Great Britain (RPSGB) (Anderson, 2001). 
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This medieval guild system, however, was highly localised and proved to be 
less than robust in light of increasing town populations during the industrial 
revolution (Parry and Parry, 1976). As such, given the increase in town populations, 
the development of an urban middle class and increased international migration, the 
localism on which the rigid boundaries and structures of the guild system depended 
were blurred. Hence, whilst many physicians crossed the boundaries of their practice 
and employed assistants to make medicines, similarly apothecaries began offering 
and charging for medical advice as the workload of physicians increased and an 
increasingly impoverished population were unable to pay for their expertise (Eaton 
and Webb, 1979).  
 
In blurring the practice boundaries in this way, nineteenth century 
apothecaries began to take on more general medical practice and provided the basis 
of what would later become GP work. As they expanded their practice jurisdictions 
in this way, their monopoly over making and dispensing medicines began to be 
challenged by druggists and chemists, who became skilled in using apothecary’s 
technologies and adopted the role of medicines makers and dispensers (Parry and 
Parry, 1976). In the UK, these druggists became commonly referred to as 
‘pharmacists’ and, in 1815, gained formal recognition and protection for their 
specialism with the passing of the Apothecaries Act. This Act stated that the work of 
pharmacists should continue as it had done prior to the passing of the Act with 
nothing affecting ‘the trade of business of a Chemist and Druggist, in the buying, 
preparing, compounding, dispensing, and vending of Drugs, Medicine and 
Medicinable Compounds, wholesale or retail’ (Matthews, 1962: 115). This Act 
represents a formal acknowledgement of pharmacists as experts in medicines and 
their associated ‘stuff’, which provides the basis for what Barber (2005) calls the 
‘pharmaceutical gaze’. The Apothecaries Act was followed by the Medical Act of 
1858 which separated ‘medical professionals’ from other medical or healthcare 
practitioners by establishing a register of all surgeons and GPs (those formerly 
known as apothecaries). In doing so, these practitioners became united as one 
‘medical profession’ around which professional boundaries were drawn (Eaton and 
Webb, 1979). Importantly here, pharmacists were not included within these 
boundaries of the new ‘medical profession’.  
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2.2.2 The Royal Pharmaceutical Society 
The encroachment by druggists and chemists on to the apothecary’s role of making 
and dispensing medicines led to the mobilisation of the former to protect their 
livelihoods against the re-establishment of the latter’s making and dispensing 
privileges. This mobilisation and organisation led to the development of a 
committee, which was later to become the Royal Pharmaceutical Society of Great 
Britain (hereafter RPSGB), now the Royal Pharmaceutical Society (herein RPS). 
This professional society was formed primarily to oppose an 1841 Bill which sought 
to enforce strict examination and licensing procedures on pharmacists and prevent 
them offering any medical advice or services (Matthews, 1962). The formation of 
this committee was, then, centred on a proposed erosion of pharmacists’ practice 
boundaries.   
 
  Following the defeat of the Bill, the need for a highly organised group to 
protect pharmacists and enhance the profession’s prestige (to protect it from any 
future boundary threats) was recognised. At a well-documented meeting on April 
15
th
 1841, in the Crown and Anchor Tavern in The Strand, a motion put forward by 
Jacob Bell, the son of a London pharmacist, for the formation of such a society was 
passed and the Pharmaceutical Society of Great Britain (PSGB) was formed  (Royal 
Pharmaceutical Society of Great Britain, no date). The Pharmacy and Poisons Act 
(1933) subsequently made clear the requirement for all pharmacists and their 
premises to be registered with the Society (Taylor et al., 2003). Despite being 
granted its royal charter in 1843, the Pharmaceutical Society did not become the 
Royal Pharmaceutical Society until 1988 when Queen Elizabeth II agreed that the 
name ought to incorporate the word ‘Royal’ (ibid.). Anderson (2001) notes that 
following the establishment of the PSGB the status of pharmacy increased and, as 
such, he argues the practice began to become professionalised. According to 
Anderson, this increase in status was also linked to a number of other events such as 
the development of a more formal curriculum and specific schools for pharmacists in 
London in 1842 and in forty five other towns at the turn of the twentieth century; the 
legal sanctioning of pharmacy multiples following a Court of Appeal ruling in 1880; 
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and the increase in the products and services that pharmacists offered to include 
toiletries and cosmetics and dental services
3
.  
 
This increase in the professional status of pharmacists can be understood as 
being related to the specific time in medical history in which it occurred. In the 
century following the formation of the PSGB the fields of pharmacology and 
analytical chemistry advanced significantly. These advances led to the discoveries of 
new and pervasive drug technologies, most notably several antibiotics which were 
heavily documented in scientific journals between 1877 and 1939 including 
penicillin in 1929 (Drews, 2000).  
 
These new drugs and the large pharmaceutical companies which were formed 
to manufacture them shifted the role and identity of pharmacists. As such, 
pharmacists’ everyday work moved away from compounding medicines to 
dispensing and offering advice on increasingly technical and standardised drug 
products which were becoming more available to the whole population. What this 
indicates, then, is that the early history of pharmacy can be understood sociologically 
by placing technological developments and innovation at the centre of the story.  
 
2.2.3. The Role of Technology in Drawing Expert Boundaries 
Within such a sociological analysis John Pickstone’s (2000) Ways of Knowing 
framework provides a useful analytical tool through which to examine the shifting 
role, identity and professional boundaries of pharmacy. This framework links 
science, medicine and technology (SMT) as mutually dependent on and co-
constitutive of the five ‘ways of knowing’ which have characterised medical practice 
from the seventeenth century onwards. In other words, Pickstone argues that the 
ways in which SMT understands and explains the world are central frameworks in 
shaping the ways in which medicine is practised. He posits the following five ways 
of knowing; 
4. Hermeneutics or ‘world readings’ refers to the textual rhetoric of medicine which 
limited physical intervention in favour of an interpretive model of illness. Within 
                                                 
3
 Many pharmacists offered dental services in their pharmacies and when the first dental register was 
taken in 1879, two thirds of the people on the list noted that they also practised pharmacy.  
33 
 
this, nature and its symbolism was prioritised as a way of understanding illness. 
This way of knowing was linked with religious explanations of illness where 
disease was understood as a punishment for sin.  
 
5. During the late sixteenth and seventeenth centuries, this hermeneutic approach 
was displaced by enlightenment rationality when the natural world and the 
illnesses within it were conceptualised as explainable and manageable rather than 
supernatural. Pickstone calls this second way of knowing ‘natural history’.  
 
6. Thirdly, ‘analysis’ as a way of knowing refers to the increasing rationalisation of 
medicine and the endeavours to discover and explain the composition of both the 
human body and the compounds which are used to treat it. Perhaps the best 
example of such an analytical endeavour is William Harvey’s discovery of the 
human circulatory system which replaced previous quasi-Galen theories of 
human blood (see Schultz, 2002).  
 
7. This analysis led to the fourth way of knowing which Pickstone terms 
‘experimentalism’ which involves the trial and error of various forms of 
innovative devices which formed the basis for medical diagnosis and treatment.  
 
8. The final way of knowing, for Pickstone, is ‘technoscience’ which refers to the 
contemporary structural form of SMT which is based on laboratory and industrial 
medicine and utilises a variety of innovative technologies, such as genomics, to 
understand the body, illness and cures. Links can be seen here with Clarke et 
al.’s (2003) biomedicalisation thesis where the body, and the medicines 
administered to it, increasingly mobilise innovation through technoscientific 
technologies and practices. 
His argument contends there is a connection between these ways of knowing, 
the medical technologies of the time and the extent to which medicine is understood 
as a ‘science’, which then impacts upon the professional identity of the actors 
involved. In a later work, he uses the example of orthopaedics to exemplify his 
model (Pickstone, 2006).  
34 
 
Orthopaedics, as a specialist branch of medicine, he argues, was reconfigured 
from an individualised craft which was disseminated through familial ties, to a 
mainstream medical practice rooted in a technoscience way of knowing. Within this 
process of change, the nature of the body and prosthesis were analysed (i.e. in 
understanding the ways in which joints move) and experimented with (i.e. in using 
different materials to optimise prosthesis). These ways of knowing the body and 
prosthesis were particularly prominent in the early twentieth century when 
orthopaedics became central to wider social shifts such as rapid urbanisation (with 
many workers requiring treatment for broken bones sustained during construction 
work); the dominance of manufacturing (with many workers requiring accident 
services for injuries sustained at work); the occurrence of two world wars (with the 
‘reconstruction’ of soldiers following injury being a key priority); and the increasing 
availability of motor cars (with an increase in the number of accidents involving 
them).  
 
The changes made in the ways of knowing in orthopaedics influenced a 
change in the status of the field as a ‘science’ and the professional status of the actors 
working within it. Hence in the early history of orthopaedics, the practice was 
carried out by individuals who were seen as craftsmen rather than professional 
medical practitioners and whose specialist status was rooted in the local community. 
After early periods of analysis and experimentalism, orthopaedic practitioners were 
configured as specialist medical professionals and their practice relocated to the 
hospital setting. As such, the professional status of orthopaedic specialists became 
entwined with their engagement with advanced technologies developed by industrial 
companies.  
 
Pickstone’s model can also be employed to understand the early history of 
pharmacy. Within this, pharmacists’ professional association with grocers through 
the medieval guild system places pharmacy (and grocery) in an unspecialised 
hermeneutics way of knowing. During the sixteenth century, pharmacy adopted more 
of an analytical way of knowing as the natural history of plants became widely 
documented (for example, William Turner’s Herbal, published in three volumes 
between 1551 and 1568 (see Hoeniger and Hoeniger, 1973)). Following this, the 
medicinal uses of the plants described in these publications began to be explored (for 
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example, in William Salmon’s The Practice of Curing, published in 1681) and 
pharmacy took on a more experimental way of knowing. Within this, the 
professional status and specialisation of pharmacy was formalised through the 
granting of the apothecaries guild in 1617. More recently, pharmacy could be 
understood to have entered into Pickstone’s technoscience way of knowing where 
practice is based on the use of complex, technical devices and medications. Within 
contemporary pharmacy practice (particularly in community practice), however, 
elements of an experimentalist way of knowing can still clearly be seen with the 
predominance of trial-and-error prescribing and dispensing models. This is discussed 
in more detail in Chapter Eight. For now this chapter turns to an examination of the 
effects of this early history on the professional identity of pharmacy and the ways in 
which this has been interpreted in sociological literature.  
2.3 The Pharmacy Profession? 
Anderson (2001) argues that following the formation of the PSGB, pharmacy 
became increasingly professionalised. Even so, although undoubtedly the formation 
of a professional body and the protection from boundary encroachment that it offered 
influenced the development of a more professional identity for pharmacy, the extent 
to which pharmacy can legitimately be regarded as a ‘profession’ is subject to much 
debate within the sociological literature in this area. Much of this debate centres on 
Freidsonian ‘trait’ analyses of pharmacy practice.  
 
 Briefly, Freidson’s (1970) classical sociology of professions work argues that 
a profession is a ‘special kind of occupation’ associated with certain characteristics 
or traits which make it different from, and superior to, less professionalised 
occupations. Taylor et al. (2003)  note that being a profession, rather than an 
occupation, is not related to the intrinsic superiority of the former’s knowledge and is 
instead a process of convincing what Freidson (1970: 72) calls an ‘elite segment of 
society’ that the sector’s work is of special value. In STS scholarship, Mclaughlin 
and Webster (1998) refer to this process as the ‘professional project’ whereby a body 
of expert knowledge and the professional identity develop concurrently, affecting 
each other and carving out the jurisdiction over which that given profession will 
preside. Wright (1979) exemplifies the importance of the professional project to the 
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successful understanding of an occupational sector as a profession. Comparing the 
fields of astrology and medicine (both of which espoused unproven theories about 
illness prior to the renaissance period), he argues that the success of medicine over 
astrology was due to the superior social positioning of medicine’s clients who were 
able to influence lay public and governmental opinions of, and discourses 
surrounding, medicine (also see Freidson, 1970: 72-73).  
 
 In the case of pharmacy, Freidsonian trait approaches are dominant in 
understanding the sectors’ professional identity. As an example, Taylor et al. (2003) 
adopt such a Freidsonian trait approach in understanding pharmacy as a profession 
based on a number of features of practice. I discuss this argument here, offering 
alternative views along the way.  
 
Firstly, according to Freidson, a profession occupies a dominant position in 
an occupational division of labour and has an autonomous monopoly over the area in 
which it specialises. Taylor et al. (2003) argue that this trait is evidenced in the 
pharmacy profession as only registered pharmacists are able to join the RPS and only 
registered pharmacists are permitted to sell Pharmacy Only Medicines. In contrast, 
writing some years ago, Denzin and Mettlin’s (1968) classic paper on pharmacy 
argues that pharmacists do not have autonomy over the area and products around 
which their practice is centred as the act of dispensing medications is most 
commonly done under the orders of a doctor. As such, control over what medications 
to provide lies with the doctor and not the pharmacist. This is also echoed by the 
assertion that pharmacists still ‘take their lead from physicians’ (Harding and Taylor, 
2002: 443). Moreover, the following quote from a community pharmacist in Hughes 
and McCann’s (2003: 604) study of inter-professional communication demonstrates 
the hierarchical organisation of community pharmacy work;  
The GP sits with his prescription pad and until he does something 
with it, we sit with our degrees, impotent, until we get the piece of 
paper. He is the instigator, the prescriber is the instigator of the 
whole thing. 
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Cooper et al. (2009) identify this relatively low status of community 
pharmacy as being manifested in challenges in everyday practice. As such, the 
community pharmacists that they interviewed highlighted this subordination as 
contributing to ethically challenging situations in everyday practice where their 
professional status meant that they felt unable to challenge GPs’ prescription 
decisions despite their being aware of potential toxicity. Additionally, Cooper et al. 
(2009) argue that the structure of primary care fosters a professional identity for 
community pharmacists as ‘islands’ and as ‘doctors’ tools’. Inasmuch, the relative 
isolation of community pharmacy practice and its mediation through GP’s 
prescribing work are argued to be central to the subordinate professional identity of 
community pharmacy.  
 
 In addition, the increasing number of pharmacists working in large multiple 
organisations or supermarkets
4
 is understood to limit the extent of community 
pharmacy’s autonomy given the routinisation of work in these settings (McDonald et 
al., 2010). In these large multiple and supermarket pharmacy environments it is 
argued that interactions between patients and pharmacists become based around 
‘asking structured, formulaic questions’ rather than those devised autonomously by 
pharmacists using their pharmacological expertise (Harding and Taylor, 1997: 556). 
The result of this is the corporatisation of community pharmacy and the emergence a 
‘breed of ‘McPharmacists”’ undertaking routinised work within large corporate 
organisations (Bush et al., 2009: 307 (emphasis in original); Harding and Taylor, 
2000). 
 
 It has also been argued that pharmacy’s autonomy over medications has been 
further eroded by the increasing deregulation of medicines which has opened up 
knowledge and control of medications to the lay public (Hibbert et al., 2002). This 
erosion of pharmacy’s monopoly over medications can be understood as part of a 
wider process of declining medical hegemony where expert medical knowledge 
administered in clinical settings is being eschewed in favour of information from the 
internet being consolidated by ‘expert patients’ (Shaw and Baker, 2004). As an 
example of this erosion of medical hegemony, Fox et al. (2005) examined the way in 
                                                 
4
 In a 2008 pharmacy workforce census, Sesston and Hassell (2009) found that 54% of community 
pharmacists were employed in large multiples whilst 12.2% worked in supermarkets.  
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which people ‘suffering’5 from anorexia undermine the monopoly of both GPs and 
pharmacists by ordering drugs intended to treat obesity from the internet without any 
clinical intervention. Such questioning and foregoing of medical expertise is most 
commonly located within sociological analyses of late-modernity.  
 
Secondly, Taylor et al. (2003) point to the requirement for pharmacists to 
complete a four year undergraduate degree, one year’s pre-registration training and a 
registration examination as evidence of their specialised knowledge and, thus, 
professional status. This fits with Freidson’s (1970) perspective of professionals 
where objective proof of expertise through specialist training is central to a 
professional identity. Despite this extensive education, the extent to which pharmacy 
counter assistants and doctors share some elements of this specialised knowledge 
could be understood as undermining these expertise claims.  
 
Thirdly, Freidson identifies the service-orientation and professional 
trustworthiness as traits which define a profession. The extended role of pharmacy 
(see below) is argued by Taylor et al. (2003) to be evidence of this orientation 
towards patient services and confirmation of the independent trustworthiness of 
pharmacists’ knowledge and advice. However, in an earlier publication Harding and 
Taylor (1997) noted that the expectation of professional altruism and impartial 
medical advice is challenging for community pharmacists to negotiate as they 
experience ‘role strain’ due to heir somewhat paradoxical roles as both health 
advisors and retailers. This retail focus is central to the vast majority of sociological 
analyses of community pharmacy given the importance of retail activities in 
community pharmacists’ everyday work. In their seminal paper, Denzin and Mettlin 
(1968) identify retail work as being central to limited professionalisation in 
community (or ‘retail’ as it was at the time of their paper) pharmacy. More recently, 
the professional identity of community pharmacists has been argued to be tied into 
this ‘shopkeeper’ (Masongo, 2005) image which is pervasive amongst both patients 
and practitioners. Rapport et al. (2010) argue that this leads pharmacists to 
experience an ‘identity crisis’ given their dual role as medications dispensers/sellers 
                                                 
5
  The application of the term ‘suffering’ to anorexia is problematic as, although the participants in 
Fox et al.’s study acknowledged anorexia as a disease, they took an ‘anti-recovery’ stance, whereby 
they were keen to maintain their status as ‘pro-anas’ and reluctant to adopt biomedical programmes of 
rehabilitation.      
39 
 
and healthcare practitioners. They conceptualise this as leading to ‘double alienation’ 
of community pharmacists and elsewhere Harding and Taylor (1997) have 
characterised the pressure of providing both clinical and retail services as ‘role 
strain’ whilst Hibbert et al. (2002: 49) note that the re-branding of ‘retail pharmacy’ 
as ‘community pharmacy’ hints at the professions’ own acknowledgement of ‘a 
tension between commerce and professionalism’.  
 
Fourthly, Freidson argues that self-regulation is central to professional status. 
The ability to self-regulate is understood by Freidson to be justified on three 
grounds; (i) that the level of skill and knowledge within the profession means 
outsiders are ill-equipped to act as regulators; (ii) that professionals are responsible 
and do not require constant external regulation; and (iii) that professionals are 
trustworthy enough to be entrusted to regulate themselves effectively. The existence 
of internal regulatory bodies, most recently the General Pharmaceutical Council, is 
argued by Taylor et al. (2003) to be evidence of these three characteristics and, thus, 
the ability to self-regulate.  
 
The case of medicine in the UK provides an interesting insight here. 
Although medicine is largely self-regulating and therefore fits Freidson’s model of 
defining a professional well, its ability to self-regulate is not a stable facet of 
contemporary practice and is subject to change according to political and public 
discursive and attitudinal shifts. Hence although medicine’s ability to self-regulate 
has been somewhat limited, it has still retained its professional dominance. Ham and 
Alberti (2002) note that the establishment of the NHS in 1948 marked the political 
enshrinement of a ‘compact’ between the public, the government and the medical 
profession which allowed the medical profession to ensure high clinical and care 
standards through self-regulation. Although the professional knowledge and 
competence of medicine was taken for granted within the compact through the 
prevailing discourse of ‘doctor knows best’, its dominance as a model for 
public/government/medical relations was not enduring and from the 1960s onwards 
it began to weaken as a result of increased visibility of patient groups, public 
identification of poor clinical and care standards and frequent demands for increased 
budgets by doctors keen on technological innovation. Ham and Alberti argue that 
over the course of the next thirty years, a number of incremental changes occurred in 
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the NHS which undermined the public/government/medical compact and decreased 
the freedom of self-regulation that doctors had previously enjoyed. As such, an 
increased public voice within the NHS (both at the macro policy-making level and at 
the one-to-one doctor/patient encounter level) served to shift the relationship 
between the public, the government and the medical profession to one where the 
latter was not all-powerful (Ham and Alberti, 2002). In particular the move towards 
‘new managerialism’ within the NHS during the 1980s shifted the balance of power 
between doctors, the government and the public as doctors were forced to become 
more accountable for their clinical and care standards, which undermined the self-
regulation ability that doctors had had previously. Moreover, the professional skills 
and expertise of the doctors, which formed much of the rationality behind their 
ability to self-regulate, were sidelined in the new managerial discourse by an 
increased focus on effective budgeting, cost reduction, patient satisfaction and turn-
around times (Ham and Alberti, 2002; Poole, 2000).  
 
Ham and Alberti (2002) note that more changes occurred within the NHS 
since New Labour was elected in 1997 than in the preceding forty nine years 
following the creation of the NHS. Although the Conservative doctrine of new 
managerialism within the NHS continued to redesign the relationship between the 
public, the government and doctors, the extent to which the state could restrict 
medical self-regulation was limited following defensive responses to governmental 
attempts to invade the traditional medical territory of self-regulation (see Salter, 
2004). Salter narrates the period at the beginning of New Labour’s period in office 
when the ‘policy window’ (2004:122) opened following the Bristol Royal Infirmary 
and Alder Hey organ retention scandals and the discovery of the serial murders 
committed by GP Harold Shipman and New Labour’s subsequent attempts to limit 
the self-regulation of medicine. He argues that despite the establishment of numerous 
regulatory bodies and the issuing of several official documents, the response from 
the medical profession was negative which, coupled with the government’s lack of 
managerial capacity to overhaul the regulatory model of the NHS, meant that the 
government were forced to retreat from the medical professions regulatory territory 
and allow self-regulation to continue. In other words, although medicine is still self-
regulated to some extent, its regulation exclusively by medical professionals has 
been stunted. What this means is that self-regulation and autonomy are not always 
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traits to be associated with professional status as medicine has become less able to 
self-regulate but has nonetheless retained a professional status.  
 
In addition to Freidson’s analysis of professions, Johnson’s (1977) idea of 
‘mystification’ in everyday practice can also be considered in regard to pharmacy. 
Johnson argues that a sense of mystery around the activities and expertise of 
professionals is a key characteristic of a professional identity. Although many of the 
activities of pharmacists are fairly invisible (i.e. carried out in community or hospital 
dispensaries to which the public do not have access), Harding and Taylor (1997) 
argue that there has been a decline in the mystification of the work of pharmacists 
due to the advent of large scale drug production in the latter half of the twentieth 
century. Whilst pharmacists’ compounding skills and detailed knowledge of 
medicines were once exclusive of the lay public, the ubiquity of pre-packaged 
medicines has largely displaced this compounding role. Moreover, the patient 
information leaflets (PILs) which are supplied with these pre-packaged medicines 
codify and black-box pharmacists’ expertise in pharmacology for patient 
consumption; in this way the mystification of pharmacists’ pharmacological 
expertise could be understood as being undermined. On the other hand, Bjerrum and 
Foged (2003) found that even when companies were manufacturing identical 
products, their PILs did not provide identical information. This led to an increased 
need for pharmacists’ expertise where the mystified knowledge of pharmacists was 
configured as increasingly important given the shortcomings of the codified 
information in PILs.  
 
 In short, the above review suggests that pharmacy possesses some of the 
traits which might define it as a profession but does not possess the degree of 
autonomy associated with other professional practices, especially medicine. Denzin 
and Mettlin (1968) characterised pharmacy as a ‘quasi-profession’ because of this.  
This characterisation echoes Freidson’s notion of ‘paraprofessional’ practice where 
he argued that paraprofessional practices mimic many of the activities of professions 
such as the formation of professional groups; the development of a code of ethics; 
the creation of a specific curriculum for training novices; and the development of a 
licensing process. However, he argued that paraprofessionals occupy a lower 
position in the division of labour and are never fully granted autonomy in their work. 
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Denzin and Mettlin (1968) suggested that community pharmacy underwent a process 
of ‘incomplete’ professionalisation during its formation in the nineteenth century 
because of its failure to create an exclusive knowledge base; its failure to refrain 
from profit-making and advertising; and, above all, its failure to gain complete 
control over the objects around which its everyday work is centred (i.e. drugs).  
 
 Denzin and Mettlin’s (1968) paper is seminal in pharmacy practice research 
and somewhat enshrined the ‘trait’ approach as a standard for sociological analyses 
of pharmacy practice. More recently, Dingwall and Wilson (1995) have offered a 
critique of Denzin and Mettlin’s (1968) paper challenging this trait approach to 
understanding professions and professional identities. They argued that adopting a 
trait approach does little more than allow researchers to point out where occupations 
and professions demonstrate (or do not demonstrate) professional traits rather than 
analyse the context in which these traits become culturally significant. Specifically, 
they argued that Denzin and Mettlin’s assertion that pharmacists failed to gained 
control over the object around which their practice is based, fails to distinguish 
between drugs as material objects and drugs as a basis for social action. As such, 
they proposed that pharmacy practice and its professional identity should be 
understood sociologically in terms of the cultural role of pharmacists in symbolically 
transforming chemical compounds into socially meaningful objects of drugs. 
Harding and Taylor (1997) concur with this more dynamic analysis and argued that 
pharmacists are socially sanctioned to carry out this cultural role and imbue 
medications with particular social meaning for the benefit of patients.  
 
Although some sociological analyses have tentatively moved away from a 
Freidsonian trait approach to pharmacy, the relative status of pharmacy as a 
profession is still an important analytical framework given the nature and structure of 
contemporary pharmacy work. Most of these analyses have tended to (and continue 
to) focus on community pharmacy whereas hospital pharmacy work has tended to be 
neglected. As such, most of the questions about the professional status of pharmacy 
are really questions about the professional status of community pharmacy. 
Nonetheless, the following section shows how the late twentieth century changes to 
the nature of pharmacy work affected those practising in both community and 
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hospital settings. Moreover, the later analytical chapters in this thesis deal with the 
sociological importance of both community and hospital practice.  
2.4. Pharmacy in the Late Twentieth Century: Shifting Professional 
Boundaries  
In the latter half of the twentieth century, pre-packaged medications produced by 
large pharmaceutical companies removed the need for pharmacists to compound 
their own medicines. This led to concerns around de-skilling, particularly in 
community pharmacy where Eaton and Webb (1979: 73) argued that they became 
‘over trained for what they do and under-utilised in what they know’. Davey (1983) 
argued that this could be financially problematic for the NHS with patients using up 
GP appointments where the expert knowledge of pharmacists’ would be sufficient 
or, in the case of questions about medications, more appropriate. These concerns 
were addressed in the National Pharmacy Association’s 1982 Ask Your Pharmacist 
campaign and by a 1986 report by the Nuffield Foundation which suggested an 
‘extended’ role for community pharmacists. This extended role expanded the 
community pharmacy contract to provide extra clinical services  through prescribed 
medicines management; chronic illness management; common ailments management 
and the promotion of healthy lifestyles (Harding and Taylor, 1997). Much of this 
was undertaken under the rubric of the Pharmacy in a New Age (PIANA) strategy, 
which was launched by the Department of Health in 1995. This strategy was, and 
continues to be, a gradual process of change in community pharmacy within which 
the boundaries of practice are shifted towards a more clinical focus (Longley, 2006; 
Parkin, 1999). This extended role, and the initiatives such as PIANA which existed 
around it, somewhat shifted the professional identity of pharmacists as they became 
reconfigured as healthcare practitioners (Anderson, 2001). As such, pharmacy 
shifted from product-based to more clinically focused (Benson et al., 2009; Petrakaki 
et al., 2012). Moreover, their increased clinical work and one-to-one contact with 
patients altered the spatiality of community pharmacy practice in relocating 
pharmacists outside of the dispensary. In doing so, pharmacists became discursively 
posited as ‘first port of call’ for patients (Anderson, 2001: 23). 
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 More recently, the government published a White Paper in 2008 outlining the 
ways in which pharmacy’s extended role will be shaped in the future. In terms of 
practice, Pharmacy in England: Building on Strengths- Delivering the Future 
(Department of Heath, 2008) advocates that pharmacies and pharmacists ought to 
concentrate on expanding access to clinical services, supporting healthy living and 
lifestyles and providing better care for patients managing long-term conditions. 
Within this, the report recommends that community pharmacies become ‘healthy 
living centres’ where the public are able to obtain information about preventative 
health strategies such as nutrition and exercise, as well as about medications for both 
acute and chronic conditions. What this suggests is that contemporary policy is 
instrumental in shifting the professional identity, and practice boundaries, of 
community pharmacists.  
 
 This extension of the role of pharmacists into more clinical practices also 
affected hospital pharmacists where a report by the RPSGB (1977) suggested that; 
 
There is an important role for pharmacists to play in direct contact 
with patients on all matters concerning medication. On the 
patient's admission, pharmacists can take the previous medication 
history; because of their specialist knowledge they can make an 
invaluable contribution in the selection of the drug treatment for 
the patient; they can monitor the progress of the medication, 
particularly in relation to possible side effects or adverse 
reactions; and they can counsel a patient on the proper use of 
drugs and medicines both in the hospital and when they return 
home  
 As in community settings, this extension of pharmacy work reconfigures 
pharmacists as healthcare professionals whose pharmacology expertise and 
pharmaceutical gaze (Barber, 2005) are of benefit to both the hospital organisation 
and the patient. In the hospital setting, this extended role was implemented, arguably, 
more readily than in the community setting given the increasing standardisation in 
hospital pharmacy and the absence of retail pressures.  
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 In both settings, the expansion of pharmacy’s professional role shifted the 
boundaries of practice and the professional identities of practitioners. Historically, 
Eaton and Webb (1979) argue, medical professionals have been anxious about 
paramedical occupations (such as pharmacy) encroaching on their traditional roles 
and duties and eroding their professional hegemony. As such, the shifting boundaries 
of the extended role which expanded pharmacy’s jurisdictions to include more 
clinical activities created sociologically interesting questions about potential 
boundary encroachment by pharmacists. More recently, the shifting of pharmacy’s 
jurisdictions to include supplementary and independent prescribing has also raised 
these boundary encroachment issues (Avery and Pringle, 2005). These issues can be 
understood with regards to Gieryn’s (1983) boundary work framework.  
 
Briefly, Gieryn (1983) draws on the examples of anatomy and phrenology in 
the nineteenth century to demonstrate the demarcation of ‘science’ (anatomy) from 
‘non-science’ (phrenology). He argues that boundary work is the process of groups 
drawing on their cultural and professional repertoires to define themselves and their 
expertise for the lay public and its authorities (Freidsons’s elite segment of society). 
In doing so, groups which become defined as ‘science’ are able to maintain their 
professional status and autonomy and lay legitimate claim to resources. They then 
secure a privileged position within the ‘intellectual ecosystem’ which makes them 
largely immune from government regulation and enables them to enjoy the social 
status of experts and the advantages associated with it (such as being called upon as 
a reliable expert witness in a court of law).  
 
The most common sociological analyses of boundary work within medical 
practices tend to centre of the negotiation of professional boundaries between 
doctors and nurses within the hospital setting (see Allen, 1997; Wicks, 1998). Much 
of the focus of these analyses tends to be the official boundaries which are drawn 
between high-status doctors and low-status nurses and the concurrent expectation 
that nurses will transcend this boundary for the benefit of both patients and doctors 
but not expect the official boundaries of their work to be moved into the professional 
territory of doctors. Additionally, Mizrachi et al. (2005) point to the boundary work 
which perpetually occurs between co-located biomedical and complementary and 
alternative practitioners. They argue that biomedical practitioners have been able to 
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draw on their cultural repertoires to discursively construct alternative practitioners as 
unreliable and unscientific which serves to maintain the hegemony of the biomedical 
practitioners.  
 
Contrary to concerns about the potential encroachment of pharmacists onto 
the jurisdiction of medical practitioners, Eaton and Webb’s (1979) empirical data 
suggested that doctors were willing to delegate or relinquish certain tasks to 
pharmacists as part of their clinical work. Eaton and Webb (1979: 85) argue that a 
‘negotiated’ settlement between medical practitioners and clinical pharmacists was 
reached whereby pharmacists accept the responsibility of medics in return for 
permission to practice certain ‘medical activities’. In the hospital setting they found 
that pharmacists most often shifted their boundaries into areas which medics have 
previously neglected, such as patient counselling or ADR monitoring. In doing so, it 
is argued that pharmacists take on some of medicine’s ‘dirty work’. 
 
More recent work by Edmunds and Calnan (2001) also found that these 
concerns about boundary encroachment as a result of increased clinical work in 
pharmacy were unfounded in everyday practice. In their empirical study of 
community pharmacists involved in extended role projects, they found that 
pharmacists drew relatively rigid boundaries between their role as dispensers and 
doctors’ role as prescribers within the patient care team. As such, pharmacists were 
keen not to encroach on the work of doctors, particularly in relation to the 
management of chronic conditions, and discursively configured themselves as a 
point of guidance for patients rather than a substitute for doctors’ advice. Eaton and 
Webb’s (1979) and Edmunds and Calnan’s (2001) papers suggest that the boundary 
work between medical and pharmacy practitioners in both community and hospital 
setting is somewhat less pressing than that of Gieryn’s nineteenth century anatomists 
and phrenologist.  
 
2.4.1 The Extended Role as a (Re)Professionalisation Project 
According to Edmunds and Calnan (2001), the development of an extended role in 
community (and hospital) pharmacy can be understood as an attempt to 
(re)professionalise the sector. In the US context, Birenbaum (1982) presents this 
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(re)professionalising project as an attempt to maintain prominence for pharmacy in 
the context of increased routinisation and uncertain financing of healthcare and 
pharmaceuticals. Pharmacists’ participation in extended role projects (such as 
adherence services; ADR monitoring; and chronic illness management) is 
understood by Edmunds and Calnan as a way for pharmacists to redefine their status 
as professionals and take full advantage of their training and expertise. Hence, the 
pharmacists in Edmunds and Calnan’s (2001) study understood the extended role as 
a positive (re)professionalising strategy for community pharmacy. In contrast to this, 
Harding and Taylor (1997) argued that the extended role as recommended in the 
1986 Nuffield Report had, after ten years, ultimately failed to make significant 
impacts on the professional status of community pharmacy for a number of key 
reasons outlined below. They argued, instead, that the extended role has actually had 
a de-professionalising effect on community pharmacy in focusing too heavily on 
non-medicines related activities.  
 
Firstly, they argued, the extended role does not acknowledge that professional 
status is based on the exclusivity of expert knowledge and the creation of a chasm 
and power imbalance between experts on the one hand and the lay public on the 
other. Here, Johnson’s (1977) notion of ‘mystification’ again becomes central. 
Harding and Taylor argued that the extended role is flawed in that it does not 
capaitalise on this chasm and instead concentrates on promoting services which are 
centred around technological devices (i.e. testing devices) which routinise work and 
undermine pharmacists’ claims to expertise (see Ritzer and Walczak, 1988). 
Moreover, they argued, the extended role necessitates pharmacists offering advice on 
non-medicine related issues, such as smoking cessation, which undermines their 
rightful claims to expert status in the field of medicines.  
 
Secondly, the extended role fails to take into account the relatively limited 
autonomy of community pharmacists employed in large multiples, which contrasts 
with Freidon’s (1970) understanding of professional identity. Moreover, part of the 
extended role involves the provision of medicines advice services for patients which 
is based around a set of protocols. This protocol standardisation, Harding and Taylor 
(1997: 556) argued, removes the ability for pharmacists to use their professional 
judgement, curtails the scope for pharmacy-patient relationships (see Worley et al., 
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2007) and reduces their interactions to ‘nothing more than asking structured, 
formulaic questions’.   
 
Thirdly, the 1982 Ask Your Pharmacist campaign regarded community 
pharmacists as a first port of call for patients who did not want to ‘waste’ doctors’ 
time (Harding and Taylor, 1994). The necessity of pharmacists being available all of 
the time without appointments or gatekeepers undermines a fundamental principle of 
a professional identity, which is the organisation of time by the professional. 
Harding and Taylor (1997: 556) contended that patients’ ability to make immediate 
demands on pharmacists’ time serves to ‘demystify and devalue’ the skills and 
judgements of pharmacists.   
 
Finally, as mentioned, a key social role of pharmacy is the symbolic 
transformation of inert chemicals into socially meaningful objects of medications. 
Harding and Taylor (1997) argued that the jurisdictional reconfiguration following 
the implementation of the extended role has meant the delegation of many 
dispensing activities to pharmacy counter assistants in order for pharmacists to 
undertake more clinical activities. There is potential, then, for the dispensing process 
to be undertaken without the input of a professional. This removes the opportunity 
for pharmacists to enact the process of imbuing medications with social and cultural 
meanings which sociological analyses have identified as being central to community 
pharmacy’s professional identity.  
 
More recently, in a study of EPS in community pharmacy, Petrakaki et al. (2012) 
centralise technological innovation in the professionalisation question which fits into 
a wider sociological focus on the role of technologies in shaping professional work, 
identity and jurisdictions. Petrakaki et al. (2012) argue that the integration of EPS 
into community pharmacy changes pharmacists’ everyday activities in the areas of 
nature of work; professional values; professional roles; jurisdictions; boundaries; and 
power. For example, they demonstrate the ways in which increased automation as a 
result of EPS may reconfigure the nature of work by altering the materiality, 
temporality and manual aspects of pharmacy activities. As such, EPS may eliminate 
paper in community pharmacy work; allow pharmacists to pre-dispense prescriptions 
(also see Motulsky, 2008); and remove the need for pharmacists to manually 
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population patients’ demographic information. The consequences of the changes in 
these areas of everyday practice are not linear or deterministic and instead, they 
argue, open up the possibility of simultaneous de- and re-professionalisation of 
community pharmacy. Inasmuch, they argue that de-professionalisation may occur in 
four key ways; (i) by shifting the temporal and spatial aspects of community 
pharmacy work; (ii) by eroding inter-professional trust through a depersonalisation 
of communication with other healthcare practitioners; (iii) by rendering community 
pharmacy more visible and opening up opportunities for governmental control; and 
(iv) by expanding pharmacy’s professional boundaries to other occupational groups 
with different professional values- in doing this professional identities become 
blurred and, they argue, being a professional ‘could mean anything and therefore 
nothing’. Running concurrently to this, they identify three key ways in which EPS 
may re-professionalise community pharmacy; (i) by freeing pharmacists from 
mundane tasks to allow them to undertake more challenging clinical activities; (ii) by 
expanding community pharmacy’s jurisdictions and allowing them to exercise more 
discretion and professional judgement; and (iii) by expanding professional 
boundaries and allowing pharmacists to become more integrated in the ‘NHS 
family’.  
 
This final point is also echoed by Barrett et al. (2011) in their study of the 
integration of robots into hospital pharmacy settings. They note that pharmacy robots 
reorganise professional relationships and boundaries throughout the hospital 
structure. In doing so, pharmacy assistants’ everyday work became increasingly 
focused on the maintenance of the robots (i.e. fixing technical problems and 
restocking) whilst pharmacists were freed from mundane dispensing tasks and able 
to undertaken more clinical work away from the dispensary. This reconfiguration of 
pharmacists’ work and jurisdictions, Barrett et al. (2011), argue, allowed pharmacists 
to become further integrated into medical teams and increased their ‘institutional 
legitimacy’. This can be understood in line with Petrakaki et al.’s (2012) analysis as 
a re-professionalising consequence of technology in everyday work.  
 
So far this chapter has examined the historical context of pharmacy in the UK 
from its association with grocers in the medieval guild system to the increase in 
clinical pharmacy during the latter half of the twentieth century. In order to 
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contextualise the later sociological analyses in this thesis, the chapter now turns to an 
overview of contemporary pharmacy practice primarily drawing on the most recent 
(2008) RPS Pharmacy Workforce Census.  
2.5 Contemporary Pharmacy Practice 
2.5.1 Demographic Data 
At the time of the 2008 RPS workforce census, there were 48,749 registered 
pharmacists in Great Britain (England, Scotland and Wales). Of those actively 
employed
6
, 71% worked in community pharmacy, making it the most common 
source of employment for British pharmacists. Within community pharmacy there is 
a degree of heterogeneity in employment patterns with pharmacists working in 
independent (30.2%), small chain (11.8%), medium chain (12.9%), large multiples 
(54%) and supermarket (12.2%) pharmacies. Moreover, pharmacists often work in 
multiple locations (hence these percentages totalling more than 100). The nature of 
work in these different community pharmacy settings can be highly divergent with 
large multiples, generally, restricting the autonomy of pharmacy employees given 
the focus on profit-generation.  
 
 The 2008 census highlighted that 21.4% of British pharmacists were 
employed in hospital settings making it the second largest sector of employment. 
Hospital practice is characterised by a banding system based on expertise, experience 
and responsibility and specialisation in specific disease areas or pharmacy practices. 
Hence, where community pharmacists are fairly generalist practitioners, hospital 
pharmacists practise in a specific area of medicine (such as Oncology or Cardiology) 
and/or a specific practice (such as aseptic manufacturing). Table 1 shows the 
breakdown of employment patterns in contemporary UK pharmacy.   
 
 
 
 
                                                 
6
 Actively employed refers to pharmacists actively practising their profession in a pharmaceutical 
setting of some description and is different from simply being registered as member of the RPS, 
which all qualified pharmacists (practising or not) are required to do. 
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Sector Percentage of active pharmacists 
Community 71.0 
Hospital 21.4 
Primary Care 7.2 
Industry 4.1 
Academia 2.8 
Other 3.8 
Table 1: Proportion of actively employed pharmacists working in each sector. Taken from 
Seston and Hassell. (2009: 20). 
This table shows that smaller proportions of active pharmacists are employed 
in primary care, industry and academia. Primary care pharmacy is a relatively 
modern phenomenon and so relatively neglected in the academic literature. Primary 
care pharmacists are, generally, co-located in GP surgeries and work more 
collaboratively with GPs and practice nurses than those practising as ‘islands’ 
(Cooper et al., 2009) in other community settings (see Silcock et al., 2004). 
Pharmacists working in industrial settings are generally employed by large 
pharmaceutical companies as part of their drug manufacturing processes. Their role 
within these companies removes them from the dispensing tasks which are central to 
other pharmacy practises. Similarly, those working in academia are also removed 
from dispensing activities and are more focused on research and educating trainees 
(Taylor et al., 2003). However, as the table shows, pharmacists working in all sectors 
are entitled to have more than one pharmacy job. As such, whilst working in industry 
or academia as a primary role might preclude pharmacists from dispensing activities, 
they may undertake dispensing work in a secondary community, hospital or primary 
care role.  
 
Taylor et al. (2002) note that given its historical trajectory, the profession of 
pharmacy is often associated with middle-aged white men. Contrary to this, 
however, the RPS members list contains 27,746 women, which constitutes 56.9% of 
the total population of registered UK pharmacists. This number represents an 
increase of 5.4% from the 51.5% that women constituted in 2001 (Hassell et al., 
2002). Moreover, in the hospital setting, women pharmacists outnumber men by 3 to 
1.  
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This relatively high proportion of women in the pharmacy profession is 
arguably related to the belief that community pharmacy is a flexible area in which 
qualified female pharmacists are able to combine family commitments with their 
desire to continue working within their chosen profession (see Symonds, 1998). This 
‘feminisation’ of the pharmacy workforce may have consequences for pharmacy’s 
professional project. Adams (2005) notes that professions which become feminised 
find attaining, or maintaining, a high professional status difficult. To demonstrate, 
Adams (2005) draws on clerical work which suffered a decline in its status as the 
proportion of women working in the sector increased during the early part of the 
twentieth century and Sampselle (2008) points to the perpetual relatively low-status 
of nursing which tends to be dominated by women. Moreover, Gidman and Hassell 
(2005) note that although the increase in the proportion of female pharmacists 
reflects a wider achievement vis-à-vis women’s employment, the position of women 
within pharmacy needs to be analysed more fully within feminist frameworks to 
understand why women are underrepresented as senior managers and owners in the 
community sector and overrepresented in lower grade occupations with the hospital 
sector.  
 
In addition, although pharmacy still continues to be dominated by 
practitioners from a ‘white British’ ethnic background (59.7%), there has been an 
increase in the number of pharmacists from non-white ethnic backgrounds. Hassell et 
al. (1998) note that in 1991 practitioners from ethnic minorities constituted 23% of 
the total number of pharmacists in the UK, compared to 30% in 2008. These 
demographic characteristics around gender and ethnicity raise interesting 
sociological questions.  
2.5.2 Paying for Pharmacy  
Hospital pharmacists are employed, and therefore paid, by the NHS Trust which 
governs the hospital in which they practice. As mentioned, hospital pharmacists are 
paid based on a nationally standardised salary framework where inexperienced 
pharmacists begin on a lower salary tier and move up as they become more 
experienced in their specialist area.  
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 In the community setting, the funding for pharmacy is less standardised. 
Community pharmacists’ salaries are paid by the private companies within which 
they are employed with large multiples generally offering higher salaries. 
Pharmacies are then contracted by the NHS to provide Essential, Advanced and 
Enhanced services within the terms of the nationally standardised community 
pharmacy contract. Within this, ‘Essential services’ refers to services which must be 
provided by all pharmacies such as dispensing, repeat dispensing and medications 
disposal. ‘Advanced services’, such as Medicines Use Reviews (MURs) and New 
Medicines Services (NMS), can be provided by all pharmacies once practitioners 
have been accredited to carry out such work. ‘Enhanced services’ are commissioned 
by the Primary Care Trust (PCT- as was at the time of writing) within whose 
jurisdiction the pharmacy falls. These Enhanced services include activities such as 
needle exchange programmes and Chlamydia screening. Pharmacies are remunerated 
a nationally standardised amount (set by the Pharmaceutical Services Negotiating 
Committee) for each service that they carry out (i.e. each prescription they dispense 
or MUR they complete). In this way, community pharmacies earn around 90-95% of 
their income from this NHS work.  
 
 It should be noted here that this overview of funding in pharmacy was correct 
as of July 2012. With the current focus on disbanding PCTs and implementing GP 
commissioning, the future structure of pharmacy funding in the community setting is 
not yet clear.  
2.5.3 Professional Collaboration in Pharmacy  
Contemporary pharmacy practice is characterised by something of a disjuncture 
between work in community and hospital settings (see Bhakta, 2010; Bond, 2001). 
Until the 1960s, the work of community and hospital pharmacists was relatively 
similar in that both were primarily focused on compounding and dispensing 
medications. Following the increased availability of pre-packaged medicines, work 
activities in these two sectors moved away from compounding and the work of 
hospital pharmacists began to become more integrated into wider clinical team 
working (Taylor et al., 2003). This was particularly the case given the specialisation 
model in hospital pharmacy. The result of this was the evolution of ‘ward pharmacy’ 
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where pharmacists mobilised their pharmacological expertise to become increasingly 
involved in prescription decision making which was thought to be beneficial for both 
the hospital organisation and the patient (Brookes et al., 2000). As such, pharmacists 
in the hospital setting are fairly well integrated into clinical care teams.  
 In the community setting, as noted above, Cooper et al. (2009) identified 
pharmacists as practising as ‘islands’ given the lack of collaboration or inter-
professional communication which they experience. Moreover, the collaboration 
between pharmacists working in different settings is minimal. In the 1990s the 
RPSGB recommended that hospital pharmacists provided elderly patients with 
medication checklists upon their discharge to be given to community pharmacists 
who would then take over responsibility for that patient’s medicines management. 
This, it was proposed, could increase and formalise the communications between 
these two sectors of practice and minimise the risk of discrepancies and adherence 
issues (Bond, 2001). Although these discharge checklists were shown to reduce 
problems as proposed, they also proved to be expensive and labour-intensive and so 
were not rolled out on a large scale. Hence, communication and collaboration 
between pharmacists working in different sectors remains minimal.   
2.5.4 From Medicines Management to Medicines Optimisation 
As mentioned, medications are the key components around which pharmacy practice 
and Barber’s (2005) pharmaceutical gaze are centred. The management of the safety 
and efficacy of these medicines, then, underpins the practices of pharmacy in both 
community and hospital settings. Stowasser et al. (2004) identify nine steps in what 
they term the ‘medicines management pathway’ in the hospital setting. In each of 
these steps, the mobilisation of the expertise of the pharmacist is clear; 
(i) deciding to treat and prescribe; once a clinician has ascertained that 
treatment is necessary, the bioclinical collective team negotiate the most 
appropriate and cost-effective route to take.  
(ii) recording medicines order; once a medication has been decided on, this 
decisions needs to be carefully and accurately recorded. 
(iii) reviewing medicines order; the medicine is then reviewed for issues such as 
funding challenges, drug-drug interactions and ease of compliance. 
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(iv) issuing medicine; once a medication is verified as being safe and 
appropriate, it is manufactured or issued from the producer (this may have 
already been undertaken and be in storage)  
(v)  providing medicines information; the producer should also provide 
sufficient information on how to take/prepare the medicine and its potential 
toxicity. 
(vi) distributing and storing medicine; once issued, a medication is delivered to 
the care space (e.g. wards) and stored appropriately. 
(vii) administering medicine; this involves assessing when and how a medication 
should be administered (e.g. pain relief medication) 
(viii) monitoring for response; on-going monitoring of patients also includes 
monitoring for ill effects from medications. 
(ix) transferring verified information; information about the steps above needs to 
be communicated effectively with other health care professionals (typically 
via the patient medical record) to affect future medications decisions.   
In 1990 Hepler and Strand proposed the notion of ‘pharmaceutical care’ as a 
more patient-centred approach to medicines management which would increasingly 
work towards a ‘greater social good’ (Hepler and Strand, 1990: 533). As such, 
through pharmaceutical care, pharmacy practice moved on from just involving 
dispensing the correct medicines to a focus on the minimisation of ADRs and the 
improvement of patients’ experiences of their medications.  
 
More recently, medicines management has discursively evolved further to the 
notion of ‘medicines optimisation’. This term first appeared in the Department of 
Health (2010) report Equity and Excellence. Within this, it is noted that pharmacists 
‘working with doctors and other health professionals, have an important and 
expanding role in optimising the use of medicines and in supporting better health’ 
(Department of Health, 2010: 26). In a short article responding to this report, Martin 
Stephens (one of the National Clinical Directors for Pharmacy at the time) reported 
that medicines optimisation reconfigures the medicines management and 
pharmaceutical care agenda of pharmacy in three key ways. Firstly, he argues that it 
places a new emphasis on patient-centred care; secondly it focuses heavily on 
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patient outcomes; and thirdly it discursively engages multiple practitioners. This 
final point is of particular interest in the case of community pharmacy which has 
traditionally been characterised by isolated working practices (Stephens, 2011). 
Additionally, Cutler (2011) argues that medicines optimisation provides a key 
opportunity for pharmacists to demonstrate their skills in patient-centred practice 
and to work more closely with other healthcare practitioners. At present, medicines 
optimisation is in its infancy and little academic work has been done in the area with 
no social science commentary currently in existence. However, this approach has 
been translated into NHS policy where medicines optimisation forms a distinct work 
stream in the NHS Quality, Innovation, Prevention and Productivity (QIPP) 
framework which is focused on making savings within the NHS whilst 
simultaneously maintaining or improving quality. Future sociological commentaries 
on this discursive shift to medicines optimisation will be of interest.     
2.6 Conclusion 
In sum, this chapter has provided a historical narrative of British pharmacy from the 
medieval period to the contemporary focus on medicines optimisation. It has shown 
that notions of professional identity and status (primarily centring on questions of 
autonomy) are central to previous sociological work in this area and that 
technologies can play an important role in reconfiguring this professional identity 
through shifting ‘ways of knowing’ (Pickstone, 2000) and professional boundaries 
(Barrett et al., 2011; Petrakaki et al., 2012). This sociological work, however, is 
limited in a number of areas. Firstly, it does not properly take into account the 
sociality of the patient body to which medications are administered. The patient in 
sociological analyses of pharmacy practice seems to exist as an implicit biological 
object to which medications are administered and within which they perform their 
action. This is despite Ryan et al.’s (2004: 51) assertion that given pharmacy’s focus 
on adherence, the body ‘must be fertile ground for [sociological] exploration’ and, 
elsewhere, the body being highlighted as being of great sociological importance (see 
Chapter Four) 
 
 Secondly, very few sociological analyses of pharmacy focus on both 
community and hospital practice. Instead, community and hospital pharmacy are 
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often treated as discrete analytical milieus or the latter setting is neglected entirely. It 
would seem useful, then, for an analysis of pharmacy which examines the themes 
and practices which are common to both community and hospital given their shared 
focus on medications.  
 
Thirdly, sociological analyses of community pharmacy highlight the lack of 
autonomy afforded to practitioners working in large multiple organisations. Perhaps 
because of the more general lack of focus on hospital practice, there is a lack of 
research on the relationship between everyday hospital pharmacy practices and the 
organisations in which practitioners are employed. As such, an examination of the 
ways in which organisational structures shape everyday work in hospital pharmacy 
seems necessary. 
 
Fourthly, the work of Barrett et al. (2011) and Petrakaki et al. (2012) give 
interesting insights into the potential effects of technologies in the reorganisation of 
pharmacy work, the reconfiguration of professional boundaries and the consequences 
for pharmacy’s professional identity. There is limited work, however, on the ways in 
which genetic technologies, as technologies with a particular set of ethical, 
educational and practice concerns, may affect pharmacy practice.  
 
Given the discussion above, the following research questions have been 
identified from the existing literature presented here.  
 How is the patient body configured in pharmacy practice? 
 
 How do the structures of pharmacy in community and hospital settings shape 
pharmacists’ everyday work activities? 
 
 What themes and practices are common to both community and hospital 
pharmacy practice?   
 
 How might the integration of (pharmaco)genetic technologies affect 
pharmacy practice? 
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 Findings from the empirical data feed into the examination of these questions 
in the later analytical chapters. In order to contextualise this final question, the thesis 
now turns to an overview of PGx and the sociological literature associated with it.
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Chapter Three: Pharmacogenetics: A Sociological 
Approach 
3.1. Introduction 
Chapter Two traced the development of contemporary pharmacy from the medieval 
period to the more clinical role of modern pharmacy. This chapter argues that  
although some recent social science work has examined the impacts of robotic and 
EPS technologies in pharmacy practice (Barrett et al., 2011; Petrakaki et al., 2012), 
the specific issues involved in the integration of PGx into hospital and community 
pharmacy settings have been neglected. To contextualise this analysis this chapter 
presents an overview of previous sociological analyses of PGx.  
  
Before this, the chapter provides a descriptive overview of the technical 
elements of PGx (i.e. why drug response variation occurs) and its recent 
development within biomedical research. In doing so, PGx is located within a wider 
genomics framework which characterises many of the approaches in contemporary 
biomedical research.  
  
The chapter then moves on to examine the public and private stakeholder 
interest in PGx and the promises which have been constructed in these areas. These 
are related to the sociological literature through the field of the ‘sociology of 
expectations’. The sociological literature in the area of PGx is also central to the 
chapter’s analysis of the integration of PGx into practice and the ethical and social 
implications which that presents.  
3.2. Understanding ADRs  
ADRs are argued to account for 6.5% of all hospital admissions (Pirmohamed et al., 
2004) and are identified by the left-wing pressure group Compass (2008) as costing 
the NHS £2 billion annually. Elsewhere, Lazarou (1998) identifies ADRs as the 
fourth leading cause of death in the USA. As such, the need to understand the factors 
which influence drug response variation is a ‘critical issue’ (Beard and Lee, 2005: 2).  
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 There are a number of physiological, environmental, individual and genetic 
factors which can cause variation in drug metabolism such as liver, lung or kidney 
function; alcohol intake; smoking; age; sex; body fat and genetic polymorphisms 
(Gibson and Skett, 2001). Within this, there are two categories of ADRs; type A 
reactions are common, can occur in any individual and can be controlled through 
dosage adjustment (Severino and Zompo, 2004) whilst type B reactions (also known 
as ‘idiosyncratic’ reactions) are uncommon and strongly related to genetic variation 
(Uetrecht, 2007). 
 
 These type B drug reactions occur as a result of chemical or structural genetic 
polymorphisms, the most common form of which are single nucleotide 
polymorphisms (SNPs- pronounced ‘snips’) which account for 80% of all known 
genetic changes (Jain, 2009). SNPs are allelic variations at the site of one base pair 
which affect the encoding function of the gene, which affects the protein which is 
expressed and, thus, can result in a phenotypic variation (Jain, 2009). As well as 
SNPs, insertions and deletions (INDELS) of DNA and copy number variation 
(CNV) are also responsible for type B ADRs. Briefly, INDELS are the insertions or 
deletions of segments of DNA which, when occurring on encoding genes, can result 
in a ‘frameshift’ meaning different proteins and, subsequently, different phenotypes 
are expressed. Jain (2009) notes that if one understands the human genome as an 
instruction book, SNPs are the equivalent of altering single letters whilst INDELS 
are analogous to inserting or deleting whole sentences or paragraphs. Finally, CNV 
refers to a deviation from the normal human diploid (two copies of each gene) 
genome potentially resulting in INDELS or duplications of DNA. This can then 
cause over- or under-expression of protein which, in terms of drug response, is 
phenotypically manifested as either non-responsiveness due to abnormally quick 
metabolism or an ADR due to inadequate metabolic activity (Jain, 2009).  
 
 Studies of genetically-determined drug response variability tend to focus on 
chemical SNP variations rather than structural INDELs or CNV. Jain (2009) notes 
that this focus on SNPs tends to overlook the importance of structural variations, 
which Korbel et al. (2007) suggest may be responsible for most human genetic 
variation. Nevertheless, what is demonstrated by this genomic understanding of 
ADRs is that molecular variability is central to the ADR story.  
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3.2.1. Terminology 
 Pharmacogenetics, then, is centred on mobilising the data emerging from 
these molecular understandings of ADRs and using it in order to manufacture safe 
and effective drugs and making safe and effective prescription decisions. Within this, 
there is an ontological distinction between pharmacogenetics and pharmacogenomics 
where the former is widely understood to refer to single genetic changes whilst the 
latter focuses on protein expression in a whole genome. However, there have been, 
and continue to be, debates within the scientific community about the definitions of 
these two terms (see European Agency for the Evalutation of Medicinal Products, 
2002). 
 
 Table 2 shows Jain’s (2009) characterisation of the differences between 
pharmacogenetics and pharmacogenomics vis-a-vis a number of scientific and 
clinical features (also see Lindpaintner, 2003). Here Jain (2009) demonstrates the 
focus of pharmacogenetics as individual gene variability and pharmacogenomics as 
whole genome protein expression. As such, the techniques employed in 
pharmacogenetics are most commonly associated with clinical practice whilst 
pharmacogenomic techniques are more commonly associated with drug discovery 
processes.    
Table 2: Differences between pharmacogenetics and pharmacogenomics. Taken from Jain 
(Jain, 2009: 70).  
Feature Pharmacogenetics Pharmacogenomics 
Focus of studies Patient variability Drug variability 
Scope of studies Study of sequence variations 
in genes relevant to drug 
response 
Study of the entire genome 
Methods of studies SNPs and expression profiles Gene expression profiling 
Relation to drugs One drug, many patient 
genomes 
One patient genome, many 
drugs 
Examination of drug effects Study of one drug in vivo in 
sample of patients with 
inherited gene variants 
Study of differential effects 
of several compounds on 
genome in vivo or in vitro 
Prediction of drug efficacy Moderate High 
Prediction of drug toxicity High Moderate 
Application relevant to 
‘personalised medicine’ 
Patient or disease-specific 
healthcare 
Drug discovery and 
development or drug 
selection 
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 It is noted elsewhere that the terms pharmacogenetics and pharmacogenomics 
can be interchangeable since they are both concerned with the same broad area of 
research (Pirmohamed, 2001; Wieczorek and Tsongalis, 2001). This inter-
changeability has led to the conflation of these two terms under the umbrella heading 
‘PGx’, which is defined as ‘collectively …the science and technologies associated 
with dividing patients or populations into groups on the basis of their biological 
response to drug treatment using a genetic test’ (Hopkins et al., 2006: 403). This has 
also been called ‘the new pharmacogenetics’ (Pfost et al., 2000) and 
‘pharmacogenetics-pharmacogenomics’ (Wang, 2010).   
 
Alongside these somewhat technical terms, Liggett (2001) notes that less 
formal terms have also been applied to this paradigm of research and practice. 
Hence, terms such as ‘personalised medicine’, ‘stratified medicine’ and ‘tailor-made 
treatments’ have become synonyms for pharmacogenetics/genomics in more popular 
literature. Hedgecoe (2004) notes that whilst such definitions can be useful for 
conveying the core approach of this area, they can create a disparity between 
patients’ and practitioners’ operationalisation of ‘personalisation’; whilst 
practitioners may understand it relative to existing blockbuster models, patients may 
understand it as a wholly tailored drug programme.  Hedgecoe and Martin (2003: 
515) also note that the ascription of a name to a scientific discipline is not an 
arbitrary or accidental process and argues that ‘the names we use to label particular 
disciplines have a role in structuring them, and this in turn affects the uptake of 
particular technologies’. Pharmacogenetics and pharmacogenomics are examples of 
this, where pharmacogenomics first appeared in the scientific literature in 1997 and 
utilised the interest and hype surrounding the more general field of genomics which 
existed at this time. As such pharmacogenomics was discursively posited as a 
‘natural or evolutionary development’ of pharmacogenetics due to its utility of 
contemporary genomic techniques (Vesell, 2000: 119) 
 
For the purposes of this thesis, pharmacogenetics and pharmacogenomics are 
conflated under the heading ‘PGx’ given that many of the nuances between the two 
are not likely to be significantly relevant in the context of everyday pharmacy 
practice. Hence, whilst most pharmacists’ interaction with PGx is likely to involve 
pharmacogenetic technologies and data, pharmacogenomic principles are also likely 
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to be present, not least because the most commonly used PGx test (HER2 testing) is 
pharmacogenomic in nature. However, most pharmacists’ interaction with PGx 
technologies is likely to be in the form of black-boxed testing devices and/or 
binaried output data where the scientific methods (i.e. whether these results are 
arrived at through protein or gene tests) underpinning them are not visible or 
necessarily relevant for organising PGx work activities. Where the distinction 
between pharmacogenetics and pharmacogenomics is relevant, however, this is made 
clear.  
 
3.3 A Brief History of Personalised Medicine 
According to Jain (2009: 5), the adoption of PGx into mainstream medicine 
represents an ‘evolution and not a revolution’ as personalisation has always been 
central to medical practice. As such, the clinical practices arising from PGx represent 
the next phase of the personalised medicine story rather than a completely novel 
ideology or approach.  
 
Perhaps the earliest known example of personalised medicine principles is 
Pythagoras’ observation in 510BC that some individuals developed a fatal reaction 
to ingesting fava beans. More recently, nineteenth century Korean Sasang 
Constitutional Medicine (SCM) divided the human population into four discreet 
categories based on individuals’ physiological, psychological and physical 
characteristics which are thought to result in herbal medicine response variation 
(Kim et al., 2009; Shim et al., 2008). Drawing upon these characteristics, 
practitioners in this sphere of medicine are able to diagnose the constitution of each 
patient and offer them a personalised therapy regime. In this vein, SCM can be 
understood as a form of Pickstone’s (2000) ‘natural history’ medical practice where 
patients’ constitution is explained and managed in natural, rather than supernatural 
terms. More recently, this personalised natural history approach has been somewhat 
legitimised by ‘technoscience’ discourses of genetics where the four categories of 
patients identified in SCM have been shown to have a genetic basis (Kim et al., 
2009).   
 
Tutton (2012) also provides a useful overview of the history of personalised 
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medicine. He argues that personalised care and therapy can be seen throughout the 
history of western medical practice where a conflict between ‘universalism and 
specificity’ can be seen throughout recent medical history. This is not to say that 
‘personalised medicine’ per se has always existed in medical practice but rather that 
different historical forms of personalisation have been enacted throughout 
nineteenth and twentieth century medicine (Tutton, 2012). He traces the trajectory 
of personalised western medical practice since the mid-19
th
 century at which time 
new emerging field of scientific research, most relevantly therapeutics, shifted the 
focus of medical practice away from what Jewson (1976) calls ‘bedside medicine’ 
to ‘laboratory medicine’. Within this way of seeing and practising, bodies, diseases 
and therapeutics became less individualised and more focused on quantifiable 
universality.  
 
This approach, however, was contested from within the medical profession 
throughout the nineteenth and twentieth centuries where the conflict between the 
‘universalism’ of laboratory medicine and the ‘specificity’ of medical practice 
routines developed. Tutton (2012) argues that whilst nineteenth century British 
doctors discursively positioned the practice of personalised medicine as a set of 
skills- or ‘art’- which no-one else could claim to possess, twentieth century 
researchers drew attention to the individual psychological and socio-economic 
factors affecting patients’ health. More recently, laboratory science itself has begun 
investigating personalisation and individuality through the field of 
pharmacogenetics. 
 
 The foundations for what one might call the scientific discipline of PGx were 
discursively laid down by the English physician Sir Archibald Garrod in 1931 when 
he observed that inherent individual differences were medically significant and 
should be taken into account during treatment decisions (Kalow, 2006). Following 
this, the discreet field of PGx emerged during the 1950s as an experimental science 
focusing on inherited differences in human reactions to drugs (Council for 
International Organisations of Medical Sciences, 2005). The majority of the 
empirical groundwork in the field was done in the early 1950s using succinylcholine 
(a short-term muscle relaxant), isoniazid (an anti-TB medication) and primaquine (an 
anti-malarial medication) (Weber, 2008).The results from these, and other, 
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experiments were drawn together in arguably the most seminal and influential paper 
in the discipline, Arno Motulsky’s (1957) Drug Reactions, Enzymes and 
Biochemical Genetics. In this paper, Motulsky (1957: 170) argued that the 
differential reactions found in these studies demonstrated that ‘hereditary gene-
controlled enzymatic factors determine why, with identical exposure, certain 
individuals become ‘sick’, whereas others are not affected’. Two years after the 
publication of this seminal work, the term ‘pharmacogenetics’ was coined by 
Friedrich Vogel to describe this burgeoning field of research and in the following 
decade the importance of genetics in drug metabolism variation was demonstrated 
through numerous twin studies (Vesell and Page, 1968a; Vesell and Page, 1968b). 
 
 Although the interest in PGx gained and sustained a great deal of interest in 
the decades following the foundation of the discipline in the 1950s, the field 
expanded at a relatively slow pace with drug-gene relationships being extrapolated 
as researchers came across them rather than there being an active search for such 
relationships (Hedgecoe, 2004). In the 1980s, however, the ‘molecular turn’ in 
biological science meant that molecular testing was becoming more widespread in 
laboratories and scientists working within PGx  were able to identify polymorphic 
nucleotides within the genes which encode enzymes which were known to be 
responsible for drug response variance (Weber, 2008). The molecular turn in PGx 
more specifically can be traced to 1988 when Frank Gonzalez and colleagues at the 
National Cancer Institute in the USA successfully cloned the complementary DNA 
(cDNA) of the CYP2D6 gene, which forms part of the P450 cytochrome system of 
enzymes. This was a significant breakthrough in the field of PGx as the enzymes of 
cytochrome P450 are responsible for clearing over half of all clinically used drugs, 
with the genes CYP2D6 and CYP2C19 being responsible for the metabolism of most 
of these (Gonzalez et al., 1988; Meyer, 2004). Hence, changes on these genes have 
subsequently been shown to affect drug reactions and metabolic ability. 
 
 Findings from Gonzalez’s study and the development of a number of new 
technologies, such as recombinant DNA and polymerase chain reaction (PCR) 
opened up the field of PGx to ‘the new genetics’ which was sparked by the 1953 
discovery of the double helix structure of DNA and concerned with providing 
genetic explanations for various traits, diseases, behaviours and idiosyncrasies 
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(Conrad and Gabe, 1999). Latterly, in the 1990s, the HGP provided a tool with 
which scientists could deepen their understanding of genetically-influenced human 
diversity and located PGx within the biomedical field of genomics (Clarke et al., 
2003).  
 
 Following the successful completion of the first draft of the HGP’s findings, 
PGx was seen as ‘the next great challenge’ (Liggett, 2001: 285) for the application of 
the technologies and information generated from the Project. Building on the 
somewhat diverse, although ultimately successful, partnership between public and 
private approaches to the HGP, the SNP Consortium was founded as a collaborative 
effort between eleven private companies
7
 and the medical charity the Wellcome 
Trust to locate, detail and make publicly available, 3,000,000 SNPs in the human 
genome over a two year period (Holden, 2002; Thorisson and Stein, 2003).  When 
the project reached its conclusion in 2001, it had far exceeded this expectation and 
successfully located and published details of 1.4 million SNPs, which helped to 
mobilise industrial interest in PGx research (see Hedgecoe, 2004). Following this in 
2002, the International HapMap Project was launched as a means of detailing the 
most common haplotypes (a set of related SNPs which are important in drug 
response variability) in the global human population. More recently, in 2011 the UK 
Technology Strategy Board announced stratified medicine as a key five year priority 
area and launched the Stratified Medicine Innovation Platform with the objective to 
invest £200 million in stratified medicine projects by 2016.  
 
The principles of personalisation, then, can be traced from an early ‘natural 
history’ way of knowing to their centralisation within contemporary technoscientific 
biomedicine approaches to the body, disease and wellbeing. The disjuncture between 
personalisation discourses in traditional medicine and more contemporary 
biomedicine is, arguably, a reflection of the multiplicity of interests which are 
currently served in the latter. In other words, personalised approaches in traditional 
medical practice existed primarily for the benefit of patient vis-a-vis maximising 
efficacy and reducing ADRs. Contemporary approaches to personalisation, however, 
                                                 
7
 The companies involved in the SNP are: Amersham Biosciences, AstraZeneca, Aventis, Bayer AG, 
Bristol-Meyers Squibb Company, F. Hoffmann-LeRoche, GlaxoSmithKline, IBM, Motorola, 
Novartis, Pfizer and Searle (Hedgecoe, 2004: 11).   
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co-construct the interests of a number of groups of actors- public healthcare 
institutions, private drug development companies and patients. This chapter now 
turns to an examination of the ‘promises’ (Hedgecoe and Martin, 2003) which PGx 
holds for these different groups of actors.  
3.4 Public and Private PGx Promises 
In the wake of the HGP, technical developments in molecular science were 
accompanied by an ideological shift towards constructing disease and treatment in 
genomic terms (Bell, 1998). This technical and ideological shift aroused the interest 
of private industry (both large pharmaceutical companies and small biotechnology 
firms) in PGx as it combined the promise of innovative genomic technologies with a 
focus on drug development activities (Hedgecoe and Martin, 2003). Hedgecoe and 
Martin (2003) note that a number of ‘visions’ for the future of PGx were then 
articulated in the scientific and clinical research literature. Of particular note are two 
visions which focus on (i) drug metabolism and the genetic basis for ADRs and (ii) 
the associations between markers for drug response and genes involved in the 
development of specific pathologies. These visions co-construct both public and 
private interests with a focus on reducing the cost of ADRs for public healthcare 
institutions whilst decreasing the potential for litigation and reducing the costs of 
drug production for private drug development companies. 
 
 Prior to the genomics turn, pharmaceutical companies demonstrated a 
ubiquitous ‘one-size-fits-all’ attitude to medicine and drug reactions, and opted for a 
blockbuster
8
 business model in which new molecules were tested in large clinical 
trials and aggressively marketed as revolutionary new therapies (Liggett, 2001). 
Traditionally there has been reluctance within the pharmaceutical industry to 
acknowledge the extent of drug response variation and so reluctance to fully 
participate in the PGx field. However, the gradual increase in the pharmaceutical 
industry’s interest in PGx and the successful ‘shot-gun’ marriage of public and 
private approaches in the HGP (Hedgecoe, 2004: 11) led to a burgeoning of 
public/private collaborative research whereby publically-funded university groups 
were, and are, able to benefit from industry’s large amount of capital, retention of 
                                                 
8
 Blockbuster drugs are drugs which generate more than $1 billion annually (Cutler, 2007) 
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contact with patients and readily-accessible supply of clinical trial data (McCarthy, 
2001). 
 
 In a recent review of the status of the pharmaceutical industry (so-called ‘Big 
Pharma’) the accountancy firm PriceWaterhouseCoopers (2009) assert that the 
traditional ‘profit alone’ business model of the pharmaceutical industry, whereby 
blockbuster drugs are developed quickly and marketed extensively in order to 
generate profit solely for the company which owns the relevant molecules, is not a 
viable model for the future of the pharmaceutical industry. Instead, they argue that 
Big Pharma need to adopt a ‘profit together’ business model by joining forces with 
academic institutions, hospitals and health service companies to meet the changing 
needs of patients who are less willing to accept the traditional blockbuster model and 
are increasingly conscious of the cost-benefit ratio of therapies.  
 
The proposed collaboration between the pharmaceutical industry and other 
sectors is presented by PriceWaterhouseCoopers (2009: 2) as a ‘do or die’ 
requirement. The report proposes a ‘federated’ business model for the future of 
pharmaceutical companies, within which key actors at various stages of drug 
development and clinical work form networks which collaboratively work towards 
the mutual goal of effective patient care. The PriceWaterhouseCoopers report 
constructs this personalisation of medicine as a phenomenon centred on the 
personalisation of patient experience as well as the personalisation of therapy and 
thus locates PGx within a wider paradigmatic shift towards personalised medical 
care which cuts across both private and public healthcare sectors and institutions. In 
other words, although PGx is concerned with the personalisation of medicinal 
products, personalised approaches are also increasingly central to general clinical 
practice through what is commonly labelled ‘patient-centred care’. This approach 
focuses on the personalisation of clinical encounters and interventions based on 
patients’ values, needs and preferences; in this way, there is a move away from a 
homogenisation of patient bodies within a ‘one size fits all model’ of clinical care 
(see Michie et al., 2003). Hence, the personalisation of medications through PGx can 
be located within a wider discursive shift towards personalisation and patient-
centeredness within the healthcare sector. This can, perhaps, be understood more 
sociologically as sitting within a postmodern framework of patient understandings 
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whereby the ‘truths’ of medical expertise are questioned and deconstructed (see Fox, 
1999). 
3.4.1 Public Sector PGx Promises 
This shift towards personalisation of care is identified by Coulter (2002) as being 
beneficial for both the NHS and patients in terms of better patient adherence to 
medications and a reduction in ADRs. These promises of personalised care resonate 
with the visions generated for PGx within the NHS wherein PGx is imagined as a 
way to improve the safety and efficacy of medications through the identification of 
patients at risk of ADRs and those who are likely to respond well to therapy regimes. 
Here Martin et al.’s (2006) fourth and fifth innovation options are particularly 
relevant. Briefly, Martin et al. (2006) and, earlier, Webster et al. (2004) analysed 
data from a number of private sector companies to ascertain the commercial and 
clinical development of PGx. From this they identified six ‘innovation options,’ 
based around the discovery of better drugs; improving the safety and efficacy of 
drugs in development; and improving the safety and efficacy of licensed drugs. For 
the NHS, their identification of PGx as a tool for identifying patients at risk of ADRs 
and those who are likely to be good responders are of central importance.    
 
Firstly, identifying patients who are at risk of ADRs is, arguably, the most 
commonly cited application of PGx in clinical practice. The personalisation promises 
behind it appeal to stakeholders who are interested in reducing the financial burden 
of ADRs and the application of PGx in this way has previously been identified as a 
key way in which the NHS could reduce costs (Department of Health, 2003). Results 
from studies of ADRs as they relate to hospital admission or medical treatment 
should be treated with some caution as less serious ADRs, such as constipation, tend 
to be overlooked and under-reported in medical records (Pirmohamed et al., 2004). 
Nonetheless, it has been widely noted that ADRs place a large financial and labour 
burden on the NHS with the left wing pressure group reporting that ADRs cost the 
NHS £2 billion annually (Compass, 2008). Elsewhere, Lazarou (1998) has given a 
‘mantra-like’ (Hedgecoe, 2004: 14) figure of ADRs being the fourth leading cause of 
death in the USA after heart disease, cancer and strokes. In the UK, based on 
admission data for seven UK hospitals, Smith et al. (1996) found that 68.7 per 1,000 
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hospital admissions were caused by ADRs whilst Pirmohamed et al. (2004) found 
that 6.5% of admissions to the two Merseyside hospitals in their study were ADR-
related. More recently, Davies et al. (2009) found that 2,000 NHS hospital beds are 
being utilised by ADR patients at any one time. This, they argue, equates to a £171 
million cost for ADRs which occur during patients’ stays in hospital and at a cost of 
£466 million for ADR-related admissions. Taken together, this places a financial 
burden of over £637 million annually on the NHS, which is the equivalent of £5,000 
per hospital annually. The data pertaining to the financial cost of ADRs is, then, 
complex and diverse in nature. Nonetheless, ADRs clearly do place a financial 
burden on the NHS and the promises of PGx to identify those patients at risk of 
ADRs clearly align with a perceived need to reduce this financial burden.  
 
 Secondly, pre-prescription screening is also constructed as a way to identify 
patients who are likely to respond well to medications. Within this, PGx promises to 
negate the need for trial-and-error prescribing approaches and to reduce the need for 
repeat practitioner appointments by identifying poor- or non-responders before they 
are prescribed a medication. As an example, Lichter and Kurth (1997) highlighted 
the osteoporosis drug Fosamax which only begins to show signs of efficacy after a 
year of use. During this initial year, there is no way to stratify patients who are 
responding well, those who are responding poorly and those who are not responding 
at all. Hence, money and time may be wasted in treating poor responders because of 
the lack of pre-prescription identification. They argued that pre-prescription testing 
for Fosamax could pay for itself within two years by identifying good responders 
and only prescribing the drug to them. Although Lichter and Kurth’s (1997) paper is 
somewhat dated, their visions for PGx in clinical practice align well with Martin et 
al.’s (2006) innovation options and feed into the concerns of public healthcare 
institutions around reducing the cost of ineffective prescriptions.  
 
 These concerns around reducing the cost of healthcare also become 
increasingly relevant in light of the ever-decreasing costs of genotyping (Service, 
2006). Moreover, the promises of PGx to reduce NHS costs in this way also sit 
within the contemporary medicines ‘optimisation’ discourse noted in Chapter Two. 
As such, medicines optimisation is premised on increasing the efficacy of medicines 
for individual patients whilst simultaneously reducing NHS costs through, amongst 
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other things, curtailing the use of ineffective medications. Given this, the promise of 
PGx to reduce the financial burden of ADRs and to improve patient experience 
through predicting non- or poor-responders discursively locates PGx within 
contemporary medicines optimisation approaches.  
3.4.2 Private Sector PGx Promises  
Private drug development companies have previously been relatively reluctant to 
engage with PGx as this would necessitate something of a public acknowledgement 
that their products are not always effective. In 2003, however, Alan Roses, the then 
worldwide vice-president of genetics at GlaxoSmithKline, reported that ‘90% [of 
drugs] only work in 30 or 50% of people’ (Connor, 2003), which somewhat 
legitimised private sector interest in PGx.  
 
 When analysing the promises of PGx for private sector institutions, Martin et 
al.’s (2006) innovation options become useful once again. Three of these options are 
particularly relevant; PGx to improve drug discovery; PGx to improve the safety of 
drugs in development; and PGx to improve the efficacy of drugs in development. 
Within this, they noted that PGx can be used to improve drug candidates by targeting 
genomic sub-populations. This has the potential to decrease the risk of drugs being 
rejected at the later stages of clinical trials and increase the chances of effective 
drugs being approved, if only in a limited market.  PGx is also identified as 
potentially improving the safety of drugs in development by screening participants to 
identify those with a genetic predisposition to ADRs. This, they argued, would 
reduce clinical trial bias, improve the safety profile of approved drugs and could 
‘rescue’ products which have been abandoned due to ADRs (also see Phillips et al., 
2000; Shah, 2006). PGx can also be used to improve the efficacy of drugs in 
development by identifying trial participants who are likely to respond well and only 
testing on, and marketing to, them. The breast cancer therapy Herceptin, which is 
explored in more detail below, is an example of this application of PGx.  
 
 The promises of PGx for private drug development companies, then, centre 
on the potential streamlining of the R&D process and the associated reduction in 
R&D costs. The total cost of developing a new pharmaceutical product is subject to 
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much debate although the figures offered by economist Joseph DiMasi are usually 
the most commonly cited
9
. In 1991 DiMasi et al. (1991) calculated the cost of 
developing a new pharmaceutical product as being around $500 million and updated 
this in 2003 to a figure of $800 million (DiMasi et al., 2003). More recently, Collier 
(2009) argued that the cost could now be as high as between $1.3 and $1.7 billion 
whereas Munos (2009) calculated the cost to be $3.9 billion.  
 
 Irrespective of the true cost, it is a truism that the cost of producing a drug is 
substantial, whilst the FDA approval rate is low at 11.5% (Munos, 2009). Tollman et 
al. (2001) argued convincingly for the substantial effect that PGx could have on the 
cost of R&D by providing a more flexible scenario at the later stages of clinical 
trials. Whilst traditionally the later stages of drug development have been 
characterised by a binary scenario (drugs are either shown to be effective, pushed 
through clinical trials and marketed or shown to be in- or minimally-effective and 
abandoned as unmarketable), the adoption of PGx technology could allow for a more 
flexible model whereby drug effectiveness and ineffectiveness could co-exist 
through stratified populations. These changes, Tollman et al. (2001) argued could 
save $140 of the R&D cost and see the length of the drug development process 
reduced by one year per drug.  They also advocated the benefits of PGx technology 
for drug companies in terms of gaining advantages in the current ‘blockbuster’ drugs 
market where drugs developed using PGx technologies could be marketed as less 
risky and more effective. In this way, doctors would be more likely to prescribe less 
risky and more effective drugs, patients would be willing to pay a higher price for a 
decreased risk of an adverse reaction and patients who have previously avoided 
medication (typically owing to previous experiences of adverse side effects) would 
be more willing to try less risky therapies. As such, the discursive promises created 
around PGx could be mobilised by private sector companies in their marketing 
activities.  
 
 Although their paper was written a number of years ago, Hedgecoe and 
Martin’s (2003) reflection that many of the promises of PGx are highly speculative 
owing to the limited number of PGx products available in routine clinical practice 
                                                 
9
 DiMasi’s figures are subject to much critique. See Light andWarburton (2005), Young and Surrusco 
(2001) and Collier (2009).  
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still holds true. As such, although private drug development companies seem less 
reluctant to engage with PGx principles and pre-prescription testing is routinely 
practised in some medical specialisms, PGx is still a fairly new paradigm of practice 
which has not displaced the blockbuster model in drug development or the trial-and-
error model of prescribing in clinical practice. As such, it seems beneficial for this 
chapter to turn to an overview of the current use of PGx in clinical practice.  
3.5 Putting PGx into Practice 
PGx in both drug development and clinical practice is still largely in the 
developmental stages. In some clinical practices, genetic factors affecting drug 
efficacy are tested for as a matter of routine (for example, HER2 testing in breast 
cancer and KRAS testing in colorectal cancer) but in the majority, PGx remains 
more of a promise than a reality. Within this, PGx tests are most commonly carried 
out in hospital settings and in medical specialisms (namely Oncology) where the risk 
and severity of ADRs are increased. Given this, PGx has made almost no impact on 
clinical practice outside of hospital settings although Grice et al. (2006) identify the 
potential application of PGx principles to a number of primary care drugs arguing 
that at least one in four primary care patients takes a drug which causes ADRs. 
Moreover, elsewhere Warfarin, which is most commonly administered in primary 
care, is discursively framed as a key area of the application of the principles of PGx 
(see Rajanayagam, 2009; Wadelius and Pirmohamed, 2006).  
 
 Given this relatively limited impact to date, the translation of PGx from 
‘bench to bedside’ (Erlich et al., 2003; Weinshilboum and Wang, 2006) is subject to 
much debate and these debates can often raise more questions than they answer. At 
the development side of the process, Weinshilboum and Wang (2006) identify four 
challenges to be overcome to successfully translate PGx technologies into beneficial 
outcomes for patients. Firstly, they argue, genomic science will need continual 
optimisation in order to produce cost effective and clinically applicable results. This 
necessitates collaboration between practitioners and researchers from a diversity of 
fields and is, thus, echoed by the PriceWaterHouseCoopers’ (2009) report which saw 
private and public sector scientific collaboration as a necessary future mode. 
Secondly, they argue that incentives will need to be created in order for drug 
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development companies to mobilise PGx techniques rather than the traditional 
blockbuster model. Thirdly, healthcare practitioners will need to be educated in 
genomic principles in order to provide the best service and advice to patients. This is 
also echoed in UK policy where the Human Genetics Commission (2003) asserted 
that the successful integration of genetic principles into routine medical practice 
would rely on, and necessitate, the cultivation of a ‘genetically literate’ primary care 
workforce. In addition, the White Paper Our Inheritance, Our Future (2003a) also 
proposed the need for increased genetic education amongst healthcare practitioners 
and was followed, in 2004, by the establishment of the National Genetics Education 
and Development Centre (NGEDC), which offers genetic training to a variety of 
practitioner groups, including pharmacists. Finally, Weinshilboum and Wang (2006) 
argue that this education needs to be expanded to include patients in order for them 
to understand how any why PGx principles are applied to their treatment. For Condit 
(2010), this incorporates both patients’ understanding of the testing process and their 
ability to make sense of genetics-based risk information. Elsewhere, the limited 
understanding of, and value invested in, statistical risk-based information has been 
highlighted by social scientists (Gross and Shuval, 2008). Within this, Gross and 
Shuval (2008) highlight the rejection of this construction of risk as a rejection of the 
biomedicalisation of illness, disease and, in this particular case, pregnancy.  
 
 In addition to these challenges presented by Weinshilboum and Wang (2006), 
Erlich et al. (2003) pose a number of questions about PGx as part of everyday work 
actitivies which, they argue, will need to adequately answered in order for PGx to be 
successfully integrated. They ask, then, who should perform PGx tests? When 
should a PGx test be done? What actions should be taken based on a test result? And 
what is the cost-benefit ratio of PGx testing? This final question is particularly 
pertinent to the public sector interest in PGx highlighted above. Within this, the 
promises of PGx to reduce the financial burden of ADRs and non-responsive 
patients only become relevant where pre-prescription testing is cost effective when 
compared with trial and error approaches to prescribing. Since different PGx tests 
require different scientific products and expertise and, moreover there can be a 
number of other non-genetic factors affecting drug response, the extent to which the 
cost effectiveness of PGx as a whole can be analysed is limited. For example, whilst 
Rosove and Grody (2009) argue that PGx testing for Warfarin treatment is not cost 
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effective given the inability of pre-prescription testing to identify all response 
variation, Vijayaraghavan et al. (2011) identify KRAS testing for colorectal cancer 
patients as being cost effective to the tune of $7,500-$12,400 for each US patient. 
Elsewhere, however, Payne et al. (2009) question the parameters of PGx economic 
evaluation models and suggest a cautious approach to their conclusions. Moreover, 
as mentioned above, the decreasing cost of genotyping technologies is likely to 
further shift these economic evaluations.  
 
 What this shows is that the process of putting PGx into routine clinical 
practice is challenging on a number levels from the everyday organisation of 
healthcare work to the economic evaluations which are used to assess PGx’s cost-
effectiveness for the NHS. A future question also arises here which is related to the 
integration of PGx into routine clinical work. Here, the internal structures of 
different medical practices and the social and political implications of different PGx 
tests come into play.     
3.6 Integrating PGx  
Classic STS theory has demonstrated the ways in which innovations are socially 
constituted and how their integration into everyday practices, infrastructures and 
routines is mediated by a range of heterogeneous social, political, economic and 
technical processes (Bijker et al., 1987; Bijker, 1997). In the case of PGx, Hedgecoe 
(2004) argued that in some areas of medicine, practitioners may be ‘resistant’ to 
employing PGx technologies because of the perceived limited advantages they offer. 
In a later paper he develops a more complex model of differential integration across 
medical fields and PGx tests and argues for this ‘resistance’ to, instead, be 
understood more sociologically in terms of ‘clinical usefulness’ (Hedgecoe, 2008a). 
In doing so, he foregrounds the socially constituted nature of PGx tests and medical 
practices and the effects that this has on their integration into routine clinical work. 
He identifies four social aspects of medical practice which contribute to 
understandings of PGx tests as clinically useful or otherwise.       
 
Firstly, he argues that clinicians do not always share the same perspectives 
and understandings of disease classifications with scientists developing PGx tests. 
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He points to genetic tests on the gene causing cystic fibrosis (CF) which have meant 
other diseases, such as the male infertility condition CBAVD (which is also encoded 
by this CF gene), being ‘folded into’ a CF diagnosis even where the other diseases 
are experienced without classic CF symptoms. In this way, a genetic test can provide 
patients with a distressing diagnosis of CF where their initial symptoms are not lung 
related.   Secondly, as is outlined in more detail below in the case of Tacrine, 
Hedgecoe (2008a: 187) notes that ‘genetic tests...do not exist in a vacuum’ but can 
have wide ranging implications for family members vis-a-vis inherited disease 
susceptibility. Practitioners, then, are faced with the dilemma where the benefits of 
using a test to gain a more certain diagnosis need to be weighed against the potential 
negative impacts on the wider family network (also see Cox and McKellin, 1999). 
Thirdly, although one of the key visions for PGx in the UK is the reduction of the 
financial burden of ADRs, Hedgecoe (2008a) notes that PGx tests may not be 
clinically useful or cost-effective in certain medical specialisms if those departments 
do not bear the financial burden of ADRs.  Finally, he argues that there is 
widespread scepticism about PGx testing in the UK healthcare system where a 
clinician’s diagnostic opinion is still given priority over genetic test results (also see 
Latimer et al., 2006). Even where genetic test results contradict this professional 
diagnostic opinion, the latter is often still given precedence. This finding is also 
echoed in Will et al.’s (2010) study of practitioners involved in the diagnosis and 
treatment of familial hypercholesterolemia (a genetic pre-disposition to high 
cholesterol) where genetic tests were understood as being less useful than other 
information, namely cholesterol tests, in making diagnoses.  
 
Hedgecoe’s (2008a) notions of ‘clinical usefulness’ is central to 
understanding the different levels of integration of PGx in different clinical settings 
and across different PGx tests. However, his framework is limited in only taking into 
account the perspectives of practitioners as to the usefulness of PGx tests. Elsewhere, 
Møldrup (2002) notes that public acceptance of PGx technologies as clinically useful 
or otherwise is central to their uptake and routinisation in healthcare. In a study of 
lay peoples’ perspectives on PGx, whilst Fuks Nielsen and Møldrup (2007) found 
that whilst most respondents were generally positive about PGx because of the 
potential improvements to patient outcomes and experiences, its perceived 
preventative, rather than curative, nature could weaken the publics’ view of it as 
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useful and thus ‘weaken the motivation for adopting it’ (Fuks Nielsen and Møldrup, 
2007: 235). A more recent public perception survey by O’Daniel et al. (2010) also 
highlights concerns about privacy as a factor which could restrict the clinical 
usefulness of pharmacogenetics from the patient’s perspective. 
 
What this conveys is that the perceptions of PGx tests as useful or otherwise 
in everyday clinical practice affect the extent to which they are used, and become 
‘normalised’ (see May and Finch, 2009; also see Chapter Four) in different contexts. 
To exemplify this, the chapter now turns to an examination of two PGx therapies 
which represent very different integration journeys within two different medical 
practice fields.   
3.6.1 The Case of Herceptin  
According to Hedgecoe (2004: 99), the breast cancer drug Herceptin ‘may just be the 
first example of a pharmacogenetic drug in regular clinical use’. Herceptin may be 
considered within a PGx tradition as it only works in the 25-35% of metastatic breast 
cancer patients whose tumours over-express the human epidermal growth factor 
receptor 2 protein (HER2), which is produced by amplification of the tumour’s 
HER2 gene. Those patients who are identified as HER2 positive (i.e. those in whom 
Herceptin will have some clinical benefit) are usually prescribed Herceptin as an 
adjuvant therapy with traditional cytotoxic therapy (Hortobagyi, 2005). 
 
 Personalisation principles are central to both the development of Herceptin 
and its use in everyday clinical practice. As such, clinical trials of Herceptin were 
conducted using specially selected samples of patients whose tumours were 
identified as HER2 positive rather than the traditional randomised trials in a whole 
patient population. This can be understood as the use of Martin et al.’s (2006) third 
innovation option whereby the development of Herceptin mobilised genomic data on 
patients involved in phase III trials in order to design subsequent trials to only 
include good responders. These personalisation principles are also translated into 
everyday clinical practice where therapy decisions about Herceptin are made based 
on the results of a PGx test.  
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 The use of Herceptin can be analysed within Hedgeoe’s (2008) model of 
clinical usefulness. The widespread introduction of HER2 testing in the UK faced 
significant financial barriers, which Roche (to whom Herceptin is licensed) 
overcame by funding all HER2 tests for a period leading up to, and past, Herceptin’s 
introduction in the NHS in order to get clinicians ‘into the habit’ of HER2 testing 
(Enzing et al., 2009: 66). Since there has traditionally been a culture of resistance to 
testing in the UK medical community whereby testing is only conducted when it is 
deemed absolutely necessary, Roche’s funding of all HER2 testing can be 
understood as an attempt to alter the UK medical testing culture (Enzing et al. 2009)  
 
 This attempt to change testing culture was, ultimately, successful with HER2 
tests now being carried out on all metastatic breast cancer patients within a safe age 
limit and an increase in testing for early stage HER2 positive breast cancers 
following recent clinical trials (Walker et al., 2008). What the case of Herceptin 
demonstrates, then, is the successful integration and ‘normalisation’ of a PGx 
therapy within everyday clinical practice. Within this, the severity of ADRs 
associated with traditional cytotoxic Oncology therapies, the poor prognoses for 
HER2 positive metastatic breast cancer patients and Roche’s decision to fund HER2 
testing can be seen as biological, social and political features of breast cancer which 
converged to facilitate this ‘normalisation’ story. What the case of Herceptin also 
highlights is the increasing complexity of disease ontology brought about through 
developments in genomic technologies. Hence, whereas breast cancer may 
previously have been understood as one disease, genomic information can be 
understood as broadening and adding complexity to definitions of breast cancer by 
reconfiguring it as a set of heterogeneous genetic diseases (see Curtis et al., 2012). 
Running concurrently to this genomic broadening of the definitions of diseases such 
as breast cancer, however, has been the narrowing of treatment options for these 
different disease areas. In other words, whereas genomics has created more 
categories within breast cancer (for example, HER2 positive and HER2 negative 
metastatic breast cancer), the therapy options for treating these are narrowed where 
Herceptin can only be administered to a particular genomic sub-population (those 
who are HER2 positive).  
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 In contrast to the ‘normalisation’ of Herceptin, the Alzheimer’s drug Tacrine 
can be understood as sitting at the other end of what one might call a continuum of 
integration whereby PGx testing for potential drug response has not been adopted 
into routine clinical practice.    
3.6.2 The Case of Tacrine     
Whereas Herceptin can be understood as an example of the successful integration of 
PGx into clinical practice based on its clinical usefulness, the case of the 
Alzheimer’s drug Tacrine is an example of stalled translation and limited clinical 
usefulness. As such, PGx tests for Tacrine can be placed at the other end of the 
continuum of integration where the social and ethical implications outweigh the 
clinical benefits. Tacrine is used to slow the development of dementia symptoms 
although responses to it vary widely with up to half of the 468 patients in Farlow et 
al.’s (1998) study not improving significantly when treated with the drug. This 
variability in response to Tacrine was ascribed to an allele of the APOE gene 
(APOE4), which had been linked with increased risk of late-onset Alzheimer’s 
disease during the 1990s. 
 
 Despite the initial enthusiasm over APOE4/Tacrine PGx, the picture became 
somewhat muddied as multiple experiments were carried out and the exact 
relationship between APOE status and Tacrine response was increasingly difficult to 
determine with studies presenting conflicting results in the scientific literature (see 
Farlow et al., 1998; Macgowan et al., 1998). This tension between those who 
understood APOE as central to variations of response to Tacrine (and were 
supportive of further research in this area), and those who were more sceptical was 
not easily resolved and specialists in the area of Alzheimer’s disease increasingly 
disregarded notions that Tacrine response variation was linked to genotype. As a 
result, the clinical usefulness of PGx tests in the case of Tacrine therapy was 
questioned on a number of levels. 
 
 The case of Tacrine can be related to Hedgecoe’s (2008a) notion of clinical 
usefulness in two ways. In one way, the Tacrine story clearly demonstrates a 
difference in the interests of the scientists researching the APOE4/Tacrine link and 
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the clinicians who would ultimately be using the information to inform therapy 
decisions. Hence, whilst scientists understand the APOE4/Tacrine link as 
‘interesting’ (Hedgecoe, 2004: 65) clinicians require quantifiable conclusions in 
order to build such genetic information into routine clinical practice. In another way, 
Tacrine perfectly demonstrates that PGx tests ‘do not exist in a vacuum’ and can 
have wide-ranging familial implications (Hedgecoe, 2008a: 187).  In 1993, a link 
between the E4 allele of the APOE gene and late-onset Alzheimer’s disease was 
discovered (Saunders et al., 1993). The scientific importance of this finding is ‘hard 
to overestimate’ (Hedgecoe, 2008a: 187) given that (i) it was the first gene 
discovered that increased the risk of developing a disease rather than directly causing 
it and (ii) that all other genes which had been identified as significant in Alzheimer’s 
disease were linked to early, rather than late-onset, the latter of which was, during 
the 1980s and early 1990s, increasingly constructed as an epidemic (see Korczyn and 
Vakhapova, 2007).  
 
Following this there was much debate around the use of genetic tests for 
identifying Alzheimer’s risk, which feed into debates about the clinical usefulness of 
PGx for Tacrine therapy. Notwithstanding the debate briefly described above about 
the actual role of the APOE4 allele in Tacrine response, the presence of this allele is 
not only a predictor of drug response but also a risk factor for the development of 
late onset Alzheimer’s disease. As such, PGx tests for this allele would have familial 
implications in potentially revealing the presence of an increased Alzheimer’s risk 
factor.  Given that the test for the APOE4 allele can have far-reaching implications 
for family members, but has not been shown conclusively to provide information on 
drug response and only increases the certainty of diagnosing Alzheimer’s disease 
(rather than another form of dementia) by 4% when it is used as an adjunct 
diagnostic tool (Roses, 1995), the clinical usefulness of PGx testing in Alzheimer’s 
disease is minimal. Hence, PGx testing for Tacrine was never extensively practised 
and, as such, can be understood as being at the opposite end of the continuum of 
integration from Herceptin.  
   
 Although Warfarin, Herceptin and Tacrine are used extensively as exemplars 
of PGx in practice they represent only three of a large number of drugs for which 
pharmacogenetic biomarkers have been identified which the FDA list on their 
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website
10
. The cases of Herceptin and Tacrine have, however, been used extensively 
to demonstrate the different patterns of integration of PGx across different medical 
specialisms and disease areas. These case studies are useful as a way of 
demonstrating that although the visions and promises created around PGx tend to 
construct its benefits as somewhat universal, the ethical and social issues which exist 
around PGx can have a pervasive influence on the extent to which it is mobilised in 
everyday practice. It is to these ethical and social issues in PGx that the chapter now 
turns.  
3.7 Ethical and Social Issues in PGx 
As is noted by Hedgecoe (2008a: 187), genetic tests ‘do not exist in a vacuum’ and 
are subject to construction and understanding through the ethical, social and political 
structures of wider society and medical practice. Previous sociological reflections on 
genetic testing have been far-reaching and have focused on a diversity of issues such 
as implications for doctor-patient relationships (Lehtinen and Kääriäinen, 2005; 
Pilnick, 2002; Pilnick, 2004); the ‘new eugenics’ (Kerr et al., 1998; Rembis, 2009; 
Shakespeare, 1998); implications for family and kin (Cox and McKellin, 1999; 
McLaughlin and Clavering, 2011; Weiner, 2011); medical or lifestyle decisions 
(Hallowell, 1999; Hallowell and Lawton, 2002); construction of (bio)sociality and 
citizenships (Brekke and Sirnes, 2011; Rose and Novas, 2008); and racialised 
medicine and research (Ellison et al., 2008; Smart et al., 2006; Smart et al., 2008; 
Tutton, 2004; Tutton, 2007b; Tutton et al., 2008).  
 
PGx, as a specific form of genetic research and clinical practice, does not 
necessarily involve the same ethical and social implications as other genetic methods 
which have been dealt with by social scientists.  For example, where Hallowell and 
Lawton (2002) found that results indicating an increased risk of ovarian cancer 
prompted some women to undergo major invasive surgery, the focus of PGx on 
predicting drug response is unlikely to involve such significant clinical or personal 
decisions. As another example, whilst Rose and Novas (2008) argue that genetic 
information around increased disease risk might lead to the configuration of new 
social identities, it is unlikely that such biocitizenship would be organised around 
                                                 
10
 See http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm 
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potential drug responses as ascertained from PGx tests.   Hence, although the ethical 
and social implications of PGx are central to its nature and of sociological interest, 
Buchanan et al. (2002) argue that the ethical and social challenges of PGx should not 
be over-analysed and aligned with other more ethically challenging fields arising 
from genomic science. They argue that this ‘genetic exceptionalism’, which assumes 
that genetic research and clinical practice involve a particular set of exceptional 
ethical circumstances, should be avoided (this is echoed by the Nuffield Council on 
Bioethics, 2003). They also highlight ‘overbroad genetic generalisation’ as a 
potential issue in considerations of the ethics of PGx. Within this, they argue that 
PGx tests should not all be arbitrarily amalgamated and assumed to involve the same 
social and ethical considerations. In a more general sense, Martin and Dingwall 
(2010: 524) note that the extent to which genetic information is ‘exceptional’ is 
highly dependent on the social and clinical setting within which it is constructed. 
Hence, whilst genotype information may be useful for predicting future health in the 
context of practices which deal with monogenic diseases (i.e. those caused by a 
single gene), this genomic information is ‘significantly less valuable’ in the context 
of common diseases within which genetic changes are linked to risk (Martin and 
Dingwall, 2010: 524). In this instance, then, genetic information may be of little 
more value than other clinical information, such as blood test data. 
 
Nevertheless, there are a number of ethical and social issues which are 
central to the PGx story. Here, these are identified under the broad headings Privacy 
and Confidentiality and Inequality and Access. An examination of each of these is 
taken in turn.     
 3.7.1 Privacy and Confidentiality 
Issues of privacy and confidentiality are central to social science analyses of PGx in 
both drug development and clinical practice. In a response to the Nuffield Council on 
Bioethics’ (2003) report on PGx, Corrigan (2005) highlights the potential for an 
increased burden on patients involved in PGx clinical trials. She argues that because 
consent in PGx trials gives companies the ability to link patients’ genetic samples 
with personal medical information and to store patients’ samples indefinitely to be 
used in future unspecified genetic tests, the limits of participants’ informed consent 
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are ‘transgressed’ (Corrigan, 2005: 146). She notes that these compromises in the 
consent process cannot be offset against the benefits of trial participation as in 
regular clinical trials given that participants’ receive no direct benefit in PGx clinical 
trials.  
 
This issue of informed consent is also evident in using PGx in clinical 
practice where Buchanan et al. (2002) question whether specific informed consent is 
necessary every time a PGx is undertaken. They argue that most PGx tests have a 
limited capacity for causing psychological harm and so should be treated in the same 
way as more routine clinical tests to avoid genetic exceptionalism. In a review of 
current PGx practice in Europe, Woelderink et al. (2005) demonstrate that informed 
consent for PGx tests is not always requested by practitioners although the authors 
argue that written consent for each test is ‘of great importance’.  
 
Elsewhere, privacy and confidentiality issues are foregrounded.  Within this, 
the ability of some PGx tests to also identify disease susceptibility means that 
sufficient anonymisation of patients’ genetic samples and medical records to avoid 
them being linked back to a particular individual is key. In the insurance-based US 
healthcare model, the issue of genetic discrimination is particularly notable. In this 
context, concerns around genetic discrimination led to the passing of the Genetic 
Information Non-discrimination Act (GINA) in 2008, which prevents employers and 
health insurers discriminating against individuals based on their genetic information. 
Although genetic discrimination was already illegal before the passing of the GINA, 
most lay people believed that such discrimination was legal and so those who might 
have benefitted from genetic testing sometimes opted out. This misunderstanding of 
the law by lay people, according to Rothstein (2008), was the main impetus behind 
the GINA and other anti-discrimination legislation at the federal level. Despite this 
legislation, however, individuals in the US are still vulnerable to discrimination 
based on genetic information as the GINA does not apply to life insurance, disability 
insurance, long-term care insurance or other uses of genetic information. The GINA, 
then, only applies to asymptomatic people and although GINA prevents employers 
requesting genetic information specifically as a condition of employment, they can, 
under the Americans with Disabilities Act (1990) request all health records as a 
condition of employment (Rothstein, 2008; Slaughter, 2008). As such, the extent to 
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which anti-discrimination legislation is wholly effective is questionable (Martin and 
Dingwall, 2010). 
 
 In the UK, similar concerns about employment and insurance discrimination 
on the grounds of disease susceptibility are present with Tutton (2007a) noting that 
concerns around genetic discrimination partly underpin ambivalence to UK Biobank 
participation (also see Kerr et al., 2007). Elsewhere, Joly et  al. (2010) note that the 
UK insurance model takes a combined ‘moratorium/fair limit/rational discrimination 
approach’ where insurers do not request genetic information unless it is clinically 
significant and scientifically valid or the insurance policy is above a specific 
monetary amount. Moreover, Morris (2010) notes that UK insurers are bound by the 
Data Protection Acts of 1988 and 2003 to handle personal and medical information 
in the same confidential way as doctors. Her interviews with lay people in the 
Republic of Ireland highlight a concern that genetic information is too ‘personal’ to 
be shared with people and companies outside of the medical profession or the family. 
As such, despite legislative moves to restrict genetic discrimination, the nature of 
genetic information as a central facet of personhood continues to fuel concerns 
around privacy and confidentiality in genetic testing practices (Morris, 2010). It 
would also appear that as genetic testing increases in sophistication and, potentially, 
becomes more widely available in primary care and retail settings these concerns 
will become more acute.   
 
 Ethical questions about the use of PGx information also incorporate 
confidentiality issues when considered in the context of potential familial 
implications. The question of whether family members who may be affected by the 
results of a PGx test should be informed is a recurrent ethical challenge which is not 
adequately, or explicitly, addressed by the Data Protection Acts of 1988 and 2003. 
Knoppers (2011) argues that although the decision to have any genetic or PGx test 
should always be the decision of the individual patient alone, it ought to be 
acknowledged that the results are necessarily familial and, as such, the needs of and 
risks to, other family members ought to be taken into consideration during any 
genetic testing process. This ties in with Martin and Dingwall’s (2010) assertion that 
the nature of medicine itself is, ultimately, family or community medicine in which 
individuals cannot easily be separated from their social or cultural environments 
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given the genetic ties (and responsibilities) with which they are bound (also see 
Finkler et al., 2003; Rapp, 1998; Rapp, 2000). The Nuffield Council on Bioethics 
(2003) note that such decisions around familial implications cannot be arbitrarily 
legislated and, instead, recommend that decisions about informing family members 
about genetic test results and risk should be taken by the healthcare practitioner 
involved in the testing and results counselling process based on the circumstances of 
each individual case.  
 
 What this section has demonstrated is that privacy and confidentiality issues 
are central to the ethical and social nature of PGx research and practice. These issues 
are inherently tied in with kinship and familial risk and, has been demonstrated 
above in the case of the Alzheimer’s drug Tacrine, can have significant impacts on 
the clinical uptake of PGx testing in everyday clinical practice.  
3.7.2 Inequality and Access 
A second issue which has been prominent within sociological analyses of PGx is to 
do with inequality and access to biomedical innovation. Healthcare inequality is of 
central importance in medical Sociology and has a lengthy history within the 
discipline. The recent expansion of genomic medicine has generated a focus on the 
(in)equality of access to biomedicine and the ways in which existing patterns of 
(in)accessibility are reproduced in genomic practices.  
 
 To being with, Barash (2001) questions whether the resources allocated to 
PGx drug development in the wealthy West would be better spent on national and 
international public health concerns, such as the provision of clean water in 
developing countries, which she understands as being more ‘urgent’. These 
sentiments are also echoed by Holm (2008) who questions how useful PGx will be 
for low- and middle-income countries where access to basic healthcare provisions is 
problematic. Global healthcare inequalities may, then, be reproduced through the 
apportioning of genomic research resources within wealthy Western countries. As a 
result, the chasm between Western ‘lifestyle’ diseases and those which are endemic 
in poor countries (see Trouiller et al., (2001) for an overview) may widen as 
genomic interventions are identified for the former but neglected for the latter.  
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 In contrast, Pang (2009) argues that PGx will in fact be useful for developing 
countries in providing genomic solutions to tropical diseases, problems associated 
with increased globalisation and by allowing these countries to make valid 
contributions to global expertise in this area. This final point is also echoed by 
Boulyjenkov and Schapper (2007) who argue that genomic variation research (they 
particularly note research in Mexico, India and Thailand) will allow developing 
countries to compete in the global knowledge economy as well as improving health 
in these countries. Although Boulyjenkov and Schapper’s (2007) and Pang’s (2009) 
papers provide useful counter-arguments to traditional views of PGx as out of reach 
of developing countries, these papers do not fully analyse the existing structures of 
inequality in these countries which place biomedical expertise and techniques out of 
reach of certain population sub-groups.  
 
 Other commentators have explored the potential for PGx to compound or 
transgress existing structures of ‘race’11 and race inequality in biomedicine and 
scientific research. Briefly, whilst some scientists argue that racial categories are a 
potentially scientifically valid and important way of categorising populations (see for 
example Ioannidis et al., 2004; Shriver et al., 2004), others argue that race is socially 
and politically constituted and is ‘a proxy for socio-cultural, economic, and 
particular historical processes and experiences’ (Lee, 2009: 1184). Race as a means 
of categorisation is a pervasive issues and was addressed in a 2004 special issue of 
Nature Genetics which examined the links between race, ethnicity and genetics. In 
interviews with the then editors of Nature, Smart et al. (2006) note that this special 
issue was produced as a way of addressing the potential measurement and 
communication problems raised by using race as a means of stratification. They 
identify two broad strategies for addressing these problems; continuing to use race 
and ethnicity for categorisation until these become scientifically obslete or replacing 
racial and ethnic categories with alternatives based on socio-cultural and 
geographical ancestry. This first strategy bears similiarities to Cooper (2003) who 
argues that genomic technologies could offer a way in which the contentious use of 
                                                 
11
 ‘Race’ has been acknowledged as a a problematic term and is, as such, commonly presented in 
inverted commas (see Ware and Back 2002, Gilroy 2000). For stylistic reasons, ‘race’ is not presented 
in this way throughout the thesis.  
87 
 
race for characterising variations might be questioned and undermined. He notes that 
whilst genomics has identified variations between racial groups, it has also identified 
that these are minimal when compared with variations within population sub-groups 
and, so, race as a means of categorisation should be questioned. 
 
However, contrary to Cooper’s (2003) reflections in interviews with genetic 
scientists Ellison et al. (2008) found that the minor differences between racial groups 
identified by genomic science provided scientists with evidence of the importance 
and scientific validity of racial categorisations. As such, they argue that there has 
been a resurgence of race in genomic research where racial groups are redefined by 
these scientists as ‘genetically-distinct subspecies’, despite efforts to move to a more 
socio-cultural definition of ‘ethnicity’ (Williams, 2011).  
 
 In terms of PGx specifically, it has been argued that race is a poor proxy for 
PGx knowledge (Holm, 2008)  and that race-based PGx risks ‘medicalising’ 
(Hansson, 2010), ‘geneticising’ (Ellison et al., 2008) and ‘molecularising’ 
(Fullwiley, 2007) race. Fullwiley (2007: 21) argues that the structure of PGx science 
in the US compounds and reproduces racial distinctions through the recruitment, 
organisation, storage and comparison of DNA mandated by the National Institutes of 
Health (NIH). As such, racial distinctions are practised in everyday laboratory work 
without discussion or critique and scientists cultivate a ‘racialised gaze’ whereby 
DNA is labelled in racial terms before it is even extracted from the participants’ 
body. Central to much of these sociological debates about race and PGx is the 
congestive heart disease drug BiDil, which was licensed by the FDA in 2005 for use 
in African-American patients only. As such, Duster (2007: 702) understands BiDil as 
the world’s ‘first racial drug’ and argues that characterising drugs and drug responses 
along racial lines attributes health purely to biological factors and so risks 
overlooking the environmental inequalities, such as education, housing and nutrition, 
which can have significant effects on health (also see Kahn, 2005). Elsewhere, 
Duster (2005) argues that such racialised categorisation can lead to the simplistic 
construction of ‘black’ and ‘white’ diseases where large private companies are more 
likely to make profits on the latter owing to the, generally, greater wealth of white 
populations. This echoes Trouiller et al.’s (2001) work where they argue that 
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diseases found in developing countries are neglected by pharmaceutical companies 
who are likely to see larger profits from treatments of white, Western diseases.   
 
Elsewhere,  taking BiDil as their point of departure, Tutton et al. (2008) 
interviewed PGx scientists and found that high throughput DNA technologies in both 
research and clinical settings may overcome racial categories as patients become 
defined by their allelic variations rather than their race-based genetic traits  (also see 
Foster et al., 2001). As such, Tutton et al.’s findings suggest that Cooper’s (2003) 
vision of genomic techniques undermining racial categorisation may be a possibility.  
 
 Also central to the concerns around inequality and access to genomic 
medicine are concerns around the creation of a ‘genetic underclass’. Writing some 
years ago, Nelkin and Tancredi (1994) argued that the widespread availability of 
genetic testing could mean the evolution of a class of people who are socially and 
politically marginalised and economically disadvantaged as a result of genetically-
based discrimination (also see Emmott, 2011; Wilkinson, 2010). Most of the work 
examining this potential ‘genetic underclass’ has focused on the insurance and 
employment problems potentially faced by those identified as being at an increased 
risk of developing a disease (Evans, 2007; Lee, 1993, Mehlman and Botkin, 1998; 
O'Hara, 1992), although Jasny and Zahn (2011: 872) argue that such fears were 
‘much overblown’ in the early days of genomic science.  
 
As, primarily, a means to identify drug response variations, PGx testing does 
not have the same potential as regular genetic testing to contribute to the production 
of a supposed ‘genetic underclass’. However, there is the potential for the creation of 
a ‘pharmacogenetic underclass’ (Brown et al., 2001: 52 (emphasis added)) whose 
drug reactions fall outside of those which are most common (Hansson, 2010). 
Elsewhere, Webster et al. (2004: 666) conceptualise this as creating ‘orphan 
patients’ (as opposed to orphan drugs) who are denied access to mainstream drugs 
because of their rare metabolism and reaction patterns (also see Robertson et al., 
2002). Wertz (2003: 194) notes than in countries without nationalised healthcare 
systems, legislation may be necessary to ensure the insurance coverage for those 
who are ‘pharmacogenetically different’.  
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What this section highlights is that the ethical and social concerns and 
commentaries around PGx fit into a wider social science focus on the impacts of 
genomic medicine whilst also presenting a number of distinct ethical and social 
concerns related to PGx specifically. Within this, the ethical and social impacts for 
patients (or consumers) are, necessarily, central. What is not extensively analysed 
within these frameworks are the potential impacts of PGx, or genomics more 
generally, on the professional identity, status and everyday work practices of the 
healthcare professionals using them as part of their routine practice. Where social 
scientists have been concerned with the positioning of practitioners, they have tended 
to be concerned with genetic counsellors (for example Pilnick, 2002, Lehtinen and 
Kääriäinen, 2005) and, as such, the role of more generalist practitioners such as 
pharmacists, has been neglected.  
 
Outside of the social science literature, there has been some speculative work 
examining the potential impacts of PGx on pharmacy practice but little of this has 
utilised empirical data or analysed the issue in sociological terms. Nonetheless, this 
work provides a useful entry point into understanding the potential impacts of PGx 
on pharmacy practice.  
3.8. PGx in Pharmacy  
PGx has been presented as the ‘next challenge’ for pharmacy practice (Clemerson et 
al., 2006) where pharmacists are said to have an ‘essential role to play’ (Akthar, 
2002: 299) in delivering PGx medicine in the future. Within this, PGx is understood 
as a way in which the work of supplying safe and effective medicines could be 
supported and extended by introducing gene-drug, as well as drug-drug interaction 
information into pharmacy (Clemerson et al., 2006; Dotson Jaggers, 1999; Ensom, 
2001; Penick Brock et al., 2003). Here, then, pharmacists’ expertise in the area of 
pharmacology is married with genomic techniques to improve the safety and efficacy 
of prescriptions in line with the promises outlined above (Hedgecoe and Martin, 
2003). This expertise, moreover, is imagined as a way in which pharmacists might 
offer increased support to clinicians in the prescribing decisions (Johnson, 2002; 
Penick Brock et al., 2003). In doing so, PGx is framed as a mechanism through 
which pharmacists can work more collaboratively with other healthcare 
90 
 
professionals and researchers (Cryan, 2004; El-Ibiary, 2008; Jaggers, 1999; Maitland 
van de Zee et al., 2004; Penick Brock et al., 2003) and may, as a result become a 
more central part of what Petrakaki et al. (2012) call the ‘NHS family’. In this way, 
PGx could be understood as a way in which the professional status of pharmacy, 
which in the community setting has traditionally been characterised by isolated 
practice models (Cooper et al., 2009), may be shifted towards a (re)professionalised 
identity. PGx is, thus, identified by Streetman (2007: 2040) as a way to ‘help the 
profession transition to the future’.  
 
This potential for PGx to bring about a shift in the professional identity of 
pharmacy is also evident in works which posit pharmacists as healthcare 
practitioners vis-a-vis providing ‘in-house’ testing services (Clemerson et al., 2006: 
129) and advising patients on the clinical implications of PGx test results (Akhtar, 
2002; Ellingrod and Moline, 2007; Streetman, 2007). In this ‘logical progression’ 
(Akhtar, 2002: 289) of the extended role, community pharmacists will potentially be 
positioned as genomic healthcare practitioners if PGx tests for common, primary 
care conditions become more mainstream. Sociologically, this can be understood as 
representing a move towards a more biomedicalised (Clarke et al., 2003) form of 
pharmacy practice based on more technoscientific ways of knowing (Pickstone, 
2000) medications and the patient body. This echoes Johnson et al.’s (2002) 
assertion that the integration of PGx into pharmacy will make the practice ‘less of an 
art and more a science’.    
 
Much of the literature in this area has, then, been fairly optimistic about the 
role of pharmacists within PGx practice. In contrast to this, Morley and Hall (2004) 
are sceptical about the practicalities of community pharmacists’ involvement with 
PGx given the current structures of practice which mean that the storage and utility 
of patient PGx information is problematic given that (i) patients do not have one 
dedicated pharmacy from which they collect all prescribed medicines and (ii) 
community pharmacists receive very little patient-specific information to assist them 
with the safety aspects of the dispensing process. Integrating PGx into community 
pharmacy practice, they argue, would necessitate a significant and impractical 
restructuring of the primary care practice structure primarily based on pharmacists’ 
increased access to patient medical information.  This issue has, however, previously 
91 
 
been approached with consternation by members of the UK Patients Association 
who demonstrated a clear belief that community pharmacists were not in a position 
to be able to claim legitimate access to such confidential information (The Patients 
Association, 2008). Two primary strategies to overcome this are found in the 
literature. Firstly, Maitland-van der Zee et al. (2004) propose a software-based 
approach where PGx test results are included on patient prescriptions and can be 
cross-referenced with gene-drug information software which ought to be available in 
all community pharmacies. Secondly, medical identification cards containing 
information about patients’ genetic profile, prescription history and external risk 
factors, such as smoking and drinking habits may be an alternative to a fall medical 
record in the pharmacy setting (Akhtar, 2002; Maitland-van der Zee et al., 2002). 
Access to such information raises questions around pharmacists’ knowledge of 
issues of privacy and confidentiality and the risks of other pharmacy staff coming 
into contact with sensitive information about patients. Moreover, the assumption that 
pharmacists want access to such patient information should not be too readily made. 
This issue of medical record access is returned to in the later empirical chapters.  
 
Elsewhere, Alcade and Rothstein (2002) identify ethical, social and 
educational implications as potential challenges to the full implementation of PGx 
into pharmacy practice. They also argue that PGx will present increased challenges 
for pharmacists in their dispensing activities as the greater range of drug dosages 
mean that there will be an increased risk of prescribing and dispensing errors which 
will place more responsibility for spotting mistakes on pharmacists who are already 
overburdened by their workloads.  
 
Alcade and Rothstein’s (2002) focus on the educational challenges of 
integrating PGx into pharmacy sits within a wider body of work on this topic  
(Clemerson et al., 2006; Cryan, 2004; Newton et al., 2007). The extent to which 
PGx is currently incorporated into pharmacy training is difficult to accurately 
measure although there is a general agreement that pharmacists’ present knowledge 
of this area is ‘relatively poor’ (Streetman, 2007: 2040) owing to the limited PGx 
teaching pharmacology students receive during training. As an indication, in a 
survey of nineteen UK medical schools, Higgs et al. (2008) found that, in 2005, 84% 
of the institutions surveyed provided some PGx training, although this varied 
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between less than 1 hour and 8-12 hours of teaching in this area throughout the 
course of the degree, despite the International Society of Pharmacogenomics’ (ISP) 
(Gurwitz et al., 2005) recommendation that medical students receive a minimum of 
four hours of pharmacogenetic teaching. The extent to which pharmacy students are 
taught PGx in the UK is under-explored but, in the US context, Figg and Cox (2003) 
found that only 5 out of 85 pharmacy schools offered any form of genetics 
education, leading them to question how far graduating pharmacists will be able to 
engage with future (pharmaco)genetic medicine if they do not possess an adequate 
grasp of the basic principles of genetics. These concerns around pharmacists’ 
education in PGx medicine have also been voiced in the UK where Burton and 
Shuttleworth (2003) noted that although genetics was present in some areas of the 
UK undergraduate curriculum, it was not prioritised during preregistration training 
or professional development. Following recommendations from the UK Department 
of Health’s White Paper Our Inheritance, Our Future (2003a), the National Genetics 
Education and Development Centre (NGEDC) was established in 2004 with a 
specialist dedication to pharmacy education in British universities. In 2007 this 
centre, in collaboration with the Royal Pharmaceutical Society of Great Britain 
(RPSGB; as was) published a report which highlighted the need for increased PGx 
education for undergraduate, preregistration and more experienced pharmacists 
(Newton et al., 2007). In this report, Newton et al. (2007) highlighted the need to 
implement specialist PGx training (for example, Oncology pharmacists will require 
specialist knowledge of family history methodologies whereas this will not be as 
relevant for generalist community pharmacists) which is relevant to contemporary 
and immediate future practice since pharmacists may not see PGx as wholly relevant 
at the moment.  
 
Important here is what the potential implications of this relative lack of 
engagement with (pharmaco)genetic principles may be for pharmacy. Fargher et al. 
(2007) conducted semi-structured interviews with patients and healthcare 
professionals and identified a problematic gap between patients’ high expectations of 
PGx test results and healthcare professionals’ limited literacy in PGx principles. This 
could affect how far patients understand pharmacists as important practitioners in 
their PGx experiences, which could affect pharmacy’s claims to a legitimate role 
within the PGx medical team (Streetman, 2007).  
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What is shown here is that the particularities of integrating PGx into 
pharmacy practice have been explored elsewhere but little of this has taken a 
sociological perspective. Ryan et al. (2004: 51) argue that since pharmacists are 
likely to be ‘at the forefront’ of PGx medicine, it is important to develop a 
sociological understanding of the ways in which pharmacy constructs PGx and the 
ways in which PGx may (re)construct pharmacy. This acknowledges that within 
previous papers looking at PGx in pharmacy, the nature of pharmacy and its patients 
is somewhat taken for granted. Hence, whilst Morley and Hall (2004) identify the 
need for a restructuring of community pharmacy practice in light of the demands of 
PGx, there is a paucity of work undertaken to ‘map’ the actual nature and lived 
experience of this work structure. This thesis addresses this gap in the literature.   
3.9 Conclusion 
In sum, this chapter has located PGx within the genomic turn in biomedical research 
and practice which arose from the HGP in the 1990s. Within this, PGx is understood 
as one of the key applications of the data and technologies arising from this Project 
and has, more recently, started to make inroads into clinical practice through 
specialisms which are characterised by particularly problematic ADRs (such as 
Oncology).  It has been demonstrated here that PGx is central to contemporary social 
science reflections on genetic medicine more generally, and the implications of PGx 
specifically. Within this field, the ethical and social implications of PGx are shown 
to be different from those in more general genetic medicine but, nonetheless, central 
to the PGx story.  
 
 The chapter finished by highlighting previous work which has considered the 
specific nature of PGx in pharmacy. Here it was shown that although these 
reflections provide a useful platform from which to begin an analysis of PGx in 
pharmacy, the lack of empirical data and social scientific analyses are areas which 
need addressing.  
 
Although the sociological and scientific reflections on PGx in drug 
development and clinical practice are fairly extensive, there are a number of areas in 
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which these analyses are limited. Firstly, the patient body has a limited presence 
within sociological understandings of PGx. Although some sociologists have 
focused on what might be understood as a racialised body, the body is mostly 
constructed as a space in which the genome resides and, subsequently, an object to 
which tests are done, medications are administered and within which PGx research is 
carried out. As such, sociological analyses have tended to view the patient body as a 
tacit element of PGx without extensive analysis of how this body is brought into 
being in research and clinical settings involving medicines, compared with the 
considerable body of work on the sociology of medicine. 
 
Secondly, there has been no social science research undertaken exploring the 
role of pharmacists within PGx practices. This is despite pharmacists being involved 
in drug development processes (with 4.1% of active pharmacists being employed in 
industry), pharmacists being the dispensers of PGx drugs within hospital settings, 
hospital pharmacists being involved in PGx clinical trials (especially in Oncology) 
and community pharmacists being likely to be increasingly familiar with PGx if 
these personalisation and stratification principles continue to be applied in drug 
development. This lack of social science research also extends, as mentioned above, 
to a lack of research examining the nature of the contemporary pharmacy practice 
landscape into which PGx technologies may be integrated. 
 
Thirdly, there is a lack of focus on the micro-level (re)organisation of 
everyday work practices to define and accommodate PGx. Specifically for this 
project, there has been no work done examining the micro-level work undertaken in 
hospital and community settings to integrate PGx practices. Hence, whilst the 
reflections on PGx in pharmacy presented in this chapter highlight the 
implementation of PGx into pharmacy as a whole, there is a lack of research 
examining the ways in which this comes to played out in everyday practice and 
interactions. Moreover, an investigation of the effects of integrating PGx into 
pharmacy practice vis-a-vis professional identity, status and autonomy as outlined in 
Chapter Two, seems timely.   
 
Given this, then, the following research questions have been identified from 
the literature outlined in this chapter; 
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 How is the patient body configured by PGx in clinical practice? 
 
 How might pharmacists be involved in PGx? And what might be the impacts 
of this? 
 
 How might the contemporary pharmacy landscape be sociologically mapped? 
 
 How is everyday work in pharmacy settings (re)organised to integrate PGx 
practises? 
 Findings from the empirical data are key to answering these questions in the 
later analytical chapters. The thesis now turns to an examination of the theoretical 
frameworks which are mobilised in analysing the qualitative data collected. Within 
the next chapter, then, the sociology of the body and May and Finch’s (2009) NPT 
are highlighted as being of central importance in answering the research questions 
which have been identified in Chapters Two and Three.  
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Chapter Four: Theoretical Insights 
4.1 Introduction 
The empirical chapters in this thesis develop a novel framework within which to 
analyse contemporary pharmacy practice and the integration of technologies and 
PGx into it. This novel framework draws on a number of theoretical notions 
presented in the academic literature, broadly related to the sociology of the body and 
the process of integrating new technologies into medical practice.  
 
Chapters Two and Three both concluded by noting that sociological work in 
the areas of pharmacy practice and PGx has tended to neglect the patient body. This 
thesis argues, however, that the patient body is a central component of pharmacy 
practice and in examining the construction of the body in pharmacy addresses this 
gap in the literature. This chapter, then, outlines the theoretical framework of the 
sociology of the body with particular attention to Foucault’s ‘clinical gaze’ which 
forms a key starting point for the later analysis.  
 
 It is shown here that central to sociological understandings of the body are 
new medical technologies and the terms in which they configure it. Despite this, the 
micro-level interactional work undertaken to integrate technologies into everyday 
practices and discourses is neglected within sociology despite being noted as an area 
of interest some years ago (Kinmonth et al., 1998). In order to analyse the micro-
level interactional work involved in integrating PGx into different pharmacy settings, 
May and Finch’s (2009) NPT is identified as a useful framework which is mobilised 
as a tool for data analysis in the empirical chapters.  
4.2 Centring the Patient Body  
The body is subject to much contemporary sociological attention, so much so that 
Williams (2003: 3) notes that ‘many bodies...now roam the sociological landscape’. 
Within this, Nettleton (2010) posits three key sociological approaches to the body; 
the regulation of the body, the ontology of the body and the lived experience of the 
body (embodiment). Pervasive throughout these approaches is the notion of 
‘medicalisation’ which emerged in the mid twentieth century from neo-Marxist 
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perspectives and centres on the increasing power and influence of contemporary 
medical science and its practitioners. This perspective understands society and 
bodies within it as being increasingly subject to control by the medical profession 
and ‘facts’ about society being increasingly constituted through medical knowledge 
and expertise. Within this, medicine is understood to have taken on the regulatory 
role previously occupied by religion and law (Zola, 1972). In doing so, Ivan Illich 
(1975) argued that medicine severely diminishes lay people’s capacity to exert 
autonomy over their own health, bodies and wellbeing and, paradoxically, 
undermines health through this diminished autonomy and the side-effects produced 
by contemporary blockbuster medicines.  
 
Through these seminal writings medicalisation was posited as a negative 
phenomenon where, as Lupton (1997: 97) puts it, ‘to be ‘medicalised’ is never a 
desirable state of being’. Proponents of this medicalisation critique argue for ‘de-
medicalisation’ as a tool of resistance where challenging doctor’s decisions, joining 
patient groups and seeking the expertise of complementary and alternative (CAM) 
practitioners are emphasised. As an example, Lindenmeyer et al. (2011) identify a 
‘political-critical’ approach in women’s uses of CAMs for menopausal symptoms 
where utilising the expertise and products of CAM is understood as a way of 
critiquing and resisting the power of mainstream medicine over the female body.   
 
At the core of the medicalisation critique is the proposal that increasing 
medicalisation constructs the body in medicalised terms where ‘social’ issues 
become redefined as ‘medical’ issues (Conrad, 1992). Scull (1975) and Schneider 
(1978) provided examples where mental illness and alcoholism entered into the 
jurisdiction of the medical profession and, thus, became subject to medical control. 
Within this, the body is understood to become subject to increasing surveillance, 
definition and enhancement by expert medical practitioners where expert knowledge 
is increasingly given precedence over embodied experiences. Pregnancy, as a highly 
medicalised bodily experience, is a key example where expert knowledge and 
ultrasound images of the foetus have displaced women’s embodied experiences of 
their own pregnant bodies where being pregnant only becomes ‘real’ when it is 
defined and represented in clinical terms (Duden, 1993). Given its focus on 
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discursive construction, surveillance and control, links can be seen between the 
principles of medicalisation and the work of Michel Foucault.    
4.3 From Medicalisation to Biomedicalisation: Redefining Body 
Boundaries 
More recently, the medicalisation critique has been questioned in the context of 
developments in scientific research and medical practice. Conrad (2005) argues that 
changes in medical knowledge and organisation have engendered a shift in the 
‘engines’ driving medicalisation. He argues that patients acting as consumers, 
increasing managed care organisations in the USA and the dominance of the 
pharmaceutical industry have all become new ‘engines’ driving contemporary 
medicalisation. Within this, genetic medicine is positioned as occupying a central 
place in pharmaceutical companies’ agenda of medicalisation. As such, he argues 
that genetic testing has the potential to medicalise social, but (potentially) 
genetically-based body-specific ‘problems’ such as baldness and obesity. This, he 
argues, may lead to demand for genetic enhancement of bodies and may also create a 
new category of patients which he describes as the ‘potentially ill’ (Conrad, 2005: 8)  
 
Whilst Conrad (2005) understands the contemporary organisation of 
medicine as shifting medicalisation, Clarke et al. (2003) understand this organisation 
as transforming medicalisation. They argue that increasingly ‘technoscientific’ 
approaches and methods in research and clinical practice mean that older practices in 
medicine, what may be labelled as medicalisation practices, become displaced by 
more technoscientific innovations and approaches which seek to control the interior 
of the patient body. As such, these technoscientific developments are understood to 
involve a more molecularised construction and management of the patient body than 
in previous medicalisation processes. Within this biomedicalisation thesis, 
developments in genomic science are key to contemporary constructions of, and 
alterations to, the body. As such, they suggest that genomic biomedical science and 
practice are engendering a move away from the ‘normalisation’ of bodies to their 
‘customisation’. Within this customisation, individualised gene therapies and PGx 
are understood as ways in which genomics focuses on changing (or in the case of 
PGx, targeting medicines to) individual bodies rather than universalising bodies 
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through, for example, one-size-fits-all drug development and prescribing. They argue 
that this move away from bodily homogeneity in medicine has created multiple 
‘technoscientific identities’ (Clarke et al., 2003: 182) wherein bodily identities are 
created through the application of technoscientific methods.       
 
Gross and Shuval (2008) note that this move from medicalisation towards 
increasing biomedicalisation has recreated the terms through which bodies, and their 
pathologies come to be known and defined. As such, they argue that whereas 
medicalisation was centred on the process of diagnosis (meaning through-knowing), 
biomedicalisation is centred on prognosis (meaning before-knowing) and the 
definition of the body in terms of the risks presented by, and to, it. Elsewhere, the 
characterisation of contemporary society in terms of risk has been well documented 
with Beck (1992) and Giddens (1999) perhaps being the most pervasive scholars 
within this tradition. Within contemporary risk society, it has been argued, the body 
becomes a site within which risks may be manifested and through which risks need 
to be managed. Biomedicalisation, then, focuses on the maintenance of health and 
the minimisation of potential risks rather than the fighting of acute illnesses when 
they occur. This maintenance of health is, elsewhere, argued to be an individual 
social and moral responsibility within which the maintenance of an individual’s 
health becomes beneficial for the health of society as a whole (Bunton et al., 1995).   
 
Central to such health maintenance projects, Clarke et al. (2003) argue, is 
surveillance medicine (Armstrong, 1995). Within this, surveillance and risk are 
understood to co-construct each other with surveillance being necessary in instances 
of increased risk and increased risk being identified through surveillance. This risk is 
understood as being increasingly constructed through technoscientific tests for 
understanding the patient body where such tests construct both epidemiologically 
and individually significant results where, for example, ‘high risk’ breast cancer 
patients are offered interventions for the breast cancer which they do not have yet.  
Clarke et al. (2003) position such risk and surveillance practices within the 
disciplinary nature of the Foucauldian clinical gaze and argue that genomic and 
profiling technologies represent the ‘next wave’ of risk assignments.   
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This salience of risk discourses leads to the development of ‘uncertain 
bodies’ where new medical and health technologies increasingly construct bodies in 
uncertain terms. Hence, emerging medical technologies are shifting the boundaries 
of what bodies actually are. Elsewhere, this has been characterised as ‘reordering 
life’ (Brown and Webster, 2004) and leading to the development of ‘cyborg’ bodies 
(Balsamo, 1996; Haraway, 2000), constituted by a marriage of human organisms and 
machines; the cyborg body, then, is part-human, part-machine on account of the 
technologies which have variously enhanced, altered and acted upon it. For Shilling 
(2003; 2005) this blurring of body boundaries through new technologies represents a 
key paradox; whilst expertise and knowledge of the body is increasing through these 
technologies, certainty about what the body actually is, what its boundaries are and 
what it might be in the future is decreasing.  
4.4 Foucault and the Body 
The work of Michel Foucault is central to the medicalisation and biomedicalisation 
theses and the sociology of the body more generally. Lupton (1997: 94) notes that 
whilst Foucault and his followers have not necessarily subscribed to the visions of 
power and dominance presented within the medicalisation critique or mobilised the 
term ‘medicalisation’ specifically, they nonetheless represent a ‘vision of a world in 
which individuals’ lives are profoundly experienced and understood through the 
discourses and practices of medicine’. In The Birth of the Clinic (1975), Foucault 
argues that medical paradigms have developed over time and have provided 
frameworks through which bodies have been defined, understood and experienced. 
According to Foucault, then, medical expertise and power is the framework through 
which bodily pathologies are identified and dealt with in various epochs of history
12
.   
 
A point of departure between Foucauldian perspectives and those forwarded 
by proponents of the medicalisation critique is the existence of an ‘authentic’ human 
body. Whilst the medicalisation critique understands the body as being an essential 
object, albeit a socially and politically constituted one, Foucauldian analyses 
understand the body and its component parts as being constituted only through 
                                                 
12 Tentative links can perhaps be made here between Foucault’s ideas and those found within 
Pickstone’s (2000) way of knowing presented in Chapter Two 
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discourses and practices through the ‘clinical gaze’ which is exerted by medical 
practitioners.  This clinical gaze is used by Foucault to describe the ways in which 
medical practitioners from the eighteenth century onwards became increasingly 
focused on the observation of patient bodies as a series of symptoms and signs to be 
managed through discourse and practice (Armstrong, 1997). Unlike in the 
medicalisation critique, medical power is not imagined in Foucauldian terms to be 
consciously cultivated and reproduced by medical practitioners but is, instead, 
regarded as a form of disciplinary power within which medical practitioners mobilise 
their clinical gaze to observe individuals and compare them against the ‘norm’ in 
order to arrive at a diagnosis.  
 
Foucault’s notion of the clinical gaze is pervasive within sociological 
analyses of the body and a full representation of the span of its employment would 
be impossible here. However, the notion of a practitioner gaze has previously been 
empirically employed where the characterisation of a ‘nursing gaze’ has been 
developed (see Gastaldo and Holmes, 1999; Henderson, 1994; May, 1992). As an 
example, May (1992) highlights the ways in which the nursing gaze is employed as a 
way to ‘know’ patients, their bodies and their clinical needs. He suggests that nurses 
develop foreground and background knowledge of patients, the former of which 
establishes a clinical definition of the body and the nursing work which it 
necessitates whilst the background knowledge constructs patients as private 
idiosyncratic subjects upon which appropriate nursing work is carried out. The 
structures of nursing work (for example, being based on wards, having more time 
than doctors to talk with patients and building more personal relationships with 
patients) and their relatively subordinate position within hospital divisions of labour 
are posited in May’s (1992) paper as facilitating the development and employment of 
this specific nursing gaze. In the case of pharmacy, Ryan et al. (2004) argue that a 
Foucauldian analysis of pharmacy could be employed in a number of ways such as 
an examination of discursive construction of pharmacy in different countries, the 
power relations within healthcare teams and the position of the body in pharmacy 
vis-a-vis medications adherence practices.  
 
Barber (2005) argues that pharmacists employ a ‘pharmaceutical gaze’ in 
their everyday practice given their ability to ‘see’ the properties of medicines and 
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their potential effects. Despite employing a Foucauldian framework to analyse 
pharmacy, however, he suggests that pharmacy practice ‘is not based on parts of the 
body…manipulating, cutting or caring for the body’. It is argued below, and 
demonstrated throughout the later empirical chapters, however, that in fact the body 
is central to pharmacy practice as Ryan et al. (2004) suggest. Nonetheless, Barber’s 
(2005) tentative employment of the Foucauldian gaze perspective highlights its 
widespread applicability.  
 
Despite this widespread application of Foucauldian perspectives, his 
understanding of the body as ‘totally imprinted by discourse’ (Butler, 1990: 130) and 
having no ‘essential’ physical qualities (see Nettleton, 1992) has provided the basis 
for critiques of his construction of ‘docile bodies’ subject to, but unable to challenge, 
the clinical gaze. As such, in Foucauldian terms, to attribute agency to a body would 
be to provide it with some essential qualities which is in opposition to Foucault’s 
idea of body being wholly constituted through discursive practices. Bodies, then, 
must lack agency on account of their wholly discursive constitution. To proponents 
of the medicalisation perspective such an understanding of the body is problematic 
as this limits the capability of the patient body to exert agency and resist medical 
power. This construction of docile bodies also presents a paradox within Foucault’s 
own terms where he purports that ‘power, after investing itself in the body, finds 
itself exposed to a counter-attack in the same body’ (Foucault, 1980: 56), suggesting 
that power itself generates resistances. The contradiction, then, comes from the 
inability of docile, discursively constructed bodies to exert resistance to power. 
Within this Foucauldian understanding of the body it becomes ‘futile’ (Armstrong, 
1997: 21) to speculate on any essential features that the body might have. This 
understanding of the body, it is argued, is challenging for sociologists to effectively 
engage with as sociological analyses are more often premised on a body which 
represents an interface between elements such as the biological and the social; the 
collective and the individual (Fox, 1997: 41)  
 
Foucault’s influence on the work examining the sociology of the body is 
empirically wide and theoretically deep and only its very surface can be scratched 
here. Nonetheless, the overlaps between increased (bio)medicalisation and 
Foucault’s clinical gaze are important here as new technologies redefine bodies 
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through altered practitioner gazes. This is reflected on in more detail in the case of 
PGx in the later empirical analysis. 
4.5 Positioning the Body in Pharmacy  
Despite the centrality of the body to sociological analyses of contemporary health 
and medicine practices, Chapters Two and Three noted that the body has been 
markedly absent from analyses of pharmacy practice and PGx research and clinical 
practice. Ryan et al. (2004) suggest that a Foucauldian analysis of pharmacy practice 
is necessary, although little empirical work has been subsequently forthcoming from 
within Sociology. As mentioned, they propose a number of ways in which pharmacy 
might be subject to a Foucauldian analysis such as an analysis of the discursive 
construction of pharmacy across different countries, a focus on the power relations 
between pharmacists and other practitioners working collaboratively and a focus on 
the positioning of the body within pharmacy.  
  
 In the later empirical chapters, this thesis analyses the construction of the 
body within pharmacy practice and the ways in which it might be altered by the 
integration of PGx technology. In doing so, the thesis takes Foucault’s ‘clinical gaze’ 
and Barber’s ‘pharmaceutical gaze’ as its points of departure to posit the novel 
concept of the ‘pharmacy gaze’ where the patient body and the medications 
administered to it are argued to be co-constructed through a focus on the 
management of risk and toxicity based on pharmacists’ pharmacology expertise. In 
doing so, this thesis goes someway to addressing a gap in the academic literature 
where Ryan et al. (2004: 50) argue that pharmacy ‘has not been subjected to a 
Foucauldian exploration’  
4.6 New Technologies in Healthcare 
The medicalisation and biomedicalisation theses outlined above are premised on the 
increased availability and use of new medical technologies. More latterly, the move 
towards biomedicalisation posited by Clarke et al. (2003) is underpinned by an 
increase in genomic technologies in medical research and practice. Hence, medical 
innovations are central to the (re)constitution of patient bodies in practice. Despite 
this, there is limited sociological attention give to the ways in which new innovations 
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are integrated into everyday medical practices. Whilst there is a wealth of literature 
within what might be labelled the diffusion theory body of work dealing with 
innovation integration within a macro structure, there are few sociological 
frameworks which deal with the micro-level interaction and work which occur to 
integrate new technologies into routine practice structures. Given this, May and 
Finch’s (2009) NPT is identified as a useful framework for an analysis of qualitative 
data pertaining to the integration of PGx in hospital and community pharmacy 
settings because of its focus on the micro-level work undertaken to define and 
integrate new innovations into routine practice and capture the effects of new 
innovations at this micro-level. What follows here is a rationale for use of this 
framework as a key reference point in the later empirical chapters.   
4.7 Defining ‘Innovation’ 
Despite increased academic interest in technology and innovation, there has been 
‘little attempt to define the actual nature of innovation’ (Osborne, 1998: 1133). 
Rogers (2003: 12) defines innovation as ‘an idea, practice, or object that is perceived 
as new by an individual or other unit of adoption’. Within this definition, innovation 
does not have to be new, only perceived as such by those employing it. As such, 
innovation may as easily be a reconfiguration of existing ideas or technologies as a 
new category or paradigm (Van de Ven, 1999). 
 
According to Greenhalgh et al. (2005) this definition is useful for analysing 
the behaviour of individual innovation adopters, but not as useful when the process 
of adoption by organisations is considered since innovation tends to only be 
considered in this way within organisations when it precipitates a structural or 
systematic change. Hence, people within organisations need to go beyond simply 
perceiving an innovation as new, ‘they must do something-adopt new roles, make 
different decisions, form new relationships, use new technology, develop new 
systems and so on’ (Greenhalgh et al., 2005: 26 (emphasis in original)). Osborne 
(1998) proposes a typology of innovation which addresses this oversight by 
extrapolating the key characteristics of innovations. He argues, then, that there are 
four core characteristics which are central to innovation;  
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1. An innovation represents newness in terms of the first use of a piece of 
information.  
2. An innovation is not the same thing as invention; the latter is concerned with the 
discovery of new ideas whereas the former is concerned with their application. 
3. An innovation is both a process and an outcome whereby innovating and 
innovations it produces can both be studied. 
4. An innovation involves discontinuous change for both the beneficiaries and 
developers of innovation. 
For Osborne (1998) this final point is the key issue which differentiates 
innovation within an organisation from incremental change outside of it whereby 
such organisational innovation represents a paradigmatic shift (see Tushman and 
Anderson, 1986). In other words, discontinuous innovation within organisations can 
be understood as representing a paradigmatic shift in thinking and practice and can 
be located with something of a ‘catastrophe model’ (Herbig, 1991) whilst innovation 
outside of organisations tends to occur as a more incremental change based on the 
decisions of individual actors.   
  
Writing some years ago, Damanpour (1996) distinguishes between ‘product 
innovations’, which are new physical technological artefacts, and ‘process 
innovations’, which are additions to administrative and service processes, which are 
in place to produce a product or provide a service. Identifying technological product 
innovations is relatively easy compared with constructing a definition of process 
innovation given that processes are fluid irrespective of innovation and many 
product innovations also require process innovations (see Westphal et al., 1997). 
 
 PGx can be understood as straddling Damanpour’s (1996) product and 
process innovation categories by requiring a shift in pharmacists’ working practices 
(process) to accompany the technological artefacts of PGx testing kits (product). 
Moreover, PGx could be understood as representing something of a paradigmatic 
shift for pharmacy in line with Osborne’s typology of innovation, as genetic 
medicine in general, and PGx more specifically, has previously not been central to 
pharmacy education or practice. However, the discontinuity of PGx in pharmacy 
should not be overstated given that the integration of PGx across pharmacy settings 
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and specialist areas is not experienced as a universal paradigmatic shift. In other 
words, whilst the successful integration of HER2 testing could be understood as 
something of a paradigmatic shift towards a more genetic configuration of breast 
cancer and the patient body, the lack of pre-prescription testing for primary care 
drugs means that such a shift in approach has not occurred in the community 
pharmacy setting. Hence, a universal paradigm shift in pharmacy is unlikely given 
that PGx innovations are developed in different medical fields at different times.  
 
Nonetheless, the shift towards an increasingly molecularised approach in 
pharmacy can be linked with Pickstone’s (2000) ‘ways of knowing’ framework 
whereby the increased presence of genetic information in pharmacy can be 
understood as a shift towards a more technoscience way of knowing. Moreover, this 
also represents a shift towards an increasingly biomedicalised patient body within 
pharmacy (Clarke et al., 2003).  
 
These attempts to define what is meant by innovation all highlight the 
socially constructed nature of technologies which underpins STS approaches. Surry 
and Farquhar (1997) argue that philosophical approaches to technologies as social 
objects can be located at different points along a continuum of understandings of 
technology. In this, technological determinism, whereby technologies are understood 
as being a key driving force behind social change, and social essentialism, whereby 
technologies are understood as ‘blank slates’ on to which social meanings are 
projected, are located at opposite ends of this philosophical spectrum (see 
Timmermans and Berg, 2003). 
 
Where technological determinism and social essentialism are flawed because 
of their positions at the extreme ends of the construction of technology continuum, 
STS approaches, Timmermans and Berg (2003) show, highlight a reciprocal 
relationship whereby technology is viewed as neither a blank slate or a ‘super’ actor, 
but as one actor among many in the continual reconfiguration of the social and 
technical order. Within this, the social system shapes the design, use and 
understandings of technologies and technologies, in turn, shape the social 
interactions and environment around them. As such, STS approaches are concerned 
with science and technology in action (see Latour, 1987) and keep the question of 
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what technologies do, and how they accomplish things, open (Timmermans and 
Berg, 2003). This inevitably leads to a broad definition of technologies which 
incorporates a spectrum of mundane to highly sophisticated devices, instruments and 
regimes where individual technologies cannot easily be singled out for investigation 
since they are entwined with and embedded into relations of other tools, practices, 
groups, professionals and patients (Timmermans and Berg, 2003: 104). 
 
Such social constructivist approaches, then, are offered as a direct critique of 
technological determinism where the co-constitutive nature of technology and 
society is centralised. Within this, both ‘failed’ and ‘successful’ technologies and 
scientific knowledge become empirically important rather the latter being 
discursively framed as a matter of ‘truth’ (see Bloor, 1991). As an example, in their 
seminal article Pinch and Bijker (1984) apply this methodological symmetry to 
analysing the development of the bicycle and trace the social dimensions 
underpinning the success of some bicycle designs and the failure of others. Within 
this, the role of different social groups in shaping technology and its meanings are 
central. Whilst the users or consumers of given artefacts are the most obvious social 
group to consider, social groups who are not users also have a role in shaping the 
social meaning of artefacts. Additionally, Pinch and Bijker (1984) note that social 
groups which have a relationship with an artefact (both users and non-users) should 
not be homogenised under broad and inadequate headings but should rather be sub-
divided into specific categories. Here, they use the example of women cyclists who, 
during the nineteenth century, were only permitted to use certain types of bicycle and 
not others. By sub-dividing the social group of users along the axis of gender, certain 
stages of the bicycle’s development can be more fully documented and explained.  
 
By identifying all of the social groups which are relevant for a particular 
artefact, its development can be traced through an examination of the specific 
problems it presents for these different social groups. This continual negotiation of 
problems and solutions by interested social groups leads to continually increasing 
and diminishing degrees of stabilisation across various groups as problems, which 
can be technical, judicial or even moral, are solved for different groups and different 
phases.  
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 In terms of relating this to PGx, this thesis takes an STS view of the devices 
and artefacts within this paradigm of practice. As such, the thesis takes the 
perspective that these artefacts are social and political objects which are neither 
completely ‘blank slates’ nor super technologies with extensive organisational 
power. Instead, the thesis demonstrates that PGx technologies are constructed, and 
experienced, differently across different pharmacy settings and medical specialisms. 
Hence, PGx technologies are constructed by the settings into which they are 
integrated and, concurrently, these settings and the work which occurs within them 
are co-constructed by these technologies.  
 
Given this, the thesis is concerned with the micro-level work which is 
undertaken to define and accommodate these technological artefacts into everyday 
practices and the effects that this has on changing practices and the patient bodies 
within them. As such, the thesis departs from traditional diffusion of innovation 
theories which have tended to focus on the macro-level work undertaken to 
implement technologies into large scale structures and organisations.  
4.8 Moving Away From Diffusion Theories 
Everett Rogers (2003) is perhaps the best known innovation diffusion theory scholar 
and draws on ‘diffusion stories’ (Swanson, 2001) from various sociological 
traditions to present a comprehensive model of the ways in which new innovations 
are diffused throughout a social system. Briefly, Rogers (2003) argues that there are 
four key elements in the diffusion of innovations; the innovation itself, the 
communication channels through which messages about innovations are 
communicated, the timeframe within which innovations are adopted and the social 
system into which innovations are adopted. For Rogers (2003) diffusion is the 
process whereby an innovation is communicated through particular channels within a 
social system over a certain period of time, which feeds into the rate at which 
innovations are adopted. Also underpinning this, he argues, is the categories of 
adopters where ‘innovators’ tend to adopt early and launch new ideas within a given 
social system whilst, at the other end, ‘laggards’, who have been compared with 
nineteenth century Luddites (see Jones, 2006), are the last to adopt a new innovation 
given its discontinuation with existing technologies and routines.  
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Such diffusion theories are normative and linear in their understanding of the 
implementation of innovations. As the cases of the integration of PGx tests for 
Herceptin and Tacrine into routine clinical practice outlined in Chapter Three 
showed however, both innovations which are widely adopted and those which are 
not are highly dependent on the play of social processes and contexts. As such, 
whilst diffusion theories may see the failure of integration as symptomatic of, for 
example, a communications failure, these two case studies demonstrate the ways in 
which the social discourses surrounding innovations are manifested in this diffusion 
and integration process. Traditional diffusion of innovations theory has also been 
critiqued elsewhere.   
 
Bayer and Melone (1989) argue that diffusion theories fail to provide a 
precise definition of the term ‘adoption’ or clarify how far this term extends. In 
classical diffusion research, then, adoption is conceptualised as a binary 
phenomenon- an actor either adopts or does not adopt an innovation. Hence, partial-
adoption, reinvention, rejection and discontinuation are under-emphasised. 
Greenhalgh et al. (2005) argue that this ‘pro-innovation’ bias conceptualises the 
artefact as a fixed phenomenon and does not provide adequate room for processes of 
reinvention and modification. The interpretive flexibility of STS approaches 
remedies this issue by focusing on both successful and failed adoptions. Using STS 
to document the development and diffusion process of an innovation presents ‘an 
alteration of variation and selection’ whereby the multi-directionality of the approach 
is central (Pinch and Bijker, 1984: 411).  
 
 Early diffusion research also failed to adequately address the consequences of 
innovation and this has led to the inadequate appreciation of the different 
socioeconomic consequences of innovation within a given social system and 
between different social systems (Greenhalgh et al., 2005). For example, Mossberger 
et al. (2003) show that as information technology became more widely diffused and 
increasingly ubiquitous, the ‘digital divide’13 opened up on different fronts whereby 
                                                 
13
 Mossberger et al. (2003: 1) define the ‘digital divide’ as a conceptual tool for describing ‘the 
patterns of unequal access to information technology based on income, race, ethnicity, gender, age 
and geography’.   
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the inequality of computer access becomes too simplistic a framework for analysing 
digital inequality. They argue that as information technology passes through the 
innovation diffusion process, inequality of digital access becomes extended to 
inequality of skills; inequality of economic opportunity; and an inequality of 
democratic opportunity. As such, whilst traditional diffusion theory might 
conceptualise the ubiquity of computers as a successful innovation story, the social, 
economic and political consequences and meaning of this success are overlooked.  
 
 Individual-blame bias is also identified as a conceptual flaw in diffusion 
theory whereby adopters are categorised based on mathematical formulae rather than 
psychological or socioeconomic characteristics and micro-level interactions. Instead, 
adopters’ socioeconomic or psychological characteristics are attributed to them once 
their place on the S-curve of adoption has been established. This assumes that 
individuals who adopt late are at fault for doing so rather than being either 
economically unable, or psychologically unwilling, to do so. These adopter 
categories are, for Bayer and Melone (1989: 165), ‘arbitrary in the abstract’.  
 
  Diffusion theory often neglects the importance of context for differential 
adoption rates (Greenhalgh et al., 2005). Hence, although studies may present a 
rigorous and systematic overview of the adoption of an artefact within a particular 
context, these findings may not be applicable to other artefacts or contexts.  
Resonances can again be seen here with the Herceptin and Tacrine case studies 
presented in Chapter Three. Within this, the clinical context of dementia and cancer 
treatments contribute to the extent to which these therapies are defined as useful and 
used in everyday practice (Hedgecoe, 2008a). Relatedly, diffusion studies tend to 
concentrate on one aspect of diffusion at a time (i.e. the individual as an adopter or 
the organisation as an adopter). Bayer and Melone (1989) echo this and argue that 
although an innovation may have been adopted by an organisation, this does not 
necessitate it having been fully accepted or adopted by those within that 
organisation. Instead, Greenhalgh et al. (2005) argue that a ‘whole-systems’ 
approach to innovation diffusion research would be beneficial whereby the various 
levels and systems involved in all stages of the innovation diffusion process are 
examined within the same research programme. The later chapters in this thesis 
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demonstrate that the integration of PGx in pharmacy encompasses processes at both 
the organisational and individual practice levels.  
 
 In another critique, the methodology of traditional innovation research is 
identified as being problematic. Since time is a central tenet of diffusion theory and 
research, it necessarily relies on research participants recalling their experiences of 
adopting innovations, which Haider and Kreps (2004: 8) argue carries an inevitable 
risk of gathering incorrect data as ‘many persons cannot recall what they had for 
dinner… never mind looking back in order to recall past history with innovation 
experiences’. Garud and Rappa (1994) and Latour (1987) note that a central tenet of 
the STS co-evolution paradigm is the ‘contemporaneous’ study of technological 
development, which allows scientists and stakeholders to be observed and followed 
through the innovations’ invention, development and diffusion rather than relying on 
data gleaned from memory alone.  
 
In the context of the present research, diffusion theory can also be critiqued 
for failing to distinguish professionals as a distinct sub-group of adopters or users. 
Hence, whilst individuals within a social system are relatively autonomous in their 
innovation decision making and whilst individuals within an organisation are 
relatively controlled by, and restricted to, their organisations’ approach to 
innovation, professionals exist somewhere between these two poles. As such, a 
professional may have the autonomy to decide when and how a given artefact is used 
within their everyday practice, but this artefact can only be used once it has been 
approved by their regulatory body or its use is actively encouraged by members of 
the regulatory or professional body. An example of this can be seen in Lapointe and 
Rivard’s (2006) study of the diffusion and adoption of clinical information systems 
(CIS) in American hospitals. In this study, Lapointe and Rivard found that although 
the use of CIS was being actively encouraged by hospital management, doctors 
mobilised their professional autonomy and actively resisted using CIS as they 
experienced the technology as negatively impacting on their everyday professional 
practice.  This use of professional autonomy sits in contrast to ‘forced adoption’ of 
innovations within organisations where those occupying senior positions make 
decisions on behalf of the entire organisation and then ‘force’ this innovation on 
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those individuals who lack the professional autonomy to resist (Ram and Jung, 
1991). 
 
 In the present study, there are interesting questions around how PGx 
innovations will be diffused throughout, and integrated into, pharmacy practice. The 
above critiques demonstrate that diffusion theories are of limited use in 
understanding this integration process given their linearity and focus on macro-level 
integration. Moreover, diffusion studies are limited in not providing enough 
analytical space for the examination of effects of innovations. Within the later 
chapters the effect that PGx has on the pharmacists’ construction of the patient body 
is shown to be of critical importance which cannot be easily analysed through such 
diffusion models. Instead, STS approaches to technology offer a useful way of 
understanding the complex and multidirectional nature of integrating genetics within 
diverse pharmacy practices.  This diversity of practices in pharmacy is likely to be of 
central importance in framing the ways in which PGx becomes part of everyday 
work. In other words, the process of integration in community pharmacy is likely to 
be different from that in hospital pharmacy given the different structures, 
professional interactions and everyday work in both settings.  
 
 Given the limited value of traditional diffusion theories, then, May and 
Finch’s (2009) NPT is identified as a useful reference point for understanding the 
definition and integration of PGx innovations in pharmacy. Where traditional 
diffusion theories focus on the macro-level adoption of innovations within a fairly 
linear model, NPT examines the micro-level interactional work undertaken to 
integrate new devices and practices into everyday work structures and relationships. 
The next section of this chapter examines NPT in more detail.  
4.9 ‘Normalising’ Innovation in Healthcare  
Understanding and predicting the integration of innovations in healthcare is vital for 
NHS financial forecasting. This is particularly the case given the contemporary 
financial environment and the subsequent need to optimise services and products 
(see Department of Health, 2010). Moreover, understanding the effects of new 
innovations on constructions of the patient body and practitioner work activities is 
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sociologically interesting.  In spite of this, there is a relative paucity of research 
examining the integration of new, non-pharmaceutical technologies in healthcare 
(Robertson and Jochleson, 2006). Moreover, the particularities of integrating non-
pharmaceutical technologies into pharmacy are particularly neglected.  
 
In addition to the limitations outlined above, diffusion theory also fails to 
examine the specific conditions and impacts of integrating innovations into 
healthcare settings specifically (i.e. rather than other social settings). Roberts (1981) 
argues that the ways in which innovations are implemented into healthcare settings 
are different from the ways in which they are adopted in other settings for a number 
of reasons such as the highly politicised nature of healthcare and the extensive 
regulation found within it. Greer (1988) notes that in understanding the nature of 
innovation in healthcare, it is important to differentiate between ‘formed’ and 
‘dynamic’ technologies where the former refers to artefacts which are largely 
complete when they are introduced and the latter refers to technologies which are 
‘still emerging, still in part ideas and experiments’ (Greer, 1988: 6). In diffusion 
theory, the emphasis has tended be on ‘formed’ technologies which is less useful in 
understanding technologies in healthcare settings given that these tend to be more 
‘dynamic’ and, thus, develop as they become integrated (Greer, 1988). In this way, it 
can be seen that new healthcare innovations and the settings into which they are 
integrated are co-constructed during this adoption process. In order to understand the 
specific social actions and phenomena involved in this process, a focus on the micro-
level interactional level of integration processes is more useful.  
 
May and Finch (2009) highlight the importance of this micro-level 
interaction in understanding medical innovation. Their model proposes that 
innovations are implemented, embedded and integrated into everyday practice 
through micro-level work and interaction. Hence, their notion of ‘normalisation’ 
focuses on ‘the conditions of use and the behaviour of everyday users rather than the 
special champions and early adopters so important to diffusion theories’ (May, 2006: 
86). Central to NPT, then, is the everyday types of work that are done to embed 
innovations into routines and integrate them into existing practice. Crucially, this 
work is represented in NPT as being ‘dynamic and contingent’ whereby different 
forms of work are acknowledged as being different across varying contexts (May 
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and Finch, 2009: 542). In implementing interventions, May and Finch (2009) argue 
that there are four mechanisms;  
 
Coherence draws together the work undertaken to define and organise objects of a 
material practice. Within this, identifying differentiation from existing practice is 
important in the construction of innovative practice as meaningful or otherwise. This 
differentiation process is undertaken both communally, where the practice is 
rendered in terms understandable and applicable to all of the actors working in the 
area or field, and individually, where this differentiation is cohered as meaningful or 
otherwise within individual practitioners’ everyday routines.  
  
Cognitive Participation refers to the real and symbolic engagement of actors with 
innovations. This process of cognitive participation is highly context-dependant as 
the norms and conventions of professional groups and practices change. Within this, 
the processes of initiation, enrolment, legitimation and activation occur. Initiation 
refers to bringing a practice to the attention of a group of practitioners or 
stakeholders; enrolment refers to actors working collectively to participate in a new 
practice; legitimation, in contrast to enrolment, requires actors to ‘buy into’ an 
innovation rather than being naturally enrolled through their networks; and finally 
activation refers to the provision of the means and materials for an innovation to be 
used in everyday routine practices.   
 
Collective Action refers to the mental and material work which is done to organise 
and enact a practice. This action is located within the conditions of interactions 
between practitioners and within these conditions, interactional workability (the 
operationalisation of innovations within everyday interaction and encounters) and 
relational integration (the ways in which a practice is mediated within the networks 
around it) are central. Moreover, NPT highlights two further important qualities; 
skill-set workability, which describes the distribution of innovation within a division 
of labour and contextual integration, which describes the incorporation of innovation 
within a given social context.  
 
Reflexive Monitoring refers to the continuous formal and informal evaluation of 
collective action processes. Within this, systematisation refers to the methodological 
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formality of this evaluation work where judgements about the value of innovations 
made in everyday practice are positioned alongside more formal modes of evaluation 
such as clinical trials. This evaluation is then undertaken at two levels- communal 
and individual appraisal where communal appraisal refers to collective evaluation 
within a network of practitioners whilst individual appraisal refers to experiential 
and unsystematic judgement processes within everyday practice. These evaluations 
may, then, lead to reconfiguration where ideas about the use and utility of 
innovations may be reconstructed or modified.   
  
This model of understanding innovation in healthcare settings provides a 
more useful framework than diffusion theory for analysing qualitative data around a 
particular healthcare innovation, in this case PGx. Although NPT has this relative 
advantage over traditional diffusion studies, the model does present a number of 
limitations. Firstly, the notion of ‘embeddedness’ is at the centre of NPT where work 
is understood to be organised around the process of embedding new innovations 
within particular settings. This concept, however, can be problematic since there are 
no clear measures of embeddedness beyond the idea that a complex intervention can 
be operationalised as being embedded once it becomes part of the ‘matrices of 
already existing, socially patterned, knowledge and practices’ (May and Finch, 2009: 
540). This definition, however, assumes general agreement about the nature of these 
‘matrices’ of knowledge and practice.  
 
Secondly, NPT presents routine clinical practice, into which new innovations 
are integrated, as something of a stable phenomenon. Hence, innovations are 
presented as being introduced into a practice landscape and a population of 
practitioners which are fairly robust. Normalisation work, then, is represented as 
being undertaken within the confines of this relatively rigid landscape. This seems at 
odds with the nature of healthcare settings, however, which are fairly fluid and 
highly changeable through both local and national reconfigurations. Hence, the 
normalisation work undertaken within them is not undertaken within a set of rigid 
boundaries but is, instead, part of the perpetual renegotiation of work and routines.  
  
Despite these shortcomings, NPT could be used in one of two primary ways 
in the current qualitative data analysis; as an a priori coding frame or as a reference 
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point for an emergent coding approach (see Stemler, 2001). The somewhat 
normative a priori use of any theoretical approach within this thesis would seem to 
limit the analytical freedom which is presented. Hence, the empirical data presents a 
number of potential options for theoretical applications and so an analysis limited to 
the confines of any particular one of these risks simplifying its complexities. As 
such, a number of components of NPT are mobilised as a way through which PGx in 
pharmacy can be understood.  Coherence work, contextual integration and reflexive 
monitoring resonate with the data and so are used as reference points within which 
the importance of everyday micro-level work can be demonstrated. As such, NPT is 
not used a priori but, instead, informs the emerging novel analysis where relevant.  
4.10 Conclusion 
In sum, this chapter has outlined the theoretical frameworks which underpin the 
subsequent analytical chapters. The chapter has shown that the body is of central 
importance in sociological analyses of medical practice and, within this, Foucault’s 
work around the clinical gaze is of particular note. Sociological discourses of 
medicalisation and, more latterly, biomedicalisation (Clarke et al., 2003) have been 
shown to be relevant to understanding the body and the development of PGx in 
relationship to it. Despite this centrality of the body in contemporary accounts of 
medical practice, the patient body is argued to be markedly absent from analyses of 
pharmacy practice. Moreover, despite Ryan et al.’s (2004) assertion that Foucauldian 
principles may be useful in sociologically characterising contemporary pharmacy 
practice, the body remains absent from his analysis and, more surprisingly, from 
Barber’s (2005) Foucauldian ‘pharmaceutical gaze’. In mobilising Foucault’s notion 
of the clinical gaze to posit the novel concept of the ‘pharmacy gaze’, this thesis 
addresses this gap in the literature.  
 
 It is shown here that the biomedical configuration of the body is centred on 
the use of innovative technologies within contemporary medical practice. Despite 
this, there has been limited attention given the ways in which new technologies are 
integrated into medical practice at the micro-level. The chapter argued that in order 
to understand this, the thesis adopts an STS perspective in conceptualising new 
technologies as socially constituted by the contexts in which they are located and the 
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practitioners within. Given this, the chapter argues that the rigidity and linearity of 
traditional diffusion theory does not provide an adequate framework within which to 
analyse the micro-level interactional work undertaken around PGx technologies in 
diverse pharmacy settings.   
 
Here, May and Finch’s (2009) NPT is deployed as a useful alternative 
framework for a qualitative analysis given its divergence from this macro-level focus 
and fairly rigid linearity of diffusion theory. In its focus on everyday practice and 
interactions and work activities with it, NPT offers a useful tool upon which to 
loosely base analyses. In other words, this thesis does not adopt a wholly NPT 
perspective in the analysis but, rather, the components of NPT are mobilised as 
analytical tools where they clearly resonate with the empirical data.   
4.11 Research Questions  
The preceding chapters have contextualised this research project by locating it within 
sociological analyses of pharmacy and PGx and, subsequently, at the juncture of 
both of these. At the end of Chapters Two and Three, a number of research questions 
arising from the sociological literatures have been proposed. These research 
questions are central to the empirical fieldwork undertaken and, as such, it is useful 
here to present an overview of the key research questions and their sub-questions as 
they relate to the structure of the empirical chapters of the remainder of this thesis. 
What follows this is an overview of the methodology employed to answer these 
research questions.  
4.11.1 Conceptualising Contemporary Pharmacy Practice 
In order to characterise the potential integration of PGx into pharmacy, its effects on 
practice and the construction of the patient body within it, it is important to present a 
sociological characterisation of contemporary hospital and community pharmacy 
practice. As such, it is asked; 
 What are the defining structures of contemporary pharmacy practice in 
hospital and community settings? 
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 How do these structures shape pharmacists’ everyday work and 
communication? 
 
 What practices or approaches intersect both of these sectors? 
 
 How is the patient body configured in hospital and community pharmacy 
practice? 
 
 Through what discourses or technological practices is the body known in 
pharmacy? 
4.11.2 Technology in Pharmacy 
It is doubtless that technology plays a central role in both dispensing and clinical 
activities in pharmacy. Understanding the ways in which technologies have been 
integrated into hospital and community and the effects that these have had on the 
patient body is important in providing a framework through which the integration of 
PGx can be approached. As such, it is asked; 
 What technologies are important in everyday pharmacy practice? 
 
 How have these technologies been understood and integrated into hospital 
and pharmacy settings? 
 
 How have these technologies contributed to the (re)configuration of the 
patient body? 
 
 How have everyday work routines and activities been altered by these 
technologies? 
 
 What effects has this had on practice structures previously outlined?  
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4.11.3 Pharmacogenetics in Pharmacy  
The development of a sociological characterisation of contemporary pharmacy 
practice and the position of technologies within it provides a framework through 
which the integration of PGx can be analysed. As such, it is asked; 
 What impact has PGx made on pharmacy practice to date? 
 
 How might pharmacists be involved in PGx in the future? 
 
 What might be the impacts of PGx on the practice structures within hospital 
and community pharmacy? 
 
 What might be the impacts of PGx on pharmacists’ construction of the 
patient body?  
 
 How is PGx evaluated by pharmacists within the framework of their 
everyday practice? 
 
 What challenges does the integration of PGx present for hospital and 
community pharmacy?  
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Chapter Five: Methodology  
5.1 Introduction 
The preceding chapters have outlined the rationale behind the examination of the 
pharmacy profession and PGx technology and have outlined the research questions 
which underpinned the fieldwork which was undertaken. This chapter moves on to 
describe the methods through which the data informing the conclusions of this 
project was gathered. The chapter begins with an outline of the rationale behind 
using semi-structured interviews as a data collection tool; it then moves on to 
examining the specific challenges raised by conducting interviews with ‘elites’- in 
this case professional elites; the methods which were used to identify and recruit 
participants are then outlined; and the data analysis techniques and processes are 
then addressed.  
5.2 Choosing Interviews as a Research Tool 
Arguably, semi-structured interviews represented the most logical and 
appropriate method through which the questions raised in the previous chapters 
could be addressed. This method of data collection was the most suitable for this 
research as it allowed the opinions, experiences and perspectives of practitioners 
who are currently, or potentially, involved with PGx technology and/or pharmacy 
practice to be elicited through in-depth, detailed conversations. Whilst focus groups 
and survey research represented alternative methods through which these opinions 
could be captured, these approaches have a number of drawbacks which made them 
unsuitable for this particular project. As such, the practical challenge of gathering 
numerous busy healthcare practitioners together in the same setting was perceived as 
disproportionate to the relatively limited advantages that using focus groups would 
have presented. Moreover, survey methods were also inappropriate for the research 
as, although open-ended questionnaires can provide a space for participants to 
express their opinions and experiences, they do not allow the motives and meanings 
behind such responses to be fully explored as they can be in semi-structured 
interview scenarios.  
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Semi-structured interviews were selected as the primary method of data 
collection not simply because they represented the most effective way of collecting 
appropriate data for this project but because they were particularly useful for 
researching healthcare settings and healthcare interventions.  
 
Semi-structured interviews have been acknowledged as a particularly apt 
method for capturing the perspectives and reflections of healthcare practitioners 
owing to the nature of the interview encounter being akin to the practitioner-patient 
encounter in the clinic (Holloway and Wheeler, 2010). Owing to pharmacists’ 
extended clinical role and increased contact with patients, a form of interview is also 
‘an integral part’ of the work of pharmacists (Gantley, 2001: 458). As such, the 
semi-structured interview format was one that participants in the sample were 
thought to be familiar with. Nevertheless, conducting interviews with professional 
participants presents a number of challenges, which this chapter now addresses.  
5.3 Interviewing Professionals  
The specificities of interviewing different professional groups are under-explored in 
the academic literature. As such, the process of interviewing healthcare professionals 
is represented as a homogeneous process and experience irrespective of the 
particular professional field of participants. In practice, different fields of work place 
different pressures and constraints on professionals, which can impact on the 
research conducted with them, particularly in terms of recruitment and the 
practicalities of conducting an interview. This means that researchers need to be 
sensitive to the appropriate ways of approaching professionals from different fields 
rather than only mobilising one recruitment and interview strategy for all participants 
because they can all be classed as ‘professionals’. As an example, for this project, 
recruitment of community pharmacists mostly took place through snowballing 
techniques beginning with an initial gatekeeper who established informal contact 
between the researcher and other potential participants. This is in contrast to the 
recruitment of oncologists which took place through formal e-mail channels and, 
usually, via the potential participant’s personal assistant. Moreover, all of the 
interviews conducted with community pharmacists were done outside of their work 
setting and working hours whereas all but one of the hospital pharmacists were 
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interviewed during their allocated breaks at work. What this shows, then, is that the 
different work structures between community pharmacists, hospital pharmacists and 
oncologists mean that different recruitment techniques and interview methods had to 
be mobilised to undertake qualitative research with these diverse professionals. As 
such, amalgamating the methods used for these interviews under the rubric of 
‘professional interviews’ would be simplifying a complex methodological 
phenomenon.  
 
For junior researchers, the process of interviewing professionals can be 
particularly challenging. Drawing on his experiences of interviewing CEOs, vice-
presidents and directors of pharmaceutical and biotechnology companies during his 
doctoral and post-doctoral research, Harvey (2010) provides a useful guide for junior 
researchers conducting interviews with ‘elites’. He argues that junior researchers 
interviewing professionals have to be more organised, flexible, transparent and 
persistent and better at maintaining good etiquette than their colleagues who are 
interviewing the lay public. For junior researchers their lack of experience and 
publications and their potential (although not necessarily problematic) vagueness 
about their research questions makes the recruitment process particularly challenging 
when busy professionals in positions of responsibility are targeted for study 
inclusion.   
 
Whilst Harvey’s guide proved to be useful as an introductory source for this 
project, he does not adequately address the issue of power within the research 
process and how this might be experienced by junior researchers. Traditional 
approaches to the power relationship between interviewers and their participants rely 
on a fixed notion of power as being an ‘inscribed capacity…which is appropriated by 
particular individuals’ (Smith, 2006: 644). Traditionally, the researcher is understood 
to posses the power within a research encounter but research involving elite 
participants has tended to assume that those with power in professional spheres will 
transfer this power directly onto the interview encounter and remove the power from 
the interviewer (Smith, 2006). Post-structural approaches have, however, rejected 
this notion of power as a zero-sum game and have concentrated on power as a fluid 
and mobile phenomenon. In research involving elites, it has been argued that the 
traditional idea of elites transferring their professional power onto the interview 
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encounter is unfounded in the reality of such research (Puwar, 1997; Sabot, 1999; 
Smith, 2006). As such, these researchers have argued that ‘studying up’ presents a 
less challenging research endeavour than ‘studying down’ in that participants tend to 
be easier to identify due to their online presence; the response rate to invitations to 
participate tends to be higher; and interviews rarely present significant physical risks 
to the researcher (Smith, 2006).  
 
For junior researchers, the power relations of research encounters with 
professional elites can raise important questions. Mullings (1999) notes that junior 
researchers in particular occupy an ambiguous position whereby they can be 
perceived as ‘inexperienced’ or ‘at the cutting edge’ in contrast to senior researchers 
who are either ‘world experts’ or ‘out of touch’. As such, it is important for junior 
researchers to be aware of the power dynamics of each research encounter. 
Moreover, Mullings (1999) assumes that it is only researchers who are positioned in 
these experiential terms. During the fieldwork, however, it became apparent that 
what might be called a disciplinary chasm between the participants and I was a 
useful tool in building a mutually beneficial and intellectually reciprocal 
relationship. In other words, as well as my relatively limited knowledge of pharmacy 
and PGx, the participants’ relative ‘inexperience’ in Sociology and its applicability 
to pharmacy and PGx meant that research encounters were, more often than not, a 
mutual learning experience where the participants and I were positioned as ‘experts’ 
at various points during the encounters. As such, the experience of interviewing 
professional elites for this project was experienced in line with the post-structuralist 
view that power is not a zero sum game.  
5.4 Identifying a Sample 
In order to understand the ways in which PGx technology may impact on the 
pharmacy profession in England, it was important to capture the perspectives of a 
range of participants from a number of fields. The necessity of this diversity was 
grounded in the nature of PGx technology as a collaborative medical intervention 
(see El-Ibiary et al., 2008; PricewaterhouseCoopers, 2009). Moreover, it was 
important not to limit reflections on PGx in pharmacy to just the pharmacists who 
may use PGx in the future but, instead, to capture the perspectives of actors who are, 
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or may be, involved in PGx at various stages of its development and use in clinical 
practice. In doing this, the interviews were able to create a map of PGx technologies 
from the lab bench to the patient bedside incorporating the views of scientists and 
practitioners as well as those who may be positioned as PGx gatekeepers.  
 
In doing this, six fields of practice were identified as being important to the 
current development of PGx and its future use in medical practice. These fields were 
identified as pharmacogenetic research, Oncology, general medical practice, 
pharmacy at the administrative and policy level (herein pharmacy stakeholders), 
hospital pharmacy and community pharmacy. Table 3 outlines the rationale for 
selecting these fields of practice and the number of participants from each.  
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Field of Practice 
 
Rationale for Inclusion 
Number of Respondents 
(specialisms within these practice 
groups) 
Pharmacogenetic research Development of PGx technologies  
 
Overview of contemporary PGx landscape 
10 
(1 Medical technology consultant) 
Oncology ‘Promising’ field for PGx (see Houtsma et al., 2010) 
 
PGx currently used in routine Oncology practice 
2 
General medical practice Likely gatekeepers to PGx in primary care 
 
Medicines prescribers in primary care 
 
Relationship with pharmacists 
2 
Pharmacy stakeholders Taking decisions about PGx implementation and education 
 
Overview of contemporary pharmacy profession 
4 
Hospital pharmacy Currently practising with PGx in some specialisms 
 
Most likely setting to be implemented first 
 
Professional relationships and occupational structure  
10 
(1 Health economist) 
(2 Oncology pharmacists) 
(2 Chief pharmacists) 
Community pharmacy Potential impact on future practice 
 
Professional relationships and occupational structure 
10 
(1 special interest in Warfarin) 
 
Table 3: Participants' professional groups and the rationale for their inclusion 
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It should be noted that these six categories represent the capacity in which 
participants were approached for inclusion in the study rather representing the 
entirety of their professional activities. As such, the oncologists interviewed also 
participated in PGx research but were approached primarily in their capacity as 
Oncology practitioners. Similarly, two of the hospital pharmacists that were 
interviewed specialised in the field of Oncology and, therefore, could have been 
categorised within the Oncology field of practice. However, these two participants 
were primarily approached for inclusion in their capacity as pharmacists, albeit in the 
specialist area of Oncology.  
 
Within these six fields, potential participants were identified using a 
purposive sampling approach given their likely knowledge of PGx and/or pharmacy. 
Within this, a number of ‘key’ participants were identified by their eminence in their 
given field or by some professional activity or specialism relevant to the research. 
The mistake should not be made that these key participants were identified due to 
their role as innovators (Rogers, 2003) or opinion leaders (Greer, 1988). Rather, 
these key participants were selected for inclusion on the basis of their deeper 
engagement with PGx technology or pharmacy practice rather than their activities in 
championing these phenomena, although the two are not mutually exclusive.  
 
Deeper internet research into the professional activities of these key 
participants located them within wider professional networks, whose other actors 
were then also identified as potential participants. Here, there is a risk that this 
network mapping could have continued indefinitely if each of the key participant’s 
collaborators were to be taken as a new subject around whom to build a network 
map. In order to avoid this, each key participant’s network map was developed to a 
point at which it was unlikely that new participants would offer novel insights. An 
example of one of these network maps that was developed around one key 
participant is shown in Figure 1 below.  
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Figure 1: An example network map for Oncologist 2 
Such network mapping was not possible, or advantageous, for participants 
from all of the six practice fields. For example, such network mapping for 
community pharmacists was not possible given the relative isolation of community 
pharmacy practice. As such, those participants who were not recruited through such 
network mapping were targeted based on the feasibility of their inclusion and/or 
snowballing techniques. The contact details of these potential participants were 
identified through internet searches, which supplied contact details through academic 
papers, professional articles, professional network websites (such as LinkedIn), 
employers’ websites and conference documentation. Where snowball sampling was 
used, contact details were obtained from gatekeepers.  
5.5 Gaining Ethics and Governance Approval  
Once the sample had been identified, the research was subject to approval by a 
number of committees. The ethics review process comprised four stages: obtaining 
institutional ethics approval, obtaining local Research Ethics Committee (REC) 
approval, obtaining a Research Passport (RP), and gaining governance approval for 
each NHS Trust within which the research took place. This NHS ethics review 
process was implemented in 1991 as a way for the NHS to review the ethical 
implications of both therapeutic (i.e. clinical) and non-therapeutic (i.e. social 
science) research involving those to whom the NHS has a duty of care (Department 
of Health, 1991). What follows is a review of these four stages of ethics and 
governance approval.   
 
Key participant: 
Oncologist 2 
Hospital pharmacist 9 
Pharmacogeneticist 5 
Is working on clinical trials 
with 
Has collaborated with 
Collaborates with 
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 The initial phase of the ethics review process was obtaining institutional 
ethics approval. As the research was conducted as part of an educational programme, 
this review was conducted at the departmental level, with a report being relayed to 
the University ethics committee. In order to obtain approval at this stage, a 
standardised form was submitted along with the recruitment literature. If the research 
had not involved NHS participants, ethics approval at this phase would have been 
sufficient. However, because the research involved NHS staff members, the project 
was required to be reviewed at three further phases.  
 
 The first phase of obtaining NHS ethics approval involves researchers filling 
out an extensive online form which is submitted, along with all of the documents that 
will be taken ‘into the field’, to an 18-person REC. This documentation included; 
 Initial recruitment e-mail  
 Follow-up e-mail sent two weeks later if no response was received 
 Project information document attached to these recruitment e-mails 
 E-mail sent a week before the date of the interview to confirm details  
 Participant Information sheets for each group attached to this confirmation e-
mail and given to participants before the interview (i.e. because the practice 
groups were targeted for different reasons, each needed a different Participant 
Information sheet)  
 Interview topic guides for each group of participants (i.e. because the practice 
groups had different professional backgrounds, the questions that they were 
asked varied and different interview topic guides had to be developed for 
each) 
 Consent form   
In addition to this ‘field’ documentation, the REC also required the following 
documentation; 
 Departmental ethics approval confirmation 
 Funding information 
 A covering letter outlining the project 
 A project protocol 
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 Transcriber’s Confidentiality Agreement  
 CV for the Chief Investigator  
Given the need for large volumes of documentation, and for this documentation 
to be presented in a standardised way, preparation of the REC application took 
around one month. Following the submission of the application, researchers are then 
invited to attend a local REC meeting where they have the opportunity to discuss 
their research with the committee members and clarify any issues which arise, but 
which do not necessitate a substantial amendment to the online form (for example, 
spelling mistakes, inconsistencies within participant numbers and clarification of 
medical definitions). Following this meeting, RECs then offer a favourable, 
provisional or unfavourable opinion to the researcher (O’Reilly et al., 2009). This 
project was subject to review by the South Yorkshire REC in February 2011, 
following which a favourable opinion with conditions (to alter the name of the REC 
and clarify participant numbers) was obtained. This alteration was made and a final 
favourable opinion was obtained on 4
th
 March 2011. In the period between 
submitting the documentation to the REC and attending the REC meeting 
(approximately one month), the relevant information for obtaining an RP was 
compiled ready for the second stage of the NHS ethics and governance process.  
 
 RPs were introduced in 2009 as a ‘bureaucracy buster’ and way of 
streamlining the ethics approval process and reducing the amount of duplication that 
applications had previously required (Kielmann et al., 2007: 237). They are 
necessary for researchers who do not have a contractual relationship with the NHS 
and circumvent the need for researchers to obtain separate honorary contracts at each 
individual research site. The RP form details each individual NHS Trust in which 
research will take place and the numbers of staff that will be recruited from each 
Trust. This form, along with confirmation of a favourable outcome from the REC, a 
Criminal Records Bureau certificate, a signed and dated CV and an occupational 
health certificate, is submitted to the lead R&D department for the study, which is 
usually the NHS Trust in which the majority of the fieldwork will be conducted. For 
this project, obtaining Criminal Records Bureau and occupation health certificates 
was not necessary due to the fact that the research mobilised an interview 
methodology and did not recruit patients. Once a valid Research Passport has been 
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issued, this can then be used to apply for governance approval at each NHS Trust in 
which the research will take place. The lead R&D department to which the relevant 
documents were submitted was York Hospital NHS Trust and a Research Passport 
was issued on 24
th
 February 2011. 
 
 The process of applying for governance approval involves filling in relatively 
short Site Specific Information (SSI) and lengthier R&D forms for each NHS Trust 
from which participants are recrutied. The former is necessary to review the financial 
and practical demands being placed on specific NHS sites to assess whether the site 
is capable of hosting the research (Smajdor et al., 2009). Some of the R&D form is 
automatically populated from the REC form with details pertaining to the specific 
Trust being changed. Once these forms have been signed by the relevant people (the 
signatory for each Trust varies according to individual Trust governance 
requirements), they are submitted, along with supporting documentation to the 
relevant R&D department. Here, the documentation required is, usually; 
 Completed R&D form 
 SSI form 
 All documents submitted to, and approved by the REC 
 All correspondence with the REC 
 REC approval letter 
 RP  
 Financial assessment of the research 
 An indemnity statement 
 Letter from the research sponsor confirming the institution and governance 
frameworks to which the researcher is bound  
 Due to the lack of standardisation across different Trusts, the process of 
applying for governance approval at numerous sites is extremely challenging. For the 
present study, nine NHS Trusts were identified as potential sites of research 
activities. Whilst some of these sites requested unsigned SSI forms where signatures 
would be collected by the R&D department, others required signatures to be 
obtained from clinical leads of each specified department, which was cumbersome 
and time-consuming. Governance applications were submitted to, and received from, 
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nine NHS Trusts. Given the lack of standardisation of governance application 
timeframes, the time taken for these governance approvals to be obtained varied 
widely from 3 days to 6 months. Moreover, given that research participants cannot 
be contacted prior to governance approval being granted, two of these governance 
application were submitted somewhat needlessly since the Trusts to which they were 
submitted yielded no respondents.  
5.5.1 Reflections on the NHS Ethics and R&D Approval Process 
Although the process of obtaining NHS ethics and governance approvals is 
underpinned by rhetorics of risk protection and research rigour, the process has been 
widely critiqued by both clinical and social researchers. For social science research, 
the process has been critiqued for being bureaucratic, time consuming (Reed, 2007), 
‘unethical’ (Dingwall, 2006) and focusing too heavily on scientific, rather than 
ethical, issues (Angell et al., 2008). Moreover, the process has been identified as 
being too heavily biased towards clinical research methodologies, which means that 
NHS institutions, as research sites, are heavily gate-kept by NHS personnel, which 
places social researchers at a disadvantage due to their ‘outsider’ status (Reed, 2007; 
Richardson and McMullan, 2007). As such, there seems to be a disjuncture between 
the positivist, linear nature of the application process and the interpretivist, 
serendipitous nature of social research. Moreover, the 18-member REC is primarily 
constituted by individuals drawn from the clinical and biomedical community (Dyer, 
2004; Gauld, 1999; Reed, 2007) whose lack of qualitative and social research 
expertise can lead to questions being raised which are less centred on ethics and 
more concerned with methodological or analytical issues. In a similar vein, Richards 
and Schwartz (2002) argue that debates about the ethics of social research may be 
inaccessible for healthcare professionals who receive little training in this area, 
which can lead to RECs being perceived as missing the point, crossing the boundary 
into the assessment of academic rigour and distrusting qualitative research, all of 
which further compound the notion that the NHS ethics process is biased against 
social research.  
 
 Although there is a significant amount of social science literature addressing 
the purpose, nature, challenges and benefits of the NHS ethics and governance 
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approval process, little attention is given to the degrees of expertise and experience 
of researchers going through the process. As such, a senior academic is likely to have 
a different experience of the process than a junior PhD researcher. Based on the 
experience in this particular project, for early careers researchers, the need for NHS 
ethics and governance approvals presents three primary problems.  
 
 Firstly, these processes require researchers to identify their sample members 
(or at least the NHS Trusts from which they will be drawn) and specific research 
questions early on so that the recruitment literature and interview topic guides can be 
submitted to the REC and the relevant information be filled in on the SSI and R&D 
forms. This early confirmation, however, sits in opposition to the nature of a PhD 
which is primarily an educational undertaking during which research questions and 
theoretical perspectives develop rather than being set from the beginning.  
 
 Secondly, the entire NHS ethics and governance approval process tends to 
take around six months (Reed, 2007), although as demonstrated in the present 
proejct, this can take as long as nine months (also see McDonach, 2009). Given that 
PhD researchers who are required to undergo NHS ethics and governance review are 
not provided with extra time in which to conduct their research, these extra months 
have to be factored into the project time line. This means that because PhD 
researchers can spend around one sixth of their research project time involved in 
these processes rather than conducting fieldwork, the breadth and quality of the 
empirical research may be hampered.  
 
 Finally, despite attempts to streamline and standardise the REC system, the 
process of obtaining governance approval remains extremely ‘cumbersome’ (Al-
Shahi, 2005: 445) due to the different requirements of different Trusts’ R&D 
departments. In some instances, these departments require substantial administration 
fees or remuneration for staff time given over to non-NHS research activities, neither 
of which is factored into PhD budgets. However, the most significant challenge 
raised by this lack of governance application standardisation is the different 
requirements for obtaining authorisation. In some instances, this is obtained by the 
R&D department on behalf of the researcher but in instances where the researcher 
has to approach clinical leads for signatures, this can present a number of challenges 
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for junior researchers in particular. Given that most clinicians will be relatively 
unfamiliar with social research, the request for a signature for authorisation for a 
qualitative interview study can be somewhat unclear. In this instance, researchers 
have to work hard to demonstrate the importance of their study, which is difficult 
given their lack of experience, networks and publications (what one may call 
academic capital). As such, this process of obtaining signatures from individuals 
who are largely unconnected with the research can be extremely time-consuming for 
junior researchers. 
 
 In 2010 the ESRC published its Framework for Research Ethics which 
generated some debate within the social science literature as to the necessity and 
place of NHS-style RECs in social research. In November of 2010, the journal 
Sociological Review Online published a special ‘Debate’ section on this framework 
within which Hammersley (2010) analysed the Framework as an indication of ‘ethics 
creep’ into the governance of social research whilst Reed (2010) imagined social 
researchers as having ‘nowhere left to hide’.  
 
In contrast to these somewhat bleak reflections on the NHS ethics and 
governance process, Adam Hedgecoe (2008b) drew on observations of RECs and 
interviews with their members to argue that these perspectives on RECs’ expertise 
have over-emphasized the difference between social and biomedical research. Whilst 
traditional understandings of RECs’ lack of social science expertise have constructed 
RECs as hindering social research, Hedgecoe argues that REC members in fact see 
their role as facilitating and supporting social research. Although Hedgecoe’s 
empirically-informed conclusions provide a valuable antithesis to these traditional 
understandings, the latter remains the dominant voice in this field and is, perhaps, 
more commonly applicable to researchers’ experiences of the NHS ethics and 
governance process than Hedgecoe’s. Moreover, Hedgecoe’s paper is only 
concerned with social scientists’ experiences of the REC application process, which 
as is shown, is only the first phase of the journey towards full ethics and governance 
approval and eventual fieldwork. 
 
Notwithstanding these debates, the process of obtaining ethics and 
governance approval for this project took around nine months and placed a large 
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administrative burden on the fieldwork phase of the research. Figure 2 highlights the 
complexities of this process.  
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Figure 2: The ethics and governance approval process with time taken for governance 
approvals 
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5.6 Recruiting and Interviewing a Sample  
Due to the need for NHS REC approval of recruitment literature, the recruitment 
process and its literature were standardised for all participants in the study. In total, 
thirty eight interviews were carried out. 
 
 In the case of participants who were NHS employees, the process of 
recruitment could only begin once the relevant ethics and governance approvals had 
been finalised. Once these approvals were in place and the names and contact details 
of all potential participants had been identified, an invitation e-mail or letter, for 
participants whose e-mail addresses were not available online, with a project 
summary was sent (see Appendices A and B). In cases where no response was 
received, a follow-up e-mail or letter was sent two weeks later (Appendix C). This 
follow-up correspondence was sent based on the assumption that a lack of response 
did not necessarily indicate an unwillingness to participate in the project. As the 
research was conducted with busy healthcare professionals, allowances for 
correspondence being lost or delayed response were made.  In instances where no 
response was received following this second correspondence, it was assumed that the 
potential participant did not wish to take part in the study and so no further action 
was taken.  
 
 Where responses and expressions of interest in participation were received, 
details of the interview time and place were arranged over the telephone or by e-
mail. One week before the interview was scheduled to take place, the participants 
were sent an e-mail confirming the interview (Appendix D) with a Participant 
Information document containing details of project funding, research objectives, the 
motivations for their inclusion in the study and details of the ethical considerations 
of the project (Appendix E).   
 
 This recruitment process followed the same time scale and used the same 
literature for all participants who were NHS employees. For those that were recruited 
from outside of the NHS, the recruitment process was less standardised and the 
content of the recruitment literature varied depending on how the individual was 
recruited. As such, the non-NHS participants who were recruited through 
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snowballing techniques were contacted in a more informal manner which diverged 
from the recruitment literature used for NHS employees given the different 
circumstances.  
 
 As mentioned, the divergent structures of everyday work across the practice 
groups from which the sample was drawn necessitated different approaches to 
recruitment and conducting interviews. In conducting interviews with practitioners 
from different professional fields, divergent interview topic guides were developed 
to reflect the divergent nature of practices and to answer the research questions 
outlined at the end of Chapter Four. These divergent topic guides can be found in 
Appendices F-K. 
  
In all of the interviews, however, informed consent (Appendix L) was 
obtained prior to conducting the interview and each interview was recorded digitally. 
The following sections present an overview of the particularities of recruiting and 
interviewing participants from these practice groups.  
5.6.1 Pharmacogeneticists 
Pharmacogeneticists are defined here as scientists who are currently investigating the 
relationships between genetics and drug response/metabolism and/or developing 
technologies which may be implemented into PGx practice in the future. This group 
of participants are usually academics who run research groups and collaborate 
widely with healthcare practitioners from various fields. Due to their position at the 
forefront of the technological development of PGx, their perspectives on its current 
advancement and potential future implementation were of central importance to the 
research questions.  
 
This group of actors were selected as an appropriate sample of key 
participants with whom to conduct pilot interviews given that they would be likely to 
be able to provide something of an ‘overview’ of the PGx story from the lab bench to 
the patient bedside. For these pilot interviews, seven pharmacogeneticists were 
identified through internet searches of current and previous UK PGx research 
projects. These pharmacogeneticists were contacted by e-mail for inclusion in the 
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study. Of the seven identified and contacted as potential pilot study participants, five 
were interviewed, one recommended a more appropriate colleague and one stated 
that they did not have time to participate. Six pharmacogeneticists, then, were 
interviewed during the pilot stage of the fieldwork (an overview of pilot studies is 
detailed below).  
 
During these pilot interviews, four more pharmacogeneticists were identified 
by participants as potential interviewees and were subsequently contacted for 
participation once the rest of the recruitment and fieldwork was started. Two of these 
pharmacogeneticists did not respond to being contacted about participation. The 
other two agreed to participate and one of these recommended two of their research 
group members for participation, who were also then interviewed via telephone.  
 
In total, then, ten pharmacogeneticists were interviewed. Six of these were 
interviewed for pilot research and four were interviewed subsequently as part of the 
main body of fieldwork. Seven of these interviews took place face-to-face in the 
university offices of these participants whilst four took place over the telephone. 
Each interview lasted between thirty and sixty minutes. Two of the 
pharmacogeneticists were female and two were in the process of researching as part 
of a PhD. Table 4 presents a breakdown of pharmacogeneticist participants. 
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 Anonymised 
Pseudonym 
Gender Specialist Job Role 
(if applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 PGx 1 F  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
2 PGx 2 M  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
3 PGx 3 M  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
4 PGx 4 M  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
5 PGx 5 M  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
6 PGx 6 F  Purposive sampling  Telephone 
 
7 PGx 7 M  Snowballed (from 
PGx 6) 
Telephone 
8 PGx 8 M  Snowballed (from 
PGx 6) 
Telephone 
9 PGx 9 F  Purposive sampling 
(Pilot) 
Face-to-face, 
university 
10 MTC 1 M Medical Technology 
Consultant, 
previously a 
community and 
hospital pharmacist 
Purposive sampling  Telephone 
Table 4: Breakdown of pharmacogeneticist participants 
5.6.2 Oncologists 
During the pilot interviews, the centrality of Oncology to the development of PGx in 
drug development and clinical practice was a recurring theme. It was identified that 
Oncology is the area of medicine where PGx is likely to have the largest and most 
imminent impact and, elsewhere, Oncology has been identified as a ‘promising’ field 
for PGx (Houtsma et al., 2010). Moreover, the provision of some PGx testing for all 
cancer patients (for example, HER2 testing in breast cancer) means that PGx 
technologies and approaches seem to be becoming fairly well ‘normalised’ within 
Oncology practice. It was, therefore, imperative that the perspectives of Oncologists 
were reflected in the study.   
 
Whilst field of Oncology is not homogenous and so is, instead, constituted by 
different specialisms dealing with different areas of the body (for example, breast, 
colorectal,  gynaecological) and different treatment pathways (medical Oncology, 
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surgical Oncology and radiation Oncology), these nuances were not thought to have 
any significant bearing on the present research. As such, it was thought that all 
oncologists would have a sufficient knowledge and, potentially, experience of PGx 
to be able to offer their perspectives.  
 
Six oncologists were targeted for inclusion in the study based on their 
position within some of the pharmacogeneticists’ network maps and the feasibility of 
face-to-face interviews. Of these six, no responses were received from two potential 
participants following both initial and follow-up recruitment materials being sent and 
one felt that his inclusion would not be appropriate given his employment status as 
semi-retired. Of the three that agreed to be interviewed, correspondence with one 
was lost whilst interviews went ahead with the remaining two. Hence, two male 
oncologists were interviewed at the hospitals where they were employed. These 
interviews lasted between forty five and sixty minutes. Table 5 presents a breakdown 
of oncology participants. 
 Anonymised 
Pseudonym 
Gender Specialist Job Role 
(if applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 O 1 M  Purposive sampling Face-to-face, 
hospital 
2 O 2 M  Purposive sampling  Face-to-face, 
hospital 
Table 5: Breakdown of oncologist participants 
5.6.3 General Practitioners 
As key actors in primary healthcare, GPs will have a central role in PGx in 
community settings. Within this, they may undertake testing within consultations or 
their prescription decisions may be negotiated with other healthcare practitioners (for 
example pharmacists) in light of PGx data (see Jamie, 2011). The delivery of PGx 
medicine in primary care settings will, then, involve GPs becoming more familiar 
with the principles of this technology and may necessitate increased collaboration 
and communication between themselves and community pharmacists. Given this, 
obtaining the perspectives of GPs was important to (i) understand the working 
relationship that pharmacists and GPs have at the moment, (ii) how this may change 
and (iii) what roles GPs see for themselves in delivering PGx medicine.  Moreover, 
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the introduction of GP commissioning may impact on the way in which PGx 
technology is implemented into primary care practice in the future. Hence, the 
perspectives of GPs about their professional relationship with other healthcare 
practitioners, the introduction of GP commissioning and the potential future of PGx 
in primary healthcare were central to the research questions.  
 
GPs were contacted by post given that few had their e-mail addresses 
published online. Twenty two GPs within York were contacted about their potential 
inclusion in the study via letter. Of these three responses were received and two 
subsequent interviews were carried out whilst correspondence with the other 
potential participant was lost. In addition, a GP from another city was contacted by 
e-mail on account of his previous involvement with a PGx research project. 
Although this GP was willing to participate, the practice manager at the surgery 
where he was employed did not give permission for access as is required by the NHS 
governance process. As such, this GP could not be interviewed. 
 
In total, then, one male and one female GP were interviewed. These 
interviews were conducted in their consultation rooms during the participants’ lunch 
breaks and lasted around thirty minutes. Table 6 presents a breakdown of GP 
participants. 
 Anonymised 
Pseudonym 
Gender Specialist Job Role 
(if applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 GP 1 F  York GP sampling 
frame 
Face-to-face, 
GP surgery 
2 GP 2 M  York GP sampling 
frame  
Face-to-face, 
GP surgery 
Table 6: Breakdown of GP participants 
5.6.4 Pharmacy Stakeholders 
What are being called ‘pharmacy stakeholders’ here are defined as individuals who 
are involved with the profession of pharmacy beyond being practicing pharmacists. 
This includes a diversity of policy makers, those involved with the development of 
pharmacy education, and chair people of various pharmacy practice groups. It was 
important to capture the perspectives of these stakeholders as (i) they were thought 
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to have an extensive overview of structure of the contemporary pharmacy, (ii) they 
may be positioned as central decision makers in processes of integrating PGx into 
pharmacy practice and (iii) they may be central actors in the ways in which PGx is 
understood and represented to pharmacists.  
 
 One potential participant was identified within correspondence with the 
Pharmacy Practice Research Trust as being potentially important for pilot work in 
order in order to understand PGx and pharmacy and the nature of contemporary 
everyday practice. Hence, during the pilot fieldwork whilst six pharmacogeneticists 
provided reflections on PGx from the lab bench side of the story, this pharmacy 
stakeholder provided reflections on the nature of contemporary pharmacy practice 
and the potential location of PGx within it from the patient bedside side. During the 
main phase of the fieldwork, five chair people of pharmacy professional groups were 
contacted as potential participants. One response was received to this recruitment 
correspondence and this stakeholder was subsequently interviewed. A further two 
academic pharmacy stakeholders were identified due to their research interests in 
ADRs and genetics education in pharmacy. Both of these stakeholders were 
interviewed.  
 
In total, then, four interviews were carried out with what are being called 
here ‘pharmacy stakeholders’. Three of these participants were male and one was 
female. Three of these interviews were conducted in the participants’ office and one 
was conducted over the telephone and they lasted between thirty and sixty minutes. 
Table 7 presents a breakdown of pharmacy stakeholder participants. 
 Anonymised 
Pseudonym 
Gender Specialist Job Role 
(if applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 PS 1 F Previously a hospital 
pharmacist 
Purposive sampling 
(Pilot) 
Telephone 
2 PS 2 M Professional group 
chairman 
Purposive sampling  Face-to-face, 
university 
3 PS 3 M ADRs in pharmacy 
practice 
Purposive sampling Face-to-face, 
university 
4 PS 4 M Pharmacy genetics 
education 
Purposive sampling Telephone 
Table 7: Breakdown of pharmacy stakeholder participants 
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5.6.5 Hospital Pharmacists 
Previous research into PGx and pharmacy have focused almost exclusively on 
community pharmacy, which excludes a vast portion of the pharmacist population 
and those that are likely to have the most experience of the technology. This 
research, in contrast, focuses on the entire field of pharmacy and, as such, the 
perspectives of hospital pharmacists are central in answering the research questions. 
At present, PGx is more commonly practised in hospital, rather than community, 
settings and so it was assumed that hospital pharmacists would have a fairly high 
degree of familiarity with this paradigm of practice even if they did not use PGx 
technologies within their individual everyday practice. As such hospital pharmacists 
were included because of their current, as well as potential future, engagement with 
PGx. Additionally, their perspectives on the structure of contemporary pharmacy 
were also sought in order to map the hospital pharmacy practice landscape into 
which PGx will be integrated.  
 
Hospital pharmacists were recruited through both individual purposive 
sampling and snowballing techniques. Three hospital pharmacists were identified as 
potential participants due to their occupational role as directors of hospital pharmacy 
services. Of these, two agreed to be included and were subsequently interviewed. 
Two other hospital pharmacists were identified as potential participants due to their 
specialism in Oncology and their location within the research networks of other 
participants. Both of these Oncology pharmacists agreed to be interviewed. Finally, a 
hospital pharmacist who was also a health economist with a particular interest in 
PGx and had previously collaborated with a number of other participants was also 
specifically targeted and interviewed. In total, then, five hospital pharmacists were 
recruited through this purposive sampling method. Four other hospital pharmacists 
were snowballed through one of the pharmacy directors and a final hospital 
pharmacist was snowballed through one of the community pharmacists.   
 
 In total, six female and four male hospital pharmacists were interviewed. In 
the majority of cases, these interviews were carried out during pharmacists’ breaks in 
hospitals. In the case of the health economist, however, the interview was carried out 
in her university office whilst the hospital pharmacist snowballed through a 
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community pharmacist participated in a focus group with five community 
pharmacists. Each of these interviews lasted between forty and ninety minutes. Table 
8 presents a breakdown of hospital pharmacy participants. 
 Anonymised 
Pseudonym 
Gender Specialist Job 
Role (if 
applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 HP 1 M Chief Pharmacist Purposive sampling Face-to-face, 
hospital 
2 HP 2 F  Snowballed (HP 1) Face-to-face, 
hospital 
3 HP 3 F Oncology 
Pharmacist 
Purposive sampling Face-to-face, 
hospital 
4 HP 4 F  Snowballed (HP 1) Face-to-face, 
hospital 
5 HP 5 M  Snowballed (CP 2) Face-to-face, 
hospital 
6 HP 6 M Pharmacy 
Director 
Purposive sampling Face-to-face, 
hospital 
7 HP 7 F  Snowballed (HP 1) Face-to-face, 
hospital 
8 HP 8 M  Snowballed (HP 1) Face-to-face, 
hospital 
9 HP 9 F Oncology 
Pharmacist 
Purposive sampling Face-to-face, 
hospital 
10 HE 1 F Health Economist 
(previously a 
hospital 
pharmacist) 
Purposive sampling Face-to-face, 
university 
Table 8: Breakdown of hospital pharmacist participants 
5.6.6 Community Pharmacists 
The perspectives of community pharmacists were important for an understanding of 
the potential future of PGx in pharmacy and for an overview of the contemporary 
structure of pharmacy practice.   Compared with potential participants from the other 
five categories detailed above, recruiting community pharmacists presented a 
number of unique challenges.  
 
In papers where interviews with pharmacists have been conducted, very little 
attention is given to the recruitment process, although this is an aspect of research 
that would benefit from a deeper exploration and analysis. Community pharmacists 
were very difficult to establish contact with as they rarely have personal e-mail 
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addresses available online; tend to only respond to medical or general queries (for 
example, questions about opening times or the availability of testing services) 
through their practice e-mail addresses; and receive a large volume of post which 
means that non-essential postal correspondence is usually discarded. Professional 
bodies such as Local Practice Forums offer a potential way of accessing a sample of 
pharmacists but these were unresponsive to correspondence in the case of this 
project. Given this, the most effective and appropriate methods for establishing 
contact with pharmacists proved to be through informal gatekeepers and 
snowballing.  
 
Unlike the other categories of respondents, it was difficult to identify 
individual pharmacists to target for participation. Two pharmacists were purposively 
sampled because of their previous involvement with Warfarin projects. One of these 
agreed to be interviewed and subsequently acted as a gatekeeper for six of the other 
community pharmacists interviewed, five of whom were interviewed in a focus 
group (along with one hospital pharmacist). These informal networks were also used 
to recruit two other community pharmacists who were acquaintances of colleagues. 
Alongside these recruitment methods, a sampling frame of local pharmacies in York 
was constructed and letters sent out for attention of the proprietor. Of the seven 
pharmacies contacted in this way, no responses were received to the first invitation 
letter and subsequent follow-up correspondence yielded only one participant. Given 
the high number of participants accessed through informal networks and snowballing 
techniques, this lack of responses to the York letter drop was not problematic in this 
instance.  
 
In total, ten community pharmacists were interviewed. Two of these were 
interviewed on the telephone, three were interviewed face-to-face and five were 
interviewed as part of a focus group. Each interview lasted between forty five and 
ninety minutes and the focus group lasted two hours. Table 9 presents a breakdown 
on the community pharmacy participants.  
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 Anonymised 
Pseudonym 
Gender Specialist Job Role 
(if applicable) 
Sampling 
Technique 
Interview 
Method and 
Location 
1 CP 1 M  Snowballed (from 
colleague) 
Telephone 
2 CP 2 F Warfarin practice Purposive sampling Face-to-face, 
cafe 
3 CP 3 M  Snowballed (from 
colleague) 
Telephone 
4 CP 4 F  York pharmacy 
sampling frame 
Face-to-face, 
cafe 
5 CP 5 M  Snowballed (from 
CP 2) 
Focus group, 
restaurant 
6 CP 6 F  Snowballed (from 
CP 2) 
Focus group, 
restaurant 
7 CP 7 F  Snowballed (from 
CP 2) 
Focus group, 
restaurant 
8 CP 8 F  Snowballed (from 
CP 2) 
Focus group, 
restaurant 
9 CP 9 F  Snowballed (from 
CP 2) 
Focus group, 
restaurant 
10 CP 10 M  Snowballed (from 
CP 2) 
Face-to-face, 
cafe 
Table 9: Breakdown of community pharmacist participants 
5.7 Pilot Fieldwork 
Pilot fieldwork is useful for social scientists to test their research methods, questions 
and participants prior to beginning the main bulk of the fieldwork (Bryman, 2008). 
Maxwell (1996: 75) argues that conducting pilot interviews in qualitative research 
studies is important for refining interview questions to gauge ‘how people will 
understand them and how they are likely to respond’. Pilot interviews are also useful 
for identifying areas of importance which may have been missed out on the original 
interview guide.  
 
 For the present project, most of the pilot interviews were undertaken with 
pharmacogeneticists. They were identified as an appropriate group within the sample 
with whom to conduct pilot interviews because (i) it was felt that it was important 
for the project to ‘map’ out the current state of PGx technology in order to place the 
study findings within the context of the scientific development of this field; (ii) those 
developing the technology are likely to have well-informed insights into how it will 
come to be delivered in medical practice; and (iii) pharmacogeneticists work in 
147 
 
collaborative teams, which sometimes include pharmacists. The pilot interviews with 
pharmacogeneticists also served to establish where the original interview guide had 
omitted important topics relevant to the research. In total, six pilot interviews with 
pharmacogeneticists were conducted.  
 
 Necessarily, the pilot interviews with pharmacogeneticists focused primarily 
on the nature and development of the technologies of personalised medicine with the 
implications for pharmacy practice being the secondary topic of the interview. For 
the hospital and community pharmacists that were interviewed for the project, the 
primary focus was pharmacy practice and the implications of new technologies for it. 
Therefore, a pharmacy stakeholder was identified in collaboration with the Pharmacy 
Practice Research Trust as an appropriate participant with whom to test questions 
about pharmacy practice and the positioning of PGx within it.  
 
 The pilot fieldwork was useful for the subsequent fieldwork as it identified a 
number of areas of interest which were absent on the original interview topic guides. 
Following this fieldwork, then, the interview topic guides were amended to include 
these topics (see Appendices F-K). This was particularly helpful with respect to the 
NHS ethics and governance approval process where final versions of documentation 
such as interview topic guides are required before fieldwork begins. In conducting 
pilot interviews with non-NHS staff, these interview topic guides could, thus, be 
finalised before they were submitted for NHS approval.  
5.8 Data Analysis 
Following the data collection, the interviews were transcribed by a contracted 
transcriber. It should be noted that this transcriber signed a Confidentiality 
Agreement (see Appendix M) in order to protect the confidentiality of research 
participants, although the audio files were anonymised prior to being e-mailed to the 
transcriber. The data was transcribed verbatim but without conversational details 
such as pauses and hesitations as these were not crucial to the research questions and 
would have limited the readability of the transcripts (Potter and Wetherell, 1987).   
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 As the interviews were transcribed by a contracted transcriber, the process of 
reading and re-reading them was particularly crucial. Undertaking their own 
transcription is acknowledged as a key way in which researchers become immersed 
in the data and come to construct themes arising from it (Bird, 2005). As such, in 
instances where this transcription has been sub-contracted, a period of the research 
should be wholly dedicated to familiarising oneself with the content of the interview 
transcripts. In this case, a month was taken solely to read through the data.  
 
 Data analysis took the form of a thematic analysis which was approached in a 
‘bottom-up’ fashion whereby analytical frameworks were not imposed on the data 
but the data was allowed to speak for itself. This is not to say that the data analysis 
took a wholly grounded theory approach as the theoretical frameworks identified in 
the preceding chapters were used as sensitising tools to make sense of and explain 
the data (Murray et al., 2010). This thematic analysis was a two level analysis. 
Firstly, the data pertaining to three broad categories of interest was identified; the 
structure of contemporary pharmacy practice, technologies and pharmacy, and PGx 
and pharmacy. A secondary analysis of the themes intersecting these categories was 
then carried out. It was within this secondary analysis that the empirical frameworks 
used in the following empirical chapters were identified. Within this, then, medicines 
management practices were identified as a key feature of pharmacy which 
intersected both hospital and community settings and was central to the 
understandings of new technologies in pharmacy. Within this, it was identified that 
pharmacists undertake something of a dual approach to medicines management 
where formalised, codified practices are undertaken concurrently to more negotiated 
practices which are argued to be enacted through what has been called here the 
‘pharmacy gaze’. This Foucauldian framework provided a way through which the 
construction of patient bodies within pharmacy could be analysed. It also provided a 
framework through which to analyse the effects of new technologies (specifically 
PGx) on everyday pharmacy practice.   
 
The next three chapters present findings from this thematic analysis of the 
data. These chapters are structured around three broad topic areas of (i) the structure 
of contemporary pharmacy practice, (ii) technologies and pharmacy and (iii) PGx 
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and pharmacy with the themes of dual medicines management, risk and toxicity, and 
patient bodies constructed through the ‘pharmacy gaze’ cutting across each.   
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Chapter Six: Conceptualising Contemporary Pharmacy 
Practice 
6.1 Introduction 
This chapter draws on empirical data to present a sociological conceptualisation of 
contemporary pharmacy practice through the analysis of what I propose to call the 
‘pharmacy gaze’. This pharmacy gaze takes Foucault’s notion of the ‘clinical gaze’ 
as its point of departure and argues that pharmacists construct patients in a distinct 
way, as at-risk medications users. The chapter argues that the management of 
medicines is undertaken within a dual process where a codified, formalised approach 
is enacted simultaneously with a less formalised, more negotiated process. The 
pharmacy gaze, then, is shown to be central to this more negotiated practice. 
 
In order to understand this engagement with these dual medicines 
management processes, it is important to present an empirically-informed overview 
of the roles and statuses found within the contemporary pharmacy practice 
landscape. Mapping such a landscape will also be of benefit in framing the 
professional environment into which PGx technology may be implemented, 
discussed more fully in Chapter Seven and Chapter Eight. To begin with, then, this 
chapter outlines the status of contemporary pharmacy using the contrasting concepts 
of ‘medical technocracies’ (Serra, 2010) and ‘bioclinical collectives’ (Bourret, 2005; 
Rabeharisoa and Bourret, 2009) as frames of reference for understanding the way in 
which pharmacy is practised in different medical settings. This analysis is intended 
as an empirically-informed adjunct to the theoretical issues explored in Chapter Two 
and, together with an elucidation of the pharmacy gaze, presents an outline of the 
practice environment into which new technologies are implemented. Through 
constructing this conceptual map of contemporary pharmacy practice, the key 
analytical elements of this chapter can be employed to understand the way in which 
new technologies generally, and PGx more specifically, are engaged with by 
pharmacists. 
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6.2 Status of Pharmacy Profession 
As Chapter Two showed, the relative status of pharmacy as a healthcare profession 
has been continually debated in the academic literature. In the South African context, 
Masongo (2005) asks whether pharmacists should be seen as healthcare 
professionals or shopkeepers as the retail pressures on pharmacists have tended to 
inform understandings of the sector as less service oriented and, thus, less 
‘professional’ than practitioners in other healthcare sectors (see Harding and Taylor, 
1997). Despite Evetts’ (2003) assertion that professionals can have a ‘dual character’ 
which allows them to mobilise services for economic benefit, the discussion around 
the professional status of pharmacy continues.  
 
A thematic coding of fieldwork data suggests that the professional status of 
pharmacy is highly aligned with the relevant practice sector, whose regimes govern 
the extent of collaborative working and the pattern of interaction with technologies. 
As such, there is a fairly clear status difference between community and hospital 
pharmacists which is mediated by the model of practice in each setting where 
community pharmacists practice in relative isolation and subordination (Cooper et 
al., 2009) whilst hospital pharmacists engage in much more collaborative working 
with other health professionals. In order to contextualise the analysis of the 
pharmacy gaze later in the chapter, an analysis of these two practice models is now 
provided using the contrasting notions of medical technocracy (Serra, 2010) and 
bioclinical collective (Bourret, 2005; Rabeharisoa and Bourret, 2009) as frames of 
reference. 
6.2.1 Community Practice: A Medical Technocracy 
Community pharmacy practice traditionally involved compounding and dispensing 
medications that had been prescribed by other healthcare professionals, namely GPs. 
As demonstrated in Chapter Two, expansion of the role of community pharmacists 
over the past two decades has increased the clinical responsibilities of pharmacists 
and reconstituted the pharmacy space as an area for clinical consultations, public 
health information and direct drug purchasing (Taylor et al., 2003). Despite this 
increased clinical role, the retail focus of community pharmacy, which has been 
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conceptualised elsewhere as ‘role strain’ (Harding and Taylor, 1997), remains central 
to debates as to the professional status of pharmacy in comparison to that of general 
medical practice.  
 
 In the main, the data presents an implicit assumption that community 
pharmacy practice occupies a lower status position in the primary care division of 
labour than general medical practice. Here, the retail aspects of the community 
pharmacy role are central to perceptions of its status, as Community Pharmacist 3 
notes: 
“they still prefer to go to GPs…that’s a perception that a lot of 
patients have about pharmacies. We are still the glorified 
shopkeepers” (CP 3)  
 Although Community Pharmacist 3 talks specifically about patients’ 
perceptions of community pharmacy’s status, the data suggests that GP’s limited 
understanding of the work of community pharmacists leads to assumptions about a 
lack of clinical focus and a potential “conflict of interest” (GP 2) due to the retail 
role of community pharmacists. These assumptions made by GPs reinforce the 
hierarchical division of primary care labour. Given this, the primary care 
practitioners interviewed reflected that most interaction between GPs and 
community pharmacists tends to be centred on ‘retail’ issues such as stock 
availability, rather than clinical collaboration, although more collaborative practices 
are thought to emerge when GPs have a greater understanding of pharmacists’ work 
(see below).  
 
 Given this apparent conflict of interest between GPs and community 
pharmacists and the hierarchical primary care model that emerges from it, GPs often 
assume that they should be the practitioners who set the agenda for practice in the 
community setting, as General Practitioner 2 highlights: 
“I’m personally okay to make use of that [pharmacy clinical 
services] provided it’s within the spirit of the practice and within 
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the professional boundaries or expectations we need to fulfil” (GP 
2) 
Such boundary work rigidly demarcates the practices of pharmacy and 
general medicine and creates a technocratic hierarchy where the expertise and 
practice technologies of GPs are perceived as being higher in status compared with 
those of pharmacists. Within this, as the above quote from General Practitioner 2 
highlights, GPs become gatekeepers not only for certain medicines through 
prescribing activities (see Busfield, 2010), but also for clinical services provided by 
the pharmacy. As such, these pharmacy-based clinical services will only be 
discussed with, or recommended to, patients when they fit within the terms of the 
GP’s technocracy. As such, pharmacists’ autonomy over their own clinical activities 
is somewhat limited by the rigid hierarchy in primary care practice.  
 
This hierarchical technocracy, however, is not a universal community 
pharmacy experience and is, instead, dependent on the location of pharmacy practice 
and the level, and form, of GP and community pharmacist interaction. The 
differences between rural and urban pharmacy practice and the, generally, higher 
levels of inter-professional collaboration in the former have been examined 
elsewhere (Ranelli and Coward, 1996; Rogers et al., 1998). The data collected here 
concur with previous findings and suggest that this technocratic hierarchy is less 
dominant in rural pharmacy settings where GPs and community pharmacists work 
more closely than those in more urban settings, as Community Pharmacist 2 (a rural 
community pharmacist) observes: 
“I think because we were in a village and we had really strong 
links with our GP practice”  
“Maybe for more town centre pharmacies it’s harder because they 
don’t always see the same patients all the time as you do if you’ve 
got more of a village or that kind of setting” (CP 2) 
 Serra’s (2010: 170) notion of a medical technocracy in liver transplantation 
medicine suggests a highly contested process of establishing practice boundaries in 
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which ‘each of these groups [of practitioners] seeks to conquer the areas dominated 
by the other group, controlling new practices’. The present data pertaining to 
community practice suggest that the boundary work undertaken by GPs and 
community pharmacists is done so through a relatively consensual (rather than 
conflictual) process. Within this, the differential status of GPs and pharmacists is 
accepted by the latter as an inevitable, and not necessarily undesirable, aspect of 
practising pharmacy. Hence, the boundaries between general medical and pharmacy 
practice are, generally, informally negotiated owing to the different expertise and job 
role of each occupation; 
“doctors are up here and pharmacists are down here… we do a 
good job but we don’t do a doctor’s job” (CP 2).  
 In a number of cases, community pharmacist respondents had experience of 
providing clinical services in collaboration with GPs. Where community pharmacists 
have engaged in such practices, they note that they were able to demonstrate their 
ability to engage with clinically-focused activities and thereby question assumptions 
about their heavy retail focus. Such collaborative working is perceived as an 
opportunity for community pharmacy to integrate into the primary healthcare team 
and increase the trust that other practitioners have in the sector (see Chen and de 
Almeida Neto, 2007). Whilst a lack of trust was not made explicit during the 
interviews, GP’s lack of knowledge around the expertise and work of pharmacists 
can mean that the former are reluctant to hand over too many clinical services that 
have traditionally been the domain of general medical practice. When community 
pharmacists and GPs work closely together, however, this reluctance is often 
overcome by an acknowledgement of pharmacists’ capabilities of undertaking such 
roles, as Community Pharmacist 10 highlights: 
“Once they [GPs] know you can be clinical then they’re happy to 
hand over some work or smoking cessation or diabetes clinics” 
(CP 10)  
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 The above quote demonstrates that this relatively consensual boundary work 
is, nonetheless, hierarchically managed whereby GPs hand over work to pharmacists 
only when the latter have demonstrated their clinical abilities and so weakened 
notions of their being simply ‘shopkeepers’ (Masongo, 2005). The data highlighting 
this consensual boundary work sits in opposition to Eaton and Webb’s (1979) 
assertion that the increase in clinical responsibility of pharmacists might be 
experienced by medical practitioners as ‘boundary encroachment’. They argue that 
given the potential for these new pharmacy roles to increase the status of pharmacy, 
acquire resources otherwise invested in medical practice and affect the ‘informal 
ranking of specialities’ (p.82), the boundaries around medical practice need to be re-
asserted to confirm the autonomy of the medical profession and guard against 
boundary encroachment by these new clinical practitioners. The data, however, 
suggest that GPs are willing to re-negotiate boundaries around some clinical work 
where local pharmacists are able to provide services. Much of this willingness is 
rooted in GP’s experiences of other boundary shifts and changes to their working 
practices, such as increased bureaucracy, increased research burden and extended 
opening hours.  
6.2.2 Hospital Practice: A Bioclinical Collective  
Reflecting on her own experiences practising as both a community and hospital 
pharmacist, Heena Bhakta (2010), notes that there are substantial differences 
between these practice sectors with the latter being more ‘interdisciplinary’ and 
specialised. As such, in accordance with the Audit Commission’s (2001) 
recommendations, hospital pharmacists are more integrated into the medical practice 
team in comparison to those practising in the community who tend to be more 
‘isolated’ (Cooper et al., 2009). Moreover, hospital pharmacy is typified by 
disciplinary specialisation in which pharmacists opt for a particular area of medicine 
to specialise in, such as Oncology or Paediatrics. This specialisation in hospital 
pharmacy practice means that hospital pharmacists cultivate a set of expertise and 
skills based around one substantive area of medical practice and the medications 
associated with it. In doing so, hospital pharmacists play a significant role in 
assisting physicians with prescription and treatment decisions, in contrast to their 
community-based colleagues (Taylor et al., 2003: 22).  
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 This more collaborative model of practice in hospital settings can be analysed 
through the use of Bourret’s (2005) and, latterly,  Rabeharisoa and Bourret’s (2009) 
notion of a ‘bioclinical collective’. This model of practice is centred on clinicians 
and researchers working collaboratively to decide on the best course of treatment for 
a patient given the increased complexity of disease in the post-genomic era. 
Although much of hospital pharmacy practice is not routinely engaging with 
genomic techniques or information, the collaborative principles underpinning 
bioclinical collective practice are central to hospital pharmacy practice, as Hospital 
Pharmacist 4 notes: 
“I work pretty closely with them [consultants] and the other 
specialist nurses and the whole team really” (HP 4) 
Given this, the division of labour in hospitals is not hierarchically based on 
occupational categories but based on particular specialist fields where numerous 
practitioners from one specialism share their diverse expertise with others in order to 
identify the best course of action for the patient. In this way, the bioclinical 
collective practices that characterise professional relationships in hospitals tend to 
ascribe equal value to the expertise and work of practitioners from across 
occupational areas. This bioclinical collective model is particularly typical of 
specialist fields which require careful medicines management due to the increased 
risk of toxicity of the medications used in that field. Oncology is a particularly 
notable example of such a practice model where multi-disciplinary teams are a 
routine feature of practice due to the complexity of disease in this area and the 
increased risk of medications, as Hospital Pharmacist 3 (an Oncology pharmacist) 
and Oncologist 1 highlight below. Ideas around this understanding and framing of 
toxicity are discussed further below. 
“You’ll have the junior doctors and the nurses and pharmacy… so 
there is certainly collaboration” (HP 3- Oncology) 
 
157 
 
“The multidisciplinary team is the surgeon…the pathologist…the 
oncologist…the specialist nurse…usually somebody from 
radiology…sometimes you’ll have somebody from palliative care” 
(O 1)  
The relative lack of hierarchical divisions of labour between hospital 
pharmacists and other hospital practitioners means that hospital pharmacists are 
often perceived as higher in status or more ‘professional’ than those practising in the 
community (Elvey et al., 2011). Here the absence of professional role strain or 
commercial pressures is central to patient and practitioner perceptions of hospital 
pharmacists as clinical practitioners, rather than just dispensers (see Rapport et al., 
2010). Moreover, this elevated professional status of hospital pharmacy through a 
central role in bioclinical collective working practices is mediated through the 
technological interventions which hospital pharmacists mobilise in their routine 
work. Through an analysis of EPS technologies, Petrakaki et al. (2012) argue that 
pharmacists’ engagement with innovative technologies can increase their 
professional status by expanding their professional jurisdictions; engaging them in 
clinical judgements through an increased information pool; strengthening inter-
professional trust; and rendering them part of the ‘NHS family’ (Petrakaki et al., 
2012). This analysis of EPS demonstrates the ways in which the professional status 
of pharmacy can be influenced by engagement with technology. As hospital 
pharmacy practice engages with various diagnostic, ICT and medical technologies at 
the centre of its practice, this may go someway to understanding the disparity 
between the status of hospital and community pharmacists. This can be particularly 
witnessed in the case of patient medical records, as is touched upon below and 
discussed more fully in Chapter Seven.  
 
Although previous commentaries (Bassey, 2011) and research (Rapport et al., 
2010) have focused on the practice and status differences between community and 
hospital pharmacy, this binaried representation of pharmacy practice ignores the 
diversity found within each sector. The empirical data upon which this chapter is 
based suggests that the diverse contexts in which pharmacy is practised mean that 
those practising within the same sector (i.e. hospital or community) do not 
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necessarily share similar experiences. In the case of community pharmacy, for 
example, the experiences of owner-occupiers, large or small multiple employees and 
urban or rural practitioners can differ greatly because of this diversity of practice 
settings.  
 
Nonetheless, the safe and effective dispensing and administration of 
medications is a central principle underpinning all forms of pharmacy practice. 
Hence, although their experiences of everyday practice routines may vary greatly, 
the philosophy of good pharmaceutical care and medicines management is a central 
foundation in all practice contexts. The remainder of this chapter offers a 
sociological analysis of the everyday practices of pharmacists through their 
engagement with pharmaceutical care and the medicines management processes. The 
chapter presents a dual approach to these processes by arguing that alongside 
pharmacists’ engagement with formalised, bureaucratic pharmaceutical care and 
medicines management we find a more negotiated form of care and management, 
which co-constructs both medications and patients. Here, this is conceptualised as 
the ‘pharmacy gaze’. To place this notion in context, the chapter first outlines the 
formalised processes of medicines management and pharmaceutical care.  
6.3 Pharmaceutical Care and Medicines Management  
There are philosophical distinctions between the practices of pharmaceutical care 
and medicines management. Pharmaceutical care entered the medical and pharmacy 
vocabulary in the 1990s with Hepler and Strand’s (1990: 533) assertion that 
pharmacy practice ought to move beyond simply dispensing the correct medications 
towards ‘the greater social good’ of patient-centred care vis-a-vis pharmaceutical 
products. This patient-centred philosophy locates the minimisation of ADRs and the 
improvement of patient experience of medications at the centre of pharmaceutical 
care. As Chapter Two highlighted, this pharmaceutical care approach has recently 
discursively shifted to a focus on medicines optimisation in which the care of 
patients, as medications users, is increasingly centralised in pharmacy practice. As 
such, pharmaceutical care and, more recently medicines optimisation, are models of 
practice through which medicines are managed to be most effective for the patient. 
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Within this, the relationship between the patient and the pharmacist becomes defined 
as a covenant, although Barber (2001) argues that this framing of the relationship is 
somewhat insufficient in capturing the other commitments of the pharmacist (such as 
to the health of the population as a whole).  
 
 In contrast to the patient-centred practice of pharmaceutical care, medicines 
management is rooted in organisational interests to make medicines more effective 
and efficient for the organisation, rather than the individual patient (ibid.). Hence, 
medicines management is largely practised within the hospital and pharmacists play 
a central role in its delivery according to centralised directives. This aspect of 
hospital pharmacy practice is highly routinised and bureaucratised where decisions 
around patient medication are made with financial implications and local policy in 
mind. Here, the management of risk vis-a-vis potential ADRs is located within legal 
and corporate responsibility, as Hospital Pharmacist 1 (a chief pharmacist) points 
out:  
“You have corporate responsibility for medicines management in 
the Trust...If something goes wrong with medicines within the Trust 
it’s the Chief Executive and myself who are ultimately responsible. 
We are the ones who end up in court and ultimately in prison” (HP 
1- Chief Pharmacist).  
Stowasser et al. (2004) argue that there are nine steps in what they term the 
‘medicines management pathway’ with the role of the hospital pharmacist being 
well-defined at each. These steps are; 
(i) deciding to treat and prescribe; once a clinician has ascertained that 
treatment is necessary, the bioclinical collective team negotiate the most 
appropriate and cost-effective route to take.  
(ii) recording medicines order; once a medication has been decided on, this 
decisions needs to be carefully and accurately recorded. 
(iii) reviewing medicines order; the medicine is then reviewed for issues such as 
funding challenges, drug-drug interactions and ease of compliance. 
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(iv) issuing medicine; once a medication is verified as being safe and 
appropriate, it is manufactured or issued from the producer (this may have 
already been undertaken and be in storage)  
(v)  providing medicines information; the producer should also provide 
sufficient information on how to take/prepare the medicine and its potential 
toxicity. 
(vi) distributing and storing medicine; once issued, a medication is delivered to 
the care space (e.g. wards) and stored appropriately. 
(vii) administering medicine; this involves assessing when and how a medication 
should be administered (e.g. pain relief medication) 
(viii) monitoring for response; on-going monitoring of patients also includes 
monitoring for ill effects from medications. 
(ix) transferring verified information; information about the steps above needs to 
be communicated effectively with other health care professionals (typically 
via the patient medical record) to affect future medications decisions.   
The centrality of the hospital pharmacist to this medicines management 
pathway establishes patient medications, as opposed to patient diagnosis, as their 
field of expertise within the bioclinical collective practice team. It is through this 
pathway of medicines management that pharmacists enact a central role in their 
practice, which is the symbolic transformation of inert chemical compounds into 
socially meaningful medicines (see Dingwall and Wilson, 1995; Harding and Taylor, 
1997). In this sense a chemical compound becomes a social object central to the 
patient illness experience through its operationalistion through the medicines 
management pathway as, for example, the most appropriate, the easiest to comply 
with or the most cost-effective.  
 
Since the vast majority of this medicines management pathway occurs within 
the hospital space, medicines management becomes central to hospital (pharmacy) 
practice. Stowasser et al. (2004) argue, however, that the medicines management 
pathway will play an increasingly important role in community pharmacy as more 
services are offered through community pharmacy and, in the UK, as more patients 
move on to ‘shared care’ programmes.  
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Generally in the community setting medicines management is not as 
prominent as in hospitals and a potential explanatory factor here is the co-location of 
numerous healthcare practices in the latter setting. Hence, whilst community 
pharmacists are involved in certain steps in the pathway described above, the 
structure of community pharmacy in the UK (for example not being co-located with 
other health care professionals and not being extended access to patient medical 
records) means that they cannot easily be involved in all of the steps owing to the 
spatial separation between them and their other primary care colleagues. However, 
the importance of community pharmacists to effective pharmaceutical care has been 
identified elsewhere (Farris et al., 2005; Grainger-Rousseau et al., 1997; Scottish 
Executive, 2006). Arguably the most salient example of pharmaceutical care in 
community practice is the undertaking of medicines use reviews (MURs). MURs 
were introduced as an Advanced pharmacy service in 2005 as a way for 
polypharmacy patients to make sense of their medications and voice any concerns 
with them (Latif and Boardman, 2008). Copies of the report generated from the 
MUR are given to patients and, if necessary, forwarded to the GP. Despite MURs 
being central to the pharmacy contract and pharmaceutical care, numerous 
challenges for pharmacists performing MURs have been identified such as low 
levels of patient engagement and lack of access to enough information to complete a 
comprehensive review (ibid.).  
 
This means that although community pharmacists are increasingly involved 
in a community-based version of pharmaceutical care and medicines management, 
these practices remain closely linked with hospital practitioners and are facilitated by 
the hospital structure. As is shown below, the ontology of primary care drugs as 
being less complex and risky than hospital drugs may be significant in understanding 
why the labour of medicines management is apportioned in this way.  
 
The data demonstrate that pharmacists practice a dual process in 
pharmaceutical care and medicines management. That is, their engagement with 
codified and formalised policy-based processes is enacted simultaneously with a 
more negotiated and informal pharmaceutical care and medicines management 
process, which here is conceptualised as the ‘pharmacy gaze’. This pharmacy gaze 
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operates to co-construct medications as socially meaningful, risky objects and 
patients as at-risk medications users. Within this, the risk to patients is rooted in both 
the potential presence of ADRs and the potential absence of therapeutic benefit. As 
such, the notion of toxicity cannot easily be separated from efficacy, which points to 
the relational nature of drug toxicity and risk where the absence or presence of 
clinical benefits plays a role in constructing the pharmacological risk to the patient. 
In other words, risk and toxicity can be discursively constructed as the absence of 
therapeutic benefit as much as the presence of adverse reactions. Moreover, it should 
also be noted that toxicity may also occur simultaneously with efficacy, for example 
in cytotoxic medicine. The point is, then, that what constitutes toxicity should not be 
simplified as just a presence of adverse effects with little or no drug efficacy. In a 
short reflection on pharmacy’s history, Barber (2005) notes that pharmacists have 
cultivated a ‘pharmaceutical gaze’, which he conceptualises as an ‘ability to see into 
the properties of medicines and predict their effects’. He notes that this 
pharmaceutical gaze enables pharmacists to create a common language and to 
differentiate themselves from other healthcare practitioners.  
 
Barber’s concept is a useful starting point for a more detailed sociological 
conceptualisation of pharmacy practice. Hence, whilst Barber’s pharmaceutical gaze 
gives some indications as to the ways in which pharmacists ‘know’ medicines, the 
pharmacy gaze outlined here conceptualises the way in which pharmacists also 
‘know’ their patients and their patients’ bodies, capturing the increased centrality of 
clinical practice to pharmacy. In doing so, the pharmacy gaze relates this co-
construction of medicines and patients through understanding the ontology of a drug 
in terms of its relationship with the patient body. The chapter now turns to an 
overview of the Foucauldian principles underpinning the pharmacy gaze, before 
drawing on the interview data to expound the particular features of it.  
6.4 The Pharmacy Gaze 
6.4.1 Introduction 
The notion of the pharmacy gaze takes Michel Foucault’s notion of the 
‘clinical gaze’ and Barber’s ‘pharmaceutical gaze’ as its points of departure. 
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Foucault coined the term ‘clinical gaze’ to describe the way in which medical 
practitioners in the eighteenth and nineteenth centuries became increasingly focused 
on clinical observations of patients which reduced the patient body to a system of 
observable symptoms and signs. Through this reductionist approach, medical 
practitioners were able to gain power over their patients through their cultivation of 
an ‘expert’ discourse of disease and illness. This reductionist understanding of the 
patient body further served to construct a mind-body dualism whereby the sick body 
(and the particular disease pathology within it) became discursively detached from 
the human patient occupying it (Armstrong, 1997). 
 
Foucault’s notion of a ‘clinical gaze’ has been employed subsequently in 
sociological studies of health and illness and applied across disease areas and patient 
populations. Despite pharmacy practitioners playing a key role in patient experiences 
of health care, the ‘gaze’ through which pharmacists view and interact with patients 
and their drugs is under-analysed in the sociological literature (see Ryan et al., 
2004). The pharmacy gaze departs from the clinical gaze in the sense that the latter is 
concerned with reducing patients to a series of signs and symptoms which medical 
practitioners mobilise to arrive at the ‘truth’ about a patients’ illness. In contrast, the 
pharmacy gaze is relatively unconcerned with diagnosis of illness and is, instead, 
centred on the construction of the patient as a user of these medicines and the 
reduction in the risk of toxicity arising from the relationship between these two 
elements. Hospital Pharmacist 5 highlights this division of expertise and labour:  
 “I speak to patients about their medicines. It tends to be very 
based around the medicines that they’re currently on rather than 
generalities” (HP 5) 
It is through the co-construction and configuration of these elements that 
pharmacists are able enact a central role in their practice, which is the ascription of 
social meanings to ‘stuff’ (Barber, 2005: 78), such as chemicals and formulas, that 
are at the core of pharmacy principles. It is through this enactment that such ‘stuff’ 
takes on the status of a socially meaningful object in a patient’s experience.  
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6.4.2 Making Medicines Meaningful 
Dingwall and Wilson (1995)  draw on Becker’s (1967) work on the social 
construction of illicit drugs to argue that pharmacists occupy the role of symbolically 
and culturally transforming inert chemical compounds (Barber’s ‘stuff’) into socially 
meaningful medications. This is done through their mobilisation of knowledge of the 
patient; advice on use of medications; and drug interactions expertise. In doing so, 
medications become social objects within the patient’s wider ‘lifeworld’ and are 
imbued with connotations and meanings through the pharmacist’s dispensing and 
counselling activities. One such example of the way in which medicines can take on 
social meanings is highlighted by Cribb et al. (2011). In their exploration of shared 
decision making in diabetes treatment, they note that being prescribed insulin can be 
understood by patients as indicative of their ‘failure’ (p. 38) to effectively manage 
their condition through dietary regimes.  
 
Although Dingwall and Wilson’s perspective is a useful analysis of the social 
role of pharmacy and feeds into understandings of the pharmacy gaze, their insights 
do not acknowledge the extent to which medications and patients are co-constructed 
by pharmacists. In this way, Dingwall and Wilson’s (1995) perspective is limited in 
much the same way as Barber’s (2005) pharmaceutical gaze in that they focus solely 
on medicines and do not examine pharmacists’ construction and understandings of 
patients. The data collected here, however, show that pharmacists cultivate a 
particular way of knowing and understanding patients through this construction of 
medicines as socially meaningful objects. Hence, whilst chemical compounds are 
symbolically transformed into social objects, patients are simultaneously 
symbolically transformed into medications users around whom a discourse of 
toxicity and risk is constructed based on their individual patient journey and therapy 
regime.  
 
This discourse of toxicity sits at the centre of the pharmacy gaze and relates 
to pharmacists mobilising their expertise in pharmacology to verify the ‘proper’ use 
of the ‘best’ medication (Dingwall and Wilson, 1995: 120). The construction of a 
discourse of toxicity is particularly applicable to hospital pharmacists whose gaze 
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extends beyond the one-off dispensing encounter to one prolonged for the duration 
of the patients’ stay in hospital.  
6.4.3 Constructing a Discourse of Toxicity 
Central to the nature of social meanings afforded to medications is the ascription of 
their relative risk and toxicity. This is a key aspect of Barber’s pharmaceutical gaze 
whereby pharmacists are able ‘to see’ into the properties of medicines and predict 
their potential effects. Barber’s conceptualisation does not, however, place an 
emphasis on the specificities of the individual patient body through which, and 
within which, these potential effects occur. Although he notes that pharmacokinetics 
historically enabled hospital pharmacists to control risk, he suggests that pharmacy 
practice ‘is not based on parts of the body…manipulating, cutting or caring for the 
body’ (Barber, 2005). Ryan et al. (2004) argue in contrast that an analysis of the 
body in pharmacy is needed and the data presented here suggest that the potential 
(adverse) effects of drugs cannot be so easily separated from the biological patient 
body upon which they are acting. Hence, through the process of making medicines 
meaningful, pharmacists also make the patient body pharmacologically meaningful 
by constructing them, and in so doing gazing at them, as at-risk medications users. 
This co-construction of medications and patient bodies creates a need for 
medications and at-risk medications users to be expertly managed by the pharmacist 
through the employment of a discourse of toxicity.  
 
This discourse of toxicity is centred on the way in which potential drug 
toxicity is communicated to patients and managed through the characteristics of 
pharmacy practice. The data suggest that there are two key ways in which this 
discourse of toxicity is manifested in routine pharmacy practice; through the timing 
and location of drug dispensing and administration.  
 
The timing of medicinal interventions is central to pharmacy’s management 
of toxicity and ensuring drug effectiveness. This timing is practised in a sequential 
and cyclical model whereby medications administration is located at a specific point 
within a sequence of clinical interventions in order to offer maximum effectiveness, 
as Hospital Pharmacist 9 (an Oncology pharmacist) says:  
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 “Because there is a risk of anaphylaxis with it and the risk is 
reduced over time so if patients are okay after the first three cycles 
or whatever then they should be reasonably okay after that” (HP9- 
Oncology) 
In communicating the importance of drug timing to patients through the 
discourse of toxicity, pharmacists ascribe sociality to medications by locating them 
within the patient’s ‘lifeworld’. In doing so, medicines become meaningful through 
the management of the risks associated with them by becoming a part of the patient’s 
wider social and cultural practices, such as being re-configured as part of meals or an 
evening regime. Through this reconfiguration as social objects, it is thought that 
increased adherence to medications regimes can be achieved. Adherence to 
medications regimes has been highlighted elsewhere as being a particular challenge 
for pharmacists and other healthcare professionals (Farmer, 2010). Farmer (2010) 
notes that a lack of adherence with medications can be due to a medication regime 
being understood by patients as sitting outside of their  normal lifeworld. This is 
central to the discursive shift towards medicines optimisation where patient 
involvement in medications decisions is centralised as a way in which the use and 
management of medicines can be optimised through increased patient engagement 
(Cutler, 2011; Stephens, 2011). Given this, by mobilising practices which counsel 
patients extensively and locate therapy regimes within a patient’s normal routine, 
pharmacists are able to contribute to the improvement of adherence and, 
subsequently, patient outcomes, as Hospital Pharmacist 1 highlights: 
 “They’ve divided up into time periods to help them take their 
medicines at the right time” (HP 1- Chief Pharmacist) 
 This management of medicines timing is particularly important and highly 
centralised in the discourse of toxicity where the risk of ADRs is particularly high. 
Here, the dispensing of Oncology drugs is accompanied by relatively extensive 
counselling practices, as Hospital Pharmacist 3 (an Oncology pharmacist) notes:   
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 “So the pharmacy staff, when they’re handing over prescriptions, 
will be doing a certain amount of patient counselling about how 
many tablets to take, how to take them, should they be taking them 
with food, after food” (HP 3- Oncology) 
 Hospital Pharmacist 3’s comment here, and much of the focus on timing in 
the discourse of toxicity, is located around discharge practices. Hence, much of the 
focus is on the effective timing of taking hospital drugs in community settings. The 
data also show that the location in which drugs are dispensed and administered is 
central to their ontological status. Here, the discourse of toxicity creates a distinction 
between primary and secondary care drugs vis-a-vis their potential toxicity and the 
expertise necessary to manage this toxicity.  
 
In this distinction, primary care drugs, and the healthcare practitioners that 
routinely practise with them, become associated with what are perceived to be 
simple, common ailments that can be effectively managed with minimal risk of 
toxicity. Secondary care drugs, on the other hand, are ontologically associated with 
complex diseases and polypharmacy regimes which mobilise comparably toxic 
medicinal interventions.   
 
 Such toxicity of secondary care drugs is managed in the hospital setting by 
being contained within the physical boundaries of the hospital and the co-location of 
different practices within it. This is in contrast to the primary care setting where such 
toxicity cannot be easily contained within one environment as practitioners (most 
notably GPs and pharmacists) are geographically dispersed and do not practice as 
bioclinical collectives as do those in hospital-base settings.  
 
Given this ontological and discursive binary between primary and secondary 
care drugs, healthcare practitioners working within each sector cultivate a particular 
set of expertise around the diseases and medications that they routinely encounter. In 
this way, boundaries are drawn between the knowledge and work of GPs and 
hospital doctors and community and hospital pharmacists, as the quotes below 
demonstrate.  
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“Community pharmacists don’t even deal very much with cancer 
drugs. That’s still secondary care” (CP 8) 
 
“GPs are not happy about sharing responsibility for prescribing 
and monitoring these patients. They want to stick with what they 
know - diabetes, hypertension. They don’t want to see patients, 
generally I’m talking and there will be the occasional GP who 
might be happy but by and large they perceive oncology as being 
high-tech, complex, complicated” (HP 9-Oncology) 
 
 “There is quite a big gap at the moment but we shouldn’t forget 
that these patients are not only treated for the condition that they 
get all singing all dancing medicines for they’ve also got general 
medical conditions… And they will be getting treated by their GP 
and getting their medicines from the community pharmacy for a 
whole wide range of things as well as specialist care” (HP 6- 
Director of Pharmacy) 
 This discursive binary between hospital and community medical and 
pharmacy practices around the notion of complexity (both disease and drug) is, 
arguably, increasingly blurred as more patients are managed through shared care 
arrangements and hospital drugs are increasingly administered in community 
settings. One particular example here is the breast cancer drug Herceptin
14
 which is 
increasingly prescribed in hospitals but administered in patient’s homes in the 
community. Nevertheless, Herceptin is prescribed for a relatively complex disease 
and, due to it often being used as an adjunct therapy with traditional chemotherapy, 
reflects this complexity in regard to its potential toxicity and managing adverse 
effects. Given this, timing remains integral to the management of toxicity that 
surrounds this therapy, as Hospital Pharmacist 9 (an Oncology pharmacist) 
highlights below.  
                                                 
14
 This drug is described by Hedgecoe (2004) as the first example of a pharmacogenetic drug in 
routine clinical practice. In the present discussion, however, the pharmacogenetic status of Herceptin 
is purely coincidental and not related to the argument at hand.   
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“Those drugs [Herceptin] were then made up by the third party 
supplier and then they were transported by the nurse to the 
patient’s home at a predetermined time, predetermined date” (HP 
9-Oncology) 
Moreover, this quote demonstrates that although the binary between hospital 
and community medicine is somewhat blurred, there is still a degree of boundary 
work being carried out around the management of Herceptin’s toxicity. As such, 
only practitioners with expertise in this area (in this case a specialist oncology nurse) 
are able to interact with this medication and the patient as a user of it.  Such expertise 
moves beyond the confines of the hospital into the wider community setting, 
accompanying and enabling the movement of the drug. This suggests that the 
hospital regime for toxicity management is embedded within the drug itself. As a 
result, when the drug moves to the community setting, it carries the medicines 
management regime of the hospital with it, which brings secondary care drug 
ontology and primary care cultural practices together into the patient experience of 
drug taking.  
 
 These anxieties, grounded in discourses of complexity, and the boundary 
work they necessitate provide a useful framework for analysing the potential 
implementation of PGx technologies. As Community Pharmacist 6 highlights, at 
present there is an alignment between PGx principles and practices with highly 
specialised hospital-based fields which are routinely utilising relatively complex 
medications:  
 “I think there’s an assumption that it’s [pharmacogenetic 
medicine] very much secondary care led therefore you wouldn’t 
necessarily see that in the community and an assumption that it’s 
very specialist” (CP 6). 
The role of disease and drug complexity in affecting the implementation of 
pharmacogenetics in hospital and community pharmacy practice is discussed in more 
detail Chapter Eight. 
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6.4.4 Gazing at the Patient Body 
 Central to this primary/secondary care binary within the discourse of toxicity 
is the patient body as this is the site through which the discourse of toxicity is 
enacted and within which the ontological status of drugs comes into being. In other 
words, the discourse of toxicity cannot exist without the presence of the patient body 
as it is the patient body within which adverse reactions take place and, thus, through 
which understandings of drugs as potentially toxic are developed. The data suggest 
that pharmacists have a particular way of constructing and knowing the patient body 
through this discourse of toxicity. As such, central to the pharmacy gaze is a co-
construction of medications as risky pharmacological interventions and patient 
bodies as a site of complexity and risk brought about by the pharmacological action 
of these medications. Given their expert knowledge of pharmacology, the pharmacy 
gaze claims the management of these dual elements as pharmacists’ field of practice 
and expertise.  
 
The traditional role of pharmacists as compounders and dispensers meant that 
the majority of their time was spent in the dispensary with limited contact with 
patients. As such, the patient body only became apparent to the pharmacist through 
adverse reactions and toxicity.  
 
Although the increased clinical role of pharmacists has created new ways 
through which pharmacists interact with patient bodies (see below), the patient body 
is still primarily apparent to pharmacists within, and through, the discourse of 
toxicity. Within this, the patient body is constructed as a complex site of potential 
risk brought about by the actions of medications working within it, which 
pharmacists claim as their field of expertise. As such, particularly in the hospital 
setting where prescription decisions are arrived at through a highly collaborative 
process of negotiation, pharmacists bear a degree of responsibility for ensuring the 
maximum efficacy and minimal toxicity on the patient body of therapy regimes, as 
Hospital Pharmacist 3 highlights:  
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“The body is very complex so how does it handle the drugs? 
Effects from the tumour, effects from the patient’s body, the rate of 
liver metabolism” (HP 3- Oncology) 
This quote demonstrates the need to effectively manage the complex and 
risk-laden patient body vis-a-vis drug action and potential side effects. Particularly in 
the hospital setting and in fields with highly toxic medications, this is done through 
the reduction of the ill body into a series of criteria and algorithms through which 
prescription decisions are made, as Hospital Pharmacist 9 (an Oncology pharmacist) 
and Hospital Pharmacist 4 highlight: 
 “In order to screen a prescription for chemotherapy you would 
need to check certain aspects of the patient” (HP 9-Oncology) 
 
“You’re going to have to check that those criteria have been met 
before the drugs actually released or dispensed” (HP 4) 
In addition to determining these characteristics of the patient body, a key 
driving factor for these prescription decisions is also the cost of the medications. 
Hence, the ill body is understood as a potentially expensive body. Particularly in the 
hospital setting, where high-tech, innovative and comparatively expensive therapies 
are more likely to be prescribed, treatment decisions are often mediated by the 
potential financial implications.  
 “There were these new treatment options coming onboard all the 
time and yet we were told to save money all the time” (HE 1- also 
previous a HP) 
 This centrality of financial implications to therapy decisions also provides 
another way through which the implementation of PGx into routine practice can be 
analysed. Elsewhere pre-prescription PGx testing has been regarded as a way 
through which traditional ‘trial and error’ prescription models can be improved 
(Martin et al., 2006). This improvement, however, relies on these tests being 
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relatively cheap (in contrast to trial and error approaches) and providing reliable 
results on which prescription decisions can be made. Here, again the differences 
between primary and secondary practices and medications become important. Hence, 
in primary care settings the relatively cheap price and low toxicity of medications is 
understood to make the ‘trial and error’ prescription model relatively unproblematic, 
as Community Pharmacist 6 notes: 
 “It will depend very much on the cost because if we look at things 
like Codeine, you could just try it and if it don’t work you try 
something else because it’s so cheap to try” (CP 6) 
 In contrast, in secondary care where there is an increased risk of toxicity and 
higher financial burden of ineffective medications, pre-prescription PGx test results 
are understood as constituting another ‘aspect’ (to use Hospital Pharmacist 3’s term) 
of the patient body through which prescription decisions are made. Hence, pre-
prescription PGx testing in hospital settings is a potential way for the ill patient body 
to become a less expensive body.  
 
 As mentioned above, pharmacists’ interactions with the patient body are 
increasingly enacted through pharmacy’s clinical role.  In the community setting in 
particular, these clinically-based interactions often occur through testing services that 
are part of the extended role. Through this aspect of practice, the patient body 
becomes a biological entity about which ‘truths’ can be ascertained through the 
results of black-boxed tests, as Community Pharmacist 3 demonstrates: 
“I was offering cholesterol testing as well as CVD 
[Cardiovascular Disease] calculations. So that was cholesterol, 
blood pressure test, heart monitoring and in that respect 
calculating patients’ CVD risk” (CP 3) 
Unlike in hospitals, however, the results of these tests do not necessarily 
serve to construct the patient body as a series of criteria or algorithms or feed into 
prescription decisions.  Instead, these tests provide patients with access to 
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biomedical knowledge about their own bodies. At the same time, the patient as a lay 
manager of medicines is increasingly an object for community pharmacy as part of 
the move by government to better medicines management in the community 
(Department of Health, 2000; Department of Health, 2003b). This is further reflected 
in the recent discursive policy shift away from medicines ‘management’ and towards 
medicines ‘optimisation’ which places an increased focus on the ways in which 
medicines are used by patients (see Colquhoun, 2012). Within this, community 
pharmacy services such as the New Medicines Service
15
 (NMS), are posited as 
examples of this ‘policy in action’ which locate the community pharmacist as a 
central practitioner in this optimisation process.  This reconfiguration of the 
pharmacist as a healthcare practitioner has necessitated the incorporation of a 
divergent skill set around increasingly physical interactions with the patient body 
into routine practice; as Community Pharmacist 2 notes, this was something unlikely 
to happen in the past:  
 “We’ve never actually touched patients before, you know, you do 
the medication for them, you stick it in a bag and you hand it over. 
Pharmacists are generally not used to touching patients. 
Communication skill as well is not something that pharmacists in 
the past have needed” (CP 2)  
The pharmacist/patient relationship is also configured around the status of the 
patient body as being chronically or acutely ill. Here, the acutely ill patient body is 
present for a relative short period of time and, generally, represents fewer 
complexities or risks vis-a-vis toxicity and adverse reactions. It is through 
interactions with this sort of patient body that pharmacists are most likely to enact a 
‘shopkeeper’ role (Masongo, 2005) and experience the role strain and status issues 
associate with it. In contrast, chronically ill bodies tend to be more complex and 
risky due to the increased chance of polypharmacy regimes. As such, pharmacists’ 
interactions with them tend to be lengthier, more sustained and more akin to that of 
                                                 
15
 The New Medicines Service was introduced as an advanced service in the community pharmacy 
contract in October 2011. It is focused on supporting patients with long-term conditions to comply 
with new medications that they have been prescribed (Buxton, 2011). 
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other healthcare professionals. The quote below highlights the central role 
pharmacists can play in the experience of chronically ill patients;  
 “People who were post-bone marrow transplantation and they’d 
be on quite extensive drug regimens... I’d go through their 
medications with them and help them about how to organise their 
25 medicines they were taking a day” (HE 1- also previous a HP) 
This difference between pharmacy/patient interactions with acutely and 
chronically ill patient bodies may also be a central factor in understanding the status 
differences between community and hospital pharmacists outlined at the beginning 
of this chapter.  
6.4.5 The Bioclinical Collective Gaze 
Another key difference between hospital and community pharmacists’ interactions 
with the patient body is the status of the hospital pharmacy gaze as one of many 
practitioner gazes which the patient body is subject to given the number of 
practitioners who become involved in the patient’s care.  Here, then, the pharmacy 
gaze which constructs the patient as a medications-user is one of a number of 
perspectives through which the ill body is narrated by the bioclinical collective. 
Unlike in community settings, where practice co-location and collaboration are much 
more limited, these varying gazes are not deployed in isolation but instead, as May 
(1992) suggests, work interactionally to construct a narrative of the patient body 
which is aligned with hospital expertise, knowledge and policy.  
 
As an example of such divergent gazes at work in the hospital setting, May 
highlights the particular way in which nurses utilise the structure of their practice 
(i.e. being based on wards and having more time to speak with patients) and position 
within the hospital division of labour to cultivate both a foreground and background 
knowledge of patients. Hence, nurses gaze at patients both as a particular, clinically-
defined set of care requirements (foreground knowledge obtained through a clinical 
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gaze which seeks ‘truths’ about the patient body) and as idiosyncratic and private 
subjects (background knowledge obtained through a more nursing-specific gaze).   
 
The exploration of different gazes in the hospital setting is useful in 
understanding the different ways in which patients are constructed by different 
health care professionals and for placing the pharmacy gaze within wider 
understandings of patients. Much of the work in this area, however, treats different 
clinical gazes or ways of knowing patients as discrete and related solely to that 
particular field of practice. The data, however, show that through bioclinical 
collective practices, pharmacists engage with and negotiate ‘gazes’ other than that of 
their own profession, particularly around the time of discharge.  
 
This multi-gaze that the patient body is subject to in hospital settings is 
facilitated through hospital policy generally allowing all health care professionals 
that interact with patients to have access to patient medical records. Berg and 
Bowker (1997) have analysed patient medical records from a Foucauldian 
perspective and argue that patient medical records produce a history, geography and 
memory of the patient through verified (i.e. tested) ‘truths’ about the patient body. 
Moreover, they argue that patient medical records are fundamental to the everyday 
production of the patient body and to the production of the organisations that enact 
and treat it. Hence, the relations in the hospital (between actors in the bioclinical 
collective and between patients and practitioners) are mediated through the medical 
record.   
 
The data here confirm this general argument that access to patient medical 
records is of central importance to hospital and community pharmacy practice. In 
hospitals, allowing multiple and diverse practice populations to access, and 
contribute to, patient medical records collates multiple practitioner gazes in one 
documentary space. This documentary space serves to construct a history, geography 
and memory of a multi-faceted patient body through the mobilisation of various 
fields of expertise, as Hospital Pharmacist 6 shows;   
176 
 
“So it’s not just pharmacy but OTs and physios and all sorts of 
people who have access... all write in the patient’s notes” (HP 6- 
Director of Pharmacy)  
In the community setting, the boundaries of expertise that are drawn around 
GPs create an intellectual and practice hierarchy between GPs and pharmacists 
which is manifested in the restriction of medical record access to the GP and, 
potentially, staff working in the GP surgery. As such, pharmacists practising in 
community settings are not granted the power to see patient records, or enter onto 
them observations based on pharmacy expertise. As such, the record is an important 
‘inscription device’ that acts to confirm diagnostic power and expertise. This 
limitation of the gazes through which community pharmacists see patients was 
understood by respondents as being restrictive for practice as the complexities of the 
ill body, and their potential impact on the pharmacological action of therapies, could 
not be effectively managed by the community pharmacist in the same way as in 
hospitals, as Community Pharmacist 8 demonstrates; 
 “How community pharmacists are supposed to make sure that the 
patient is moving on with the correct medication- it’s virtually 
impossible without records” (CP8) 
 In their analysis of EPS, Petrakaki et al. (2012) unsurprisingly argue that 
increased pharmacist access to patient medical records would enhance community 
pharmacy’s status in terms of increased capacity for decision-making; expanding 
their professional jurisdictions; engaging them in clinical judgements through an 
increased information pool; strengthening inter-professional trust; and rendering 
them part of the ‘NHS family’. Moreover, as the quote above highlights, resetting the 
boundaries of medical record access may also be beneficial for patients through 
improved counselling practices and adherence. This extension of access to patient 
medical records, however, presents a number of practical and ethical challenges. 
Hobson et al. (2010) note, for example, that patients are reluctant for pharmacists to 
access sensitive, and what is largely perceived to be irrelevant, medical information 
such as sexual health issues. This perspective is reflected in an earlier Patients’ 
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Association (2008) report where the practical issues of limiting medical record 
access to pharmacists alone (rather than all staff working in pharmacies) was also 
centralised. Additionally, extending medical record access undermines a central 
feature of the medical technocracy that exists in primary care practice. Hence, the 
potential for community pharmacists to interact with patient bodies through a 
biomedical gaze is primarily limited by the restrictions placed on medical record 
access in routine primary care practice. However, the increasingly clinical future of 
pharmacy (detailed below) means that such debates around record access will 
become more common.  
6.4.6 Future Pharmacy Gazes 
An analysis of the present character of any field of practice somewhat necessarily 
invites a reflection on its future. The data demonstrate three broad directions in 
which it is thought the pharmacy gaze may travel; an increasingly clinical gaze, 
which is highly aligned with an increasingly public health-oriented gaze and an 
increasingly molecularised gaze. Each of these is taken in turn.  
 
The traditional role of pharmacists as primarily medicines compounders, 
manufacturers and dispensers located their practice within the dispensary with 
minimal patient contact. The ubiquity of pre-packaged medicines and extended role 
of pharmacy in the post World War Two era, however, increasingly located 
pharmacy practice outside of the dispensary and entailed increased patient contact in 
both the hospital and community setting.  
 
The data show that the pharmacy gaze is increasingly focused on medicines-
centred clinical activities. Hence, somewhat in opposition to the clinical gaze 
forwarded by Foucault, the pharmacy gaze has shifted from viewing the patient from 
within the dispensary as a set of medications requirements disconnected from the 
patient body to seeing patients in a more multi-faceted way through increased 
clinical contact. This is particularly true in the hospital setting where pharmacists 
spend large amounts of time in face-to-face contact with patients on wards. In the 
community setting, the pharmacy gaze was understood to become increasingly 
focused on clinical and public health activities. Within this, the respondents noted 
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concerns around funding for pharmacy, particularly in light of GP commissioning 
practices, as being particularly prominent for community pharmacists. Given this, 
the future of community pharmacy was thought to lie in a diversified practice which 
aligns with current public health concerns, as Community Pharmacist 2 outlines; 
“I think community pharmacy can only increase its public health 
profile really. Get more involved in screening for things like sexual 
health…get more involved in some if the issues we’ve got around 
obesity, weight management problems” (CP 2). 
This view of the future role of community pharmacy aligns with Taylor’s 
(2005) conceptualisation of community pharmacy’s future, which he envisages as 
being centred around increased co-location with clinical practice and a 
reconfiguration of community pharmacists as ‘the people’s doctors’ (p. 292) owing 
to their increased prescribing abilities and public health advisory role.  
 
In the hospital setting, this increased clinical focus is understood as the most 
effective method through which drug toxicity can be managed. Hence, the discourse 
of toxicity is increasingly communicated to patients by active face-to-face 
counselling by the pharmacist rather than through passive patient information 
leaflets. This method of managing toxicity is thought to encourage adherence, 
improve patients’ experiences of their illness and medicines and reduce the financial 
burden of drug-related readmissions (for example Bajramovic et al., 2004). This 
sense of the effectiveness of face-to-face clinical work and counselling is 
encapsulated by Hospital Pharmacist 1 (a chief pharmacist); 
 “It’s all about asset stripping staff out of the dispensary and 
getting them to be able to work on the ward…you cannot do 
effective medicines management in the dispensary” (HP 1- Chief 
Pharmacist) 
 Another broad area of development for the pharmacy gaze was 
conceptualised as being in increased molecularisation. With developments in testing 
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technologies (both DNA-based and otherwise), the data show that hospital 
pharmacists are interacting with patients framed as molecular subjects at the 
diagnostic and prescription phases of the patient’s journey. Within this, monoclonal 
antibodies (mAbs) and PGx were identified as particularly central to this 
molecularised gaze, which can be understood in line with Clarke et al.’s (2003) 
biomedicalisation thesis. As such, it might be argued that the patient body in 
pharmacy is being increasingly biomedicalised through the integration of new 
molecular genomic technologies.  
 
 The implementation of these technologies into routine clinical practice was 
posited within the discourse of toxicity as offering effective ways to reduce the 
toxicity of (particularly Oncology) therapies. As such, they were not understood to 
represent a paradigmatic shift in pharmacy practice but, instead, to introduce new 
methods of practising the core principles of pharmacy. To demonstrate, in the case of 
PGx, there was an understanding that personalised principles were already at the 
centre of pharmacy practice as the discourse of toxicity relies on the idiosyncrasies 
of the patient body to determine drug response predictions. Implementing PGx 
testing into routine practice was thought to molecularise this personalised approach, 
as Hospital Pharmacist 1 (a chief pharmacist) shows; 
“Tailor made therapy - yeah, I suppose we can all argue that we 
tailor make people’s therapy but not on a genetic basis. I don’t 
think we’ve got down to the molecular level yet as pharmacists” 
(HP 1- Chief Pharmacist). 
6.5. Conclusion 
The pharmacy gaze provides a useful way of sociologically conceptualising 
contemporary pharmacy practice. This chapter provides an overview of the roles and 
statuses found within the contemporary pharmacy practice landscape and, in turn, 
provides a framework through which the implementation of innovative technologies 
into pharmacy practice can be analysed. Using empirical data, this chapter has 
demonstrated the way in which working practices in community and hospital 
pharmacy can be understood in line with Serra’s (2010) and Rabeharisoa and 
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Bourret’s (2009) notions of medical technocracies and bioclinical collectives. In this 
way, the demarcation of roles in community practice can be understood as 
maintaining hierarchical relationships between GPs and community pharmacists and 
feeding into perceptions of the latter as primarily retail focused. Within this, the 
relatively rigid boundaries that are drawn around the work of GPs and their 
capability to define the terms of practice in primary care are legitimated. In contrast, 
the data demonstrate a more bioclinical collectivity in hospital practice where the 
absence of retail identities and role strain contribute to the attribution of higher status 
to hospital pharmacists than those working in community.  
 
The chapter argues that central to both hospital and community pharmacy is 
good medicines management and pharmaceutical care practices. Here, the pharmacy 
gaze is a useful tool for analysing the ways in which formalised, bureaucratic 
medicines management and pharmaceutical care policies operate concurrently with 
more negotiated processes. The pharmacy gaze, then, is centred on the co-
construction of chemical compounds as risky medications and patients as at-risk 
medications users around whom a discourse of toxicity and risk is constructed based 
on their individual patient journey and therapy regime. The pharmacy gaze makes a 
novel Foucauldian contribution to sociological understandings of pharmacy practice 
in that it centralises the patient and their body as the site within which ADRs occur 
and, thus, through which discourses of toxicity are created. Moreover, this 
positioning of the patient body as a site of complexity and management makes 
medicines meaningful through locating them within patients’ wider lifeworld. This 
process of making medicines meaningful further indicates differing practice and 
expertise in hospital and community pharmacy. As the chapter demonstrates, the 
location in which drugs are dispensed and administered is central to and a reflection 
of their attributed ontological status as being more or less toxic. Within this, 
relatively complex secondary care diseases and their comparatively toxic 
medications require a particular set of pharmacy expertise and practices which are 
divergent from those in primary care that are mainly associated with relatively 
simple diseases and therapies.  
 
This notion of divergent status and working practices in primary and 
secondary care pharmacy is a central feature of the following chapters. Through the 
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use of the dual medicines management process and the pharmacy gaze as a 
conceptual framework, these chapters demonstrate that engagement with new 
medical technologies in general, and PGx specifically, is mediated through the 
practice relationships and environments into which they are implemented. This is a 
particularly pertinent issue to address given the contemporary policy focus on GP 
commissioning, which may alter the relationship between GPs and community 
pharmacists and the way in which pharmacy services are provided in primary care. 
As such, the following chapters make use of May and Finch’s (2009) NPT as a point 
of reference to show the ways in which the differential structures and practices of 
hospital and community pharmacy necessitate the mobilisation of different forms of 
work in order to implement new technologies into routine practice. In addition, by 
returning to the notions of medical technocracy and bioclinical collective, the 
following chapters demonstrate the ways in which the implementation of innovative 
technologies into different pharmacy practice settings can re-configure them vis-à-
vis their roles and status.  
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Chapter Seven: Technology in Pharmacy 
7.1 Introduction 
Pharmacists interact with technologies in their everyday practice as part of their 
engagement with medicines and their associated ‘stuff’ (Barber, 2005). Particularly 
in community pharmacy, the extended clinical role has necessitated pharmacists’ 
increasing use of a variety of diagnostic devices such as carbon monoxide monitors, 
blood glucose tests and pregnancy testing kits. This chapter draws on empirical data 
to argue that pharmacists’ engagement with these clinical devices enables the 
pharmacy gaze to move beyond a focus solely on medicines to one which 
incorporates the patient body, as outlined in Chapter Six. Hence, the outputs from 
these devices provide a means through which the patient body becomes known as a 
site of complexity and risk.  Pharmacists’ engagement with such technological 
devices is, then, central to the practice of a pharmacy, rather than pharmaceutical 
gaze (Barber, 2005).   
 
In the hospital setting, technologies that have impacted on pharmacy have, 
for the most part tended to be less clinical and more operational. As such, innovative 
technologies in hospital pharmacy practice have tended to be centred around 
dispensing practices rather than testing and monitoring devices. Dispensing robots, 
electronic prescribing systems and computerised medical records are clear examples 
of this. These technologies fit within the corporate responsibility framework of 
hospital pharmacy by assisting with audit activities, streamlining processes and 
reducing dispensing errors. This focus on reducing errors also resonates with the 
implementation of technology within community pharmacy where technologies are 
operationalised as a means of improving patient safety through both improving 
general health and managing medicines’ toxicity.  
 
Innovative technologies in pharmacy can act to reconfigure the occupational 
role and identity of the profession. This process of defining professional boundaries 
and jurisdictions of various practices through innovations has been explored 
elsewhere (Korica and Molloy, 2010; Mclaughlin and Webster, 1998; Zetka, 2001). 
The implementation and effects of technology in pharmacy have not, however, been 
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extensively analysed. The research that does exist in this area tends to focus on the 
macro-level of the pharmacy sector in its entirety rather than the micro-level work 
which is carried out to integrate technologies, and their effects, into practice. This 
reflects a wider paucity of attention given to how technology features in the routine 
practice of medical professionals, through which Heath et al. (2003:1881) argue 
technology ‘gains its significance’. 
 
Given this, this chapter examines the ways in which new technologies are 
configured into everyday pharmacy working practices. The chapter draws on the 
dual medicines management model described in Chapter Six to argue that innovative 
technologies in pharmacy are operationalised and configured in two ways: through 
their positioning within codified formalised, organisational medicines management 
processes and through their centrality to the pharmacy gaze as a more individualised, 
negotiated method of medicines management in everyday practice.  
 
May and Finch’s (2009) NPT provides useful insights for conceptualising the 
ways in which new technologies are integrated into everyday pharmacy work as the 
components of NPT resonate with much of the data collected here. Given this, these 
components are used here as reference points for understanding the work that 
pharmacists undertake with respect to embedding new technologies. As Chapter Five 
(Methodology) notes, NPT is not methodologically deployed as an analytical 
framework for the thesis overall, rather some of its components are drawn on 
heuristically to help understand how innovative technologies and practices are taken 
up. Together, the dual medicines management approach and elements of NPT 
provide a general framework through which the implementation of technologies into 
hospital and community pharmacy can be analysed.  
7.2 Drug Technologies 
Much of the emphasis on new technologies in pharmacy is centred around devices 
and black-boxed artefacts which are most commonly mobilised as part of 
pharmacists’ clinical practice.  
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Much of the data collected here which focuses on new technologies in 
pharmacy is concerned with new drug technologies, which is to say new 
pharmaceutical products that reorganise or reconfigure pharmacy work. Within this, 
the discourse of toxicity around these new drug technologies is central to their 
reorganisational capacity. As such, these new drugs represent new ways of 
constructing and managing toxicity. The most pertinent example of this to be 
highlighted in the interview data is monoclonal antibody (mAb) technology. This 
field of drug technology specifically targets areas of single proteins (epitopes) which 
are over-expressed as a result of disease. Hence, mAb drugs do not rely on the 
‘shotgun’ approach of, for example, cytotoxic medications and, as a result, are less 
likely to cause adverse effects (Keller, 2009).  
 
They are also important because they are seen to enable more targeted, 
personalised treatment regimes. This is reflected in the way that mAbs are most 
commonly prescribed to cancer patients whose bodies are constructed within the 
pharmacy gaze as particularly complex and risk-laden in terms of their morbidity, 
but made more so given the effects of traditional chemotherapy regimes. 
Pharmacogeneticist 9 (who has a particular interest in Oncology) highlights this; 
“We give them enough drugs to just not quite kill them but actually 
sometimes it’s the drugs that kill you and not the cancer so we 
need to try and get away from that because there’s more morbidity 
associated with the drugs” (PGx 9) 
Hence, the prescription of mAbs is understood as a positive step in cancer care given 
their reduced toxicity, as Hospital Pharmacist 8 highlights;  
 “I know that you’ve got your monoclonal antibodies now and they 
are not without their side effects but they are in many ways 
superior in terms of side effect profiles to conventional 
chemotherapy” (HP 8) 
This perceived superiority to traditional cytotoxic medications is discursively 
aligned with increasingly targeted prescription behaviour patterns where a 
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‘molecular gaze’ is adopted by prescribers in making therapy decisions. Rose (2007) 
argues that this molecular gaze sits within a more general molecular ‘style of 
thought’ (see Fleck, 1979) that underpins contemporary medical practice. Given this 
‘style of thought’ in treatment decisions, the pharmacy gaze has also become 
increasingly molecularised with the pharmacological action of drugs, and their 
potential toxicities, being understood at the molecular level. Hence, the discourse of 
toxicity around mAbs is created based on the molecular characteristics of the patient 
body, which are identified through testing for specific biomarkers, as in the case of 
pre-prescription HER2 testing for Herceptin regimes. Hospital Pharmacist 9 
(Oncology pharmacist) demonstrates this well;  
“MAbs where you are focusing on markers and testing. For the 
conventional chemo type drugs there’s no way of predicting which 
patients are going to do well with this treatment and so you end up 
giving it to everybody” (HP 9- Oncology) 
This quote also highlights the paradigmatic shift in Oncology practice from 
“willy-nilly” (HP 9- Oncology) universal chemotherapy regimens to increasingly 
molecularised and personalised courses of therapy. While, at first sight, more 
personalised treatment regimes might be presumed to be expensive, from the 
perspective of formalised medicines management, such an approach reduces cost 
because of the reduction of adverse drug effects: 
“So it’s all now about targeted therapies…And it’s good because it 
means that you don’t over treat patients. You’re not treating 
patients willy-nilly. I think it’s good because it’s a lot more 
individualised now in terms of making sure that patients get the 
treatments that are best for them” (HP 9- Oncology) 
Given this decreased propensity for toxicity, mAbs can potentially 
reconfigure the everyday work of pharmacy by refocusing work away from the 
management of adverse drug effects which has previously been central to Oncology 
pharmacy practice. Moreover, this decreased toxicity and the potential for mAbs to 
be administered to patients orally means that there is a drive towards relocating 
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Oncology medication administration away from the hospital (So, 2010). In moving 
towards the administration of relatively low toxicity medications outside of the 
hospital setting, these drugs are made meaningful to patients through their existence 
within their wider ‘lifeworld’. So (2010: 35) also highlights the way in which this 
relocation of medications is defined through formal medicines management policies 
and organisational interests as a ‘more cost effective way’ of treating Oncology 
patients.  
7.3 Medicines Management and Pharmaceutical Care Technologies 
Defining new technologies in pharmacy is central to their configuration as useful or 
otherwise for everyday working practices. The specificities of this ‘coherence’ work 
(see May and Finch, 2009) depend upon the sector of pharmacy into which these 
technologies are being implemented. As such, the ‘scope’ of the technology in 
question (i.e. whether it focuses on chronically or acutely ill patient bodies or low or 
high risk medications) affects the process of defining the utility of technologies in 
different pharmacy settings.  Here, again, the differences between hospital and 
community pharmacy practice become apparent through this process of defining the 
innovation. Within this, the meaning of the new technology is linked with the 
particular nature of toxicity management being undertaken in that location. As such, 
the practices and discourses of medicines management and pharmaceutical care are 
central to this process of defining new technologies in hospital and community 
pharmacy respectively.  
 
New technologies are, then, located within formal, codified and bureaucratic 
strategies of improving pharmaceutical care and medicines management at local and 
national levels (see Audit Commission, 2001). Chapter Six demonstrated an 
epistemic distinction between hospital and community pharmacy practice around the 
notions of medicines management and pharmaceutical care with medicines 
management being related to an understanding of organisational interests in 
improved medicines efficacy and pharmaceutical care being more focused on 
individualised patient-centric efficacy and risk.   
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Within this, medicines management in hospital pharmacy is grounded in 
organisational interests in medicines efficacy, where therapy decisions are based 
around local policies and financial implications. Moreover, risk management in this 
practice model is located within legal and corporate responsibilities. In this vein, the 
implementation of innovative practice technologies in hospital pharmacy is 
understood as a way of both streamlining dispensing practices in order to improve 
overall pharmacy efficiency and improving and monitoring dispensing quality, as 
Hospital Pharmacist 6 says;    
“The computer does all that [inputs prescription details such as 
dates and signatures] for you which means that we’ve been able to 
focus the pharmacist resource more on safety and appropriateness 
of drug treatment.” (HP 6- Director of Pharmacy) 
 
“And the way the information can be used in terms of we can do 
audits that were impossible to do previously” (HP 6- Director of 
Pharmacy) 
Here, the electronic patient record and the computer system on which it 
depends are defined through bureaucratic policy rhetorics as technological 
instruments which can make more efficient use of staff resources and assist with 
better quality audit activities. On the less formalised, more negotiated level of 
everyday practice, these technologies are central to the discourse of toxicity 
generated through the hospital pharmacy gaze. In this, toxicity is managed through 
the application and mobilisation of these technologies, as Hospital Pharmacist 6 
highlights in reference to electronic prescribing systems: 
“Under electronic prescriptions and administration records... And 
that’s made a massive difference in terms of the information you 
can present to prescribers at the point their doing prescriptions 
about interactions and allergies and all sorts of other things” (HP 
6- Director of Pharmacy)  
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 Another example of this is computerised labelling where medicines are made 
meaningful and located within a patients’ wider lifeworld through the information 
(for example, dosage and administration details) provided on these labels. Shrank et 
al. (2007b) note that effective labelling is central to toxicity management as, in 
contrast to Patient Information Leaflets, medication labels are part of the medication 
itself given that labels cannot as easily be separated from medications. Although this 
labelling work has always been a central feature of pharmacy practice, its 
computerisation represents a new paradigm of medicines management where 
computer-generated (rather than hand-written) labels are thought to be clearer, thus 
making medicines easier for patients to engage with and adhere to (Shrank et al., 
2007a). The comment from Hospital Pharmacist 4 highlights the impact of electronic 
medication labelling;  
“When I started we had typewriters. From that point of view 
technology has really improved in terms of…patient labelling” 
(HP 4) 
The implementation of technologies into community pharmacy is centred 
around two primary concerns: the pharmaceutical care of individual patients vis-à-
vis potential drug reactions, and the increase in clinical practice, the latter of which is 
explored in more detail below.  
 
The discourses and practices of pharmaceutical care are central to the process 
of defining new technologies in community pharmacy. Similar to the medicines 
management discourses mobilised in hospital pharmacy, pharmaceutical care 
processes are central to the operationalisation of new technologies in everyday 
community practice. As such, the community pharmacy computer is understood as a 
means to improve pharmaceutical care, patient adherence and outcomes and reduce 
toxicity through various functions and packages. The data suggests that the most 
pertinent example of this is the implementation of computer systems into everyday 
pharmacy work.  
 
The arrival of computer systems in community pharmacy represents a 
significant departure from traditional experiences of pharmacy work, in which 
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manual documentation and procedures played a central role and underpinned much 
of the GP/pharmacist communication (Motulsky et al., 2008). Writing some years 
ago, Foster (1992) noted that producing labels, storing patient prescription 
information, producing patient safety documentation and managing stock were the 
key areas that applications of computer technology addressed in pharmacy; the data 
collected here suggest that these work activities are still the primary applications of 
computer technology in community pharmacy.  
 
Making sense of the meaning and significance of computerisation of 
community pharmacy is strongly linked with pharmaceutical care processes and 
discourses through the use of computers to identify potential toxicity. Within this, 
the pharmacy computer is framed as advantageous in its capacity to store patient 
medication records and algorithmic information which can help identify potential 
drug interactions. In doing so, the community pharmacy computer is understood as a 
way to improve pharmaceutical care by increasing patient and practitioner awareness 
of potential toxicity (Abarca et al., 2006). This is in addition to the capacity for 
electronically producing labels and safety information, which is central to patient 
adherence and outcomes policies.  
 
At the less formalised, policy-bound level of everyday pharmacy practice, the 
community pharmacy computer is seen to enhance rather than undermine the 
pharmacy gaze. Patient information on the computer acts as a documentary space for 
the recording and management of toxicity which at the same time brings the patient 
body to life through its presence within this toxicity documentary. The community 
pharmacy computer, then, is used to store patient drug histories which construct a 
discourse of toxicity through the identification of potential risk-laden drug 
interactions. Within the documentary space of this drug history the patient body is 
configured as a complex site of potential toxicity to be managed by the community 
pharmacist through labelling, advice and counselling. Community Pharmacist 2 
highlights the centrality of the computer to toxicity management in contemporary 
community pharmacy practice;    
 “I think the computer coming into the pharmacy opened so many 
doors really. Prior to that we didn’t even have a record of what 
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patients had ever had. We’d nothing to help us with drug 
interactions. We’d no computer to flash up warnings. I mean, I 
often think - well I worry, to be honest - how much harm we did to 
patients because of drug interactions that we never even - we may 
have known about but not to the extent that we do today. And we 
had nothing to remind us of them at all. We didn’t put particular 
patient warnings on labels” (CP 2) 
Defining the utility and meaning of new technologies in pharmacy is a 
process which sits within both formalised, codified pharmaceutical care and 
medicines management practices and less formalised, more negotiated everyday 
work practices which are enacted through the pharmacy gaze. Within bureaucratic 
medicines management and pharmaceutical care rhetoric and practices, the 
integration of new technologies into pharmacy is operationalised as a way to 
improve the safety and efficacy of pharmacy dispensing. At a more negotiated, 
pharmacy gaze level, new technologies act as inscription devices to configure the 
patient body as a set of particular risks and toxicities which are then observed 
through the pharmacy gaze and managed through the discourse of toxicity. 
Moreover, in community pharmacy new technologies can also act to configure a 
more clinically-focused pharmacy gaze. It is to this application of technology that 
the chapter now turns.  
7.4 Clinical Roles and Technologies 
This chapter is concerned with the ways in which new technologies shape and 
reorganise everyday pharmacy work and relations. The changes that have occurred, 
and continue to occur, in everyday pharmacy work are multi-dimensional and arise 
from both macro and micro policies and strategies such as the Department of Health 
and RPSGB’s extended role (see Chapter Two). One key way in which pharmacy 
work and relations have been reorganised in the last three decades is in its more 
clinical focus, in which new technologies have played a central role.  
 
New technologies are central to this more clinical reorganisation of pharmacy 
in two key ways. In one way, new technologies which are central to clinical activities 
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have become increasingly present in (particularly community) pharmacy. These are 
defined here as technologies of clinical work. In another way, technologies such as 
electronic prescribing and pharmacy robots are conceptualised as central actors in 
the process of reorganising pharmacy work. As such, new innovations are 
understood as reorganising pharmacy work towards an increased clinical focus by 
removing pharmacists from the dispensary and what Hospital Pharmacist 6 (Director 
of Pharmacy)  describes as “traffic warden duties” and increasing their clinical 
workload. These are defined here as technologies enabling clinical work. Each of 
these is taken in turn.  
7.4.1 Technologies of Clinical Work: Configuring the Individual and Public 
Health Body 
New technologies are central to much of the clinical work that pharmacists, 
particularly in the community setting, now undertake as part of their everyday 
practice. These black-boxed devices, such as blood glucose and carbon monoxide 
monitors, act as new ways of knowing the patient body. Moreover, given their 
association with the maintenance of health and wellbeing, they also act to 
reconfigure the pharmacist as a health promotion or public health practitioner. 
Through this reconfiguration, pharmacy practice becomes less spatially-bound to the 
dispensary and is increasingly practised in the consultation room (in the case of 
community pharmacy) and at the patient bedside (in the case of hospital pharmacy).  
 
Chapter Six noted that the clinical role of community pharmacists has created 
new ways through which pharmacists interact with, and come to know, patient 
bodies. The outputs from black-boxed clinical devices, such as those mentioned 
above, provide patients and pharmacists with access to biomedical knowledge about 
patient bodies. Unlike in hospital pharmacy and GP work, this knowledge does not 
necessarily feed into prescription decisions but instead becomes central to the 
individual patient health project and risk profile. In this way, the clinical monitoring 
work that is undertaken by community pharmacists can be understood as sitting 
within a health promotion and surveillance medicine approach where the 
‘extracorporal space’, otherwise referred to as ‘lifestyle’ (Armstrong, 1995:401), 
becomes important in the pharmacists’ configuration of, and interaction with, the 
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patient body. Through testing and monitoring individual patient bodies, the scope of 
the pharmacy gaze is modified to focus on what is described here as the collective 
‘public health body’. Within this, the health profile of individual patient bodies 
contributes to the configuration of a ‘public health body’ which is located within 
wider public health discourses and foci.      
 
This clinical dimension represents a significant shift in the pharmacy gaze 
beyond the medication needs of patients, which is highly spatially-bound to the 
dispensary, to one that incorporates the wider ‘lifeworld’ of patients and the impact 
this has on health. Such an example of this is provided by Community Pharmacist 2 
who ran a health promotion clinic which mobilised a number of devices to provide 
patients with knowledge about their own bodies, which was then used for health 
advice. In this monitoring clinic, blood pressure, blood glucose and cholesterol 
monitoring kits and scales were used to configure the patient as a set of health risks 
and behaviours which could be managed by the pharmacist; 
“Just come along, get your blood pressure taken, get your blood 
glucose/cholesterol done and we’ll give you a bit of healthy 
lifestyle advice, etc.... We did it for about eight or nine months and 
it was really popular. We got husbands and wives coming together 
in the evening, which was great. Because we used to say, well, your 
cholesterol may be up, do you eat a lot of cheese? The husband 
would say no and the wife would say yes you do...this is something 
new for pharmacy” (CP 2) 
 This quote demonstrates that monitoring devices and the ‘extracorporeal 
space’ (in this case regarding eating habits) are central to the clinical community 
pharmacy gaze and the public health body it constructs. Moreover, Community 
Pharmacist 2’s reflection suggests a significant practice shift from the traditional role 
of pharmacists to this more public health or health promotion oriented focus, through 
which individual patient’s health profiles and what we can call a collective public 
health body are brought into being. Elsewhere, the relationships between public 
health and medical practice more generally (Armstrong, 1995) and public health and 
pharmacy (Anderson, 2007; Department of Health, 2005a) have been explored. In 
193 
 
the case of public health and pharmacy, however, there is a marked absence of the 
patient body through which public health discourses are enacted in the pharmacy 
setting. In much the same way as Chapter Six argues that an analysis of medicines 
management is limited without the presence of a medications using body, neither can 
public health practice be fully analysed without a body, or collective of bodies, 
discursively constructed by public health concerns. 
 
Whereas the traditional pharmacy gaze centres on individual patient bodies as 
sites of medications use and potential toxicity, the public health and health 
promotion focus of the pharmacy gaze is centred on multiple bodies and their 
collective relationship with wider public health foci. As such, the testing and 
monitoring technologies that are central to the performance of clinical pharmacy 
activities configure both individual health and risk profiles and a collective public 
health and risk profile which feeds into macro- and meso- level public health 
strategies. The following quote from Community Pharmacist 2 demonstrates the way 
in which the individual health profile and what we can call a collective public health 
body are created through testing and monitoring activities;   
 “so they [patients] just used to go away with their own results. We 
kept a copy of the results because we had to give that anonymised 
information to the PCT” (CP 2) 
This type of clinical work in community pharmacy has previously fed into 
questions around boundary encroachment (Eaton and Webb, 1979; Edmunds and 
Calnan, 2001) and the General Pharmaceutical Council recently argued that 
pharmacists are not competent to ‘undertake a physical examination which includes 
the touching of a patient’s body’ (General Pharmaceutical Council, 2012: 122). 
These concerns are located within a relatively rigid model of primary care practice 
where the medical technocracy in which GPs retain power is seen as at risk from 
disadvantageous jurisdictional realignments. Contrary to this, however, Community 
Pharmacist 2 notes that pharmacists’ relative professional status can be advantageous 
for engaging patients in public health and health promotion activities, in which 
technological devices play a key role: 
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“And people do sometimes feel less worried about coming into that 
kind of environment than going to the GP practice... Pharmacy can 
actually play a part in health promotion like that if people are 
more willing to come and see it as less official than going to the 
doctors’ practices I think” (CP 2) 
This notion was also suggested by Community Pharmacist 1 who notes that 
pharmacists utilising flu vaccination technologies enabled a wider population to have 
the vaccine than would have done if this remained a GP activity. Through 
administering vaccinations, the activities of pharmacists are placed within the 
boundaries of public health practices and their role in configuring, and managing the 
public health body is assured. This also supports Taylor’s (2005: 292) vision of the 
community pharmacist as ‘the people’s doctor’ and, elsewhere, the benefits of 
pharmacists’ involvement with vaccination programmes and technologies have also 
been noted (Steyer et al., 2004);  
“Some of the larger Boots stores have got involved in 
administering flu vaccines...the flu vaccinations enabled a few 
more people to get vaccinated who wouldn’t otherwise have been 
able to” (CP 1) 
Clinical devices are central to the construction of the collective public health 
body through the community pharmacy gaze. Within this, potential toxicity is 
understood as a risk not just of medications and the body’s relationship to them but 
through the body’s characteristics which are defined within public health and health 
promotion norms and discourses. These characteristics, such as weight, body mass 
index and cholesterol levels, are then made socially meaningful as characteristics of 
a public health body through these clinical devices. In other words, the public health 
body comes into being through the outputs from clinical devices and the relationship 
of these outputs with wider public health foci. Whereas the complexity of the body 
in the traditional pharmacy gaze is rooted in the body as a site of medications use 
(see Chapter Six), the clinical pharmacy gaze operationalises the complexity of the 
public health body as being rooted in the body’s characteristics and the health risks 
that they present. As such, bodily characteristics such as blood pressure or weight are 
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central to the clinical pharmacy gaze and organise public health interventions in 
community pharmacy.  
 
In this sense, the clinical community pharmacy gaze is strongly linked with 
the wider pharmacy gaze outlined in Chapter Six in that it is, at the base level, 
concerned with toxicity. The departure comes from the clinical community 
pharmacy gaze’s relationship with the patient body through a surveillance approach 
with understands health risks as being more generally linked to the ‘extracorporal 
space’ rather than just medications.  May and Finch (2009) note that a central part of 
coherence work is defining innovations by their differences from existing practices. 
In this case, the reconfiguration of pharmacy work to focus on the public health body 
is defined by its difference from the traditional pharmacy gaze, which focuses on 
medications and their local toxicities alone. This reshaping of pharmacy’s focus is 
aligned with macro-level policies, such as the provision of Essential services through 
the extended role, and micro-level work activities, such as providing specialist 
clinics.  
7.4.2 Technologies Enabling Clinical Work: Practising Away From the 
Dispensary 
Chapter Six noted that one of the most significant shifts in both hospital and 
community pharmacy work is the relocation of pharmacy practice, and practitioners, 
away from the dispensary. Increased patient contact was presented in this chapter as 
being an effective medicines management (or more recently, medicines optimisation) 
strategy. This relocation of pharmacists away from the dispensary is primarily 
facilitated through the integration of new technologies, such as dispensing robots and 
electronic prescribing and labelling services, which perform a number of the 
functions previously undertaken by dispensary-bound pharmacists.  
 
Such technologies are more commonly associated with hospital pharmacy 
and sit within formal medicines management policies. The integration of such 
technologies reconfigures the role and position of pharmacists within the hospital 
practice structure given their increased integration into the bioclinical collective 
(Rabeharisoa and Bourret, 2009). Given this, the use of such technologies in 
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pharmacy can be understood in line with the collective action aspect of NPT (May 
and Finch, 2009). According to May and Finch (2009:544) when new technologies 
are integrated into everyday practices, work is undertaken to ‘reorganize 
relationships’ which ‘involves collective purposive action aimed at some goal’. In 
this case, the goal is the increased pharmacy clinical work and patient contact where 
relationships are reorganised around the integration of pharmacists within the 
bioclinical collective practice team. Given this, the ‘relational integration’ of these 
new technologies is mediated by an understanding of their being necessary for 
improved medicines management within clinical pharmacy.  
 
Hospital Pharmacist 1 (a chief pharmacist) demonstrates the way in which 
the local relationships (between pharmacists and other healthcare practitioners and 
between pharmacists and patients) are reconfigured by the presence of technologies:  
“So we’re investing quite heavily in technology. We’ve got very 
sensible computer systems to support the dispensing processes. 
We’ll be getting a robot in the next few months to make sure that 
that’s all automated. It’s all about asset stripping staff out of the 
dispensary and getting them to be able to work on the wards” (HP 
1- Chief Pharmacist) 
The integration of these technologies has also altered the sorts of everyday 
activities that hospital pharmacists undertake. Hospital Pharmacist 6 (Director of 
Pharmacy) notes that the entrance of the computer into hospital pharmacy has shifted 
the focus of pharmacists’ work away from somewhat mundane activities which can 
now be effectively enacted by technological devices. Hospital Pharmacist 6 locates 
these activities within the pharmacists’ ‘checking’ role as “traffic warden duties” 
and defines the use of a computer for them as beneficial for medicines management 
and safety processes:     
“It’s what I describe as prescribing traffic warden duties, if you 
like. It’s everything written in block capitals, can you read it, has 
the doctor signed it, has it got a date on it, are the doctor’s 
intentions clear?...the computer does all that for you which means 
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that we’ve been able to focus the pharmacist resource more on 
safety and appropriateness of drug treatment rather than dotting 
i’s and crossing t’s and writing the print names in block capitals 
like we used to do.” (HP 6- Director of Pharmacy) 
In this quote, the clinical work of pharmacists is privileged over dispensary-
bound checking duties where the former is understood as a more effective use of 
pharmacy resources. These sentiments are echoed by Hospital Pharmacist 4 vis-a-vis 
dispensing robots; 
“From the point of view of [the] department probably yes. 
Releasing staff to other duties I think it’s probably going to be 
beneficial” (HP 4) 
Pharmacy robots have received some attention in the academic literature. In 
their study of hospital pharmacy robots in two UK hospital pharmacies, Barrett et al. 
(2011) note that pharmacy robots reorganise professional relationships throughout 
the hospital structure. In this way, pharmacists became further integrated into 
medical teams and increase their ‘institutional legitimacy within the hospital’ (p, 13) 
whilst pharmacy assistants expanded their jurisdiction into knowledge of robotics. 
Hence, the collective action involved in integrating pharmacy robots into everyday 
work is far-reaching yet ubiquitously underpinned by the need to reduce prescribing 
errors and improve medicines management in accordance with local and national 
policies (see Audit Commission, 2001).  
 
The implementation of dispensing robots, as well as other technologies, in 
routine pharmacy practice could be analysed from an actor-network theory (ANT) 
perspective. Briefly, ANT is premised on the notion that the social world and social 
relations within it are constituted by networks of heterogeneous actants. These 
actants can be either human or nonhuman since it is the capacity for enabling action 
which is central to the actant’s existence within the network (Latour, 2007). Hence, 
reflexivity and intentionality are not essential characteristics of actants, which means 
that anything can be an actant provided it ‘is granted to be the source of action’ 
(Latour, cited in Cerulo, 2009: 534). In an analysis of metered dosage inhalers 
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(MDIs), Prout (1996: 210) notes that the MDI network is constituted by a complex 
set of associations between a large number of human and nonhuman actants which 
are ’mutually configured in the process’. As such, the MDI network is constituted by 
designers, clinicians, patients, patients’ families, nurses, pharmacists, MDIs, 
monitoring devices and instructional documentation, the qualities of all of which are 
configured through, and within, this network. Pharmacy robots could be analysed 
from an ANT perspective and understood as actants within the hospital network 
given their centrality to everyday pharmacy work and processes. Hence, pharmacy 
robots, and other technologies, could further be understood as actors, or participants, 
in the bioclinical collective which Chapter Six argues typifies hospital practice.   
 
However, constructivist perspectives, such as ANT, have been subject to 
critique for their understanding of artefacts as nothing more than a sum of the 
interpretations and negotiations which happen around them. Hutchby (2003) draws 
on the field of the psychology of perceptions to offer a middle ground theory 
between realism and constructivism in the understanding of technologies. In a direct 
critique of Grint and Woolgar’s (1997) ‘technologies as text’ perspective (i.e. where 
technologies ought to be understood as texts written by producers and read by 
consumers), he argues that the constructivist understanding of technologies as 
tabulae rasa is limited through its failure to acknowledge that technologies possess 
properties outside of the interpretations of them. As Rappert, (2003: 566), in his 
response to Hutchby, points out ‘interpretations of technology are still interpretations 
of something and what that ‘something’ is must be acknowledged’. However, while 
not proposing a return to determinist understanding of technology, Hutchby suggests 
that technologies possess different ‘affordances’ (that is to say possibilities for action 
and use) which frame, but do not determine, action related to them.  
 
Hutchby’s middle ground perspective offers a more useful way to approach 
an analysis of technologies in pharmacy as the data resonate with the idea that 
technologies offer different affordances to different actors in different contexts. As 
such, when technologies are located within bureaucratic medicines management 
arenas by those with increased, and corporate, medicines management 
responsibilities (i.e. chief pharmacists and hospital chief executives), they afford the 
possibility of improving organisational medicines management processes and 
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efficiency throughout the pharmacy department. In another arena, the location of 
technologies in everyday practice of pharmacy affords the possibility of shifting the 
location, and nature, of everyday pharmacy work away from dispensary-based 
activities to more clinical patient engagement. In this way, a technology such as a 
pharmacy robot may be seen by different actors as affording different actions; whilst 
the chief pharmacist might see the possibility of reducing drug-related morbidity 
statistics, the pharmacists might see the possibility of an increased clinical workload, 
and the pharmacy technician might see the possibility of becoming a skilled robotics 
engineer. 
 
Technological innovation, then, is a key element in changing pharmacy 
practice and is central to the reorganisation of pharmacy work and relationships 
around a more clinical focus. Technology has, in the main, reshaped technology 
around this clinical focus in two key ways: in providing clinical devices through 
which clinical monitoring is enabled and providing technologies, such as computers 
and robots, to perform more mundane pharmacy work activities which allows for the 
relocation of pharmacists away from the dispensary. The chapter now turns to an 
analysis of the evaluation of these reorganising capacities of innovations in 
pharmacy.  
7.5 Reflexive Monitoring and Integration of New Technologies 
May and Finch (2009) argue that ‘reflexive monitoring’ is the process through which 
technological innovations are both formally and informally evaluated. Within this, 
judgements are made as to the effectiveness and utility of a new practice, based on 
‘socially patterned and institutionally shared beliefs’ (May and Finch, 2009: 545) 
This process, therefore, offers a framework for understanding why some 
technologies are integrated into everyday practice (or ‘normalised’) and others are 
not. According to May and Finch, this reflexive monitoring process is undertaken 
through both communal and individual appraisal techniques, which can be 
understood as mapping onto the formalised and more negotiated medicines 
management processes outlined in the thesis so far. Hence, communal appraisal 
involves assessment within an organisational context and mobilises formalised 
‘mechanisms of institutional knowledge production’ whilst individual appraisal 
200 
 
involves informalised judgements about the value and outcomes of an innovation 
which are rooted in individual practices (May and Finch, 2009: 546). Here, then the 
communal appraisal process can be understood as sitting within formal, 
organisational medicines management policy whilst individual appraisal can be 
related to informal medicines management processes enacted through the pharmacy 
gaze and the discourse of toxicity.  
 
The data from the fieldwork demonstrate that pharmacists undertake 
reflexive monitoring through both communal and individual appraisal in their 
everyday interactions with new technologies. As a result of this reflexive monitoring 
process, some innovations fail to be normalised in everyday practice. Two examples 
of this were highlighted by Community Pharmacist 1 in discussing the drugs Zocor 
(to treat cholesterol and coronary heart disease) and Clamelle (to treat Chlamydia). 
In both of these instances, pre-prescription testing is undertaken to determine the 
appropriateness of the drug. In the case of Zocor, which was declassified to an over-
the-counter medication in 2004, this is done by the pharmacist constructing a patient 
risk profile through a pre-prescription consultation. In the case of Clamelle, this is 
testing done by the patient following the purchase of a testing kit from the pharmacy. 
In cases where the patient tests positive for Chlamydia, they can then return to the 
pharmacy to purchase the necessary antibiotics. In both of these cases, Community 
Pharmacist 1 notes that these “didn’t really take off” and “didn’t make a massive 
impact”. 
 
This lack of normalisation can be understood as related to the professional 
jurisdictions that are relatively rigidly enacted in the community setting. In this 
division of labour, pre-prescription testing is a work activity most commonly 
associated with GPs and located within particular healthcare settings. The 
reallocation of testing activities to pharmacists and patients for these particular 
innovations can be understood as a potential barrier to their normalisation; 
“It [Zocor] was something they could get with less hassle from the 
doctors and the doctor was able to arrange the necessary blood 
tests to do this” (CP 1) 
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This quote highlights the inconvenience and limited capacity of pharmacy 
testing as factors explaining Zocor’s lack of normalisation. This can be analysed 
within May and Finch’s (2009: 545) notion of ‘contextual integration’ whereby 
innovations are incorporated into a social context where new work is linked with 
existing structures and procedures. In this case, the declassification of Zocor did not 
incorporate pre-prescription blood testing into pharmacy practice. Given this, 
Community Pharmacist 1 highlights the comparative ease with which Zocor, and 
similar medicines, can be accessed through practitioners whose everyday work 
already incorporates such pre-prescription testing activities.  
 
Moreover, these examples demonstrate the issues that can occur when work 
activities necessitated by an innovation (in this case pre-prescription testing) are 
outside of a traditional professional jurisdiction. As such, the location of pre-
prescription testing work within the professional boundaries of general medical 
practice suggests that the requirement for pre-prescription consultations in the 
community pharmacy and Clamelle’s requirement for patients to self-test at home 
represent too much of a divergence from the community division of labour in which 
pre-prescription testing is carried out by the GP. Community Pharmacist 10 also 
highlights this issue of innovations representing a practice outside of the traditional 
division of labour;   
“You have to question whether patients would come to the 
pharmacy to get a test done when they could get it done at the 
doctors” (CP 10)   
Reflexive monitoring in hospital pharmacy highlights the individual appraisal 
process which is carried out in conjunction with more communal evaluations of the 
value of new innovations. In their study of hospital pharmacy robots, Barrett et al. 
(2011) juxtapose the communal appraisal of robotic innovations, which are grounded 
in government priorities for reducing dispensing errors and improving pharmacy 
efficiency, with individual appraisals grounded in the routine work of dispensing, 
loading the robot and dealing with malfunctions. Although this study does not 
employ an NPT framework of analysis, the interplay of communal and individual 
appraisal processes can, nonetheless, be seen.  
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The data here present a similar story. As such, innovations are communally 
appraised through the rhetoric of codified formalised policies as beneficial for 
medicines management, staff resourcing and pharmacy efficiency, as the above 
quote from Hospital Pharmacist 1 (a chief pharmacist) highlights. 
 
Running concurrently to this communal appraisal is a more individual 
process of evaluation where innovations are judged against wider expectations of the 
professional practice of pharmacy and the management of everyday work activities.  
 
As described above, the implementation of technology into pharmacy 
practice is central to the increased clinical role of the sector. It is also through 
defining this increased clinical work as a central feature of contemporary pharmacy 
practice that appraisals of the value of new innovations are enabled. In other words, 
as the boundaries of pharmacy practice shift to incorporate increased clinical work 
the value of new innovations is measured against expectations about what pharmacy 
is, or should be given this restructured division of labour.  As an example, 
Community Pharmacist 2 discusses computer technology as an aid to clinical work 
and states that “It’s basically unrecognisable from how pharmacy used to be, which 
is brilliant” (CP2). Within this appraisal, the implementation of computer 
technology is understood to have had a key role in shifting the boundaries of what 
constitutes pharmacy practice. This strategy in pharmacy is described by Birenbaum 
(1990) as a ‘collective mobility project’.  
 
In other instances, however, this collective mobility towards clinical practice, 
facilitated by technological innovations, can have a more negative register and be 
associated with deskilling. As such, technology in pharmacy is evaluated as artefacts 
through, and within, which ideas about what pharmacy practices is, and should be, 
are positioned too far from pharmacy’s core focus on medications and their ‘stuff’. 
Hospital Pharmacist 4 demonstrates this; 
“We don’t actually practice making medicines in the department 
anymore…that’s a bit of a negative… It’s become more patient-
focused. So actually out there on the wards working with patients 
203 
 
rather than in the department. And we’ve actually deskilled, which 
I’m not so sure is a good thing” (HP 4)  
Within this comment, the implementation of technology into hospital 
pharmacy is seen as a way in which the sector has been deskilled vis-a-vis medicines 
manufacturing. Within this, innovations which enable clinical work are regarded as 
ways in which the activities of pharmacy have been reconfigured away from the 
central focus on medicines production, which characterised traditional pharmacy 
practice. This evaluation of innovation is made despite the involvement of 
pharmacists in producing medicines through their involvement with clinical trials. 
Hence, although the work involved in making medicines has been modified (which 
is the root of Hospital Pharmacist 4’s concern about deskilling), pharmacists 
involvement in clinical trials can be understood as their continued involvement in 
medicines manufacturing.  
 
Hospital Pharmacist 4’s evaluation of technology in hospital pharmacy 
resonates with Novek’s (2000) study of automated dispensing technology in three 
Canadian hospital pharmacies. In these three hospitals this technology, which was 
implemented in line with local medicines management and safety policies, is 
appraised as a means through which medications dispensing, as the core interest and 
work of pharmacy, is routinised in order to be delegated to pharmacy technical staff. 
In doing so, technology can act to shift the professional boundaries of pharmacy and 
pharmacy technician work and, as a result, was resisted by Novek’s respondents.  
 
Individual appraisal processes also involve locating the additional labour 
necessary for implementing innovations within wider occupational demands and 
workloads. In their work on pharmacy robots, Barrett et al. (2011: 10) note that ‘new 
routines in pharmacy work’ had to be developed in order to overcome technical and 
mechanical difficulties with the technology. In this case, this new work was most 
frequently undertaken by pharmacy assistants in order to minimise the impact on 
pharmacists’ core activities. In other cases, however, new technologies which 
necessitate a restructuring of everyday workloads are a central feature of the work of 
pharmacists and are, thus, appraised within the context of pharmacists’ (as opposed 
to their support staff’s) everyday activities. An example of this is provided by 
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Hospital Pharmacist 4 who evaluated the value of email technology in the context of 
pharmacists’ everyday workload: 
“One of the downsides is, I think, we’re all burdened by email 
now. At one point you used to pick up the phone to communicate 
with somebody. Now, for example on Monday I was off and I came 
in one Tuesday to over 200 emails. And you can’t actually manage 
to keep up with them” (HP 4) 
This comment locates individual appraisal activities within workload 
management concerns. Here, the implementation of e-mail technology into everyday 
pharmacy work is understood to include increased labour which cannot easily be 
configured into everyday activities and which adds no apparent value. This 
individual appraisal sits somewhat in opposition to more communal appraisals of 
communication technologies in pharmacy which email is assessed as a useful 
technology for pharmacy practice vis-à-vis patient safety and bioclinical collective 
communication (see Pohjanoksa-Mäntylä et al., 2008).  
 
This issue of communication is also central to the above quote. The 
integration of email technology (as a means to communicate with other healthcare 
practitioners and patients) into everyday practice is regarded as a disruption of 
traditional communication methods.  
7.6 Summary and Discussion 
This chapter shows how new technologies reorganise everyday pharmacy work and 
relations in various ways. The specific sector of pharmacy within which innovations 
are implemented is key to the ways in which innovations may come to reorganise 
everyday work and relationships. This reflects both the professional relationships 
which characterise work in these settings (i.e. bioclinical collective or medical 
technocratic practices) and the framing of patient bodies and medications which 
organise this work. As such, the prevalence of acutely ill patient bodies and higher 
toxicity medications in the hospital setting means that the focus of hospital pharmacy 
is different from that in the community setting which is geared towards chronically 
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ill bodies and relatively low toxicity medication. The scope and nature of the 
technology which is introduced into pharmacy, and the perceived utility of 
technology as more or less useful is shaped by these discrete settings. For example, a 
technology designed to enable weight monitoring in otherwise healthy patient bodies 
is useful for the community pharmacy focus on the public health body but may not 
be as useful for hospital pharmacy’s focus on highly toxic medications and acutely 
ill patient bodies.         
 
In addition, the chapter highlights the importance of the dual medicines 
management model to the implementation and evaluation of new technologies in 
hospital and community pharmacy. Whereas the formalised and bureaucratic 
medicines management policies focus on the institutional operationalisation of new 
technologies, the less formalised medicines management practices which are enacted 
through the pharmacy gaze are more focused around individual patient bodies and 
the reorganisation of everyday work activities. This chapter shows the way in which 
new technologies are defined and evaluated within both of these medicines 
management approaches in both hospital and community pharmacy.  
 
In analysing the implementation of new technologies into pharmacy practice, 
then, three related themes are shown here to be important- the relationship between 
the scope of the new innovation and the sector of pharmacy into which the 
innovation is being implemented; the bureaucratic medicines management policies 
which define and evaluate the innovation vis-à-vis organisational interests; and the 
everyday practice enacted through the pharmacy gaze. In order to demonstrate the 
way in which these three themes are important in understanding new technologies in 
pharmacy, Table 10 uses examples of pharmacy technologies discussed here to show 
how these technologies relate to pharmacy sectors, the codified medicines 
management process and everyday working practices.  
 
For example, Table 10 shows that the scope of mAbs is centred on the 
acutely ill bodies of cancer patients, highly toxic cancer medications and targeted 
approaches to therapy. This scope, then, binds mAbs to hospital pharmacy practice.  
Within this setting, mAbs are operationalised through formal bureaucratic medicines 
management policies as a way to reduce the financial burden of adverse drug effects 
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and to improve patients’ experiences of their medications regimes. Moreover, as 
So’s (2010) paper suggests, the move towards the administration of some Oncology 
treatments in patient homes also means that mAbs are operationalised in line with 
organisational interests as a way to reduce drug dispensing and administration costs 
and make pharmacy departments more efficient. Table 10 shows that running 
concurrently to this operationalisation of mAbs is the construction of mAbs in 
everyday practice through the pharmacy gaze. Within this, mAbs are understood as 
central to the treatment of cancer patient bodies, which are constructed through the 
pharmacy gaze as particularly complex bodies. Given this complexity, the pharmacy 
gaze tends to construct cancer patient bodies at a more molecular level where 
prescription decisions are made based on the outcomes from pre-prescription testing 
activities. In addition, Chapters Two and Six highlighted the cultural construction of 
medications and their location with patients’ wider lifeworlds as central to the 
pharmacy professional identity and pharmacy gaze. Table 10 highlights that in the 
case of mAbs, this process of locating medications within the patients’ wider 
lifeworld is undertaken through the increasing practice of administering medications 
in patients’ homes (see So, 2010).   
 
To take an example of a more community pharmacy based technology, Table 
10 shows that the scope of testing and monitoring devices is centred on chronically 
ill bodies, public health discourses and low risk medications. As such, this form of 
technology is highly bound to community pharmacy practice. In this setting, testing 
and monitoring devices are operationalised through formalised bureaucratic 
medicines management and pharmaceutical care policies as a way to improve public 
health and position the pharmacist within public health practices (see Department of 
Health, 2005a). At the less formalised level of everyday practice, the modified 
pharmacy gaze brings the patient body into being through the results of these testing 
activities. In doing so, the pharmacy gaze is modified to focus on what is being 
called here a collective public health body. As the chapter describes, the community 
pharmacy gaze is modified to include public health concerns (such as blood pressure 
and weight) as well as being focused on individual patient bodies, medications and 
their potential toxicities. As such, the patient body is configured as a site for public 
health discourses and interventions. This testing and monitoring work, then, 
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relocates some of the everyday community pharmacy work away from the 
dispensary into the more clinical setting of the pharmacy consulting room.  
 
To summarise, Table 10 demonstrates the ways in which the key issues in 
analysing technologies in pharmacy highlighted by this thesis relate to each other in 
specific hospital and community examples. This Table is further expanded in 
Chapter 8 to highlight the ways in which the three broad concerns come into play in 
understanding pharmacogenetics in pharmacy practice.  
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  Table 10: Technologies in pharmacy. Exploring the relationship between technology, pharmacy sector, bureaucratic policies and everyday practice  
Technology Relationship between pharmacy 
sector and technology scope 
Formalised Codified Process Everyday Practices (Enacted 
Through the Pharmacy Gaze) 
Monoclonal antibodies Sector: Hospital pharmacy 
Scope: Acutely ill bodies; high 
toxicity medications; targeted 
therapies  
 
-Decreased capacity for toxicity 
-Reduce burden of ADRs  
-Improve patient medication 
experience 
-Administration outside of the 
hospital: reduces cost 
-Oncology patients; complex bodies  
-Molecularised gaze and therapies 
-Administration outside of the 
hospital: places medicines in the 
‘lifeworld’ 
Pharmacy robotics Sector: Hospital pharmacy  
Scope: Large pharmacy departments; 
high stock levels; high patient 
numbers; complex regimen; high 
toxicity medications 
-Reduces dispensing errors 
-Improves pharmacy efficiency 
-Enables clinical practice; time on 
wards 
 
-Capacity for human error in 
stocking machine and data input 
-Increases pharmacists ‘legitimacy’ 
within the bioclinical collective 
(Barrett, 2011) 
Electronic patient record Sector: Hospital pharmacy 
Scope; Bioclinical collective gazes; 
complex illness; complex regimen; 
high toxicity medications 
-Improves audit processes 
-Improves medicines management 
-Removes pharmacists from “traffic 
warden duties” (HP6) 
-Brings the patient body into being 
-Constructs a discourse of toxicity 
around the patient body 
Pharmacy computer- labelling 
practices 
Sector: Hospital and community 
pharmacy 
Scope: Complex regimen (H); high 
toxicity medications (H); chronically 
ill bodies (C) 
-Improves audit processes 
-Improves patient adherence: reduces 
toxicity 
-Symbolic transformation of 
medicines into social objects 
-Places medicines in the ‘lifeworld’ 
-Shifts GP/pharmacist 
communications 
Testing and monitoring devices Sector: Community pharmacy  
Scope: Chronically ill bodies; low risk 
medications; public health focus  
-Improves public health 
-Reconfigures pharmacists as public 
health professionals 
-Constructs a collective public health 
body 
-Brings the patient body into being 
-Moves practice away from the 
dispensary 
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7.7 Conclusion 
An analysis of the implementation of technologies in pharmacy practice is a 
useful way of contextualising the ways in which the everyday work of pharmacists 
has changed. This chapter uses the dual medicines management framework 
described in Chapter Six and some concepts arising from May and Finch’s NPT to 
argue that the work undertaken to embed innovations within everyday pharmacy 
work is enacted through both formal medicines management and pharmaceutical 
care policies and through the more negotiated pharmacy gaze. In this way, new 
technologies become defined as useful or otherwise based on their relationship with 
corporate and audit activities and toxicity management of individual patients. The 
chapter also follows on from Chapter Six’s conceptualisation of hospital and 
community pharmacy practice and argues that whilst the definition of new 
technologies in hospital pharmacy is undertaken within organisational interests in 
medicines efficacy, their operationalisation in community pharmacy is focused 
around the discourse of toxicity for individual patients and their drug regimen.  
 
The chapter notes that technologies introduced into everyday practice have 
shaped pharmacy practice to make it more clinically focused. This chapter argues 
that there are two key ways in which technology has reconfigured pharmacy practice 
in this way: through technologies which are central to clinical work activities and 
through technologies which make pharmacists less spatially-bound to the dispensary 
to enable a more clinically focused engagement with patients. Technologies which 
are central in clinical work activities, namely testing and monitoring devices, are 
argued to modify the pharmacy gaze away from one solely focused on medications 
and their potential risks, to one focused on patient health and risk profiles. In doing 
so, these technologies create a new dimension to the pharmacy gaze complementing 
that of the individual patient with one which configures patient bodies collectively as 
what I have called a ‘public health body’, which is managed in line with macro and 
meso public health discourses and strategies. Technologies of this sort are mainly 
associated with the reorganisation of community pharmacy work. In the hospital 
setting, technologies which facilitate the relocation of pharmacy practitioners away 
from the dispensary are argued to be a key way in which pharmacy work has been 
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reorganised. In this way, technologies such as dispensing robots are argued to 
occupy a central position within the bioclinical collective of the hospital.  
 
Finally, the chapter mobilises May and Finch’s notion of ‘reflexive 
monitoring’ to examine the ways in which new innovations are evaluated and 
integrated into everyday routine practice. Here, the processes of communally and 
individually appraising technologies are related to the formal medicines management 
process and the less formalised pharmacy gaze and the professional jurisdictions 
within the primary care medical technocracy. In this way, technologies which 
necessitate pharmacists undertaking work which is usually done by GPs fail to be 
normalised effectively owing to the divergence from routine practice patterns that 
they represent.  
 
This chapter has drawn on a number of examples of technologies which have 
(and have not) become a routine part of pharmacy practice in both hospital and 
community settings to argue that technologies have the capacity to reorganise 
pharmacy work and inter-professional relationships. Continuing this analysis, 
Chapter Eight looks at PGx technology as a technological paradigm which has the 
potential to reconfigure pharmacy practice and modify the pharmacy gaze to one 
which is increasingly molecular. In doing so, Chapter Eight focuses on the 
operationalisation of PGx in both formalised medicines management policies and 
through the less formalised, more negotiated pharmacy gaze; the way in which PGx 
has reorganised practice roles in the field of Oncology; and the ways in which PGx 
may reshape hospital and community pharmacy practice vis-a-vis managing the 
toxicity of medications and the patient body.   
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Chapter Eight: Pharmacogenetics in Pharmacy 
8.1 Introduction 
Pharmacogenetics sits within a broad paradigm of genetics/genomics
16
 -focused drug 
discovery and medical practice where genetics/genomics have become increasingly 
central to drug development processes and therapy decisions in some medical 
specialisms (Clarke et al., 2003). This ‘geneticisation’ (Lippman, 1992) of drug 
development and medical practices is shifting definitions and understandings of 
diseases, the patient bodies in which they are manifested and the therapies which are 
appropriate to treat them. As an example, genomic information can be understood as 
broadening and adding complexity to definitions of breast cancer by reconfiguring it 
as a set of heterogeneous genetic conditions rather than one disease (see Curtis et al., 
2012), as Oncologist 1 points out;  
“It’s not one disease it’s a family of diseases and now even things 
that we used to call breast cancer or lung cancer we’re chopping 
up into smaller and smaller sections” (O 1) 
At the same time, therapy options for breast cancer have been narrowed by 
the increasing stratification of patient populations based on genetically-determined 
potential drug responses. This stratification is central to PGx which is premised on 
providing the right drug to the right patient in order to maximise therapeutic benefits 
and minimise adverse events.  
 
At present, PGx in medical practice is limited to secondary care and, within 
this, to specialist areas which deal with particularly toxic therapies, most notably 
Oncology. In primary care, although putative links between genetically-determined 
drug responses and some primary care drugs have been identified (Grice et al., 2006) 
the implementation of PGx into routine practice is less developed. Nonetheless, 
given the increasing genetics/genomics focus in drug development and some medical 
practices, it is likely that pharmacists in both hospital and community settings will 
become increasingly familiar with and well versed in applying the principles of PGx 
                                                 
16
 Chapter Three elucidates the ontological differences between genomics and genetics in drug 
development and clinical settings.  
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to their everyday practice. Hence, pharmacists’ expertise in medicines and their 
toxicities is likely to increasingly include genetic information.  
 
Despite this, there is limited empirical research on the ways in which this 
shift in practice is likely to affect pharmacists in terms of their everyday work and 
professional status. Moreover, Ryan et al. (2004) argue that given that pharmacists 
are likely to be at the ‘forefront’ of PGx medicine, a sociological understanding of 
this is necessary. Given this, this chapter uses empirical interview data to build on 
the characterisation of contemporary pharmacy practice outlined in Chapter Six and 
the analysis of new innovations in pharmacy in Chapter Seven to explore the ways in 
which PGx is affecting, and may potentially affect, pharmacy practice in different 
settings. Given the different degrees of ‘normalisation’ of PGx in primary and 
secondary care settings, this chapter takes hospital and community pharmacy as two 
discrete landscapes vis-a-vis PGx innovation. Within this, the chapter discusses 
Oncology as an example of PGx practice being normalised in secondary care 
everyday practice.  
 
The chapter, then, continues to mobilise the dual medicines management 
model that has previously been outlined to analyse the ways in which PGx is 
understood and framed by both codified, bureaucratic medicines management and 
pharmaceutical care policies and the more negotiated pharmacy gaze in everyday 
practice.  
8.2. Defining PGx 
As Chapter Seven demonstrated, the process of defining new technologies depends 
on their configuration as useful or otherwise for everyday practice.  The evidence 
from the fieldwork indicates that this also involves a move away from media ‘hype’ 
to develop a “realistic” (PS 4) picture of PGx in practice: 
“There’s obviously been too much hype in terms of what we can 
do” (PS 4) 
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“What is very important... is to try and get across the concept that 
not everything that’s called a miracle cure is actually a miracle 
cure” (PS 4) 
“The media hype it up every time there’s a study” (PS 3) 
 
“Pharmacogenetics has been bigged up by the media” (PS 3) 
 
“It’s quite hyped in the papers as well sometimes, which can do 
some harm” (PGx 2) 
Within the coherence work of defining new technologies, Table 10 in Chapter Seven 
shows the ways in which new technologies in pharmacy are defined through both 
formalised, bureaucratic medicines management policies which are concerned with 
the organisational benefits of new technologies and in everyday practice through the 
pharmacy gaze and the discourse of toxicity. Defining PGx in pharmacy centres on 
coherence work around a number of tests, drugs and practices. As a result, whilst 
some uses of PGx may be defined (through both aspects of the dual medicines 
management model) as beneficial for pharmacy and patients and come to be 
normalised in everyday practice, others may be defined as less useful and fail to be 
integrated into everyday work. This differential coherence work is discussed by 
Hedgecoe (2008a) where he notes that whilst HER2 testing has become a regular 
feature of Oncology practice, APOE4 testing is defined as less clinically useful given 
its familial impacts (see Chapter Three).  
 
Further, in defining the utility of PGx in practice it seems imperative to make 
the following distinction: “pharmacogenetics as a technology versus 
pharmacogenetics as a service...those are two quite distinct entities” (HE 1- 
previously a HP).  This quote highlights that defining the value of PGx in pharmacy 
practice depends on both the technological artefacts of the testing devices (for 
example, sample preparation and assay robustness) and the service structures around 
them (for example, the time taken for analysis and data output). This distinction can 
be understood in line with Damanpour’s (1996) model of ‘product’ and ‘process’ 
innovations. As Chapter Four argued, PGx can be understood as straddling these two 
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innovation categories as new technological products of PGx also necessitate new 
processes and services, as Health Economist 1 shows:  
“There are more and more developments in terms of the 
technologies but there’s been virtually no work done in terms of 
how do you deliver the service?” (HE 1- previously a HP) 
Oncologist 2 provides an example of this distinction with regards to the breast cancer 
drug Herceptin: 
“We need to be doing it [routinely testing for HER2 over-
expression in breast cancer patients]. Okay, how do we do it?... We 
don’t know” (O 2) 
Within this quote, the distinction between the PGx product and the PGx 
service becomes apparent. Hence, whilst the technological product of the test is 
defined as beneficial (“we need to be doing it”), the service around providing this 
test is less clearly cohered with contemporary work structures. This distinction 
between technology (product) and service (process) can further be understood in line 
with the dual medicines management model described in Chapters Six and Seven. 
Here, it could be argued that whilst the technological products of PGx are defined 
through formalised, bureaucratic medicines management policies as beneficial for 
patients and organisations because of their ability to better target therapies, the 
service processes associated with delivering these PGx tests are defined and 
evaluated in terms of everyday practice and clinical gazes.  
 
Moreover, as Chapter Seven highlighted, the discourses and practices which 
underpin hospital and community pharmacy practice (medicines management and 
pharmaceutical care respectively) are central to the coherence work around new 
innovations. In the case of PGx, there is a clear division between the coherence work 
undertaken by pharmacists working in these two sectors. Given this, this chapter 
treats hospital and community pharmacy practice vis-a-vis PGx as two distinct 
practice landscapes where the coherence, reflexive monitoring and integration work 
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around PGx are highly divergent. The chapter first turns to an analysis of PGx in 
hospital pharmacy.  
8.3 PGx in Hospital Pharmacy Practice 
The hospital pharmacists that were interviewed had a relatively high level of 
knowledge of PGx compared with those working in the community. Although the 
complexities of PGx were not common knowledge amongst all hospital pharmacists, 
there was a general awareness of this paradigm of practice amongst the population. 
Many of the hospital pharmacists, then, engaged with PGx in a similar way to 
Hospital Pharmacist 4; 
 “I’ve heard of it but I haven’t actually come across it in our own 
practice” (HP 4)    
As this chapter highlights below, practitioners in the field of Oncology are 
those with the most knowledge and expertise around PGx. As such, the Oncology 
pharmacists that were interviewed (n=2) had high degrees of knowledge about PGx; 
 
“KJ: Has genetic medicine made any other impacts on your 
practice since you qualified? 
HP9:  Oh, yeah, definitely...all the diagnostics have really come 
into their own now...We’ve got the KRAS testing for patients before 
they have Cetuximab, another one of the monoclonals. And now 
we’ve got the EGFR testing of course in non-small cell lung cancer 
before they start their Gefitinib” (HP 9- Oncology) 
Given the co-location of Oncology pharmacists and those specialising in 
other clinical areas in one physical space (as opposed to community pharmacists who 
practice in relative isolation (Cooper et al., 2009)), the bioclinical collective nature 
of hospital pharmacy practice means that the transfer of knowledge and expertise of 
PGx is relatively easy. Hence, through practising in a relatively collaborative 
environment and being in close proximity to practitioners who use PGx routinely, it 
is hardly surprising that hospital pharmacists’ knowledge of PGx is fairly high. This 
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is in contrast to community pharmacists who practise in isolation from each other 
and may find obtaining and sharing knowledge about PGx, or other innovations, 
more challenging.  
8.4 Implementing PGx into Hospital Practice 
At present, then, PGx is understood as sitting within the “domain of the hospital 
pharmacists” (PGx 5) owing to the disease areas and medications for which PGx 
testing is deemed appropriate. Within this, the epistemic differences between 
hospital and community pharmacy outlined in Chapters Six and Seven are central. 
Hence, whilst highly toxic medications are prescribed and administered to treat 
acutely ill patient bodies in the hospital setting, community practice tends to be more 
centred on less toxic medications and the chronically ill bodies to which they are 
administered. PGx, then, sits within the “domain” of hospital pharmacy given the 
comparatively toxic nature of medications and the ability of this paradigm of practice 
to predict and manage these relatively severe adverse events.    
 
The implementation of PGx into routine hospital practice is represented in 
the interview data as being a journey which universally begins with PGx 
developments in Oncology. From here, PGx technologies are imagined to “seep” 
(PGx 3) into other clinical specialisms where ADRs are a notable issue, such as 
Cardiology and Paediatrics. This understanding of the implementation of PGx 
contrasts with traditional diffusion of innovation studies which represent diffusion 
and implementation as a top-down and linear process (see Rogers, 2003). The 
interview data, however, represent the implementation of PGx into routine practice 
as being more “piecemeal” (PGx 3; HE 1) and contingent upon the outcomes from 
private sector research, as Community Pharmacist 6 observes;  
“It depends what the drugs are that come out” (CP 6)  
Moreover, Rogers (2003) presents innovations as external artefacts which are 
implemented into a social system by innovators who exist outside of that given 
social system. Again, there can be seen to be a disjuncture here between traditional 
diffusion of innovation theory and the implementation of PGx into hospital practice. 
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As such, PGx innovations are not universally developed by external actors and 
agencies and subsequently introduced to the hospital. Instead, many hospital 
practitioners are also active researchers and play a central role in development of 
PGx technology in collaboration with both public and private actors and agencies. 
As such, the very meaning of innovation is constituted by bioclinical collectives that 
comprise both internal and external hospital actors; 
“We have, here, a multi-disciplinary which comprises clinicians, 
nurses, geneticists, statisticians, cell biologists, pharmacologists 
and also includes people who are PhD students, MRES students, 
post-docs etc and clinical research fellows” (PGx 2) 
 
“The pharmacy departments basically support the clinical trials. It 
will be the consultants will be wanted to take part in a clinical trial 
which may be either sponsored by the pharmaceutical industry or 
maybe by non-commercial research, so it’s the academics... it’s 
very collaborative” (HP 3- Oncology)  
This model of PGx ‘seeping’ from Oncology into other clinical areas 
resonates with Jain’s (2009) assertion that PGx represents more of an evolution than 
a revolution in research and practice. Although popular media portrayals of PGx 
have constructed this paradigm of practice as somewhat revolutionary (Almomani 
and McElnay, 2012), the interview data suggest that practitioners envisage the 
development of PGx more in line with Jain’s evolutionary characterisation. Within 
this, the evolution of PGx technologies is understood as a series of small step-
changes associated with the development of new genetic technologies such as PCR 
and ‘Next Generation’ sequencing. The following quotes highlight this well;   
“The thing about genetics is that there is always kind of step 
changes. The Next Generation Sequencing is going to be another 
step change so it goes along and things are stable for a bit and 
then suddenly you’ll get a new discovery or technique and it will 
suddenly change what we do” (PGx 9).     
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“It’s just going to be a slow piecemeal change. I don’t think 
there’s going to be any revolution, I think there’s just going to be 
an evolution slowly over time as further information comes 
through” (PGx 3) 
 
“There’s going to be certain examples where practice is going to 
change incrementally” (HE 1- previous a HP) 
 
“It happens in a very piecemeal, very fragmented sort of way” (HP 
1) 
As Community Pharmacist 6 highlights above, much of the implementation 
story around PGx is linked with the outcomes and perspectives of private sector drug 
development. Chapter Three notes that PGx presents a potential way in which 
pharmaceutical companies’ R&D costs can be reduced, thus making this approach to 
drug development appealing. On the other hand, taking a stratified approach in drug 
development will ‘almost certainly reduce the number of patients who are likely to 
receive the drug...and perhaps end the era of blockbuster drugs’ (Pirmohamed and 
Lewis, 2004). Hospital Pharmacist 5 characterises this as follows; 
 
“There seems to be two areas in new medicines. There’s stuff you 
can give to anyone; so you can give huge volumes at low cost. And 
there’s stuff that you give only to specific conditions; so high cost 
low volumes” (HP 5) 
The data suggest that drug development companies may be somewhat reluctant to 
move away from the “huge volumes at lost cost” blockbuster model of drug 
production; 
“I suspect that drug companies in general are not keen to have to 
have pharmacogenetic tests. They will tend to push the drugs that 
are suitable for everybody” (PGx 1) 
 
“They don’t want to identify a sub-group and run the risk of 
getting a licence for a very narrow population of patients” (PGx 3) 
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“If they’re going to try and get marketing authorisation for a drug 
they want to make the money back. So they’re going to need high 
volume stuff and inevitably pharmacogenetics isn’t going to 
necessarily be high volume” (CP 9) 
Pharmacogeneticist 9 notes that where pharmaceutical companies do have an 
interest in genetic stratification, they tend to still remain focused on therapies which 
may yield high returns rather than “high cost low volumes” (HP 5); 
 
“I think things like obesity and male pattern baldness are things 
that they’ll want to have a say in” (PGx 9) 
However, Pharmacy Stakeholder 3’s comment that “the blockbuster model is 
sort of drying up” resonates with PricewaterhouseCoopers’ (2009) assertion that big 
pharmaceutical companies can no longer ‘profit alone’ within the blockbuster model. 
From this perspective, the implementation of stratified approaches to drug 
development is seen to be more likely; 
“They’ve accepted that this is going to be the norm for the future. 
The ABPI (Association of the British Pharmaceutical Industry) has 
written a report on that saying that it’s really going to go towards 
a stratification of medicines” (PGx 2) 
 
“They’re going to have to start looking at a different model of 
working. If you look at blockbusters there’s not that many come 
down the line in recent years…it makes sense to me that you would 
develop things that would reduce the risk of ADRs and boost 
efficacy and try and get a licence based on a genetic test” (PS 3) 
 
“Slowly over the next twenty years, as new drugs come along, 
which are better than the current drugs, they will be developed in a 
stratified manner” (PGx 2) 
 
220 
 
“I think it will go down the individualised route” (HP 9- 
Oncology) 
The data suggest, however, that traditional blockbuster and more stratified 
approaches are not mutually exclusive. Given this, it is suggested that drug 
development companies will continue to invest in the blockbuster model of practice 
whilst simultaneously developing drugs in a more stratified way. Moreover, this 
stratified approach may also be applied to making more effective use of existing 
medications; 
“I think it’s probably both. I don’t think it will be one or the other.  
I think we’ll still be seeing chemotherapy come out. I’m still seeing 
new drugs come out which are chemotherapy and at the same time 
we are seeing more drugs which are monoclonals and therefore 
you can test. So I think it’s both. I think there will still be plenty of 
drugs that come out that are both” (HP 9- Oncology) 
 
“The use of pharmacogenetics… will allow us to use existing 
medicine  much better by stratifying patients based on their ability 
to handle a medicine” (MTC 1) 
 
“In the case of existing drugs, it may be that we might start using 
patient genetic information to determine whether they’re suitable” 
(PGx 1) 
Running concurrently to this increasing stratification in drug development, 
the data also present a potential expansion of the work of drug development 
companies to include diagnostic testing production. Pharmacogeneticists 1 and 4 
demonstrate this well; 
 
“They don’t necessarily have a big background or commitment to 
diagnostics…Companies like GSK  and Astra Zeneca don’t,  so, 
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potentially, offering diagnostic tests is diversification for them in a 
way and is going  to make life quite difficult” (PGx 1) 
 
“The only other way [for pharmaceutical companies to make profit 
outside of a blockbuster model] is that they buy into the technology 
for testing and screening and make their money with screening and 
make less on the drugs” (PGx 4) 
These quotes suggest a conflation of the work of pharmaceutical companies, who 
have traditionally produced (blockbuster) drugs, and biotechnology companies, who 
have traditionally produced diagnostic tests. This movement into test production is 
understood as challenging for drug development companies given the potential for 
generic (pharmaco)genetic testing kits to be produced; 
“That’s difficult to work as a business model I would think because 
the technologies for screening for particular genetic markers are 
generically available and are becoming increasingly cheap and 
will be available at point of care” (PGx 4) 
Pharmacogeneticist 4’s assertion here that PGx testing will be “available at 
point of care” raises interesting questions about community pharmacists performing 
PGx testing, or supplying tests to be carried out by patients at home;  
“It isn’t at all far-fetched to believe that you can go to Boot’s the 
pharmacy, or even to your GP and out the pin prick of blood on the 
machine and a rapid sequence PCR comes up and tells you your 
particular allele while you wait. I don’t think that’s remotely out of 
the question” (PGx 4) 
 
“There will be people that would pay for that because there are 
some people who want to find out everything about themselves” 
(CP 2) 
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This is explored in more detail below. As mentioned above, however, the 
implementation of PGx into routine hospital practice is almost universally imagined 
as beginning in the specialist area of Oncology. Here, then, it is useful to present a 
brief overview of the nature of PGx in this area. 
8.4.1 PGx and Oncology 
Oncology is conceptualised as the medical specialism in which PGx has made, and 
will continue to make, the biggest impact on practice; 
“Cancer drugs is where there’s a lot of innovation at the moment” 
(CP5)  
 
“There’s going to be certain examples where practice is going to 
change incrementally and by the introduction of new tests, 
particularly oncology” (HE 1- previously a HP) 
 
“In terms of cancer drugs it’s probably going to be something 
that’s going to be much bigger in the future” (HP3- Oncology) 
 
“It probably will in terms of cancer care certainly” (HP 4) 
 
“If you do specialist wards like Oncology or Rheumatology, you 
get a lot more of it there” (HP 8) 
 
“Clearly there are some examples of pharmacogenetic type tests 
being used in Oncology” (PGx 1) 
 
“I think that it is going to come into certain areas quicker than 
others. For example, cancer is going to be one area where it is 
going to be very quick” (PGx 2) 
 
“Where I think it’s even more useful is...in the context of anti-
cancer drugs” (PS 4) 
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“I think it’s going to be mainly Oncology. That’s where I see it 
mostly” (PGx 9) 
Elsewhere, Oncology has been identified as a ‘promising field’ for PGx given 
the severity of ADRs that frequently arise from cytotoxic medications (Houtsma et 
al., 2010). The data suggest that these adverse drug reactions are understood at both 
levels of the medicines management model- through formalised policies and through 
the pharmacy gaze. At the level of formalised, bureaucratic medicines management, 
these adverse reactions to cytotoxic drugs are understood to place financial and 
resource strain on hospitals due to the number of beds and staff which are required to 
manage these adverse events; 
“If you could filter off all those people [who are at increased risk 
of drug response] through pharmacogenetics and tailor therapy 
properly, it’s bound to have an impact on performance” (HP 1- 
Chief Pharmacist) 
At the level of the pharmacy gaze, the cancer patient body is constructed as a 
site of particular complexity and risk. Given this, the cancer patient body is 
understood to require careful management through the bioclinical collective gaze of 
the multi-disciplinary team which typifies Oncology practice, as Oncologist 1 shows; 
“Everything is done through what we call a multidisciplinary team 
…The multidisciplinary team is the surgeon because they often 
make the diagnosis; the pathologist because they’re looking at the 
tissue and telling us what type of tumour it is; the oncologist who 
deals with the drug treatment and the radiotherapy side of things; 
specialist nurse; usually somebody from radiology to look at all the 
x-rays and scans. And then sometimes you’ll have somebody from 
palliative care, it depends on the tumour type, somebody from 
orthopaedics” (O 1)  
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Given the complexity of the cancer patient body, the disease within it and the 
medications used to treat it, the Oncology pharmacy gaze is highly specialised and 
linked with cutting edge research in the field. Within this, Oncology medications are 
discursively located within a particularly toxic patient experience arising from both 
the toxicity of disease and the toxicity of medications. As such, as 
Pharmacogeneticist 9 highlights, the toxicity of disease and the toxicity of therapy 
are inextricably linked; 
“And that’s because we give them enough drugs to just not quite 
kill them but actually sometimes it’s the drugs that kill you and not 
the cancer” (PGx 9) 
Given this, then, PGx is identified as a way in which highly toxic 
medications administered to Oncology patients can be more effectively managed. 
The data identify this as occurring on two levels; firstly through the increased 
stratification of patients in clinical trials and secondly through pre-prescription 
testing to stratify potential drug responses.  These more stratified approaches to 
Oncology prescribing are understood to improve cancer patients’ experiences of their 
disease and medication regimes;  
“When you compare the quality of life of patients who are on these 
targeted agents as opposed to cytotoxic medications you can’t 
really compare highly enough in terms of advantage, in terms of 
quality of life that it provides” (PS 4) 
 
“We might look back in 20 years’ time and think back in the 90s 
wasn’t it so bad. What such a blunt approach to just 
chemotherapy” (HP3- Oncology) 
Given the importance of PGx in the field of Oncology and its use in routine 
practice, it could be argued that PGx as a style of thought (Fleck, 1979) has become 
somewhat normalised in Oncology practice. Here, again the distinction between PGx 
products and other aspects of PGx practice are important. Hence, it is not that all 
available PGx products are normalised in Oncology, but rather that a 
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(pharmaco)genetic approach to disease, the body and medications is a part of routine 
practice. In other words a ‘molecular gaze’ (Rose, 2007) enacted through various 
molecular and genetic products has become normalised in Oncology practice. To 
demonstrate, Oncologist 1 notes that genetic approaches to diagnostic practises are 
well entrenched in Oncology; 
“It’s routine in breast cancer to do oestrogen receptors and 
HER2…Everybody else [apart from people over the age of 80] is 
tested” (O1) 
Moreover, Hospital Pharmacists 3 and 9 (both Oncology pharmacists) state 
that pre-prescription genetic testing is routine for those medications where a pre-
prescription test is available; 
“There will always be the KRAS question if you’ve got things like 
Cetuximab and Panitumumab in it... Breast cancer, there is a trial 
looking at this 70 gene signature so that’s at trial so we’ll wait to 
see the results of that. You obviously do the HER2 testing in breast 
cancer so that’s sort of routine” (HP 3- Oncology)  
 
“All the diagnostics have really come into their own now I think. 
So besides the HER2 we’ve got the KRAS testing for patients 
before they have Cetuximab, another one of the monoclonals. And 
now we’ve got the EGFR testing of course in non-small cell lung 
cancer before they start their Gefitinib” (HP 9- Oncology) 
Given this increase in stratified approaches to therapy in Oncology practice, 
the discourse of toxicity around medications in this area is shifting. Within this, the 
management of toxicity in cancer regimes is conceptualised as an exercise which 
could be effectively undertaken by practitioners in the community setting. Hence, 
given the reduction in adverse reactions which pre-prescription PGx testing 
promises, the need to administer medications and monitor patients within the 
hospital setting is less apparent.  
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Chapter Six briefly highlighted the case of Herceptin being administered in 
patients’ homes. This practice is thought to improve patients’ experiences of their 
medications by removing the need for them to visit the hospital for their therapy and 
improve the efficiency of pharmacy departments by reducing costs and waiting 
times; 
“It avoids all the having to travel in and then having to travel back 
again after the treatment” (HP 9- Oncology) 
This practice also redefines the nature of Oncology and its medications by 
making the area less spatially-bound to the hospital setting. In doing so, cancer 
becomes redefined as a more chronic condition which can be managed by primary 
care practitioners, as the following quotes point out; 
“We’ve changed cancer from being a rapidly fatal disease to being 
more of a chronic disease” (O1) 
 
“The longest standing drug is Imatinib in terms of an oral drug 
which is an ‘ib’…. I did think could we actually have this 
prescribed by GPs and have it supplied in the community” (HP9- 
Oncology) 
 
“It’s [cancer] really a chronic disease now we’re talking about so 
it would make sense for the patients to actually be monitored more 
by the GP” (HP9- Oncology) 
This shift in understanding cancer as a more chronic condition also impacts 
on the ways in which the toxicity of cancer medications is operationalised. As such, 
Phillips and Currow (2010) note that the management of toxicity of Oncology 
medications is increasingly focused on other chronic co-morbidities such as cardiac 
complications and decreased immune functionality rather than acute problems such 
as nausea and hair loss.  
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Analysing the implementation of PGx in Oncology practice provides a useful 
way of understanding the relationship between medicines management and the 
discourse of toxicity and PGx testing. Given the routine way in which 
(pharmaco)genetic principles are mobilised in Oncology, this field provides a 
potential framework for examining the implementation of PGx in other specialist 
fields and, potentially, generalist primary care. The chapter now turns to an 
examination of this process of defining PGx in more general terms.  
8.5 Defining PGx in Hospital: Medicine Management 
Within the hospital “domain” (PGx 5), the value of PGx is defined through both 
formalised, bureaucratic medicines management policies and at the more negotiated 
everyday level of the hospital pharmacy gaze and the discourse of toxicity. At the 
level of formalised medicines management policies, PGx technologies are located 
within corporate and organisational concerns about the time and financial burden of 
ADRs. Here, the promissory discourses surrounding PGx technologies are mobilised 
as part of this bureaucratised coherence work. Hospital Pharmacist 1 (a chief 
pharmacist) demonstrates this well;  
“You’re going to reduce the number of hospital re-admissions due 
to medication failure or medicines related problems. You could 
potentially cut down the costs” (HP1- Chief Pharmacist) 
Within this quote, pre-prescription PGx testing is seen as a way to reduce the 
number of patients attending hospital due to potentially preventable adverse drug 
events. As such, PGx is understood as a cost-saving technological paradigm which is 
beneficial for the organisation’s budget. These corporate discourses which 
characterise much of the formalised bureaucratic medicines management approach 
resonate with much of the promissory discourse around PGx which is developed by 
researchers in this area. In their paper examining the expectations created around the 
(then) emerging field of PGx, Hedgecoe and Martin (2003) argue that the creation of 
promises of improved drug efficacy and reduced financial burden of ADRs is central 
to the development of PGx. With regards to the above quote, it can be seen that the 
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cost saving ‘visions’ (ibid.) for PGx have come to underpin formalised, codified 
approaches to PGx.  
 
Although these promissory discourses around pre-prescription PGx testing 
are fairly pervasive, the cost-effectiveness ‘vision’ of PGx is questioned by a number 
of respondents. For example, Health Economist 1 (previously a hospital pharmacist) 
questioned the robustness of the economic evaluations undertaken;   
“I’m not convinced that all the evidence that says “yes, it’s cost 
effective” is actually true...So is it cost effective? The answer is we 
don’t really know” (HE 1- previously a HP) 
Additionally, Pharmacogeneticist 4 questions who ought to pay for the pre-
prescription testing in an era of increasingly challenging NHS budgets;  
“The NHS is already under financial strain…It’s [pre-prescription 
testing] very expensive… who pays for it?” (PGx 4)   
These promissory discourses of PGx tend to centre on PGx products rather 
than processes. As such, it is the pre-prescription testing artefacts and their outputs 
(i.e. data showing whether patients are likely to respond well to a medication) which 
are cohered as beneficial for the hospital organisation. Running concurrently to this 
formalised medicines management understanding of PGx products is a less 
formalised operationalisation of PGx processes. As Chapters Six and Seven 
demonstrated, this less formalised coherence work is less concerned with the impacts 
of innovation on the wider hospital structure than the reorganisation of everyday 
working activities which is necessitated by these innovative approaches. Again, here, 
Damanpour’s (1996) dual model of innovations becomes apparent where PGx 
products are cohered through bureaucratised medicines management policies whilst 
PGx processes and services are cohered at the level of everyday practice and the 
pharmacy gaze.  
 
The provision of PGx testing is understood as reorganising pharmacy work 
around a new set of artefacts which configure an increasingly molecularised patient 
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body. Within this, practice boundaries within the hospital are routinely negotiated 
vis-a-vis PGx services, as Pharmacogeneticist 9 highlights;  
“Consultants and specialists don’t understand it [genetic 
testing]...so we keep getting referrals and we keep having to bat 
them back and say ‘no this isn’t what we do, it’s not appropriate 
for us to see this patient’...we’re not paid to see those people...we 
do sometimes end up seeing the patient” (PGx 9) 
Here, Pharmacogeneticist 9 demonstrates the way in which practice 
boundaries are constructed around new services associated with PGx testing. Results 
interpretation and patient counselling work is reassigned to clinical genetics 
departments due to consultants’ lack of expertise in the area of genetic testing and 
medicine. Although Pharmacogeneticist 9 demonstrates a level of resistance to this 
boundary crossing, her comment that “we do sometimes end up seeing the patient” 
hints at the flexibility of these boundaries and the renegotiation which occurs around 
PGx processes. Moreover, the flexibility of boundaries which she demonstrates in 
this comment gives further evidence to the claim that hospital practice is 
characterised by bioclinical collective models of practice where practice boundaries 
are subject to negotiation given the highly collaborative nature of work and 
outcomes. Additionally, the resistance demonstrated in this quote gives an insight 
into the ways in which the dual medicines management approaches intersect in 
everyday negotiated work. Within this, although the boundaries which are being 
constructed pertain to everyday work patterns and different clinical gazes (i.e. the 
less formalised medicines management process), the organisational budgetary 
concerns of formalised medicines management policies also come into play as an 
important feature in organising professional boundaries (“we’re not paid to see those 
people”).  
8.6 Reconfiguring the Hospital Pharmacy Gaze 
Within hospital pharmacy practice, PGx reorganises the pharmacy gaze and the 
discourse of toxicity which it generates. Chapter Six noted that the pharmacy gaze 
focuses on the patient body as a site of medications use and the discourse of toxicity 
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which is generated to manage this body is concerned with the potential adverse 
effects of medications which are administered to it. Hence, the body is constructed as 
being at-risk from adverse effects of the pharmacological composition and action of 
medications. Although the patient body and the medication are co-constructed within 
this pharmacy gaze, the model of ADRs is relatively linear and one-sided with drugs 
being the risky object and the patient body being the at-risk subject. PGx testing, 
however, reorganises this understanding of adverse drug events where the genetic 
composition of the body reconfigures it as a potentially risky object. Hence, within 
what might be called a ‘pharmacogenetics gaze’, the body is not an inactive subject 
within which adverse events occur but is, instead, an active biological object whose 
(genetic) composition can contribute to adverse events.  
 
The discourse of toxicity, then, is reconfigured to take into account genetic 
information about the patient body, which is reconstructed at a more molecular level. 
PGx testing also constructs the patient body in an increasingly algorithmic way. 
Chapter Six highlights the way in which the acutely ill patient body is reduced to a 
series of criteria and algorithms through which prescription decisions are made in the 
hospital setting. This chapter noted that this is particularly the case in medical 
specialisms where highly toxic medications are routinely prescribed and the risk of 
adverse drug events is, thus, very high. The data suggest that PGx test results are 
used as part of this algorithmic construction of the patient body in hospital settings; 
“You’re going to have to check that those criteria [of the patient 
body] have been met before the drugs actually released or 
dispensed. If you think about chemotherapy you have to meet 
certain criteria... so I can’t see that it [pharmacogenetic testing] 
will be any different” (HP 4) 
 
“We have genetic predictors and we also have clinical predictors. 
We can put them together and devise a better dosing algorithm, 
which helps you to be better able to define what a patient’s dosing 
requirement will be” (PGx 2) 
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“Whether it’s other characteristics of the patient or their disease 
pharmacogenetics is just something else in a way that you put into 
the mix for deciding what is the best treatment for this individual 
patient” (HP 3- Oncology) 
 
“It’s just another piece of information like a test for lithium level. 
It’s just another layer of information” (PS 3) 
Hence, these test results are understood to add another, more genetic 
dimension, to clinicians’ prescription decisions and, subsequently, to the pharmacy 
gaze. Hence, test results are understood as an additional piece of information in 
therapy decisions; 
“This [pharmacogenetic information] is another piece of 
information that can help you in terms of your medicines selection 
and also thinking about how the medicines are going to work when 
they’re being taken” (HE 1- previously a HP) 
 
“It’s another test that leads you down a treatment pathway” (HP 
6) 
This additional information, then, also expands the pharmacy gaze to 
incorporate a focus on genetic information in medicines safety as Hospital 
Pharmacists 3 and 9 (both Oncology pharmacists) points out; 
“The pharmacogenetics issue is just another one of those extra 
things about the patient’s whole medical history and ideally we 
want the lot to be able to do the best checks and give the best for 
that patient when we’re checking this prescription” (HP 3- 
Oncology) 
 
“You do it [pharmacogenetic test] at the start of treatment and 
then you know, in terms of planning, whether the patients’ 
appropriate for treatment or not... And it’s good because it means 
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you don’t over-treat patients...it’s a lot more individualised now in 
terms of making sure that patients get the treatments that are best 
for them” (HP9- Oncology) 
The quote from Hospital Pharmacist 9 also demonstrates the way in which 
medications are made meaningful to patients through the use of PGx testing. Chapter 
Six noted that a central part of pharmacy practice and the pharmacy gaze is the 
process of locating medications and their risks within the patients’ wider lifeworld. 
In configuring chemical compounds as socially and culturally meaningful objects, 
medications become meaningful through their status as “appropriate” and “best” 
for patients. In the above quote, Hospital Pharmacist 9 demonstrates that way in 
which PGx information can be used to construct this appropriateness. In other 
instances, of course, PGx information is used to construct medications as 
inappropriate. Within this, PGx data underpins the discourse of toxicity created 
around a medication and configures it as inappropriate and toxic for the patient body. 
 
Additionally, PGx information can act to culturally configure disease as well 
as the medication used to treat it. Within this, molecular information underpins the 
definition of the nature of disease and the prognosis arising from it. Oncologist 1 
demonstrates the way in which a pre-prescription PGx test for Herceptin can make 
breast cancer meaningful through the prognosis which PGx data suggest; 
“Women were quite disappointed if they couldn’t have 
Herceptin…but what it does is it turns a very nasty cancer into one 
that’s about the same as everybody else’s. So actually not needing 
Herceptin is a positive thing. We have to say that so many times to 
patients, you know, you shouldn’t be disappointed if you don’t need 
Herceptin, that means your cancer is not as aggressive as some 
people’s” (O1) 
This practice of making medicines meaningful through PGx testing can also 
act to make genetic information culturally meaningful within a much wider scope. 
Hence, where a PGx test highlights the potential for other toxicities, this genetic 
information then becomes meaningful in the context of the patients’ wider 
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‘lifeworld’. As an example, Chapter Three highlights the wider implications of PGx 
testing for Tacrine response where this test also indicates Alzheimer’s susceptibility. 
This concern about Tacrine therapy is highlighted by Pharmacogeneticists 5 and 8;  
“There was a concern about APOE4 and about the use of that in a 
pharmacogenetic setting when it gives information about 
Alzheimer’s disease” (PGx 5) 
 
“There’s a gene called APOE4 I think that predicts Alzheimer’s 
but also predicts response to Tacrine” (PGx 8) 
Other respondents also noted similar concerns about the meanings of PGx test results 
in patients’ wider ‘lifeworld’;  
“If they test somebody and it brings up issues related to family 
links or something like that, which potentially it could, it’s 
potentially quite an emotive area” (PGx 4) 
 
“Especially breast cancer patients, they worry about other people 
in their family. I think they’re always really hopeful that there’s 
going to be a genetic solution” (HP 2) 
 
“Well, they assume that has implications for their family. Women 
worry obviously about hereditary breast cancer and will their 
daughters be at risk of breast cancer and so the genetics obviously 
has that connotation” (O 1) 
So far this chapter has located PGx products and processes within hospital 
practice and, more specifically, within the specialist area of Oncology. It has been 
highlighted here that this is because of the ontological differences between primary 
and secondary care medications which is outlined in Chapter Six. Within this, the 
relatively high toxicity of secondary care medications makes the stratification of 
patient populations more of a priority in this setting. Despite this, putative links 
between primary care drugs and genetically-determined drug responses have been 
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identified. Moreover, the primary care drug Warfarin is one of the most commonly 
cited as a beneficiary of pre-prescription PGx testing (Wadelius and Pirmohamed, 
2006). Hence, although PGx is primarily a hospital-based practice at present, an 
analysis of its implementation in the community setting is imperative. It is to this 
analysis that this chapter now turns.  
8.7 PGx in Community Pharmacy Practice 
In contrast to the picture in hospital pharmacy practice outlined above, the 
community pharmacists interviewed had a relatively limited knowledge of PGx. The 
knowledge which community pharmacists did have was, generally, unintentionally 
acquired through personal experience, meetings, practitioner publications and 
inclusion in the present research study;  
“Really my only experience [of pharmacogenetics] was a quick 
browse on Wikipedia...but it was being mentioned in the pharmacy 
press” (CP 1) 
 
“We’ve had one branch meeting that I remember and I don’t 
remember very much about it apart from the word 
‘pharmacogenetics’” (CP 9) 
In the same way that the relatively high levels of knowledge of hospital 
pharmacists can be understood within the bioclinical collective structure of their 
practice, the medical technocracy which characterises community practice can be 
understood as a factor in community pharmacists’ limited knowledge of PGx. As 
Cooper et al.  (2009) highlight, community pharmacists practise in relative isolation 
which makes the informal transfer of knowledge between them more challenging 
than in the hospital setting.  
 
Moreover, as is discussed below, the association of PGx testing with highly 
toxic medications means that this technological paradigm is uncommon in 
community practice where the potential for ADRs is reduced. Given this, the data 
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suggest that an ‘early days’ discourse is mobilised to make sense of the 
implementation of PGx in community pharmacy; 
“It’s very early days... Treatment I think will still be 10 years off” 
(CP 8)  
 
“I think it’s about a future role rather than a role that’s likely to 
develop in the next two or three years” (PS 1- also a previous HP) 
 
“I think it’s still too early to say how it will impact on patients and 
what role we can play with it” (HP 5) 
 
“I think it’s too far down the line of the worry list of things they’ve 
going to be thinking about” (HE 1- also a previous HP) 
 
“You never really know how things are going to go” (PGx 3)  
This ‘early days’ discourse generates a number of highly speculative 
scenarios for how PGx might work in everyday community pharmacy practice. 
Elsewhere, this process of imaging future scenarios has been argued to be central to 
the construction and implementation of innovations (Bell, 1996; Rappert, 1999). In 
the hospital setting such future scenarios are highly rationalised and based on 
experiential knowledge of previous genetic or molecular innovations and services. In 
the community setting, however, given the lack of experience around the 
implementation of molecular innovations, these future scenarios tend to be more 
speculative. These potential ‘PGx futures’ in community pharmacy are outlined later 
in the chapter. 
8.8 Implementing PGx into Community Practice  
PGx has made a limited impact on community practice because the trial-and-error 
model of prescribing primary care drugs is less problematic in the community than in 
the hospital. Hence, the relatively low cost and toxicity of primary care medications 
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mean that non-responsiveness and ADRs are less problematic in this setting than in 
the hospital.  
 
The data suggest that the implementation of PGx in the community setting is 
highly linked with the medical technocracy in which community pharmacy practice 
sits. Innovations in community pharmacy, then, are understood as being 
administered in a ‘top-down’ manner through governmental and professional bodies 
(for example the Department of Health and RPS) and GPs. Within this model of 
innovations in community pharmacy, links with traditional linear models of 
innovation diffusion can be seen where external actors (i.e. GPs or Department of 
Health personnel) are heavily involved in the implementation process. 
 
This relatively linear model of implementation is linked with the nature of 
community pharmacy as “reactive” (HE 1- also a previous HP), which is, in turn, 
related to the retail focus of community pharmacy work which limits the autonomy 
of practitioners. In other words, given the corporate environment in which most 
community pharmacy work is undertaken, the ability of practitioners to proactively 
engage with innovative technologies and practices is limited. Community Pharmacist 
1 highlights this well; 
“Not everybody gets a good chance to sit down and inwardly 
digest. It’s not so much a lack of interest but more a lack of time to 
learn and understand these things” (CP 1) 
The data suggest that the implementation of PGx into community pharmacy 
practice is most likely to be administered through GPs where GPs are the most likely 
community practitioners to undertake PGx work (i.e. testing and results 
interpretation). This model of PGx practice in the community is most similar to the 
present model of primary care practice (see Jamie, 2011: 694) and, therefore, serves 
to compound the boundaries of practice which construct diagnosis and prescribing 
(and all of their associated tasks) as the role of the GP and the practice of dispensing 
as that of the pharmacist. Within this, the data present pharmacists as occupying 
something of an adjunct role supporting the work of GPs in this area, as the 
following quotes demonstrates; 
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“We’ve really got to be working towards showing how we can help 
and how it [pharmacogenetics] can be good for everybody. How it 
can free up what the GPs need to do. We can do some of this” (CP 
2) 
 
“As the technology becomes a lot more widespread then that’s 
something that could spill over into pharmacy to try and take the 
pressure off other primary healthcare providers…” (CP 1) 
The above quote from Community Pharmacist 1 represents community 
pharmacists’ involvement in PGx as being necessary once this practice has become 
challenging for the structures of general practice. In this way, Community 
Pharmacist 1 represents the involvement of community pharmacists in PGx medicine 
as being similar to their involvement in flu vaccination work presented in Chapter 
Seven as he went on to say; 
“… in the same way that those flu vaccinations played a very 
valuable role in taking a bit of the pressure off GPs for the flu 
vaccinations and enabled a few more people to get vaccinated who 
wouldn’t otherwise have been able to” (CP 1) 
This potential model of PGx medical delivery draws parallels with Cooper et 
al.’s (2009) understanding of community pharmacists as subordinate ‘doctors’ tools’. 
In this way, the skills of pharmacists are only drawn upon when necessary to support 
the work of GPs, which also resonates with Harding and Taylor’s (2002: 442) 
observation that ‘pharmacists take their lead from physicians’.  
8.9 Defining PGx in the Community: Pharmaceutical Care 
Chapter Six noted the philosophical differences between medicines management and 
pharmaceutical care where the former relates the organisational and corporate 
interests in medicines efficacy and the latter is focused on medicines efficacy for the 
individual patient. In this thesis it is argued that medicines management pertains 
more to hospital pharmacy practice whilst pharmaceutical care more accurately 
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characterises community pharmacy practice. Given this, PGx in community 
pharmacy practice is defined and cohered through formalised, codified 
pharmaceutical care policies and practices and at the level of everyday practice 
through the pharmacy gaze and discourse of toxicity. At the level of formalised, 
codified pharmaceutical care, PGx is largely defined in much the same way it is in 
the hospital setting. As such, pre-prescription testing is understood as a way to 
stratify patient populations to reduce adverse drug events; 
“Patients have a very variable response. We can get a little tiny 
frail old lady and a big strapping chap and there can be 
differences. There must be a reason for this...So pharmacogenetics 
is interesting for anticoagulation, very much so… I think in the 
future it would be fantastic” (CP 2) 
Additionally, PGx in the community setting is also defined as a way in which 
medications adherence could be improved. In the community setting, patients are 
given a relatively high degree of agency over their medication regimes as, in contrast 
to in the hospital setting, these medications are not generally administered on a daily 
basis and patients are not monitored in their taking of these medicines. As such, the 
choice of whether to adhere to a medications regime lies almost entirely with the 
patient.  In their review of studies around patient non-adherence, Vermeire et al. 
(2001) highlight that patient non-adherence to primary care drugs is a ‘major 
problem’ for the NHS and present a number of reasons for this such as poor 
practitioner-patient communication; complexity of therapy regimen; polypharmacy; 
the cost and frequency of dosing; and patients’ own beliefs about their illness and 
medicines (also see Webster et al., 2009). Charland et al (2012) argue that patients 
having knowledge of the PGx reasoning behind their medication regime can 
encourage them to comply and this is echoed in the following quote from 
Pharmacogeneticist 2; 
“One of the side benefits of pharmacogenetics is actually that they 
[patients] are going to have to make more of an effort to have an 
interest in what their disease is and an interest in the treatments 
that we’re using. Obviously everyone has an interest in the disease 
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they have but don’t have much of an interest in the drugs they’re 
taking and that leads to some problems with regards to 
compliance. Fifty percent of people or more than that don’t take 
the drug regularly as they’re supposed to. So if you have more of 
an interest in your disease and how it’s being treated, then you’re 
more likely to adhere to the therapies, so that’s something that will 
be a side benefit” (PGx 2) 
Similarly, Pharmacy Stakeholder 2 noted patients’ increased receptivity to 
therapies with a personalised element; 
“If you tell someone we’re going to tailor the drug to reduce your 
chances of side effects, or increase the chances of it actually 
working, they should be hugely receptive to it...An awful large 
number of patients abandon their treatment because they’ve read 
the information leaflet or they’ve perceived a side effect; they’ll 
take one tablet or they’ll take none. So I think they would love it 
really to think that someone is tailoring a drug for them” (PS 2) 
Although PGx has made a limited impact on primary care practice so far, the 
data show that it is defined as a paradigm of practice which pharmacists will need an 
awareness of given the increased presence of genetic/genomic techniques and 
stratification approaches in drug development. In other words, as Cryan (2004)and 
Alcalde and Rothstein (2002) note, future pharmacists will prescribe a greater range 
of drug regimen (i.e. different dosages, strengths and administration directions) 
based on genetic information and will, thus, need to have an awareness of the issues. 
As such, PGx is defined as an important future paradigm in pharmacy; 
“I’m sure in the future it will be hugely useful” (CP 2) 
 
“Community pharmacists will probably need an awareness” (CP 
6) 
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“I can only see that their role is going to increase as the 
complexity of drugs and drug dosing and the spectrum of drugs 
available increases...we’re going to have to have the pharmacists 
taking a much more direct role in prescribing and monitoring” 
(PGx 4) 
 
“I would hope that they would be really...prepared for the whole 
range I was imagining of scenarios” (GP 2)  
Within this future, a number of potential roles for pharmacists are highlighted 
in the data. These are conceptualised here as ‘pharmacogenetic futures’ and are 
highly speculative given the limited impact of PGx in community practice to date. 
8.10 Community Pharmacists’ PGx Futures  
Within the adjunct role of community pharmacists presented above, the data present 
a number of options for work activities for community pharmacists in delivering 
PGx medicine. As mentioned above, these potential PGx futures are highly 
speculative given the limited impact of PGx in primary care and the ‘early days’ 
discourse which is thus developed. These future scenarios can, broadly, be divided 
into three categories of work; one around testing activities; one around results 
interpretation and patient counselling; and one around inter-professional 
collaboration and education.   
 
Firstly, community pharmacists’ involvement in PGx testing is understood as 
an extension of the testing activities which they currently undertake in their clinical 
work; 
“Well pharmacists already...do some levels of testing like 
pregnancy testing” (PS 2) 
 
“Now, because most community pharmacies have a consultation 
area... there are pharmacies that are setup already to do that. So if 
it was things like taking a finger prick test or blood test I don’t see 
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why that couldn’t be done in a pharmacy. I’d like to think that we 
could be somehow involved in it” (CP 4) 
 
“Community pharmacists do testing for blood pressure or 
cholesterol testing so they could do genetic testing in the 
community pharmacy” (HP 5) 
 
“Could [community] pharmacies do that [pharmacogenetic 
testing]? They do things like cholesterol testing and various other 
things so I don’t see why not” (HP 3- Oncology) 
 
“There may be some generic tests which come along a bit like 
cholesterol testing, which anyone can do, which may be a point-of-
care diagnostic, which you could potentially do in a pharmacy” 
(PGx 2) 
 
“As pharmacists can be involved in glucose testing and those sorts 
of things, in that setting, I think it would be entirely reasonable” 
(PGx 5) 
Here, the black-boxed nature of PGx testing (e.g. a “finger prick test” (CP 
4))  is central to the ability of community pharmacists to carry out this work as 
interpreting complex results is not easily harmonised with existing practises and 
structures in community pharmacy. Hence, the outcome from PGx testing products 
needs to be somewhat binaried in order for these outcomes to be useful in 
community pharmacy practice, as Pharmacy Stakeholder 4 shows; 
“If it’s a simple test where you do what we call an antibody test, 
like a colour test, that is doable” (PS 4) 
Secondly, community pharmacists interpreting test results and providing 
information and counselling to patients has been suggested elsewhere (Clemerson et 
al., 2006; Moffat and Dawson, 2001). The data here suggest that this role of 
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community pharmacists may be beneficial for patients by locating their PGx 
information within their wider ‘lifeworld’ and illness trajectory; 
“They [community pharmacists] definitely have an advisory role to 
the patients in terms of I’ve had this test and what does it mean” 
(HE 1- also a previous HP) 
 
“Who should explain the results of the test, who should discuss 
whether or not to have the test in the first place, what’d the 
turnaround time and what’s the effectiveness of the test, the ability 
of it to predict a particular side effect. And obviously when we’re 
talking about people who could either explain the results or think 
about the decision to have the test pharmacists are included as one 
of the option” (HE 1- also a previous HP) 
 
“The people who actually understand medicines and their effect on 
the body are pharmacists. So if anybody is going to be able to 
explain in lay terms, pharmacists are the right persons” (MTC 1- 
also a previous HP and CP) 
 
“They need to present themselves as the translator of information 
because I think that would strengthen the relationship between the 
patient and the healthcare professional” (MTC 1- also a previous 
HP and CP) 
Finally, some of the data suggest that community pharmacists are in a central 
position to provide education about PGx to other healthcare practitioners and 
patients. It is suggested that as experts in medicines and their associated ‘stuff’ 
(Barber, 2005) pharmacists occupy an optimal position to disseminate PGx 
knowledge to other primary care practitioners and patients; 
“As an education role, fine...I think that’s a very important part” 
(O 2) 
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“There has to be a big communication discussion between 
healthcare professionals and the wider world. And I happen to 
think that the best people, the best qualified people to do that are 
pharmacists...The people who actually understand medicines and 
their effect on the body are pharmacists. So if anybody is going to 
be able to explain in lat terms, pharmacists are the right persons” 
(MTC 1- also a previous HP and CP) 
This “translational” (MTC 1) role of pharmacists also offers a way through 
which pharmacists can demonstrate their expertise in the area of medicines and 
strengthen inter-professional communication and collaboration. Elsewhere Penick 
Brock et al. (2003) argue that this sort of ‘pharmacist educator’ role places 
community pharmacists in a prominent position to expand their professional 
jurisdiction by becoming involved in research which has not previously been part of 
community pharmacy work. This “translational” work, thus, presents a way in 
which PGx may undermine the relatively rigid hierarchical boundaries of the 
traditionally medically technocratic primary care structure and facilitate a more 
bioclinical collective model of practice.  
 
As mentioned above, these imagined PGx futures in community pharmacy 
are highly speculative given the limited impact that this paradigm of practice has 
made on community pharmacy so far. Moreover, these three futures present PGx as a 
set of (testing) products which are present in every community pharmacy around 
which something of a standardised process is developed. The data, however, suggest 
that the PGx roles outlined here are more likely to be undertaken by specialist 
pharmacists.  As such, in much the same way as hospital pharmacists specialise in an 
area of medical practice, the data present the most likely scenario as being one in 
which a small number of community pharmacists become accredited with specialist 
skills and expertise in the area of (pharmaco)genetic medicine; 
“I could envisage this being more in a specialist clinic” (PS 2) 
 
“At the moment pharmacists tend to be specialists around disease 
areas and specialities like that whereas maybe that 
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[pharmacogenetics] would be a specialist area that would cover 
lots of different disease specialities but it would be a specialist 
interest area” (HP 2) 
 
“I don’t think all pharmacies will do this but there will be some 
specialist pharmacists, who will become specialised in the area; 
who will then be able to interpret and help with this process, as 
there will be specialised clinical pharmacologists and specialised 
physicians in this area. So it is going to be a specialist area.” (PGx 
2) 
 
“There would be quite a profound role. I think you’re getting into 
the realms here - beyond specialist pharmacists- you’re getting 
into a realm of consultant pharmacist and that’s the area and level 
of expertise and practice I would expect somebody to have before 
they started to dip their toe into the mucky areas of 
pharmacogenetics” (HP 1- Chief Pharmacist) 
 
“I think it’s interesting whether the profession goes down the road 
where everybody needs to have those core competencies or 
whether you go down the line of your GPs with a special interest; 
so you get pharmacists with a special interest in 
pharmacogenetics…The profession is going down the consultancy, 
particularly in hospital pharmacy, route. So to me that seems a 
more logical approach” (HE 1- also a previous HP) 
The data suggest that these PGx futures will impact on the ways in which 
pharmacists interact with patients, patient bodies and medications. As such, the 
community pharmacy gaze is reconfigured by pharmacists’ practice within these 
PGx futures.  
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8.11 Reconfiguring the Community Pharmacy Gaze 
The limited presence of PGx in community pharmacy can be understood as relating 
to the nature of the pharmacy gaze and the discourse of toxicity which it generates in 
community practice. As Chapter Six noted, the pharmacy gaze and discourse of 
toxicity in community pharmacy practice are centred on relatively simple patient 
bodies to which fairly low toxicity medications are administered.   
 
The implementation of PGx into community pharmacy may reconfigure the 
community pharmacy gaze in similar ways to that described above in the case of 
hospital practitioners. As such, the introduction of genetic information into 
community pharmacy may reconstruct the previously relatively simply patient body 
as a more complex, molecular entity and the previously fairly low-risk medications 
which are administered to it as toxic regimes in need of closer management. Through 
this, the traditional trial-and-error model of prescribing in primary care becomes 
redefined as inappropriate for failing to take into account the complexities of the 
molecular patient body and the potential toxicities which it presents. In this way, 
PGx can be understood as drawing parallels between the hospital and community 
pharmacy gazes where trial-and-error prescribing in the community is displaced by 
more systematic and complex prescribing and management practices as in the 
hospital.  
 
Chapters Six and Seven highlighted increased clinical work as a key feature 
of the community pharmacy gaze. Chapter Seven argued that by mobilising various 
testing technologies, community pharmacists bring into being what is called here a 
collective ‘public health body’ which positions patients’ ‘extracorporeal space’ 
(Armstrong, 1995) and bodily characteristics (such as weight and cholesterol levels) 
as roots of toxicity and risk. The introduction of (pharmaco)genetic principles into 
community pharmacy may reshape this clinical community pharmacy gaze to 
incorporate a focus on the molecular aspects of this bodily toxicity. For example, 
community pharmacists have a strong involvement in delivering smoking cessation 
support services and providing medicinal materials, such as nicotine patches, which 
have a central role in this cessation process. Within pharmacy smoking cessation 
services, the public health body is brought into being through the relationship 
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between the at-risk smokers’ body and national smoking cessation objectives. The 
role of the pharmacist in this smoking cessation process is enacted through their 
provision of support services and administration of medicinal products. Recent work 
in the area of the pharmacokinetics and pharmacodynamics of nicotine suggest that 
there may be a genetic basis to dependence mechanisms and that smoking cessation 
products may be more effectively used through an understanding of these genetic 
elements (see Kortmann et al., 2010). In this way, PGx can be understood as 
reconfiguring the clinical pharmacy gaze to incorporate a more genetic element into 
the clinical services which community pharmacists provide.  
 
Hence, whereas PGx is most commonly understood as a series of products 
and processes around prescribed medicines, its implications for community 
pharmacy may be more pervasive in centring on clinical, as well as dispensing, 
work. As such, the community pharmacy gaze may be reconfigured around both its 
medications and clinical foci.  
 
Within this potential reconfiguration of the pharmacy gaze in community 
practice, the importance of algorithms is, once again, clear. Chapter Six noted the 
way in which the complexity of the ill patient body is managed through its 
construction in algorithmic terms. Additionally, it is argued above that PGx 
configures an algorithmic patient body in the hospital setting. The data here suggest 
that in the community setting, algorithms are of central importance in delivering PGx 
medicine in two key ways. In one way, there is an algorithmic construction of the 
patient body in much the same way as occurs in the hospital setting;  
“The information would tell you more about whether they can have 
the drug. So as well as age, weight, other drugs I guess genetics 
would also be part of it” (CP 10) 
 
“There are clinical algorithms which you can now put in- 
pharmacogenetic test result; patients’ weight; age; health etc.- put 
that all into a programme and get the dose out. I think pharmacists 
will be open to that and will use that information as they would to 
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check if the patient had had any liver problems or kidney problems 
before prescribing them certain drugs” (PGx 5) 
Within this, the complexity of the patient body is managed through its 
construction as a set of criteria which influence therapy decisions. In another way, 
the patient body is managed through algorithmic safety software which is stored on, 
and managed by, the pharmacy computer. This algorithmic software is similar to that 
which pharmacists currently use for indentifying potential drug-drug interactions as 
part of their “checking” (HP 6- Director of Pharmacy) role. The provision of PGx 
medicine is imagined to add a layer of complexity to this software by introducing 
gene-drug algorithms to the repertoire of information involved in this “checking” 
role; 
“They do drug interactions now as a matter of course...I guess that 
will become more sophisticated and might include 
pharmacogenetics” (O 1) 
Within this, the development of gene-drug reaction algorithms can be 
understood as bridging the gap between PGx products and processes. In other words, 
it is through such algorithms that the outputs from PGx products (i.e. test results) are 
translated into PGx processes through the therapy decisions that they enact.  Here, 
then, algorithmic software which manages the body, its medications and the 
potentially toxic relationship between them can be understood as both a product and 
a process innovation.  
 
As well as reconfiguring the ways in which community pharmacists gaze at 
their patients, the implementation of PGx into community practice may reconfigure 
the ways in which patients, and other practitioners, understand pharmacists as 
professionals. In other words, PGx may alter the professional identity of community 
pharmacists in a number of ways.  
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8.12 Reconfiguring the Professional Identity of Community Pharmacy 
In their study of electronic prescribing systems (EPS) in community pharmacy, 
Petrakaki et al. (2012) note that the implementation of new technologies into 
pharmacy can change pharmacists work in the following areas: nature of work; 
professional values; roles; jurisdictions; boundaries and power. Within this, they 
argue that re-professionalisation and de-professionalisation of pharmacy occur 
simultaneously where pharmacists are increasingly provided with opportunities for 
challenging clinical work and decision-making and are more fully integrated into the 
NHS (re-professionalising activities) whilst concurrently their work is increasingly 
automated, controlled and rendered invisible (de-professionalisation). As such, 
through the implementation of EPS technology, the community pharmacy identity is 
shifted. The data suggest that a similar process may occur in the community setting 
through PGx technologies.   
 
At present, the professional identity of community pharmacists is heavily 
linked with their retail role which leads to their characterisation by other healthcare 
practitioners and patients as “glorified shopkeepers” (CP 1). Their practice with 
relatively simple (in other words non-complex) bodies and medicines can also feed 
into their identity as ‘quasi’ professionals (Denzin and Mettlin, 1968). Additionally, 
community pharmacists’ practising in ‘isolation’ (Cooper et al., 2009) is shown in 
Chapter Six to be central to their position in the primary care medical technocracy 
and, thus, their professional identity.  
 
It has been suggested that the implementation of PGx into pharmacy could 
increase the inter-professional communication between pharmacists and other 
healthcare practitioners (Cryan, 2004) and thus, as Petrakaki et al. (2012) argue, 
‘bring pharmacists into the NHS family’. These sentiments are supported in the data 
where PGx being part of routine community pharmacy practice is understood to 
necessitate the movement of community pharmacy practice away from a medical 
technocracy model to one of a more bioclinical collective nature; 
“We’d need to be talking with GPs and nurses and all sorts of 
other people a lot more than we do currently” (CP 10) 
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In addition, the reconfiguration of the community pharmacy gaze outlined 
above may impact upon the professional identity of community pharmacy. Hence, 
where PGx reconfigures the primary care patient body as increasingly molecularised 
and complex, the identity of community pharmacy may become increasingly 
understood in terms of complexity; complexity of bodies and complexity of 
medications. Community Pharmacist 10 states that this would affect the way in 
which community pharmacy is perceived by patients and other healthcare 
practitioners; 
“By doing genetics, we’re saying that we can be more high-tech 
than people think we are now” (CP 10) 
Community Pharmacist 3 notes that the professional identity of community 
pharmacists is reconfigured by this added complexity; 
“You automatically send a signal that we are here for health 
reasons as opposed to just dispensing the medication” (CP 3) 
Resonances can be seen here with Pickstone’s (2000) ways of knowing, 
which was outlined in more detail in Chapter Two. Pickstone argues that there are 
five ways of knowing in science and medicine which have shaped medical practice 
throughout history. He argues that there are connections between these ways of 
knowing, the technologies that are used and the extent to which medicine (or certain 
branches of it) are understood as a ‘science’, which then impacts upon the 
professional identity of the practitioners involved. He presents the two most recent of 
these ways of knowing as ‘experimentalism’ and, more latterly, ‘technoscience’. 
Contemporary community pharmacy practice can be understood as sitting within an 
‘experimentalism’ model given the ubiquity of the trial-and-error model of 
prescribing. In integrating PGx into community pharmacy, Community Pharmacist 3 
suggests that the sector may be reconfigured to a more ‘technoscience’ way of 
knowing. In this way, PGx may help community pharmacy ‘transition into the 
future’ (Streetman, 2007: 2040) and may reconfigure community pharmacy as ‘less 
an art and more a science’ (Johnson et al., 2002: 13S).  
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8.13 Reflexive Monitoring and Integration of PGx: Products and 
Processes  
Chapter Seven highlighted May and Finch’s (2009) notions of reflexive monitoring 
and integration as useful reference points for analysing the evaluation of new 
innovations in pharmacy practice. To reiterate, reflexive monitoring is the process 
through which new innovations are formally and informally evaluated through 
communal and individual appraisal techniques. In pharmacy practice, communal, 
formal evaluation is argued, in Chapter Seven, to map onto formalised, bureaucratic 
medicines management policies and processes whilst more negotiated, individual 
appraisal is related to medicines management processes enacted through the 
pharmacy gaze in everyday practice.   
 
The data show that PGx is subject to reflexive monitoring in both the hospital 
and community setting. In some cases, this reflexive monitoring leads to the 
normalisation of PGx practice as in pre-prescription HER2 testing for breast cancer 
patients. In other instances, this evaluative work highlights problems with PGx 
products and processes which leads to a lack of integration. Although he does not 
employ the constructs of NPT specifically, parallels can be drawn here with 
Hedgecoe’s (2008a) notion of clinical usefulness. Within this, he argues that whilst 
pre-prescription PGx tests may be defined as useful and integrated into some clinical 
contexts (for example, HER2 testing in Oncology), in other areas such as APOE4 
testing for Tacrine, pre-prescription testing is defined as less useful and so fails to be 
normalised into everyday routine practice.  
 
The reflexive monitoring of PGx is an evaluation of both PGx products and 
PGx processes (see Damanpour, 1996). The data suggest that most of the evaluative 
work around PGx products is done through national and regional communal 
appraisal practises. Within this, bodies and organisations such as NICE and the 
Cancer Network are central actors in this evaluative work and define whether, and 
how, PGx testing products are useful for practice. Oncologist 2 shows, for example, 
that the value of HER2 testing in breast cancer patients was “sorted out at the 
national level” by the Cancer Network.    
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Once this national level communal appraisal of PGx products is understood 
as somewhat completed (i.e. once, for example, a clinical trial has finished), 
evaluation then begins to centre on the micro-level integration of PGx processes. 
The following quote from Oncologist 2 demonstrates this in the case of HER2 
testing for breast cancer patients;   
“We need to be doing it [routinely testing for HER2 over-
expression in breast cancer patients]. Okay, how do we do it?... We 
don’t know” (O 2) 
Within this quote the evaluative work of the HER2 testing products by the 
Cancer Network has already taken place and, as an outcome, the routine testing of 
breast cancer patients for HER2 over-expression has been recommended. The quote 
shows that the appraisal work is then centred on the integration of these testing 
processes in everyday practice.  
 
In the hospital setting much of this integration work around PGx processes is 
undertaken through national directives where the bodies which undertake much of 
the communal appraisal work then set national frameworks for implementation. 
Oncologist 2, again, demonstrates this in the HER2 testing case; 
“You can piddle about on the coalface and you don’t get a huge 
amount done. You’ve got to go back to the people in the Network 
who got the funding and the ability to just say “you’re going to do 
every sample now” and from now on you have to do it” (O2)  
Here, the integration of HER2 testing into Oncology practice is directed by 
the Caner Network which undertook the product communal appraisal work and has 
the “ability” to construct frameworks and protocols for process integration. This 
relatively top-down integration model is juxtaposed in this quote with integration 
work at the meso (organisational) and micro (everyday practice) levels which is 
carried out in everyday practice “at the coalface” and understood as having limited 
capacity for “getting a huge amount done”.  
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What this means is that in reflexively monitoring and integrating PGx, a 
number of elements become important. Figure 3 identifies these elements as being 
the scope, nature, level and focus of evaluation and demonstrates the ways in which 
these elements sit within communal and individual appraisal processes and are 
linked with each other. This Figure also highlights the relationship between 
communal and individual appraisal practises and the dual medicines management 
model proposed in this thesis. It shows that, broadly, communal appraisal processes 
are undertaken in line with formalised, bureaucratic medicines management policies 
whilst individual appraisals of PGx are enacted through the pharmacy gaze and the 
discourse of toxicity at the level of everyday pharmacy practice.  
 
Reflexive monitoring and integration of PGx in community pharmacy is 
more challenging to analyse given that little of this work has taken place because of 
the lack of PGx products in primary care. Given this, the data which discusses the 
integration of PGx processes in community pharmacy is highly speculative and tends 
to focus of the prospective challenges of this integration work. The data suggest that 
there are two ‘scopes’ to these potential challenges (see Figure 3); one which focuses 
on ‘macro’ challenges to be addressed at the organisational level of pharmacy and 
one which focuses on ‘micro’ challenges which are manifested in everyday routine 
community pharmacy practice. This is not, however, to say that these macro and 
micro challenges identified in the data are discrete sets of issues; there are quite clear 
overlaps where micro challenges require some degree of engagement from 
organisational bodies and vice versa. Moreover, many of the macro and micro 
challenges identified sit within the same overarching concerns such as logistics and 
finance.  This chapter now turns to a more detailed overview of these macro and 
micro challenges.  
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Figure 3: Reflexive monitoring of PGx. Exploring the relationship between appraisal and nature, level and focus of evaluation
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8.13.1 Integrating PGx into Community Pharmacy: ‘Macro’ Challenges 
Here, the notion of ‘macro’ vis-a-vis the challenges of integrating PGx into routine 
community pharmacy practice is employed to denote the level of the pharmacy 
‘world’ in which challenges are manifested and addressed. The notion of macro 
challenges, then, refers to challenges which affect the entirety of the community 
pharmacy structure and practice. These challenges, therefore, fall within the remit of 
organisational bodies such as the RPS and Department of Health and would require 
addressing before PGx could successfully become a routine feature of community 
pharmacy practice. 
 
Most of these macro challenges are centred on the nature of pharmacy 
practice and the integration of PGx processes within it. In addition, the nature of 
PGx products is seen as a potential macro challenge for community pharmacy by a 
number of secondary care respondents who are already using such devices as part of 
their everyday practice. Specifically, concerns around the quality assurance of PGx 
tests in primary care are highlighted where quality assurance is understood as a 
“massive, massive issue” (O2). Experiences of quality assurance challenges within 
secondary care are, then, used as reference frameworks for understanding the 
potential challenges of PGx in primary care. Oncologist 2 emphasises this in the 
following quote; 
“There are significant problems with some of the tests that we do... 
Quantification or semi-quantitative immunohistochemical assays 
are not easy, they are prone to error, systematic error, and the 
quality assurance is very labour intensive and is performed 
intermittently” (O 2)   
In this quote, Oncologist 2 highlights quality assurance vis-a-vis interpreting 
PGx test results as problematic in the hospital setting. This is then used as a 
framework for the potential challenges of PGx products in community settings as he 
goes on to say; 
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“It’s hard enough to get quality assurance in a centralised 
system...In terms of testing it would have to be an incredibly robust 
test to just be farmed out to the community” (O 2) 
The above quote suggests that the robustness of PGx products is particularly 
important in the community setting given the context in which prescription decisions 
are made and medications are dispensed. Within this such quantification tests (i.e. 
tests which determine levels of gene or protein expression) are challenging for two 
reasons.  
 
Firstly, the results which they provide are not binaried in the same way as 
other primary care test results (for example pregnancy tests) and so a fairly high 
degree of clinical judgement is necessary in translating these results into therapy 
decisions. In the hospital setting, this is facilitated through the bioclinical collective 
nature of practice, particularly in Oncology multi-disciplinary teams. This is in 
contrast to primary care practice in which practitioners, and their therapy decisions, 
are relatively ‘isolated’ (Cooper et al., 2009).  
 
Secondly, quantification testing requires multiple tests to be carried out in 
order to assure the quality of results.  Oncologist 2 notes, for example, that oestrogen 
receptor testing in breast cancer is carried out “on a three month basis”. The acutely 
ill and highly toxic nature of the bodies which are being treated in secondary care 
(and particularly in Oncology) mean that such frequent re-testing is, potentially, less 
problematic. In the community setting, however, this multiple testing work presents 
financial and labour challenges for practitioners particularly given the relatively low 
toxicity of medications which are being prescribed. Oncologist 2 goes on to suggest 
a “genomic health approach” to pre-prescription testing which would be “more 
robust and [mean] that you could theoretically do...a single sample, single test”. The 
macro challenge vis-a-vis quality assurance, then, is centred on developing such 
black-boxed “single sample, single test” devices for integration into community 
pharmacy practice.  
 
Other macro challenges in integrating PGx into community pharmacy 
practice are rooted in PGx processes and their (dis)juncture with contemporary 
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practice structures. One of the primary challenges presented in the data is the 
financing of PGx in community practice. This challenge incorporates a number of 
elements. In one instance, there is uncertainty around who would be responsible for 
paying for individual tests. There is a question around whether patients themselves 
would pay for tests given the potential for improvements to their experiences of 
medications; 
“Some patients won’t mind paying for these tests if it means they’ll 
have a better time of it on their drugs” (CP 10) 
Alternatively, Community Pharmacist 2 highlights patients’ wanting to find out 
about their own bodies as a potential reason for them paying for these tests 
themselves; 
“There will be people that would pay for that because there are 
some people who want to find out everything about 
themselves...That would be one way of getting over the cost issue if 
the patient paid themselves” (CP 2)  
This potential model for financing PGx testing is strongly linked with direct 
to consumer (DTC) testing activities. Although much of this tends to be focused on 
genomic diagnostics and risk profiling rather than PGx information, a review of 
DTC testing has shown that two companies were offering PGx testing whilst one UK 
company made testing kits available in pharmacies (Hogarth et al., 2008). This raises 
interesting questions about the role of pharmacies (and pharmacists) in DTC genetic 
testing activities. Hence, whilst most of these tests are marketed online (Williams-
Jones, 2003) and most of the results interpretation and counselling work is seen as 
the responsibility of GPs (Hauskeller, 2011), Hogarth et al. (2008) and the data 
presented here suggest that pharmacists may in practice have a role to play in this 
process of DTC genetic testing.  
 
This uncertainty about financing PGx tests is also linked to the relatively low 
cost and low toxicity of primary care medications. In this way, the data suggest that 
pre-prescription testing in primary care may not be cost-effective given the relatively 
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low cost and low toxicity of primary care drugs which make trial-and-error 
prescribing less problematic than in the hospital setting; 
“It will depend very much on the cost because if we look at things 
like codeine you just try it and if it don’t work you try something 
else because it’s so cheap to try” (CP 6) 
Additionally, challenges around financing PGx in community pharmacy 
practice centre on the remuneration process. Pharmacy Stakeholder 2, for example, 
questions whether the NHS would pay for community pharmacists to undertake PGx 
work when other primary care practitioners can undertake this work at a lower 
hourly rate; 
“If it’s just a matter of taking a blood sample and then giving those 
results to someone else to make the interpretation, like the GP, 
then you’d go for the cheapest person, not a pharmacist at £25 an 
hour...you’d go for someone on £10 an hour” (PS 2) 
Within this quote, the remuneration challenge is contingent on the nature of 
work involved in delivering PGx. Here if the interpretation of results is not being 
done by the same practitioner who is doing the testing, then the “cheapest” 
practitioners are understood to be the most appropriate to undertake testing work. 
Pharmacy Stakeholder 2 goes on to comment; 
“If the person [doing the testing] then makes an interpretation and 
a clinical judgement then you’d perhaps pay for that on top but I 
suspect it would be going back to the doctor... unless it’s a 
pharmacist or nurse running a clinic where they’re an independent 
prescriber and they make the decision at the same time” (PS 2) 
This quote demonstrates that remunerating pharmacists for undertaking PGx 
testing work is only cost-effective where clinical judgement is also being undertaken, 
envisaged as sitting within independent prescribing practices in specialist clinics. 
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Elsewhere, however, the data suggest that independent pharmacist prescribing is still 
to be normalised in community practice; 
“I’ve got a friend who’s an independent prescriber...the 
unfortunate thing is that they’ve done the training but they’ve not 
had the opportunities to practice” (CP 1) 
 
“At the moment there is a really minimal uptake by GPs on 
independent prescribers” (CP 3) 
Within this, independent pharmacy prescribing is reflexively monitored as 
being of limited use in everyday pharmacy practice. In the community setting, this 
lack of normalisation of independent prescribing further reinforces the practice 
boundaries of the medical technocracy where prescribing work is understood as the 
domain of GPs.  
 
An additional macro challenge in this area of finance and remuneration is 
overall funding in community pharmacy practice. Community pharmacies are funded 
by the Pharmaceutical Services Negotiating Committee (PSNC) where the amount of 
funding for community pharmacy is negotiated with the Department of Health and 
set each financial year. A recent PSNC and British Medical Association guide to 
community pharmacy for GPs
17
 notes that 94% of pharmacy funding comes from the 
NHS in this way. As such, funding for community pharmacy is heavily tied in with a 
wider economic picture and government policies around this. Given the current 
financial crisis in the UK (from 2008 onwards), the data highlight funding for the 
entirety of the community pharmacy profession as being a challenge in 
contemporary practice; 
“It’s a case of how do you get that [pharmacogenetics] forward 
without the funding, which is what it all boils down to” (CP 3) 
 
                                                 
17
 Available here: 
http://www.bma.org.uk/images/communitypharmacyguideforgppracticestaffapril2010_tcm41-
196435.pdf) 
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“People just have their heads down hoping that their funding’s not 
going to be cut” (CP 1) 
 
“It’s very difficult to guarantee funding from one year to the next 
and to place ahead in that way” (PS 2) 
The above quotes suggest that the implementation of PGx and the structural 
reorganisations which it may necessitate are given low priority because of the 
contemporary funding challenges in community pharmacy.   
 
This uncertainty around funding in community pharmacy can also be 
understood as indicative of a uncertainty about the future of community pharmacy 
work. The growth of precarious forms of employment is located more generally 
within neoliberal globalisation trends in the latter half of the twentieth century where 
the decreased power of unions and the increased ‘flexibility’ of employment eroded 
the hold of the ‘job for life’ model (Allen and Henry, 1997; Kalleberg, 2009). In 
their study of the UK’s cleaning, catering and security industries, Allen and Henry 
(1997) demonstrate the way in which employment ‘risk’ has become a ubiquitous 
feature of relatively low-status industries and jobs. Given this, much of the social 
science focus on precarious work has centred around these types of work. The data 
suggest that pharmacists also position themselves within this framework of 
employment risk and uncertainty.  
 
The financial challenges of PGx work are, then, highly related to the ‘early 
days’ discourse outlined above. In this way, developing standardised remuneration 
policies is challenging given the uncertainty about community pharmacy funding and 
what roles pharmacists may perform in delivering PGx in the community setting.  
 
Related to this is another ‘macro’ challenge of integrating PGx into 
community pharmacy, which is concerned with the logistics of community 
pharmacists engaging in PGx work. Much of this is centred on the location of 
pharmacists at the dispensing, rather than diagnosis and testing stage, of the patient 
journey. In other words, most patients experience a similar trajectory through 
primary care where diagnosis, pre-prescription testing and prescribing is carried out 
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by GPs with interactions with pharmacists coming later at the dispensing phase. 
What this means is that various structures and mechanisms are in place in primary 
care to facilitate and support this demarcation of activities; as Community 
Pharmacist 1 points out with regards to blood testing; 
“They already have a sort of logistical arrangement in place for 
collecting blood samples which are then taken off to the lab and 
then set back. They already have that mechanism in place whereas 
if pharmacists were to be involved in testing, they would have to 
set those kind of arrangements up” (CP 1) 
Here integrating PGx testing processes into community pharmacy practice is 
thought to necessitate significant structural shifts in order that the patient journey 
does not diverge too much from the present model. Community Pharmacist 10 
demonstrates this well; 
“It might be a bit upside down. If we’re doing testing before 
prescriptions then it’d be going to the GPs for what’s wrong with 
you, us for testing, GPs for your script and back to us for the 
drugs. I think it’d need a different way of doing things otherwise 
patients won’t know if they’re coming or going” (CP 10)   
However, this view is based on a model of PGx testing as pre-prescription 
testing. Elsewhere, it has been proposed that pharmacists could become involved in 
PGx testing where this testing is done pre-dispension (Jamie, 2011). In doing so, 
PGx data would be generated during the patient journey when pharmacists play a 
“police man” (PGx 3) role to check for gene-drug interactions in the same way as 
they do now with drug-drug interactions: 
“I can see that [pharmacists using pharmacogenetic data] in terms 
of... interpreting it the same way as they are for drug-drug 
interactions” (PS 4) 
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“They do drug interactions now as a matter of course...I guess that 
will become more sophisticated and might include 
pharmacogenetics” (O 1) 
Although this pre-dispensing model of testing would necessitate fewer 
structural reorganisations of community pharmacy, the cost-effectiveness of 
performing testing (both pre-prescription and pre-dispension) becomes central once 
again. Here, the challenges centre on pharmacy’s investment in PGx testing products 
without certainty as to whether this process would yield financial returns. This is 
demonstrated by the following quotes; 
“I wonder would it be done often enough. I suppose for it to be 
justified, you’d need to be doing tests hundreds of times a day” 
(CP 1)    
 
“Some of the community pharmacists the testing would need to be 
common enough to make it worth their while to invest in doing it. If 
they only had one patient on a particular drug and they had to buy 
in a piece of kit to do a test on that individual” (PGx 5) 
An additional logistical challenge in integrating PGx into community 
pharmacy is around the extent of information to which community pharmacists have 
access. Chapter Six demonstrated that the restriction of patient medical records 
underpins much of the medical technocracy in primary care settings. The data 
suggest that introducing genetic information into community pharmacy would 
necessitate increased medical record access; 
“You cannot access a patient’s data or medical information, at 
least nothing to do with their health...So as it is, that’s already a 
drawback so if you were to try and introduce a system where 
you’re introducing genetic data across the nation, I think that 
would be a big challenge” (CP 1) 
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Here, access to the patient medical record can be understood as a way in 
which community pharmacists would be able to manage the increasingly complex 
patient body. As detailed above, the implementation of PGx into community 
pharmacy creates a more complex and molecularised patient body and Chapter Six 
noted that in the hospital setting, the bioclincal collective gaze enacted through 
shared medical records is central to the management of risky secondary care patient 
bodies. Given this, then, as PGx information reconfigures a more complex and 
potentially toxic primary care patient body, increased access to medical records is 
understood as a way through which this can be managed.  
 
A final ‘macro’ challenge in integrating PGx into community pharmacy is 
identified in the data as being the education of community pharmacists in 
(pharmaco)genetic principles. In 2003, the Human Genetics Commission (2003) 
highlighted the need for a ‘genetically literate’ primary care workforce to manage the 
increasing presence of genetic principles in medical care. In the same year, Burton 
and Shuttleworth (2003) argued that although pharmacy undergraduates were in 
receipt of genetic training, the principles of genetics were not prioritised in 
preregistration training or professional development. Given this, the data suggest that 
whilst relatively newly trained pharmacists are fairly familiar with genetics, those 
who have been practising for some years are less knowledgeable in this area; 
“My generation of pharmacist are probably not very familiar at 
all. Now, whether some of the younger ones cover more of this in 
their undergraduate course; I would imagine that they probably do 
and so they would probably be a lot more familiar” (CP 2) 
 
“I think you’ll find that the crusty old school members of staff like 
myself pharmacogenetics is pretty much a mystery” (HP 1) 
 
“The schools of pharmacy now do teach it to some extent and some 
of them quite a lot but before that there’s a whole two generations 
of pharmacists who haven’t had much exposure” (MTC 1- also a 
previous HP and CP) 
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This creates what we might call a ‘generational knowledge gap’ which might be 
translated into differences in the quality of care across different pharmacies. 
8.13.2 Integrating PGx into Community Pharmacy: ‘Micro’ Challenges 
In addition to these ‘macro’ challenges which are presented in the data as relating to 
the structure of the pharmacy profession as a whole, a number of ‘micro’ challenges 
are also identified in the data. These micro challenges are characterised as those 
which may affect the everyday working practices of community pharmacists and, 
similarly, be resolved within these everyday routines rather than through national 
initiatives as is the case with the macro challenges outlined above. As such, these 
micro challenges are highly related to the pharmacy gaze and the medical 
technocracy of primary care.   
 
To begin with the data present the medical technocracy within which 
community pharmacy is practised as being central to the demarcation of roles and 
expertise in PGx. As such, it is imagined that PGx work activities will primarily be 
undertaken by GPs and the practitioners with whom they are co-located in surgeries. 
In this way the higher status of GPs can be maintained through the (re)production of 
practice boundaries around decision-making and responsibility. In other words, PGx 
is discursively located within clinical decision-making which is the domain of GPs 
(as the practitioners who diagnose and prescribe) rather than pharmacists; 
“I still think it’s probably going to be done more at the GP ends of 
things” (PS 3) 
 
“The prescriber would have already have taken responsibility for 
that sort of thing [genetic information] and that level of screening” 
(CP 1) 
 
“That information would need to be fed back to the GP, if the GP 
is responsible for prescribing” (PGx 3) 
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In this way, PGx can be understood as a set of expertise and technologies 
through which GPs are able to retain their higher status position in primary care. 
Community Pharmacist 3 suggests that pharmacists undertaking PGx work may be 
understood as something akin to boundary encroachment; 
“It’s their territory ultimately...some of the stumbling is because 
we are imposing on their territory” (CP 3) 
Here, resonances with Serra’s (2010) notion of a medical technocracy can 
clearly be seen. Serra argues that a medical technocracy is created by the conquering 
of a set of technologies and expertise by one group of practitioners. In this quote, 
Community Pharmacist 3 suggests that GPs may conquer PGx products and 
processes to define PGx as part of their professional role or “territory”. In doing so, 
the medical technocracy in primary care is reproduced.  
 
May and Finch’s (2009) notion of ‘skill-set workability’ also becomes 
relevant here. They argue that skill-set workability refers to the distribution of a 
practice within a division of labour. In the case of teledermatology, they note that 
this practice ‘was appropriate to the skills of nurses administering it’ (p. 545). In the 
case of PGx in primary care it can be understood that PGx practices are defined in 
the data as better suited to the diagnostic skill-set of GPs than the dispensing skill-set 
of pharmacists. In this way, PGx may be more workable in GP work than in 
pharmacy.  
 
This relates to another micro challenge of contextual integration of PGx in 
community pharmacy. As detailed in Chapters Two and Six, a key part of the 
community pharmacy professional identity is the retail aspects of practice. 
Elsewhere this has been identified as a central part of the ‘incomplete’ 
professionalisation of community pharmacy because of pharmacists’ motivations 
being heavily geared towards profit generation rather than altruistic practice (Denzin 
and Mettlin, 1968). The data suggest that this retail model of community pharmacy 
organises practice in a relatively corporate way where the focus of work activities 
centres on income generation from high volumes of dispensed prescriptions and 
retail activities as the following quotes demonstrate; 
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“Pharmacy is basically funded on a volume-based model. That is, 
the more prescriptions you do, the more you get paid” (CP 1) 
 
“With [large multiple pharmacy company] it seemed to be more 
corporate, more geared towards the retail... it was a lot more 
target-drive. So part of the bonus structure ... would be around 
promotion or selling particular products” (CP 4) 
Community Pharmacist 4’s quote suggests that the organisation of work in 
large multiples tends to be more corporate than that in smaller companies or 
independent pharmacies. As such, in large multiples, pharmacy is often co-located 
with non-health retail work given that the latter is understood to generate more profit 
for the company, as Community Pharmacist 10 highlights; 
“Your Boots and the like make their money from selling perfume 
and lipsticks and loo roll rather than pharmacy. So pharmacy’s 
stuck at the back of the shop with the make-up stands at the front 
flogging the high profit stuff” (CP 10) 
Given this, the data suggest that large multiple pharmacies are unlikely to be 
interested in adopting PGx; 
“A lot of them are employed pharmacists by big organisations and 
unless it’s more cost-effective than sticking labels on bottles and 
boxes, their employers won’t let them do it” (PS 2) 
“I don’t think some of the large companies have that much interest. 
They’re more a retailer than a clinical service so unless there’s a 
massive profit involved in it for them I’m not quite sure what the 
drivers are for them” (PS 3) 
Given that everyday work routines in community pharmacy (particularly 
large multiples) are organised around retail activities, the integration of PGx 
processes into these routines presents a significant challenge in the context of the 
current structure of everyday community pharmacy work. Generally, most 
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community pharmacies employ one pharmacist and a number of support staff. The 
data suggest that the “target-driven” (CP 4) nature of pharmacy practice in large 
multiples places pharmacists under significant time pressures. Hence, integrating a 
new set of PGx products and processes would be challenging; 
“The other [challenge] is actually getting physical time to do it 
because they’re so tied up in the dispensing process that they’re 
not available to actually do all this stuff” (PS 2) 
 
“It’s not so much a lack of interest but more a lack of time to learn 
and understand these things” (CP 1) 
 
“It’s not something that at the moment I have time to pay much 
attention to” (CP 2) 
Pharmacy Stakeholder 2 notes that the integration of PGx processes into this 
retail context may require a new model of practice where two pharmacists are co-
located in one pharmacy with one undertaking dispensing work and the other more 
clinical (including PGx) work; 
“If you were to do these kind of services, you really need ideally 
two pharmacists in a pharmacy; one making sure the dispensing 
process carries on easily...and the other freed up to do these more 
clinical services” (PS 2) 
This, however, is understood to be a model which would not “stack up” (PS 
2) in contemporary community pharmacy practice given the high cost of employing 
pharmacists. Moreover, Community Pharmacist 3 notes that the employment of 
additional staff would be particularly challenging in independent pharmacies who 
tend to offer fewer clinical services; 
“Overall most of the independent pharmacies tend to stick to just 
providing the essential services and they’re not quite geared up to 
providing the advanced and the enhanced services which involves 
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a lot more training and skills to provide those extra services” (CP 
3)  
A third challenge of integrating PGx into everyday routines centres on the 
logistics and ethics of handling PGx information in the community pharmacy setting. 
On one level, the data suggest that pharmacy IT systems are not equipped to store 
such personal information;  
“Genetic testing... involves a kit of personal data and trying to 
store all the data on to a system is quite scary and quite 
frightening” (CP 3) 
On another level, the confidentiality of genetic information on a community 
pharmacy computer is also identified as a potential challenge where 
Pharmacogeneticist 2 questions “you’re dealing with DNA so will there be 
confidentiality there?”. Given the number of people working within a community 
pharmacy, the challenge is identified as restricting access to genetic information to 
pharmacists only; 
“I don’t know how it would work with different members of staff. 
So would different member of staff have difference access?” (CP 4) 
 
“This goes back to this trust thing....they [GPs] don’t trust a 
terminal could be in a pharmacy and that people aren’t going to be 
looking over your shoulder and seeing other patients’ and 
neighbours’ records” (PS 2) 
 
“You would need to ensure that the patient record could only be 
seen by the pharmacist and potentially the patient” (MTC 1- also a 
previous HP and CP) 
Pharmacy Stakeholder 2’s quote highlights, again, the importance of the 
medical technocracy in which community pharmacy is practised. Within this, 
personal (genetic) information which would be contained within the patient medical 
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records is regarded as being the responsibility of GPs. Moreover, the above quotes 
highlight the disparity in approaches to multiple clinical gazes between hospital and 
community settings. As Chapter Six noted, in the hospital setting a narrative of the 
patient body is developed through multiple and diverse practitioners accessing and 
contributing to the patient medical record. Through this, it is argued, the patient body 
becomes subject to what I have called a ‘bioclinical collective gaze’. In contrast to 
this, Community Pharmacist 4’s quote demonstrates a resistance to this development 
of a bioclinical collective gaze in the community pharmacy setting.  
 
These concerns about personal (genetic) information in the community 
pharmacy setting highlight the nature of the contemporary community pharmacy 
gaze and the potential changes to it brought about by PGx. The current community 
pharmacy gaze is centred on a non-molecular patient body which is not linked with 
personal information. As such, practice structures (such as IT systems) do not 
facilitate the accommodation of such personal information given that this is not 
central to current practice. As is shown above, PGx may reconfigure the community 
pharmacy gaze around a more molecularised body which is intrinsically linked with 
the genetic information found within it.  The challenge arises, then, from the 
integration of molecular information into a non-molecular construction of the patient 
body which characterises the contemporary community pharmacy gaze.   
8.13.3 Discussion: ‘Macro’ and ‘Micro’ Challenges of PGx in Community 
Pharmacy 
This ‘macro’ and ‘micro’ characterisation of the challenges of integrating PGx into 
community pharmacy practice highlights the ways in which the ‘scope’ of evaluation 
work shown in Figure 3 is carried out. As such, the different scopes of evaluation 
highlight the different levels at which challenges occur and will come to be 
addressed. As mentioned, however, these challenges are not discrete and there are a 
number of overarching themes which marry the macro and micro challenges. Figure 
4 highlights the key themes of finance, expertise and structure in these macro and 
micro challenges. Moreover, Figure 4 shows the ways in which macro and micro 
challenges are related to each other through these overarching themes.  
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As an example, Figure 4 shows the way in which the theme of expertise 
encompasses a number of primary (block line) and secondary (dotted line) 
challenges. Here it is shown that the macro challenge of pharmacists’ education in 
the area of PGx and the demarcation of roles in the primary care medical 
technocracy are the primary challenges of this expertise theme. As such, providing 
pharmacists with education in the area of PGx is understood as a challenge to be 
addressed at the professional body level of the pharmacy world, whilst the 
demarcation of prescribing and dispensing roles based on their differential fields of 
expertise, is understood as a challenge for everyday practice and individual 
pharmacists and companies. Figure 4 also shows that the macro challenge of 
pharmacists’ limited access to patient medical records also sits as a secondary 
challenge in this expertise theme as, as Chapter Six noted, the demarcation of roles 
in the primary care medical technocracy is enacted through this limitation of access. 
 
The challenge of medical records access is also shown to be a primary 
challenge presented by the structure of community pharmacy. Also related to this 
structural theme are the logistics of carrying out tests in the community pharmacy 
setting and the demarcation of roles in the everyday work of pharmacists. What this 
demonstrates, then, is that the challenges presented by the implementation of PGx 
into community pharmacy are complex and far-reaching. Figure 4 shows, then, that 
the challenges which are manifested and, thus, addressed, at the level of the 
pharmacy professional as a whole are also linked with those which are manifested at 
the level of everyday pharmacy practice and the pharmacy gaze. What this shows is 
that the challenge of implementing PGx into community pharmacy practice is one 
which is multi-faceted and involves multiple actors across different sectors within 
(and outside of) the pharmacy profession. Chapter Nine discusses this in more detail. 
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Scope of evaluation Macro Challenges Overarching themes Micro Challenges 
Manifested at... Organisational/professional level  Everyday practice/ pharmacy gaze 
level 
    
Addressed by... DoH, RPS, professional bodies  Companies/ individual pharmacists 
    
Challenges Remuneration:  
Who pays for testing? 
Pharmacy funding 
Investment in technologies 
                             Finance (Dis)juncture with retail model: 
Limited autonomy of pharmacists 
 
    
 Education: 
Limited knowledge 
‘Generational knowledge gap’ 
                            Expertise Role Demarcation: 
Pre-prescription vs pre-dispension? 
    
 Quality Assurance: 
Quantification vs binaried tests 
                                                                                                                                                                                                                                                                                                           Structure 
 
 
 
Medical Record Access: 
Increasing access 
Limiting access of pharmacist only 
    
 Logistics: 
Structures for sample collection  
 
 Ethics: 
Confidentiality 
 
Figure 4: Macro and micro challenges of integrating PGx into community pharmacy practice 
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8.14 Conclusion 
In summary, this chapter has built on the dual medicines management model built in 
Chapters Six and Seven to analyse the implementation of PGx in hospital and 
community pharmacy. It is argued that there is a distinction to be made between PGx 
products and PGx processes. Within this, the former offer affordance within a 
formalised, bureaucratised medicines management process as beneficial for practice 
given their ability to predict, and thus manage, non-responsiveness and ADRs. PGx 
processes, on the other hand, are understood at the level of the pharmacy gaze given 
the work undertaken to include new genetic practises with current work activities.  
 
The chapter presents the implementation of PGx into hospital and community 
pharmacy as two discrete processes given the different nature of structure, bodies 
and medications which are practised in these two spheres. It is argued, however, that 
in both of these sectors, PGx may come to reconfigure the pharmacy gaze around a 
more molecularised and complex patient body.  
 
In the community setting, the integration of PGx is presented as a complex 
picture which is highly speculative given the limited impact of PGx on this sector to 
date. The chapter argues that PGx in community pharmacy is highly related to the 
medical technocracy in which community pharmacy practice occurs. As such, the 
most likely model of PGx practice in the community setting is presented as this 
paradigm being grounded in the work of GPs with pharmacists occupying an adjunct 
role if (or when) the delivery of PGx in the community setting becomes too 
challenging for the structure of GP work. Within this, however, the chapter presents 
a number of potential PGx futures around testing, results interpretation and patient 
counselling. These are imagined to reconfigure both the pharmacy gaze and the 
professional identity of pharmacists.  
  
The chapter also presents an analysis of the process of reflexively monitoring 
and integrating PGx into everyday community pharmacy practice. Here, it is argued 
in reflexively monitoring PGx in pharmacy practice, four elements become 
important- the nature, focus, scope and level of evaluations which are shown, in 
Figure 3, to relate to the communal and individual appraisal processes and the dual 
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medicines management process. In this way, it is shown that formalised medicines 
management policies inform formal (nature) evaluations of PGx products (focus) at 
the macro-level (scope) of the pharmacy world by its professional bodies (level). 
Concurrently, more negotiated medicines management practice enacted through the 
pharmacy gaze inform informal (nature) evaluations of PGx processes (focus) at the 
micro-level (scope) of pharmacy by individual pharmacists in their everyday practice 
(level). Figure 4 expands on this and explores individual challenges presented by the 
implementation of PGx into community pharmacy practice and argues that within 
this, three overarching themes emerge - finance, expertise and structure.  
 
Chapter Nine explores in more detail the complexities highlighted in this 
chapter vis-a-vis the integration of PGx into pharmacy. This chapter, thus, brings 
together the empirical work presented in Chapters Six, Seven and Eight to address 
the key questions and challenges for pharmacy and health policy makers in terms of 
integrating personalised medicine. In doing so, Chapter Nine questions the value of 
PGx and locates these questions within wider health policy foci. To conclude, 
Chapter Nine makes a series of recommendations based on this empirical work.  
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Chapter Nine: Concluding Discussion 
9.1 Introduction 
Pharmacists are key actors in the UK healthcare system and a central part of the 
patient experience of health and illness. With the recent extensions to their 
professional role into more clinical work activities pharmacy practice has been re-
located away from the dispensary onto the shop floor (in the case of community 
pharmacy) and to the patient bedside (in the case of hospital pharmacy). This has 
generated new ways in which pharmacists interact with medicines and patients. 
Despite this, there has been relatively limited sociological attention given to 
pharmacy practice, particularly in the hospital setting where the high degree of 
clinical focus and the absence of retail work has not generated the same questions of 
professional identity, role strain and subordination as in the community setting (see 
for example, Cooper et al., 2009; Denzin and Mettlin, 1968; Edmunds and Calnan, 
2001; Rapport, 2010).  
 
Running concurrently to the recent changes in the work of pharmacists has 
been the development of the field of PGx, otherwise referred to as ‘personalised’ or 
‘stratified’ medicine. This field of practice, which is concerned with genetically-
determined drug response variability, was seen as one of the key applications of the 
data and technologies arising from the HGP although a personalised approach to 
therapy and practice is shown in Chapter Three to sit within a longer history of 
medical practice and therapeutics. As such, PGx has been described as potentially 
‘making a major impact in commercial labs and in the clinic’ (Webster et al., 2004: 
663) and has been identified in UK health policy as important to the future of safe 
and effective medicines and healthcare services (Department of Health, 2003a).  
 
PGx, then, is concerned with better targeting medicines in order to gain 
maximum efficacy with minimal adverse events. Given this, PGx is well aligned 
with the discourses of medicines management (more latterly medicines optimisation) 
which underpin pharmacy practice and these links between PGx and pharmacy 
practice have been discussed elsewhere (see Akhtar, 2002; Clemerson et al., 2006). 
Despite Ryan et al.’s (2004) assertion that pharmacy is likely to be at the ‘forefront’ 
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of PGx medicine and, as such, a sociological analysis of this is necessary, little of 
these papers have characterised the relationship between PGx and pharmacy from an 
empirically-informed sociological perspective.  
 
As such, this thesis has addressed this gap in the literature by drawing on data 
from 38 semi-structured interviews with diverse practitioners to examine the 
potential impacts of PGx on pharmacy practice in sociological terms. Moreover, this 
thesis has presented a sociological characterisation of both community and hospital 
pharmacy and the similarities between them where previous sociological work on 
pharmacy has tended to treat these two sectors as wholly separate areas of practice.  
 
This concluding chapter draws together and reflects upon the key 
contributions of this thesis. In doing so, this discussion reflects on the sociological 
characterisation of contemporary pharmacy practice presented here and what 
implications this might have for sociologists examining pharmacy practice in the 
future. Within this, the dual medicines management framework proposed in Chapter 
Six and mobilised subsequently in Chapters Seven and Eight is drawn out as a theme 
intersecting pharmacy practice in both hospital and community settings. This 
framework is also offered as a model through which the integrating of PGx in 
pharmacy may be understood. To do this, this chapter revisits Table 10 (see end of 
Chapter Seven) but expands it to include the particularities of PGx in hospital and 
community pharmacy. This chapter also reflects on some of the limitations of the 
current study and concludes by making a number of policy recommendations for 
integrating PGx into pharmacy.   
9.2 Sociological Characterisation of Pharmacy Practice 
To begin with, a key contribution of this thesis is the development of an overview of 
contemporary pharmacy practice in which both community and hospital practice are 
taken into account. In order to effectively analyse the integration of new 
technologies, specifically PGx, into pharmacy practice, Chapter Six argued that it is 
vital to present a sociological overview of the contemporary pharmacy ‘world’ into 
which they may be implemented. Previous sociological work in the area of pharmacy 
has examined a wider variety of aspects of pharmacy practice, such as pharmacist-
275 
 
patient interaction (Nguyen, 2006; Pilnick, 1998; Pilnick, 2003), inter-professional 
communication (Cooper, 1993; Hughes and McCann, 2003) and professional status 
(Birenbaum, 1982; Denzin and Mettlin, 1968; Edmunds and Calnan, 2001), but these 
works have tended to treat community and hospital pharmacy as two fairly discrete 
landscapes owing to the highly divergent structures, work activities, patients and 
medications which are present in each. As such, studies of pharmacy practice have 
tended to be concerned with analysing either community or hospital practice, which 
has meant that a sociological overview of the whole field has been neglected. 
 
In contrast to this, this thesis has treated these two sectors of work as, it could 
be understood, two sides of the same practice coin. As such, it has been argued that 
whilst the everyday experiences of practising in community and hospital pharmacy 
settings are divergent, there are a number of elements and approaches which 
intersect the two sectors and characterise the profession as a whole. It has been 
argued that whilst community pharmacy practice can be understood in line with 
Serra’s (2010) notion of a ‘medical technocracy’ given the subordination of 
pharmacists to GPs, hospital pharmacy practice is more appropriately characterised 
using Rabeharisoa and Bourret’s (2009) notion of a ‘bioclinical collective’ given the 
degree of collaboration and multi-disciplinarity in the hospital setting. Further, the 
thesis has presented the nature of medications and patient bodies which are present 
within each pharmacy practice setting as being a central difference in structures of 
everyday practice. In this way, community practice is centred on chronically ill 
patient bodies to which relatively simple medications are administered whilst 
hospital practice is focused on acutely ill patient bodies to which complex and more 
toxic medications are administered. 
 
Despite these differences effective medicines management has been 
identified as central to practice in both community and hospital pharmacy practice 
where the management of risk and optimisation of treatment are found in both 
formalised codified medicines management policies and in everyday practice. This 
is, then, the core framework of the dual medicines management model which is 
presented in this thesis as characterising both community and hospital pharmacy 
practice.   
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9.3 Dual Medicines Management Model 
This dual medicines management model has been presented here as central to both 
hospital and community pharmacy practice. It is argued that formalised, codified 
medicines management practices are enacted alongside more negotiated practices in 
everyday work and interaction. Within this, formalised medicines management is 
centred on organisational interests in medicines safety and efficacy and is practised 
in line with governmental and institutional policies. As such, the optimisation of 
medicines in this vein is concerned with, for example, the reduction of ADRs and the 
maximisation of efficacy for the benefit of the hospital or primary care organisation. 
Concerns around staff resource efficiency and waiting times have been shown here 
to be central in this organisationally-focused medicines management approach. 
Running concurrently to this, it has been argued, is a more negotiated practice of 
medicines management which is enacted in everyday work activities through what 
has been called here the ‘pharmacy gaze’.  
 
 This pharmacy gaze is presented in Chapter Six as being the specific way in 
which pharmacists, as medications experts, co-construct patients and the medications 
which are administered to them. It is argued, then, that the ontology of drugs comes 
into being through its relationship with, and (potential) impacts upon the patient 
body. As such, medications are made culturally meaningful (in much the same way 
as Dingwall and Wilson (1995) described) through being constructed as risky and 
potentially harmful pharmacological agents. Simultaneously, the patient body to 
which they are administered is also made meaningful through being constructed, and 
thus ‘gazed’ at, as an at-risk medications using body. Around this co-construction 
process, then, what has been called here a ‘discourse of toxicity’ is created where 
medications and the patient bodies to which they are administered are positioned 
within terms of toxicity which need to be managed by pharmacists whose expertise 
are in medicines and their associated ‘stuff’  (Barber 2005).  In the hospital setting, 
the patient medical record has been shown to be of central importance to the 
pharmacy gaze through the emergence of a collaboratively-constructed history, 
geography and narrative of the patient body (Berg and Bowker, 1997). Here, this has 
been referred to as the ‘bioclinical collective gaze’, which encapsulates the diversity 
of practitioner gazes which are recorded in, and mobilised through, the hospital 
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patient medical record. This importance of the patient medical record is discussed in 
more detail below.  
 
 This novel concept of the pharmacy gaze takes Foucault’s notion of the 
‘clinical gaze’ and Barber’s (2005) ‘pharmaceutical gaze’ as its points of departure. 
Unlike Foucault’s clinical gaze, however, the power dynamics between pharmacists 
and the patient body are not centralised. This is not to say that the power 
relationships between pharmacists and patients is not of sociological interest but the 
focus of the research here did not generate an analysis of practitioner power in the 
pharmacy setting. Perhaps, as is suggested below, such a Foucauldian analysis of 
these power relations in pharmacy may be forthcoming in future (also see Ryan et 
al., 2004).  
 
The pharmacy gaze departs from previous work in the area of the sociology 
of pharmacy as it places the patient body at the centre of the analysis of pharmacy 
practice. Within this, it is argued that pharmacists cultivate a particular way of 
looking at, and understanding, the patient body based on their expertise as 
medications experts. Previous sociological analyses of pharmacy have neglected the 
patient body as a site through which medications become cultural objects. Dingwall 
and Wilson’s (1995) seminal paper shifted sociological understandings of pharmacy 
practice to centralise its role in ascribing cultural meanings to inert chemical 
compounds and, thus, symbolically transforming them into the social objects of 
drugs. Analyses arising from this cultural understanding of pharmacy practice, 
however, have failed to take into account that it is through medications’ relationship 
with the patient body that they take on their cultural meanings as, for example 
‘harmful’ or the ‘most appropriate’. Similarly, Barber’s (2005) Foucauldian notion 
of the pharmaceutical gaze focuses on the ability of pharmacists to ‘see’ the 
properties and potential toxicities of medications but does not account for the patient 
body in which these properties and toxicities are manifested. As such, the pharmacy 
gaze presented here, emphasises the co-construction of both medications and the 
patient body to which they are administered.  A central tenet of the pharmacy gaze 
perspective, then, is that medicines management practices cannot be fully analysed 
without an analysis of the patient body to which medications are administered and 
within which the effects (both harmful and otherwise) are manifested.  
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 As well as offering a framework within which to analyse contemporary 
pharmacy practice in community and hospital settings, the dual medicines 
management model provided an analytical tool for examining the definition and 
integration of new technologies in pharmacy practice.  
9.4 Dual Medicines Management and New Technologies 
Chapters Seven and Eight demonstrated that the dual medicines management model 
posited in Chapter Six is useful for understanding the ways in which new 
technologies and PGx specifically, are defined and integrated into pharmacy practice 
across different settings. Some components of May and Finch’s (2009) NPT, which 
focuses on the micro-level interactional work undertaken to integrate new 
innovations into routine practice, were also shown to be important. Within this, the 
process of defining new innovations through May and Finch’s (2009) notion of 
‘coherence’ work was shown to be highly related to the dual medicines management 
model where new innovations are defined through both aspects of the medicines 
management model- formalised, codified policies and more negotiated everyday 
practice enacted through the pharmacy gaze. Through exemplifying a number of 
recent innovations in community and hospital practice (mAbs, pharmacy robotics, 
electronic patient records, pharmacy computers for labelling practices and testing 
and monitoring devices), it was argued that defining new innovations in hospital 
settings focuses heavily on the organisational interests in medicines management 
whilst innovations in community practice are more readily defined through their 
application to more negotiated medicines management processes through the 
pharmacy gaze.  
 
  May and Finch’s (2009) notion of ‘reflexive monitoring’ has also been 
shown to be useful for understanding the ways in which pharmacists undertake 
evaluative work through both formalised, communal appraisal processes and more 
negotiated individual appraisal processes. Table 10 in Chapter Seven demonstrated 
the ways in which these communal and individual reflexive monitoring processes 
map onto the dual medicines management model where communal appraisal is 
carried out in line with formalised, codified medicines management and individual 
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appraisal is carried out through everyday practice and the constructs of the pharmacy 
gaze and the discourse of toxicity.  
 
 In addition to these more general technologies in pharmacy, the thesis also 
employed the dual medicines management model and some elements of May and 
Finch’s NPT to analyse the particularities of PGx in pharmacy.  
9.5 PGx and Pharmacy 
PGx has been subject to some sociological commentary around the implications it 
might have for doctor-patient relationships (Lehtinen and Kääriäinen, 2005; Pilnick, 
2002; Pilnick, 2004), implications for family and kin (Cox and McKellin, 1999; 
McLaughlin and Clavering, 2011; Weiner, 2011) and racialised medicine and 
research (Ellison et al., 2008; Smart et al., 2006; Smart et al., 2008; Tutton, 2004; 
Tutton, 2007b; Tutton et al., 2008). However, no sociological work has focused on 
the potential implications of PGx on pharmacy practice in hospital and community 
settings, despite being identified by Ryan et al. (2004) as sociologically important.  
 
When analysing the integration of PGx into hospital and community 
pharmacy practice, the dual medicines management model, once again, has been 
shown to be of central importance. Also of note is the disparity between the process 
of integrating PGx into hospital and community pharmacy. Here, then, the 
differences between the patient bodies and medications which are central features of 
practice in these two settings become apparent. Thus, the chronically ill patient 
bodies to which community pharmacists dispense relative simple, low toxicity 
medications and the acutely ill patient bodies to which hospital pharmacists dispense 
fairly complex, high toxicity medications construct different ‘stories’ around the 
understanding and integration of PGx. Nonetheless, the principles of the dual 
medicines management model and May and Finch’s (2009) NPT can still be seen as 
intersecting the PGx story in both pharmacy settings.  
9.5.1 PGx and Hospital Pharmacy  
Chapter Eight demonstrated that hospital pharmacists are relatively knowledgeable 
about PGx. This is understood to be, partly, due to the co-located and collaborative 
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nature of the bioclinical collective structure of hospital pharmacy practice where the 
transfer and sharing of knowledge around PGx principles is easier than in the 
community setting. Despite this fairly high level of knowledge, PGx is not currently 
a routine part of all hospital pharmacists’ routine work activities. It is shown, 
however, that a PGx approach is increasingly ‘normalised’ within Oncology practice. 
That is to say that the molecularisation of the patient body and the medications 
which are administered to treat it is something of a normalised ‘style of thought’ 
(Fleck, 1973) in Oncology practice. It is argued that this is due to the nature and 
toxicity of patient bodies and medications which characterise Oncology practice.  
Within this, then, the cancer patient body is understood as particularly complex and 
the high toxicity medications which are used to treat it are constructed as particularly 
risky. Hence, cancer patient bodies and medications are understood to require careful 
management through the bioclinical collective gaze (most commonly enacted 
through Oncology multi-disciplinary teams). One way in which this careful 
management is enacted is through the molecular construction of the body and its 
medications through, for example, molecular diagnostic and PGx testing. It has been 
argued that in doing this, the cancer patient body is constituted in algorithmic terms 
as a series of criteria which feed into prescription decisions.  
 
The PGx ‘story’ in hospital practice is understood to universally begin with 
its integration in Oncology and subsequent adoption in other fields with relatively 
high toxicity medications. In this way, PGx products in the hospital setting are 
defined through formalised, codified medicines management policies as a way in 
which the time and financial burden of ADRs could be reduced by reducing the 
number of patients being admitted to hospital due to ADRs or experiencing ADRs 
during their stay. Hence, the ‘promises’ (Hedgecoe and Martin, 2003) created around 
PGx artefacts (testing devices and their outputs) are argued in Chapter Eight to align 
with the organisational interests in reducing ADRs and it is through these terms that 
PGx is defined as useful for hospital practice. 
 
Running concurrently to this formalised, organisational definition of PGx 
products is the coherence of PGx processes at the more negotiated level of everyday 
practice enacted through the pharmacy gaze. Here, there is an important distinction 
between PGx products and processes (Damanpour, 1996). Based on the findings 
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from the empirical data, it has been proposed that there is a distinction between PGx 
products and PGx processes where the former are cohered and integrated at the level 
of organisational, formalised medicines management whilst the latter affect the 
organisation of everyday practice and the pharmacy gaze. Hence, PGx processes 
refer to the shifts in everyday practice necessary to accommodate PGx testing and 
data. Chapter Eight demonstrated that PGx testing reorganises pharmacy work 
around a new set of artefacts which configure an increasingly molecularised patient 
body. Within this, the hospital pharmacy gaze and the discourse of toxicity which it 
generates are reconfigured around a more molecularised patient body where the 
discourse of toxicity is reconstructed around increasingly molecular information. It 
was argued that this also reconstitutes the patient body and its relationship with risk 
and ADRs. As such, whilst the pharmacy gaze generally constructs the patient body 
as an at-risk subject within which ADRs are generated by the risky object of 
medicines, what might be called a ‘pharmacogenetics gaze’ constitutes the body 
(owing to its genetic composition) as a risky object, itself generating risk and 
toxicity. In other words, through PGx testing and this ‘pharmacogenetics gaze’, the 
body is shifted away from its being understood as an inactive subject within which 
ADRs occur and is, instead, understood as an active biological object whose genetic 
composition can contribute to adverse events. In managing this, it was argued that 
PGx testing constructs the body in algorithmic terms where prescription decisions 
are made based on a set of criteria through which the body and medications are made 
meaningful.  
 
It has been shown throughout this thesis that PGx has made relatively limited 
impact outside of hospital practice due to the comparatively low toxicity medications 
and unproblematic ADRs in primary care. Nonetheless, as well as the importance of 
genetics in primary care drug ADRs (Grice et al., 2006) and the centrality of PGx to 
Warfarin (Wadelius and Pirmohamed, 2006), the (potential) integration of PGx into 
community pharmacy is both clinically and sociologically interesting.    
9.5.2 PGx and Community Pharmacy 
In the community setting it was argued that there is a limited degree of knowledge 
about PGx amongst practitioners given the medical technocractic and isolated 
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structure of practice which means that the transfer and sharing of knowledge is less 
easy than in the hospital setting.  Given this, Chapter Eight presented what has been 
called here an ‘early days discourse’ which generates a number of highly speculative 
scenarios for ‘pharmacogenetic futures’ in community pharmacy practice. These 
scenarios were presented as being enacted as part of community pharmacy’s adjunct 
PGx role where pharmacists were imagined to begin taking on PGx activities once 
the provision of this service within general medical practice becomes too 
challenging. In this way, the future integrating of PGx in pharmacy practice was 
argued to be analogous to the provision of flu vaccinations by community 
pharmacists. Moreover, this adjunct role was presented as a way in which the 
medical technocracy within which GPs are the dominant primary care practitioners is 
reproduced through PGx practices.  
 
 The data suggested that the most pervasive imagined ‘pharmacogenetic 
futures’ were around testing services, patient counselling and practitioner and patient 
education. Within this, the extended clinical role of community pharmacists was 
argued to be central to their ability to deliver testing and counselling services whilst 
their position as medications experts places them in a key position to deliver 
practitioner and patient education in the area of PGx. These futures, however, 
suggested something of a universal integration of PGx across all community 
pharmacy settings whereas much of the data presented PGx as being part of a 
specialist community pharmacy practice.  
 
 In a similar way to the hospital setting, PGx is argued to reconfigure the 
community pharmacy gaze and the discourse of toxicity around an increasingly 
algorithmic and molecular construction of the patient body and medications. 
However, a key difference identified between the reconfiguration of the pharmacy 
gaze in the hospital and community settings is the impact that PGx may have on the 
professional identity of pharmacists. In the case of community practice, then, it was 
argued that PGx has the capacity to shift the professional identity of community 
pharmacists away from that of ‘shopkeeper’ (Masongo, 2005) to one based on a 
more technoscientific (Pickstone, 2000) way of knowing the patient body.  
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9.5.3 Reflexive Monitoring and Integration in Pharmacy      
May and Finch’s (2009) notion of ‘reflexive monitoring’ has been employed as a 
useful reference point within this thesis in capturing the process of evaluating PGx in 
pharmacy at both levels of the dual medicines management model. As such, May 
and Finch’s (2009) ‘communal appraisal’ has been argued to be related to 
formalised, codified medicines management policies whilst ‘individual appraisal’ 
has been shown to be carried out at the more negotiated level of everyday practice 
enacted through the pharmacy gaze. Once again, the divergence between PGx 
products and processes was shown to be important. Here, communal appraisal of 
PGx products was argued to take place through national activities and networks, 
such as the Cancer Network and clinical trials, within which whether and how PGx 
products are useful for everyday practice are evaluated. It was argued that following 
this communal appraisal work at the national level, micro-level interactional work 
becomes concerned with PGx processes and the reorganisation of everyday practice 
around them. It is argued here that the outcomes from this communal and individual 
appraisal determine whether PGx products and processes become normalised or not. 
Here, then, links can be drawn with Hedgecoe’s (2008a) clinical usefulness model 
where PGx is appraised as useful and becomes a part of routine practice in some 
sectors (for example, HER2 testing in Oncology) but not others (for example, 
APOE4 testing for Tacrine therapy).  
 
 In the hospital setting, the evaluative work around PGx was presented as 
being highly related to the national evaluative work. As such, PGx products which 
are deemed to be appropriate for treatment were argued to then be implemented into 
hospital practice in a relative top-down manner. In the community setting, this 
evaluative work was argued to be more challenging given the limited impact that 
PGx has made on pharmacy outside of secondary care. The reflexive monitoring 
work was argued to be centred on the challenges that integrating PGx into routine 
community pharmacy practice may present in the future. Here, there were argued to 
be two ‘scopes’ to these challenges; one focusing on ‘macro-level’ challenges to be 
addressed by organisational and policy bodies such as the RPS and Department of 
Health and one focusing on the ‘micro-level’ challenges which affect everyday 
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working practices and are, as such, to be addressed in everyday structures rather than 
by national and organisational bodies.  
 
 The macro-level challenges that have been identified here are centred on four 
key issues; the quality assurance of PGx tests, the financing of PGx testing in 
community, the logistics of delivering PGx services in the community and the 
educational of community pharmacists. Within this, the development of cost-
effective, robust PGx tests which can easily by carried out in the community setting 
have been shown to be of central importance. In addition, the structure of community 
pharmacy within which pre-prescription work are fairly rigidly demarcated as the 
role of GPs, rather than pharmacists, may limit the extent to which pharmacists are 
able to claim legitimate involvement in PGx practices. The education of pharmacists 
in genetic principles is returned to below. The micro-level challenges, similarly, are 
highlighted as centring on four key issues; the place of PGx with the retail model of 
community pharmacy, the positioning of PGx services within the role demarcation 
within the primary care medical technocracy, community pharmacists’ limited access 
to medical records and the ethical challenges of handling confidential patient 
formation within the community pharmacy setting. Here, increased collaboration 
between GPs and pharmacists and increased autonomy of community pharmacists 
within retail settings are understood as central. These, again, are returned to below in 
considering recommendations from this thesis.  
 
 What the analysis of integrating PGx in to both hospital and community 
pharmacy shows is that the themes identified at the end of Chapter Seven vis-a-vis 
other pharmacy technologies once again become important. Hence, the relationship 
between the sector of pharmacy and the scope of a technology, formalised medicines 
management policies and everyday practice enacted through the pharmacy gaze are 
central to understanding the integration of PGx in pharmacy. As such, Table 11 
extends that presented at the end of Chapter Seven as a way to understand other 
technologies in practice, highlighting the ways in which PGx maps on to the dual 
medicines management model.  
 
 In the hospital setting, then, it is shown that the scope of PGx is centred on 
acutely ill, complex patient bodies and the high toxicity medications which are used 
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to treat them. Within formalised, codified medicines management processes, PGx is 
operationalised as a way in which the burden of ADRs is reduced through 
medications’ decreased capacity for toxicity. In this way, patients’ experiences of 
their medications are improved. At the level of everyday practice and the more 
negotiated medicines management practices enacted through the pharmacy gaze, 
PGx is understood as configuring a more molecularised patient body through 
algorithmic prescription decisions. This is understood to make fairly complex 
hospital medications meaningful by better targeting them to patients’ individual 
profiles and needs and, thus, improving their experiences of their medications 
regimes.  
 
In the community setting, the scope of PGx is related to the chronically ill 
bodies and relatively low toxicity medications which characterise this sector of 
practice. It has been argued throughout this thesis that this is the key reason for the 
lack of impact of PGx on community practice. Within this sector, PGx is 
operationalised within formalised, codified medicines management policies as being 
a way through which toxicity and the burden of ADRs can be reduced and patient 
adherence to medications regimes can be increased. At the level of more negotiated 
practice and the pharmacy gaze, PGx in the community setting is positioned as a way 
in which the patient body can become constructed in more molecular terms where 
risk is, as in the community setting, managed through an algorithmic construction of 
the body and its medications. Pharmacists are positioned within this as potentially 
occupying an adjunct role where PGx practice is undertaken when the structure of 
general medical practice is placed under strain by the requirements of PGx. This, it 
has been argued, may shift the professional identity of community pharmacists to 
more technoscientific practitioners (Pickstone, 2000) but has also identified as 
presenting a number of macro- and micro-level challenges as highlighted above.  
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Technology Relationship between pharmacy sector 
and technology scope 
Formalised Bureaucratic Process Everyday Practices (Enacted Through 
the Pharmacy Gaze) 
Pharmacy robotics Sector: Hospital pharmacy  
Scope: Large pharmacy departments; high 
stock levels; high patient numbers; 
complex regimen; high toxicity 
medications 
-Reduces dispensing errors 
-Improves pharmacy efficiency 
-Enables clinical practice; time on wards 
 
-Capacity for human error 
-Increases pharmacists ‘legitimacy’ 
within the bioclinical collective (Barrett, 
2011) 
Monoclonal antibodies Sector: Hospital pharmacy 
Scope: Acutely ill bodies; high toxicity 
medications; targeted therapies  
 
-Decreased capacity for toxicity 
-Reduce burden of ADRs  
-Improve patient medication experience 
-Administration outside of the hospital: 
reduces cost 
-Oncology patients; complex bodies  
-Molecularised gaze and therapies 
-Administration outside of the hospital: 
places medicines in the ‘lifeworld’ 
Electronic patient record Sector: Hospital pharmacy 
Scope; Bioclinical collective gazes; 
complex illness; complex regimen; high 
toxicity medications 
-Improves audit processes 
-Improves medicines management 
-Removes pharmacists from “traffic 
warden duties” (HP6) 
-Brings the patient body into being 
-Constructs of a discourse of toxicity 
around the patient body 
Pharmacy computer- labelling 
practices 
Sector: Hospital and community 
pharmacy 
Scope: Complex regimen (H); high 
toxicity medications (H); chronically ill 
bodies (C) 
-Improves audit processes 
-Improves patient adherence: reduces 
toxicity 
-Symbolic transformation of medicines 
into social objects 
-Places medicines in the ‘lifeworld’ 
-Shifts GP/pharmacist communications 
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Testing and monitoring devices Sector: Community pharmacy  
Scope: Chronically ill bodies; low risk 
medications; public health `focus;  
-Improves public health 
-Reconfigures pharmacists as public 
health professionals 
-Constructs a collective public health 
body 
-Brings the patient body into being 
-Moves practice away from the 
dispensary 
PGx Sector: Hospital pharmacy 
Scope: Acutely ill bodies; high toxicity 
medications; targeted therapies 
-Reduce burden of ADRs 
-Decreased likelihood of toxicity 
-Improve patient medication experience 
-Molecularised gaze/body 
-Algorithmic prescription decisions  
-Improve patient experiences of 
complex medications: makes medicines 
meaningful 
PGx Sector: Community pharmacy  
Scope: Chronically ill bodies; low risk 
medications; explains lack of PGx impact 
-Reduce burden of ADRs 
-Improve patient medication experience 
-Improves adherence 
-Molecularised gaze/patient body 
-Adjunct PGx role 
-Shifts professional identity 
-Macro and micro challenges 
Table 11:PGx technologies in the dual medicines management model 
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9.6 Implications for Future Research 
Limited sociological research exists in the area of pharmacy practice and whilst there 
is a wealth of sociological reflections on PGx, none of this has empirically examined 
the position of pharmacy within the PGx story (Ryan et al., 2004).  As such, this 
thesis has made a novel contribution to these fields by empirically examining the 
potential impacts of PGx on pharmacy practice in both community and hospital 
settings. There are, within this thesis, a number of themes which have been 
highlighted which may be important in future sociological examinations of pharmacy 
and/or PGx.   
9.6.1 Centring the Patient Body 
As mentioned, this thesis has presented something of a novel contribution to 
sociological understandings of both pharmacy and PGx by centralising the body. In 
the case of the former, although the body is a central part of pharmacy practice given 
that it is within the patient body that medications have their effects the patient body 
has been conspicuously absent from sociological examinations of pharmacy practice. 
This thesis has demonstrated, however, that the body is of central importance to 
pharmacists’ medicines management role and is increasingly present through the 
clinical activities which characterise contemporary pharmacy practice, particularly in 
the community setting. Future sociological studies of pharmacy practice, and 
medications or clinical work within it, then, may benefit from an analysis of the 
constitution of the patient body within pharmacy practice and its technologies (this is 
echoed by Ryan et al., 2004). For example, Patrakaki et al.’s (2012) study of EPS in 
community pharmacy is beneficial in terms of understanding the ways in which this 
technology reconfigures the boundaries of community pharmacy practice but the 
patient body which is documented within EPS is markedly absent (see Berg and 
Bowke, 1997). This is in contrast to the findings presented here which suggested that 
the patient medical record, and particularly the collaboratively constructed one, is of 
central importance in configuring a risky and potentially toxic patient body in need 
of expert management.  
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Within this thesis, the pharmacy gaze has been presented as a key way in 
which pharmacists construct and manage the patient body. Further work examining 
the relationship between the pharmacy gaze and the everyday work of pharmacists 
and other healthcare practitioners would be useful to question whether the pharmacy 
gaze is a way of knowing the patient body which is limited to pharmacists or 
whether the pharmacy gaze can be produced and mobilised by other healthcare 
practitioners in their professional interactions with the patient body. Within this 
thesis, the pharmacy gaze is highly linked with the act of dispensing medicines but 
further work into the nature of the pharmacy gaze examining its potential use during 
prescribing practices would be useful.  
 
In the case of PGx, Chapter Three demonstrated that whilst a racialised body 
has been tacitly present in previous analyses of the ethical and social implications of 
PGx, the body is largely absent from analyses of PGx. This thesis has shown, 
however, that PGx has the potential to alter the construction of the body in everyday 
clinical practice by configuring it, and its toxicities, at a more molecular level. Here, 
the thesis has touched upon the notion of a ‘pharmacogenetics gaze’ which 
encapsulates the ways in which PGx (re)constructs patient bodies in molecular, 
algorithmic terms which may be applied to the principles of biomedicalisation 
posited by Clarke et al. (2003). The application of this principle would, perhaps, be 
of value in future sociological examinations of PGx in clinical practice.   
9.6.2 Algorithmic Bodies  
Central to this pharmacogenetics gaze is the (re)constitution of the patient body 
through the outputs from PGx tests. Chapters Seven and Eight demonstrated that 
new technologies in pharmacy increasingly characterise the patient body in 
algorithmic terms where prescription decisions are made based on series of criteria 
and features of the patient body which determine the most or least suitable therapies. 
It has been argued here that PGx represents an additional set of information through 
which patient bodies are molecularised and constituted in algorithmic terms within 
which prescription decisions can be made. Elsewhere, algorithms have been argued 
to be central to the increasingly digital nature of contemporary society (see Beer, 
2009). Despite this, there has been limited sociological work examining the role and 
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position of clinical algorithms in prescription decisions, medicines management and 
the construction of patient bodies. Given the recent sociological interest in digital 
algorithms and their impacts on society, it seems timely for a focus on algorithms 
within the Sociology of Health and Illness and STS.    
 
 Within this, a revisiting of the social life of patient medical records also 
seems imperative. It has been shown throughout the thesis that patient medical 
records, and community pharmacists’ lack of access to them, are central features in 
organising everyday clinical work and expertise. It has been argued that the medical 
technocracy which characterises primary care practice is, in part, reproduced through 
the limitation of pharmacists’ access to patient medical records and, thus, the 
demarcation of roles and expertise. In the bioclinical collective structure of hospital 
practice it has been argued that patient medical records represent the key way in 
which what has been called here the ‘bioclinical collective gaze’ is enacted through 
the collation and mobilisation of numerous practitioner gazes within one 
documentary space. As such, the patient medical record represents a sociologically 
interesting feature of contemporary medical practice which would benefit from 
analysis. Moreover, in the case of pharmacy specifically, a discussion of medical 
records which extends beyond the practice disadvantages brought about by limited 
community pharmacist access would be beneficial. As such, the implications of 
medical record access (in the case of hospital pharmacy) and limitation (in the case 
of community pharmacy) present interesting insights into professional status and role 
demarcation issues which have not been extensively sociologically analysed 
previously.   
9.6.3 Focusing on Power 
This thesis takes Foucault’s notion of the clinical gaze as one of its points of 
departure for understanding the sociality of the patient body within pharmacy and 
PGx practice. Chapter Four noted that Foucault’s concept of the clinical gaze is 
centred on the ways in which discourses and practice constitute patient bodies within 
increasingly medicalised (Lupton 1997) and biomedicalised (Clarke et al., 2003) 
societies. Central to Foucauldian analyses of clinical practice is the notion of power 
where the clinical gaze is understood as a manifestation of disciplinary power in 
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which patient bodies are defined through expertise against an established ‘norm’. 
Despite mobilising the concept of a practitioner gaze, this thesis has not centralised 
power as a key theme in pharmacists’ practice or relationship with the patient body. 
There are a number of reasons for this including (i) power dynamics not being an 
obvious theme emerging from the data, (ii) the bottom-up thematic analysis not 
specifically looking for issues of power and (iii) interviews with practitioners not 
being the best method through which the theme of practitioner-patient power would 
become clear. In other words, the perspectives of practitioners alone (rather than 
those of patients as well) do not readily provide insights into the power aspects of 
pharmacy-patient interactions whilst the application of a bottom-up analytical 
approach means that power as a specific aspect of pharmacy practice was not being 
focused on or found to be pervasive in the data. This absence of the notion of power 
might be considered to be a limitation of the thesis given that much sociological 
work in the area of the body has highlighted power as a key feature of practitioner-
patient relationships (see Pilnick and Dingwall, 2011). However, the novel concept 
of the pharmacy gaze proposed within this thesis provides a potential framework 
within which future sociological studies of pharmacy may understand pharmacist-
practitioner power through the constitution of the patient body (also see Ryan et al., 
2004).  
9.6.4 Optimisation Discourses  
Chapter Two noted that the discourse of ‘medicines optimisation’ is beginning to 
characterise contemporary pharmacy practice following its introduction in a 2010 
Department of Health White Paper. This optimisation discourse is sociologically 
interesting as it centres the patient in medicines decisions and medicines 
management processes where patients are (re)positioned as decisions makers. This 
optimisation discourse can, then, be seen as resonating with the dual medicines 
management model that has been discussed within this thesis where what has been 
called here patients’ ‘extracorporeal space’ (Armstrong 1997) and ‘lifeworlds’ 
(Cribb et al. 2011) are highlighted as important factors in constructing medicines as 
culturally meaningful objects and managing their effective administration, 
particularly in the community setting. This thesis has not mobilised the discourse of 
medicines optimisation as fully as perhaps it might owing to the time of publication 
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of the White Paper. Nonetheless, the principles of medicines optimisation appear to 
be of central importance and would benefit from further sociological investigation. 
  
Here, then, the positioning of patients as decisions makers and experts in 
their own medicines management processes would appear to speak to socio-cultural 
issues such as family, gender, age and race where these socio-cultural issues may be 
central to medicines management and adherence. A methodological approach 
involving gathering the perspectives of patients would seem to be of particular value 
here.  
9.6.5 Industry, Primary Care and Academic Pharmacists 
As mentioned in Chapter One and above, there is relatively limited sociological 
attention given to hospital pharmacy and even less providing a overview of the 
sociological issues intersecting both hospital and community pharmacy. Much less 
attention, however, is given to pharmacists working outside of these two practice 
sectors with pharmacists working in industry, primary care and academia being 
given almost entirely overlooked. Chapter One highlighted that 4.1%, 7.2% and 
2.8% of active pharmacists worked in industry, primary care and academia 
respectively meaning that a significant portion of pharmacists are currently 
employed outside of the two sectors which have received the most sociological 
attention. These sectors of practice, however, potentially raise some interesting 
sociological questions.  
 
Particularly with regards to industrial pharmacists, there are questions here 
around the role of pharmacists engaging in drug production processes where in 
community and hospital practice this production role is imagined to have almost 
entirely disappeared. The location of pharmacists within industry also raises 
questions about the construction of toxicity through a pharmacy gaze at the ‘lab 
bench’ rather than at the ‘patient bedside’. In the case of primary care pharmacists, 
the medical technocracy which has been argued here to typify the majority of 
pharmacy work in the community setting may be tested where the co-location of GPs 
and community pharmacists (along with, potentially, other healthcare practitioners) 
may produce something more akin to a hospital bioclinical collective. Moreover, this 
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co-location also raises questions about the use of space. Whilst previously the 
community pharmacy space has been represented as being a retail space, its co-
location with other healthcare practices may undermine, or reinforce, this 
representation of the community pharmacy space.  
9.7 Recommendations 
There are a number of key professional and policy issues which have emerged from 
this thesis. These issues have been briefly analysed within the empirical chapters in 
this thesis but, nonetheless, also form the basis of a number of recommendations for 
the consideration of pharmacy and health stakeholders and policy makers.  
9.7.1 Cost-effective Testing 
It was shown in Chapter Three that PGx in clinical practice represents a way in 
which medications can be better targeted to patients in order to improve their 
experiences of their medications regimen and reduce the time and financial burden of 
ADRs and non-responsiveness for the NHS. This, however, relies on the production 
of cost-effective tests where the cost of testing is not more expensive than the cost of 
treating ADRs or employing a trial-and-error model. It has been argued throughout 
the thesis that this is the key reason behind the lack of integration of PGx in primary 
care where medications are relative cheap, ADRs are fairly unproblematic and, as 
such, the cost of pre-prescription testing outweighs the costs of employing a trial-
and-error model and dealing with the ADRs which may emerge from it.  
 
 The successful integration of a PGx test into routine practice, particularly in 
primary care, appears, then, to hinge on the development of cost-effective tests 
which offer a relative advantage in terms of medications targeting. This issue of cost-
effectiveness has been, moreover, demonstrated to be particularly pervasive given 
the decreasing cost of genotyping technologies. As such, it can be recommended that 
policy makers engage with cost-effectiveness analyses of PGx technologies whilst 
funding policies focusing on the production of cost-effective PGx testing, 
particularly for primary drugs, might be timely and beneficial for the contemporary 
focus on medicines optimisation.  
294 
9.7.2 Pharmacy Funding      
Also related to this issue of cost effectiveness is the issue of pharmacy funding 
which was identified in Chapter Eight as being a potential challenge to the 
implementation of innovative practices within community pharmacy. Here it was 
shown that because community pharmacy funding is decided annually by the 
Department of Health and Pharmaceutical Services Negotiating Committee, 
pharmacists are relatively reluctant to engage with innovative technologies or 
practices, given their funding status is fairly precarious. It is recommended that this 
annual negotiation of community pharmacy funding is addressed by health and 
pharmacy policy makers. As such, it could be suggested that a shift to a longer term 
funding period may encourage more innovation in community pharmacy and, in the 
light of the research focus here, be central to the securing of a central role for 
community pharmacists in PGx practices. It is recommended, then, that shifting 
pharmacy funding terms to two or three years may be beneficial for both 
practitioners (in terms of providing more occupational stability and opportunities to 
engage with long-term projects and innovations) and patients (in potentially 
providing more innovative practices and clinical services which may, in fact, shift 
community pharmacies to ‘community-based healthy living centres’ in tune with the 
Department of Health (Department of Heath, 2008: 118)).   
9.7.3 Increased Community Collaboration 
Chapter Six demonstrated that the structure of primary care practice makes it 
something akin to Serra’s (2010) ‘medical technocracy’ whilst the collaborative 
structure in hospital settings was characterised in line with Rabeharisoa and 
Bourret’s (2009) notion of a ‘bioclinical collective’. It has been argued throughout 
the thesis that the medical technocratic structure of community practice quite rigidly 
demarcates roles and places pharmacists within a subordinate position in relation to 
GPs. Throughout the empirical chapters it has been argued that this hierarchical 
structure is not beneficial for patients given the limited degree of communication and 
collaboration between different primary care practitioners. As such, pharmacists 
checking and querying prescriptions is somewhat challenging, which Cooper et al. 
(2009) argue may lead to ethically problematic practices in pharmacy. It is 
recommended then, that, increased collaboration between GPs and community 
295 
pharmacists ought to be addressed. There are a number of ways in which this can be 
undertaken such as widening the opportunities for GPs to learn about the role and 
expertise of pharmacists. This could be encouraged early on in the medical career 
trajectory with GPs and pharmacists being co-educated. In addition, monitoring and 
chronic illness projects which GPs frequently undertake might benefit from 
pharmacists’ involvement. Here pharmacists may bring a new set of expertise to 
these projects and, thus, may contribute to improving outcomes. This, once again, 
can be seen as sitting within the contemporary medicines optimisation discourse of 
pharmacy.  
 
 In increasing communication and collaboration between GPs and 
pharmacists, the medical technocratic structure which currently typifies primary care 
practice may be eroded and replaced with something more in line with the bioclinical 
collective structure of hospital work.  
9.7.4 Medical Records 
It has been presented here that patient medical records are central to the construction 
of the divergent practice structures within hospital and community pharmacy 
practice. Hence, it has been argued that whilst the extension of medical record access 
to a diversity of hospital practitioners creates a ‘bioclinical collective gaze’ through 
which the patient body is documented and managed, community pharmacists’ lack of 
medical record access is central to the rigid demarcation of roles and work within the 
hierarchical medical technocracy of community practice. In the community setting, 
the restriction of access to patient medical records is understood as limiting the 
capacity of pharmacists to counsel patients and as reproducing pharmacists’ 
subordinate positioning. As such, the extent to which community pharmacists are 
able to fully engage with medicines management and, more recently, optimisation, 
practices is questionable. Given this, it is recommended that this issue of 
pharmacists’ access to patient medical records is revisited. Chapter Eight noted that 
although the availability of patient medical records in community pharmacy settings 
presents numerous logistical and ethical challenges, one potential solution may be 
the implementation of restricted records containing relevant disease and medications 
history but not personal or sensitive details. This examination of access to patient 
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medical records also seems timely given the contemporary focus on collaborative 
decision making (Cribb et al. 2011) and medicines optimisation.  
9.7.5 Education  
The adequate education of pharmacists in PGx principles is highlighted in Chapter 
Eight as being a significant challenge for the integration of PGx into community 
pharmacy practice. The necessity of a genetic literacy amongst practitioners has been 
identified elsewhere (Human Genetics Commission, 2003) and, in the case of 
pharmacy, this was partly addressed by the establishment of the NGEDC in 2007 
where the education of pharmacists in genetic principles is a specific focus. 
However, the data that has been presented here suggests that there is still a lack of 
knowledge about genetic medicine amongst pharmacists, particularly those who have 
been practising for a number of years (also see Burton and Shuttleworth, 2003). It 
seems timely, then, for the pharmacy profession to examine the provision of genetics 
education as part of both undergraduate curricula and professional development 
programmes. Given that PGx is understood as presenting the ‘next challenge’ 
(Clemerson et al., 2006) for pharmacy practice, it seems imperative that an in-depth 
evaluation of the education provision and educational needs of pharmacists in this 
area is undertaken. 
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Appendix A: Invitation E-mail    
Dear [Participant’s Name] 
 
I am writing to you to see whether I might be able to arrange to see you at a date 
convenient to you sometime over the next few months. I am undertaking a research 
project funded by the Pharmacy Practice Research Trust and the Economic and 
Social Research Council that explores the potential impact and implications of 
pharmacogenetics on hospital and community based pharmacy (see attached 
document). 
 
I am keen to interview people working in the field of [participant’s job role]. This 
involves conducting interviews with [participant’s job role] in order to build a 
comprehensive understanding of the perspectives of [participant’s job role] as [state 
why the participant has been approached]. As a participant in this field, I am keen to 
talk with you about your professional practice and would be very grateful if you 
could spare the time to meet with me at your earliest convenience. 
 
In addition, it would be helpful for the project if you could indicate whether there are 
any of your colleagues who it may be relevant for me to talk to. 
 
I am available [state dates of availability]. 
 
If you could let me know if you are able to meet with me, I will then get back to you 
to firm up a date. The meeting would only take about an hour. 
 
Best wishes, 
 
 
Kimberly Jamie 
 
Doctoral Researcher 
Science and Technology Studies Unit 
University of York 
Heslington  
York 
YO10 5DD 
 
T: 01904 432 632 
E:kj518@york.ac.uk 
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Appendix B: Project Summary  
Attached to Invitation E-mail 
  
 
DEPARTMENT OF 
SOCIOLOGY 
Wentworth College 
Heslington 
York    
YO10 5DD 
Tel (01904) 432632 
Fax (01904) 323043 
Email kj518@york.ac.uk 
www.york.ac.uk/sociology 
 
 
 
 
 
Pharmacogenetics and the Pharmacy Profession: Project Summary 
 
This doctoral research project is funded by the Economic and Social Research Council (ESRC) 
and the Pharmacy Practice Research Trust (PPRT), based at the Royal Pharmaceutical Society. It 
focuses on pharmacogenetic technology (PGx) and its relationship with, and potential impacts 
upon, the pharmacy profession in England at a time when this profession is experiencing major 
changes in relation to support and management of prescribed medicines and a move towards 
independent and supplementary prescribing by pharmacists themselves.  
 
Running concurrently to these changes in the pharmacy profession is the development of PGx, 
which has the potential to revolutionise how medications are produced and prescribed and reduce 
the financial burden of adverse drug reactions (ADRs). The uptake of this technology is likely to 
create greater demands on pharmacists that will require new working practices. Hence, this 
doctoral thesis will understand how the changing professional role of the pharmacists in hospital 
and community settings is likely to affect the uptake of PGx and, within this, what might be the 
specific implications of PGx, as one of the more significant diagnostic tests, for pharmacists 
working in various sectors.  
 
In line with the University of York’s and NHS ethical guidelines, the data from this interview will be 
treated confidentially with your name and details being anonymised so that the responses can not 
be traced back to you. In addition, you are free to withdraw your participation in the study at any 
time and are free to refuse to answer any question during the interview itself.  
 
Please do not hesitate to contact me using the details above if you have any questions.  
 
Kimberly Jamie 
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Appendix C: Follow-up E-mail    
Dear [Participant’s Name],  
 
Please refer to the e-mail below, which was sent on [date of first e-mail]  
 
I am keen to talk with you about your role as [participant’s job role] and I hope you 
are able to find the time to talk with me over the coming months. So far, I have 
secured interviews with a number of other [participant’s job role], and it would be 
great to have your input as well in order to build a fully comprehensive picture of the 
perspectives of professionals in your field.  
 
Just to remind you, the project is funded by the Economic and Social Research 
Council and Pharmacy Practice Research Trust and is being conducted within the 
University of York’s Science and Technology Studies Unit, under the supervision of 
Professor Andrew Webster who is the director of this research unit. 
 
An interview with yourself (or one of your colleagues) would only take around one 
hour.  
 
Please do not hesitate to get in contact with me if you have any questions or queries 
or to arrange a convenient interview time.  
 
Best wishes,  
 
Kimberly Jamie 
 
Doctoral Researcher 
Science and Technology Studies Unit 
University of York 
Heslington  
York 
YO10 5DD 
 
T: 01904 432 632 
E: kj518@york.ac.uk 
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Appendix D: Confirmation E-mail 
Dear [Participant’s Name],  
 
Thank you again for agreeing to take part in my doctoral study on pharmacogenetics 
and the pharmacy profession.  
 
I am contacting you ahead of our meeting as part of the standard social science 
research ethical procedure. I have attached for your information a Participant 
Information document, which gives details of the study and the steps being taken to 
ensure the research is done to the highest ethical standards, and a Consent Form.  
 
At this stage, you do not need to do anything with these documents; I am sending 
them to you at this stage for your information only and I will bring a copy of both to 
the meeting where I will ask you to sign the Consent Form after you have read 
through the Participant Information document and asked any questions that you 
might have. If you have a chance to read through this before our meeting, please do 
not hesitate to get in contact with any questions or queries you may have.  
 
Looking forward to meeting you on [date of interview] at [time of interview].  
 
With best wishes,  
 
 
Kimberly Jamie 
 
Doctoral Researcher 
Science and Technology Studies Unit 
University of York 
Heslington  
York 
YO10 5DD 
 
T: 01904 432 632 
E: kj518@york.ac.uk 
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Appendix E: Participant Information 
Sheet Attached to Confirmation E-mail 
  
 
DEPARTMENT OF 
SOCIOLOGY 
      Wentworth College 
      Heslington 
      York    
      YO10 5DD 
      Tel (01904) 432632 
      Fax (01904) 323043 
      Email kj518@york.ac.uk 
      
www.york.ac.uk/sociology 
 
PARTICIPANT INFORMATION  
 
 
Pharmacogenetics and the Pharmacy Profession in England 
 
You have been approached to take part in a doctoral research project focusing on 
pharmacogenetic technology (PGx) and the pharmacy profession in England. Before you 
consent to taking part, more information about the project, its funding body and projected 
outcomes are included in this information document. Please ask if there is anything which is 
unclear or you require any further clarification.  
 
Purpose of the Study  
 
The aim of this doctoral research project is to investigate how the implementation of 
pharmacogenetic technology will affect the job role of pharmacists at a time when this 
profession is experiencing major changes in relation to support and management of 
prescribed medicines and a move towards independent and supplementary prescribing by 
pharmacists themselves. 
 
Running concurrently to these changes in the pharmacy profession is the development of 
PGx, which has the potential to revolutionise how medications are produced and prescribed 
and reduce the financial burden of adverse drug reactions (ADRs). The uptake of this 
technology is likely to create greater demands on pharmacists that will require new working 
practices.  
 
Hence, this doctoral thesis will understand how the changing professional role of pharmacists 
in hospital and community settings is likely to affect the uptake of PGx and, within this, what 
might be the specific implications of PGx, as one of the more significant diagnostic tests, for 
pharmacists working in various sectors.  
 
Organisation and Funding 
This research is being undertaken as part of a doctoral studentship in the Science and 
Technology Studies Unit at the University of York. The project is funded by the Economic and 
Social Research Council (ESRC) and Pharmacy Practice Research Trust (PPRT), based at 
the Royal Pharmaceutical Society. It is being undertaken under the supervision of Professor 
Andrew Webster, who is head of this research unit.  
 
Outcomes of the Project 
 
This project is a doctoral research studentship, where the ultimate aim is to produce a PhD 
thesis which aims to answer the following research questions;  
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Appendix E: Participant Information 
Sheet Attached to Confirmation E-mail 
 how will developments in technology and patient/medicine management affect the 
occupational status of the pharmacist? 
 will the changing role of pharmacists affect the uptake of pharmacogenetic 
technology? 
 within this, what are the specific implications of pharmacogenetics, as one of the more 
significant diagnostic tests, for pharmacists working in different sectors?   
Given the governmental and academic interest in pharmacogenetic technology, the findings 
from this research will be of interest to a number of parties. Hence, in addition to the 
completion of a PhD thesis, the findings from this project will be disseminated through annual 
reports to the PPRT as the funding partner, presentations to stakeholders in the area of 
genetic research and pharmacy practice and at least one sociologically-driven academic 
paper.   
 
Your Role in the Project 
 
You have been approached as a participant in this project owing to your work [insert details of 
participant’s work]. The delivery of pharmacogenetic technology may involve practitioners 
working in your area and it is therefore imperative that the perspectives and understandings of 
[insert participant’s professional group] are reflected in this study. 
 
The Content of the Interview 
 
What you are being asked to consent to is an informal interview where you will be asked 
about your work as [insert relevant information]. Broadly, the interview will cover your current 
work and your reflections on the implementation of pharmacogenetics into routine medical and 
pharmacy practice. Please feel free to elaborate on any answer or area which you think is 
particularly relevant or important. The interview will take approximately sixty minutes and will 
be recorded on an audiotape and later transcribed for analysis.   
 
Ethics Approval  
This project has been approved by the University of York Ethics Committee and the South 
Yorkshire Research Ethics Committee and has received R&D approval for your NHS site. 
These Committees are satisfied that the following potential ethical problems have been 
addressed; 
 
Consent  
Attached to this document is a consent form, which you will need to sign ahead of the 
interview beginning to acknowledge that you are aware of what the project is about and your 
role within it. You are free to withdraw this consent at any point before, during or after the 
interview, which will mean that any responses you have given will not be used during the data 
analysis. You are also free to refuse to answer any questions during the interview.  
Confidentiality  
All of your responses will be treated in the strictest confidence and will be completely 
anonymised so that anything you say can not be traced back to you personally. In additional, 
any audio files from this interview will be destroyed upon once they have been transcribed.  
Risk 
The nature of this research presents little, if any, emotional or physical to you as a 
respondent. In the unlikely event that you are harmed by taking part in this research project, 
there are no special compensatory arrangements. 
 
Thank you. 
 
Contact Details 
Kimberly Jamie  01904 432 632  kj518@york.ac.uk 
Professor Andrew Webster 01904 434 740  ajw25@york.ac.uk 
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Pharmacogeneticists 
Interview Topic Guide for Pharmacogeneticists  
General Information 
 Background of the research work; 
o What projects are you working on? 
o Where have these projects come from? 
o How long have you been working in the area of pharmacogenetics? 
 Why is this area of work important? 
 What are the expected outcomes of the project? 
 How many group members are working on this project? 
 How is the project structured on a daily basis: is it linked to wider work you 
are doing on this front? 
 
 Are there any other international projects in this disease/drug area?  
o Are any of these other international projects pharmacogenetically-
driven?  
 How much international collaboration takes place between these projects?  
Pharmacogenetics and Clinical Research 
 Have pharmacogenetic principles affected the clinical research environment?
  
o How? 
 How will pharmacogenetics affect the clinical research environment in the 
future? 
 How far away is routine pharmacogenetic drug development? 
Pharmacogenetics and Medical Practice 
 How far away is routine pharmacogenetic medical practice? 
o Is routine pharmacogenetic medical practice desirable? 
o Are there any particular issues that will need to be addressed before 
pharmacogenetics can become a part of routine medical practice? 
What are these? How might they be addressed?  
 How has your pharmacogenetic work been integrated into the NHS/medical 
practice up to this point? 
 What do you think the pharmacogenetic future of medical practice will look 
like? 
o Who will be the key actors in delivering pharmacogenetic medical 
services? 
o How will pharmacogenetic medical service be experienced by 
patients? 
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 Have you any thoughts on the likely wider use/take-up of PGx in the 
pharmacy profession? 
o How do you think hospital pharmacists will be interacting with 
pharmacogenetic technology in the future? 
o What about community pharmacists? 
o How prepared do you think pharmacists are for this sort of medical 
practice delivery? 
o What, if any, roles do you see community and hospital pharmacists 
having in the practice of pharmacogenetic medicine? 
Pharmacogenetic Problems 
 What are the challenges of pharmacogenetic research? 
 What are the drawbacks of pharmacogenetic medicine and pharmacogenetic 
medical practice models? 
 In your experience, how well do you think medical professionals understand 
and are comfortable using pharmacogenetics as a medical model? 
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews?  
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Interview Topic Guide for Oncologists  
General Information 
 Practice background; 
o When did you start practising? 
 Tell me about your work here; 
o What are of oncology do you specialist in? 
o How many staff do you have in your team? How is this comprised? 
 Daily Role; 
o Could you talk me through your main responsibilities and tasks here? 
Technology and Oncology 
 Do you think that new medical technologies have had an impact on the way 
in which cancer patients are treated? 
o If so, which technologies have impacted on your practice personally? 
o If so, which technologies have you seen impacting on your colleagues 
practice or practice in general? 
Genetics and Oncology 
A branch of new medical technology that is often discussed as changing medical 
practice is genetic technology.  
 How much of an impact has genetic technology made on the practice of 
oncology? 
Oncology has been identified as the areas in which pharmacogenetics is likely to 
make the largest and most imminent impact. 
 Has pharmacogenetics had any impact on your oncology practice to date? 
o What about the practice of your colleagues in other specialist areas of 
oncology? 
 What do you think the patient experience of oncology (pharmaco)genetics 
has been? 
 
Pharmacogenetics and Pharmacy 
 What do you think the pharmacogenetic future of medical practice will look 
like? 
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o Who will be the key actors in delivering pharmacogenetic medical 
services? 
o How will pharmacogenetic medical service be experienced by 
patients? 
 Have you any thoughts on the likely wider use/take-up of PGx in the 
pharmacy profession? 
o How do you think hospital pharmacists will be interacting with 
pharmacogenetic technology in the future? 
o What about community pharmacists? 
o How prepared do you think pharmacists are for this sort of medical 
practice delivery? 
Inter-Professional Communication/ Collaboration 
 How much collaboration do you have with the hospital pharmacists here? 
o What about community pharmacists? 
 Do you think pharmacogenetic medical service delivery will alter the 
collaborative working practices in the field of oncology and beyond? 
Pharmacogenetic Problems 
 In your experience, how well do you think medical professionals understand 
and are comfortable using pharmacogenetics as a medical model? 
 What are the challenges of undertaking pharmacogenetic medical practice? 
 How do you think patients understand the process of pharmacogenetic 
medicine? 
 Are there any issues that you think need to be addressed in order for 
pharmacogenetics to become a routine part of medical practice? 
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews?  
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Interview Topic Guide for General Practitioners    
General Information 
 Practice background; 
o When did you start practising? 
 Practice information; 
o How many people work at his practice? 
o Do you have any specialists working here or in collaboration with the 
practice? 
 Daily Role; 
o Could you talk me through your main tasks here?  
o Ho do you divide your time between patients and other duties? 
Technology and General Practice 
 Do you think that new medical technologies have had an impact on the way 
in general practice is delivered to patients? 
o If so, which technologies have impacted on your practice personally? 
o If so, which technologies have you seen impacting on your colleagues 
practice or practice in general? 
Genetics and General Practice 
A branch of new medical technology that is often discussed as changing medical 
practice is genetic technology.  
 How much of an impact has genetic technology made on general practice? 
 Has pharmacogenetics had any impact on your practice to date? 
 How do you think patients understand and experience pharmacogenetic 
medicine?  
 How do you see pharmacogenetic technology developing in the future and 
how will this impact on medical practice? 
o Do you see general practitioners playing a role in the delivery of 
pharmacogenetic medicine?  
o If so, what roles will they have? 
o Will these roles involve any changes to current models of working? 
What changes? 
 How prepared do you think general practitioners are for genetic medicine? 
Inter-Professional Communication/ Collaboration 
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 How much collaboration do you have with community and hospital 
pharmacists? 
o How would you describe your professional relationship with 
community pharmacists? 
 Do you think pharmacogenetic medical service delivery will alter the current 
working practices of general practitioners and pharmacists? 
Pharmacogenetics and Pharmacy 
 What do you think the pharmacogenetic future of medical practice will look 
like? 
o Who will be the key actors in delivering pharmacogenetic medical 
services? 
o How will pharmacogenetic medical service be experienced by 
patients? 
 Have you any thoughts on the likely wider use/take-up of PGx in the 
pharmacy profession? 
o How do you think community pharmacists will be interacting with 
pharmacogenetic technology in the future? 
o How prepared do you think pharmacists are for this sort of medical 
practice delivery? 
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews?  
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Interview Topic Guide for Pharmacy Stakeholders   
General Information 
 Practice background; 
o What’s your role? 
o When did you come to this role? 
 Daily Role; 
o What does your everyday work entail in this role? 
o Do you work within a team of practitioners or researchers? 
Technology and Pharmacology 
 Do you think that new medical technologies have had an impact on the way 
in which pharmacology is practised? 
o If so, which technologies do you think have impacted on practice?  
o Have these impacted on you personally? How? 
Genetics and Pharmacology 
A branch of new medical technology that is often discussed as changing medical 
practice is genetic technology.  
 How much of an impact has genetic technology made on the practice of 
pharmacy? 
 Has pharmacogenetics had any impact on your work to date? 
 How do you think patients understand and experience pharmacogenetic 
medicine?  
 How do you see pharmacogenetic technology developing in the future and 
how will this impact on medical practice? 
 
Pharmacogenetics and Pharmacy 
 What do you think the pharmacogenetic future of medical practice will look 
like? 
o Who will be the key actors in delivering pharmacogenetic medical 
services? 
o How will pharmacogenetic medical service be experienced by 
patients? 
 Have you any thoughts on the likely wider use/take-up of PGx in the 
pharmacy profession? 
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o How do you think hospital pharmacists will be interacting with 
pharmacogenetic technology in the future? 
o What about community pharmacists? 
o How prepared do you think pharmacists are for this sort of medical 
practice delivery? 
Inter-Professional Communication/ Collaboration 
 How much collaboration do you have with practising hospital and 
community pharmacists? 
 Do you think pharmacogenetic medical service delivery will alter current 
collaborative working practices? 
Pharmacogenetic Problems 
 In your experience, how well do you think medical professionals understand 
and are comfortable using pharmacogenetics as a medical model? 
 How do you think patients understand the process of pharmacogenetic 
medicine? 
 Are there any issues that you think need to be addressed in order for 
pharmacogenetics to become a routine part of medical practice? 
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews?  
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Interview Topic Guide for Hospital Pharmacists 
General Information 
 Practice background; 
o When did you start practicing? 
o Have you always worked in hospital pharmacy? 
 If not, what made you move over to hospital pharmacy? 
 If so, have you worked in different ‘types’ of hospitals?  
 Tell me about the pharmacy department here; 
o How many staff are there? 
o How do things work in terms of specialising in a medical field or any 
particular practices that this department has adopted? 
 Daily Role; 
o Could you talk me through your main responsibilities and tasks here? 
o Is this different for any of your colleagues (e.g. those with specialist 
interests or those involved in discreet projects)? Ask for details.  
Pharmacy Profession 
 In the time that you have been practicing, do you think that the pharmacy 
profession has changed in the hospital setting? 
o How? 
 Could you reflect on whether the community pharmacy sector has changed? 
o How? 
 Do you think that patients’ perceptions and understandings of the pharmacy 
profession have changed?  
o If so, how do you think patients’ understandings are different now 
from how they were when you began practising? 
Technology and Pharmacy 
 Do you think that new medical technologies have had an impact on the way 
in which pharmacy is practiced in hospitals?  
o If so, which technologies have impacted on your practice personally? 
o If so, which technologies have you seen impacting on your colleagues 
practice or practice in general? 
 Do you think they have made an impact in the community sector? 
o How? 
o Which technologies? 
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Genetics and Pharmacy 
A branch of new medical technology that is often discussed as changing medical 
practice is genetic technology.  
 How much of an impact has genetic technology made on the practice of 
pharmacy in hospitals? 
o Is this impact (or lack of) the same for all hospital pharmacists? 
 Differences between different hospitals? 
 Differences between individual pharmacists (e.g. 
specialisms)? 
 How far do you think hospital pharmacists’ knowledge of genetics extends? 
o If they have a good level of knowledge, where has this knowledge 
come from (i.e. practice, under or postgraduate education, continuing 
education)? 
 Could you reflect on the extent of genetic knowledge amongst community 
pharmacists? 
 
 What about pharmacogenetics? 
o How familiar are hospital pharmacists with pharmacogenetics? 
o What about community pharmacists? 
o Has pharmacogenetics had any impact on pharmacy practice in 
hospitals to date? 
 Could you reflect on the potential roles that hospital pharmacists might have 
in pharmacogenetics in the future?  
o Could you reflect on the potential roles for community pharmacists? 
Inter-Professional Communication/ Collaboration 
 How much communication is there between pharmacists working in different 
sectors?  
o Has this changed since you began practising?  
 How much communication is there between pharmacists and other healthcare 
professionals? 
 How far do you think other healthcare professionals understand pharmacists 
as being key professionals in patient treatment? 
Culture Change and Future Roles 
 Earlier in the interview you reflected on the potential future roles for 
pharmacists in delivering pharmacogenetic services to patients. I was 
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wondering if you could tell me something about where you see these roles 
fitting into everyday practice? 
o Can you foresee any changes to everyday hospital pharmacy practice 
being made in order to implement pharmacogenetics? 
 There is an argument that if pharmacists are to be involved in delivering 
pharmacogenetic patient care, they will need restricted access to patient 
medical records.  
o How feasible do you think this is? 
o How do you think other healthcare professionals would understand 
this move? 
o Do you think pharmacists have the appropriate training in order to 
effectively and ethically utilise this information? 
o What do you think the implications of this might be for community 
pharmacists? 
Specialists 
Here, if the participant is involved in any discreet projects or has a specialist role ask 
about (if they haven’t already talked about these things); 
 How they came to have this role 
 The role of (pharmaco)genetic technologies in this role 
 Different collaborative practices that this role might entail 
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews?  
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Interview Topic Guide for Community Pharmacists 
General Information 
 Practice background; 
o When did you start practising? 
o Have you always worked in community pharmacy? 
 If not, what made you move over to community pharmacy? 
 If so, have you worked in different ‘types’ of community 
pharmacies (e.g. owner-occupied, small multiples, large 
multiples)?  
 Tell me about the pharmacy here; 
o How many staff are there? 
o Do any of the staff, including yourself, have any specialist roles such 
as running clinics? 
 Daily Role; 
o Could you talk me through your main responsibilities and tasks here? 
o Is this different for any of your colleagues (e.g. those with specialist 
interests or those involved in discreet projects)? Ask for details.  
Pharmacy Profession 
 In the time that you have been practicing, do you think that the pharmacy 
profession has changed in the community setting? 
o How? 
 Could you reflect on whether the hospital pharmacy sector has changed? 
o How? 
 Do you think that patients’ perceptions and understandings of the pharmacy 
profession have changed?  
o If so, how do you think patients’ understandings are different now 
from how they were when you began practising? 
o How do you think patients understand the extended role of 
community pharmacists?  
o Do you think that the extended role is being fully utilised by patients?  
Technology and Pharmacy 
 Do you think that new medical technologies have had an impact on the way 
in which pharmacy is practiced in the community?  
o If so, which technologies have impacted on your practice personally? 
o If so, which technologies have you seen impacting on your colleagues 
practice or practice in general? 
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Genetics and Pharmacy 
A branch of new medical technology that is often discussed as changing medical 
practice is genetic technology.  
 How much of an impact has genetic technology made on the practice of 
pharmacy in the community? 
o Is this impact (or lack of) the same for all community pharmacists? 
 Differences between different types of community pharmacy? 
 Differences between individual pharmacists (e.g. 
specialisms)? 
 How far do you think community pharmacists’ knowledge of genetics 
extends? 
o If they have a good level of knowledge, where has this knowledge 
come from (i.e. practice, under or postgraduate education, continuing 
education)? 
 Could you reflect on the extent of genetic knowledge amongst hospital 
pharmacists? 
 
 What about pharmacogenetics? 
o How familiar are community pharmacists with pharmacogenetics? 
o What about hospital pharmacists? 
o Has pharmacogenetics had any impact on pharmacy practice in the 
community to date? 
 Could you reflect on the potential roles that community pharmacists might 
have in pharmacogenetics in the future?  
Inter-Professional Communication/ Collaboration 
 How much communication is there between pharmacists working in different 
sectors?  
o Has this changed since you began practising?  
 How much communication is there between community pharmacists and 
other healthcare professionals? 
 How far do you think other healthcare professionals understand pharmacists 
as being key professionals in patient treatment? 
Culture Change and Future Roles 
 Earlier in the interview you reflected on the potential future roles for 
pharmacists in delivering pharmacogenetic services to patients. I was 
wondering if you could tell me something about where you see these roles 
fitting into everyday practice? 
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o Can you foresee any changes to everyday community pharmacy 
practice being made in order to implement pharmacogenetics? 
o If so, what will these changes be? 
o Will they be easy to implement? 
 There is an argument that if pharmacists are to be involved in delivering 
pharmacogenetic patient care, they will need restricted access to patient 
medical records.  
o How feasible do you think this is? 
o How do you think other healthcare professionals would understand 
this move? 
o Do you think pharmacists have the appropriate training in order to 
effectively and ethically utilise this information? 
o What do you think the implications of this might be for community 
pharmacists? 
Specialists 
Here, if the participant is involved in any discreet projects or has a specialist role ask 
about (if they haven’t already talked about these things); 
 How they came to have this role 
 The role of (pharmaco)genetic technologies in this role 
 Different collaborative practices that this role might entail 
Different Community Pharmacy Settings 
There are likely to be differences in experiences of practice between pharmacists 
working in large multiples (such as Boots) and owner-occupied establishments. If it 
hasn’t already been covered, talk about; 
 How will managerial structures in large multiples affect the implementation 
of pharmacogenetic technology in those settings? 
 What degree of autonomy to involve themselves in innovative practices do 
pharmacists in different types of community pharmacy have? How might this 
impact on their involvement in pharmacogenetics?  
Other Information 
 Is there anything that you would like to reflect on about the pharmacy 
profession, medical technologies or pharmacogenetics that we haven’t 
covered in this interview? 
 Are there any other key people that you think I should be approaching for 
interviews? 
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DEPARTMENT OF 
SOCIOLOGY 
Wentworth College 
Heslington 
York    
YO10 5DD 
Tel (01904) 432632 
Fax (01904) 323043 
Email kj518@york.ac.uk 
www.york.ac.uk/sociology 
 
 
 
CONSENT FORM 
Pharmacogenetics and the Pharmacy Profession in England 
 
 
I confirm that I have read and understood the Participant Information 
document for the above study and have been given the opportunity to ask 
questions 
 
I understand that my participation is entirely voluntary and that I am free to 
withdraw at any time without giving a reason.  
 
I understand that I am free to refuse to answer any question during the 
interview.  
 
I agree to the interview being recorded and later transcribed. 
 
I agree to take part in the above study. 
 
 
Participant’s Signature: ………………………………………………………………… 
 
Participant’s Name:  ………………………………………………………………… 
 
Date:    ………………………………………………………………… 
 
 
Researcher’s Signature: ………………………………………………………………… 
 
Researcher’s Name:  ………………………………………………………………… 
 
 Date:    ………………………………………………………………… 
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For Transcriber 
  
 
DEPARTMENT OF 
SOCIOLOGY 
Wentworth College 
Heslington 
York    
YO10 5DD 
Tel (01904) 432632 
Fax (01904) 323043 
Email kj518@york.ac.uk 
www.york.ac.uk/sociology 
 
 
 
 
Confidentiality Agreement for the Transcription of Qualitative Data 
 
Project Title: Pharmacogenetics and the Pharmacy Profession in England 
 
In accordance with the University of York Humanities and Social Science Ethics Committee and 
the National Research Ethics Service, all participants in named study above are anonymised. 
Therefore any personal information or any of the data generated or secured through transcription 
will not be disclosed to any third party.  
 
By signing this document, you are agreeing: 
 
not to pass on, divulge or discuss the contents of the audio material provided to you for 
transcription to any third parties 
 
to ensure that material provided for transcription is held securely and can only be 
accessed via password on your local computer 
 
to return transcribed material to the research team when completed and do so when 
requested 
 
Your name (block capitals)    ……………………………………………………………………. 
 
Your signature                        ……………………………………………………………………. 
 
Date             ……………………………………………………………………. 
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Glossary 
ADRs  Adverse drug reactions 
CAM  Complementary and alternative medicines 
CF  Cystic fibrosis 
CNV  Copy number variation 
DTC   Direct-to-consumer (genetic testing) 
EPS  Electronic prescribing systems 
FDA  Food and Drug Administration (US) 
HER2   Human epidermal growth factor receptor 2  
HGP  Human Genome Project 
INDEL Insertion or deletion (of DNA) 
ISP  International Society of Pharmacogenomics 
mAbs  Monoclonal antibodies 
NGEDC National Genetics Education and Development Centre (UK) 
NIH  National Institutes for Health (NIH) 
NHS  National Health Service (UK) 
NPT  Normalisation process theory  
PGx   Pharmacogenetics (or pharmacogenomics) 
PSGB  Pharmaceutical Society of Great Britain  
 PSNC  Pharmaceutical Services Negotiating Committee 
R&D  Research and development 
REC  Research ethics committee  
RP  Research Passport 
RPS  Royal Pharmaceutical Society (from 2011) 
RPSGB Royal Pharmaceutical Society of Great Britain (as was, until 2011)  
SCM  Sasang Constitutional Medicine 
SNP  Single nucleotide polymorphism  
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